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Abstract	
Background	Community-acquired	pneumonia	(CAP)	is	one	of	the	commonest	causes	of	adult	hospitalisation	in	sub-Saharan	Africa,	but	recent	data	describing	its	epidemiology,	microbial	aetiology	and	outcome	are	limited.	Focusing	particularly	on	Malawi,	the	overall	aim	of	this	thesis	was	to	describe	the	aetiology	and	outcome	of	CAP	in	sub-Saharan	African	to	determine	the	key	predictors	of	mortality.	
Methods	Firstly,	a	systematic	review	of	studies	of	CAP	in	adults	in	sub-Saharan	Africa	was	performed	to	describe	CAP	aetiology,	estimate	the	mortality	rate	and	identify	risk	factors	associated	with	death.	Secondly,	a	prospective	observational	study	of	adults	hospitalised	with	clinically	diagnosed	CAP	to	Queen	Elizabeth	Central	Hospital,	Blantyre,	Malawi	was	completed	to	describe	microbial	aetiology	using	modern	diagnostic	modalities,	determine	outcome	and	identify	prognostics	factors.	Thirdly,	having	identified	in	preliminary	analyses	of	the	prospective	cohort	that	hypoxaemia	was	an	independent	risk	factor	for	mortality,	a	study	of	the	effectiveness	of	supplemental	oxygen	delivery	by	oxygen	concentrator	to	correct	hypoxaemia	in	adults	with	suspected	CAP	was	performed.	
Results	In	both	the	systematic	review	and	the	prospective	cohort	the	predominant	burden	of	hospitalised	CAP	was	in	young	(average	age	38	and	35,	respectively)	and	HIV-positive	(52%	and	78%)	patients	with	limited	chronic	cardiovascular	and	pulmonary	comorbidity.	Streptococcus	pneumoniae	(27%	and	21%)	and	Mycobacterium	
tuberculosis	(19%	and	23%)	were	the	most	commonly	identified	causes.	The	overall	mortality	rate	for	hospitalised	patients	in	the	systematic	review	was	9.5%,	but	data	describing	prognostic	factors	were	limited.	In	the	prospective	cohort	(n=459),	death	by	day	30	occurred	in	14.6%	and	was	associated	with:	male	sex	(aOR	2.57);	pre-presentation	symptom	duration	(aOR	1.11	per	day	increase);	inability	to	stand	(aOR	4.28);	heart	rate	(aOR	1.02	per	beat/minute	rise);	oxygen	saturations	(aOR	0.95	per	%	rise);	white	cell	count	(aOR	0.91	per	109/L	rise);	haemoglobin	(aOR	0.90	per	g/dL	rise).	A	newly	derived	four	parameter	mortality	risk	prediction	tool	based	on	male	sex,	oxygen	saturations	<90%,	inability	to	stand	and	heart	rate	≥125	/min	predicted	30-day	mortality	with	reasonable	accuracy	(area	under	the	receiver-operating	curve	(AUROC)	0.79)	whilst	existing	tools	performed	poorly	(CURB65:	AUROC	0.60;	SMRT-CO:	AUROC	
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0.66).	Hypoxaemia	was	corrected	in	86.4%	(n=59)	of	adults	with	suspected	CAP	with	supplemental	oxygen	at	standard	flow-rate	of	5	litres/minute.	Failure	to	attain	normoxaemia	was	associated	with	a	more	than	four-fold	increase	in	the	risk	of	death	(RR	4.25).	
Conclusions	The	major	burden	of	hospitalised	CAP	in	low-resource,	sub-Saharan	African	settings	is	seen	in	young	and	HIV-positive	adults,	many	of	whom	have	TB.	Extrapolating	CAP	assessment	and	treatment	algorithms	from	well-resourced	settings	where	the	epidemiology	and	aetiology	of	disease	is	very	different	is	flawed.	If	validated,	locally	derived	severity	assessment	tools	may	provide	a	rational	basis	on	which	to	stratify	CAP	management.	Strategies	to	increase	early	detection	and	treatment	of	TB	and	to	improve	supportive	care,	in	particular	the	correction	of	hypoxaemia,	hold	considerable	promise	for	improving	CAP	outcomes	and	should	be	evaluated	in	clinical	trials.		
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1 Introduction:	Community-acquired	pneumonia	in	sub-
Saharan	Africa.		
1.1 Preface	and	chapter	overview	Pneumonia	is	an	inflammatory	process	of	the	distal	airspaces	of	the	lung	caused	by	infection	that	typically	presents	with	cough,	dyspnoea	and	fever.	The	inflammatory	exudate	that	accumulates	within	the	lung	parenchyma	may	cause	physical	signs	that	are	appreciable	on	clinical	examination	and/or	is	apparent	as	opacification	on	a	chest	radiograph.	Left	unchecked,	the	local	inflammatory	process	may	compromise	gas	exchange	leading	to	respiratory	failure;	systemic	spread	of	infection	may	result	in	sepsis	and	ultimately	death.	Pneumonia	has	been	recognised	for	millennia	as	a	common	and	important	human	ailment	that	remains	-	three-quarters	of	a	century	after	the	advent	of	modern	antimicrobials	-	a	leading	cause	of	morbidity	and	mortality	across	the	globe.	The	focus	of	the	work	presented	in	this	thesis	concerns	the	assessment	and	management	of	community-acquired	pneumonia	(CAP)	in	adults	in	Malawi	where	it	is	a	leading	cause	of	hospitalisation	and	death	(SanJoaquin	et	al.,	2013).		
In	this	introductory	chapter	I	give	an	overview	of	the	epidemiology,	aetiology	and	pathogenesis	of	CAP,	and	highlight	the	important	differences	in	the	pattern	of	disease	seen	in	sub-Saharan	Africa	compared	to	well-resourced	settings,	particularly	with	regard	to	the	impact	of	HIV.	With	particular	focus	on	a	sub-Saharan	African	context,	I	discuss	key	issues	in	the	management	of	CAP,	namely:	diagnosis	and	classification;	microbiological	investigation;	severity	assessment;	antimicrobial	and	supportive	treatment.	I	then	provide	a	brief	description	of	Malawi	focusing	on	the	healthcare	system,	before	finally	presenting	a	synopsis	of	this	thesis	and	describing	the	key	aims	and	objectives.	
1.2 Epidemiology	of	CAP	
1.2.1 Incidence	Globally,	pneumonia	is	the	commonest	cause	of	infectious	disease	related	death,	the	fourth	commonest	cause	of	death	overall	and	the	second	leading	cause	of	years	of	life	lost	(Lopez	et	al.,	2006;	Lozano	et	al.,	2012).	In	2010,	it	is	estimated	that	lower	respiratory	tract	infection	(LRTI)	accounted	for	2.8	million	deaths	and	the	loss	of	115	million	disability-adjusted	life	years	(Lozano	et	al.,	2012;	Murray	et	al.,	2012).		
The	incidence	of	CAP	in	adults	rises	sharply	with	age.	In	Europe	the	overall	incidence	is	1.07-1.2	per	1000	person	years,	but	is	at	least	10-fold	higher	in	adults	over	65	
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(Gutierrez	et	al.,	2006;	Singanayagam	et	al.,	2014).	This	is	reflected	in	hospitalised	CAP	cohorts	where	two-thirds	of	patients	are	over	65	(Ewig	et	al.,	2009).	The	rate	of	rise	in	CAP	incidence	accelerates	with	advancing	age	(Fry	et	al.,	2005;	Millett	et	al.,	2013),	such	that	in	the	United	States,	for	example,	approximately	1	in	20	persons	aged	85	years	or	older	will	have	a	new	episode	of	CAP	each	year	(Jackson	et	al.,	2004).	The	incidence	of	CAP	is	increasing	rapidly,	as	the	proportion	of	older	adults	in	the	population	grows,	(Fry	et	al.,	2005;	Millett	et	al.,	2013;	Trotter	et	al.,	2008).	In	Portugal,	for	example,	adult	pneumonia	admissions	have	increased	by	28%	in	the	last	decade	(Froes	et	al.,	2013).	
In	sub-Saharan	Africa,	there	are	an	estimated	4	million	episodes	of	pneumonia	each	year,	resulting	in	200,000	deaths	(Scott	et	al.,	2012).	The	annual	incidence	of	LRTI	is	estimated	at	10	episodes	per	1000	adults	less	than	60	years,	but	is	at	least	several-fold	higher	in	the	elderly	and	HIV	infected	individuals	(Lopez	et	al.,	2006).	In	Malawi,	pneumonia	is	the	commonest	reason	for	adult	hospitalisation	(SanJoaquin	et	al.,	2013).	The	demographic	structure	of	African	populations	and	the	dramatic	impact	of	HIV	are	such	that,	in	contrast	to	well-resourced	settings,	the	predominant	burden	of	pneumonia	occurs	in	working	age	adults	(Scott	et	al.,	2012).		
1.2.2 Outcome	The	mortality	rate	of	CAP	varies	markedly	with	disease	severity	and	treatment	setting,	ranging	from	less	than	1%	to	nearly	50%	(Welte	et	al.,	2012).	Differences	in	patient	demographics	and	comorbidity	profile	and	clinical	practice,	particularly	in	terms	of	hospitalisation	rate	and	intensive	care	referral,	make	direct	comparison	between	cohorts	difficult.	In	community	cohorts	from	well-resourced	settings,	mortality	rates	typically	range	from	0-4%	(Welte	et	al.,	2012;	Yu	et	al.,	2012).	Rates	vary	widely	in	hospitalised	cohorts;	mortality	in	recently	published	cohorts	in	high-	and	middle-income	were:	Argentina	13.3%	(Isturiz	et	al.,	2010),	Australia	5.7%	(Charles	et	al.,	2008a),	Germany	14.4%	(Ewig	et	al.,	2009),	United	States	8.5%	(Yu	et	al.,	2012)	and	Vietnam	9.8%	(Takahashi	et	al.,	2013).	In	patients	admitted	to	intensive	care	units,	CAP	mortality	rates	often	exceed	25%	(Welte	et	al.,	2012).	Crude	mortality	rates	of	adults	hospitalised	with	pneumonia	in	sub-Saharan	Africa	are	comparable	at	7-14%,	but	the	average	age	of	affected	patients	is	typically	much	lower	(Aderaye,	1994a;	Onyedum	et	
al.,	2011;	Scott	et	al.,	2000;	Sow	et	al.,	1996;	Yone	et	al.,	2012).		
Inpatient	or	30-day	mortality	rates	substantially	underestimate	total-pneumonia	related	mortality.	Following	apparent	clinical	resolution,	survivors	of	CAP	have	an	elevated	risk	of	death	for	at	least	one	year	(Koivula	et	al.,	1999;	Waterer	et	al.,	2004).	In	
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well-resourced	settings	up	to	one-third	of	hospitalised	CAP	patients	die	within	one	year	of	hospital	discharge	(Kaplan	et	al.,	2003).	This	excess	mortality	is	mainly	related	to	decompensation	of	underlying	comorbid	illness,	in	particular	cardiovascular	disease	(Musher	et	al.,	2007).	Following	an	episode	of	CAP,	hospitalisations	for	heart	failure,	acute	coronary	syndromes	and	arrhythmias	are	increased	(Corrales-Medina	et	al.,	2011;	Jasti	et	al.,	2008)	and	total	cardiovascular	mortality	is	elevated	(Koivula	et	al.,	1999).	
In	long-term	survivors,	symptomatic	recovery	following	an	episode	of	CAP	is	surprisingly	protracted,	taking	up	to	six	months	for	most	patients	to	attain	premorbid	levels	of	well-being	(El	Moussaoui	et	al.,	2006).	There	are	no	data	on	long-term	mortality	or	symptomatic	recovery	following	pneumonia	in	a	sub-Saharan	African	setting.	
1.2.3 Economic	burden	CAP	imposes	a	huge	economic	burden.	In	Europe,	CAP	is	estimated	to	cost	~€10.1	billion	annually,	with	inpatient	care	accounting	for	€5.7	billion	and	€3.6	billion	in	indirect	costs	from	lost	working	days	(Welte	et	al.,	2012).	The	total	economic	cost	of	treating	CAP	in	the	US	is	in	excess	of	$17	billion	(File	et	al.,	2010).	Direct	healthcare	expenditure	is	dominated	by	inpatient	care	costs	(Colice	et	al.,	2004;	Guest	et	al.,	1997;	Tichopad	et	al.,	2013);	whilst	treatment	of	outpatient	episode	of	CAP	is	markedly	cheaper	the	indirect	costs	resulting	from	sick	leave	and	reduced	productivity	remain	considerable	(Scott	et	al.,	2004;	Tichopad	et	al.,	2013).	Healthcare	costs	remain	elevated	for	at	least	two	years	following	an	episode	of	CAP	(Thomas	et	al.,	2012).	Data	describing	the	overall	healthcare	costs	associated	with	CAP	in	sub-Saharan	Africa	are	lacking.	At	a	household	level,	illness	with	an	inpatient	hospital	stay	may	result	in	considerable	–	and	potentially	catastrophic	–	healthcare	expenditure	both	in	terms	of	out-of-pocket	payments	and	subsequent	lost	income	(Buigut	et	al.,	2015;	Chuma	et	al.,	2012).	The	predominant	burden	of	disease	in	working	age	adults	in	sub-Saharan	African	settings	is	likely	to	have	substantial	economic	impact	(Scott	et	al.,	2012).	
1.2.4 Risk	factors	After	age,	the	dominant	risk	factors	for	CAP	in	well-resourced	settings	are:	male	sex	(Ewig	et	al.,	2009;	Gutierrez	et	al.,	2006);	comorbid	illness,	particularly	COPD	congestive	heart	failure,	cerebrovascular	disease,	dementia	and	diabetes	(Almirall	et	
al.,	2008;	Jackson	et	al.,	2009;	Klare	et	al.,	2002;	Torres	et	al.,	2013;	Welte,	2012;	Yende	
et	al.,	2013);	and	smoking	(Almirall	et	al.,	1999).	Excessive	alcohol	intake	is	an	important	risk	factor	particularly	in	middle-aged	adults	(Fernandez-Sola	et	al.,	1995).	
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Immunocompromise	as	a	result	of	corticosteroid	or	other	immunosuppressive	medication	use,	underlying	malignant	disease	or	organ	transplantation	is	an	important	and	increasingly	common	risk	factor	in	elderly	patients	(Sousa	et	al.,	2013).	Even	within	high	resource	countries,	CAP	disproportionately	affects	the	most	deprived	groups	(Millett	et	al.,	2013).	
Whilst	all	of	the	above	are	likely	to	pertain	in	sub-Saharan	Africa,	the	epidemiology	of	pneumonia	in	this	region	is	skewed	by	the	dramatic	impact	of	HIV.	HIV	infection	increases	the	risk	of	pneumonia	17-fold	(Gilks	et	al.,	1996)	and	that	of	pneumococcal	bacteraemia	up	to	100-fold	(Feikin	et	al.,	2004).	Combination	antiretroviral	therapy	(ART)	reduces	this	risk	(Saindou	et	al.,	2008),	but	pulmonary	infections	remain	a	leading	cause	of	morbidity	and	mortality	amongst	patients	with	HIV	(Benito	et	al.,	2012).	Despite	widespread	rollout	of	ART,	the	burden	of	hospitalised	pneumonia	in	many	sub-Saharan	African	settings	is	still	predominantly	in	young,	HIV-infected	patients	(SanJoaquin	et	al.,	2013).	Malnutrition,	household	crowding	and	exposure	to	indoor-air	pollution	from	the	use	of	biomass	fuel	may	further	contribute	to	the	burden	of	pneumonia	in	the	region	(Almirall	et	al.,	2008;	Ezzati	et	al.,	2001;	Penner	et	al.,	2003).		
1.2.5 Aetiology	A	large	number	of	microorganisms,	including	bacterial,	viral	and	fungal	pathogens,	can	cause	CAP.	In	most	well-resourced	settings	however,	the	majority	of	cases	are	caused	by	one	of	the	following:	Streptococcus	pneumoniae;	Haemophilus	influenzae;	
Mycoplasma	pneumoniae;	Chlamydophila	pneumoniae;	respiratory	viruses;	Legionella	
pneumophila;	Staphylococcus	aureus;	Pseudomonas	aeruginosa;	Gram-negative	enteric	bacilli.	The	relative	frequency	of	each	organism	varies	with	disease	severity,	patient	immune	status	and	prior	exposure	to	healthcare	facilities	and	initial	empirical	management	is	adapted	in	light	of	these	considerations	(Charles	et	al.,	2008a;	Isturiz	et	
al.,	2010;	Song	et	al.,	2011;	Torres	et	al.,	2014;	Welte	et	al.,	2012).		
There	are	also	important	geographical	variations	in	the	aetiological	profile	of	CAP	whereby	organisms	outside	the	usual	spectrum	described	above	predominate	locally.	In	areas	of	high	incidence,	Mycobacterium	tuberculosis	is	common	cause	of	acute	CAP	(Chon	et	al.,	2013;	Liam	et	al.,	2006;	Scott	et	al.,	2000).	In	South	Africa	and	Taiwan,	hypervirulent	strains	of	Klebsiella	pneumoniae	are	a	common	of	cause	severe	bacteraemic	CAP	(Feldman	et	al.,	1991;	Ko	et	al.,	2002;	Lin	et	al.,	2010;	Yu	et	al.,	2007).	
Burkholderia	pseudomallei,	the	causative	agent	of	melioidosis,	is	endemic	in	certain	regions	in	South-East	Asia	and	often	presents	as	an	acute	pneumonic	illness	(Peto	et	al.,	
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2014;	Song	et	al.,	2011).	In	areas	of	the	southern	United	States,	coccidioidomycosis	may	be	account	for	nearly	30%	of	acute	CAP	presentations	(Valdivia	et	al.,	2006).		
In	sub-Saharan	Africa	where	many	adults	hospitalised	with	pneumonia	are	HIV-infected	the	array	of	potential	pathogens	is	broadened	further	still	(Benito	et	al.,	2012;	SanJoaquin	et	al.,	2013).	The	available	aetiological	studies	emphasise	the	importance	of	
M.	tuberculosis	and	S.	pneumoniae	as	well	as	non-infective	conditions	such	as	pulmonary	Kaposi’s	sarcoma	masquerading	as	pneumonia	(Allen,	1984;	Hartung	et	al.,	2011;	Scott	et	al.,	2000).	The	frequency	of	Pneumocystis	jirovecii	–	the	commonest	cause	of	HIV-related	opportunistic	infection	in	well-resourced	settings	–	as	a	cause	of	acute	CAP	in	sub-Saharan	Africa	is	unclear	but	is	thought	likely	to	be	common	(Aderaye	et	al.,	2007;	Hartung	et	al.,	2011;	Malin	et	al.,	1995;	Nyamande	et	al.,	2006;	Worodria	et	al.,	2003).	There	is	a	need	for	further	studies	to	describe	the	aetiology	of	CAP	in	the	region	following	the	widespread	use	of	co-trimoxazole	prophylaxis	and	ART	rollout.	
1.3 Pathogenesis	of	pneumonia	
1.3.1 Pathogen	invasion	and	host	response	Pneumonia	refers	to	inflammation	within	the	distal	airspaces	that	is	the	result	of	infection	and	is	typically	characterised	by	the	presence	of	intra-alveolar	consolidation.	The	exact	pathological	features	and	underlying	pathophysiological	mechanisms	vary	with	the	causative	organism.	This	brief	discussion	will	focus	on	the	pathogenesis	of	bacterial	pneumonia,	using	the	response	to	S.	pneumoniae	as	a	well-characterised	example	(van	der	Poll	et	al.,	2009;	Wootton	et	al.,	2014).		
Following	acquisition	by	respiratory	droplet	spread	or	close	contact,	S.	pneumoniae	adheres	to	the	upper	respiratory	tract	epithelium	to	establish	carriage	within	the	nasopharynx	(Bogaert	et	al.,	2004).	In	adults,	colonisation	is	typically	asymptomatic	and	usually	terminated	by	adaptive	host	immune	responses	without	disease	(Li	et	al.,	2012;	Zhang	et	al.,	2009).	Propagation	of	colonising	bacteria	to	the	lower	respiratory	tract	may	occur	by	aspiration	but	is	impeded	by	basic	barrier	functions	(e.g.	mucociliary	escalator,	airway	bifurcations)	and	secreted	bactericidal	proteins	(e.g.	β	defensin,	lysozyme,	lactoferrin)	(Arnold	et	al.,	1980;	Dajani	et	al.,	2005;	Tecle	et	al.,	2010;	Wootton	et	al.,	2014).	The	few	bacteria	that	typically	reach	the	alveolar	spaces	are	phagocytosed	by	resident	alveolar	macrophages	without	activation	of	inflammatory	pathways	(Dockrell	et	al.,	2003).		
When	the	number	of	pneumococci	reaching	the	distal	airspaces	exceeds	the	capacity	of	alveolar	macrophages	to	rapidly	clear	them,	the	cascade	of	inflammatory	events	that	
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result	in	pneumonia	is	initiated	(Dockrell	et	al.,	2003).	Rapidly	multiplying	bacteria	release	constituents	such	as	lipoteichoic	acid	and	bacterial	DNA,	so-called	pathogen-associated	molecular	patterns	(PAMPs),	that	activate	toll-like	receptor	(TLR)	pathways	in	macrophages	and	epithelial	cells	(Knapp	et	al.,	2008).	Concurrently,	cellular	damage	releases	hyaluronic	acid	and	host	DNA	–	damage-associated	molecular	patterns	(DAMPs)	–	that	also	activate	TLR	signalling	(Jounai	et	al.,	2012).	These	dual	signals	trigger	a	switch	in	alveolar	macrophage	phenotype	to	an	activated,	pro-inflammatory	state	with	up-regulation	of	multiple	pro-inflammatory	genes	via	NF-κB	activation	and	release	of	TNFα,	IL1β,	IL6	and	CXCL8	into	the	local	milieu	(Bordon	et	al.,	2012;	McNeela	
et	al.,	2010).	Circulating	neutrophils	up-regulate	integrins	in	response	to	CXCL8	and	migrate	to	the	alveolar	space	(Kadioglu	et	al.,	2011;	Klesney-Tait	et	al.,	2013)	Neutrophils	phagocytose	bacteria	initially	with	complement	components	(C3b	and	iC3b)	as	opsonins	and	subsequently,	as	the	adaptive	immune	response	develops,	via	antigen	specific	immunoglobulin	(Brown	et	al.,	2002;	Yuste	et	al.,	2008).	The	intense	local	inflammatory	response	may	precipitate	severe	sepsis	-	a	systemic,	dysregulated	and	maladaptive	host	response	to	infection	that	ultimately	results	in	tissue	hypoperfusion	and	organ	dysfunction	(Stearns-Kurosawa	et	al.,	2011).	
If	control	over	invading	bacteria	is	achieved,	the	inflammatory	response	is	de-escalated	to	avoid	excessive	collateral	damage	to	host	tissues.	Macrophage	phenotype	switches	to	support	tissue	repair	and	undergo	apoptosis	and	induce	neutrophil	apoptosis	(Aberdein	et	al.,	2013;	Dockrell	et	al.,	2003).	Macrophage	efferocytosis	then	clears	apoptotic	neutrophils	to	allow	restoration	of	normal	pulmonary	architecture	and	function	(McCubbrey	et	al.,	2013).		
1.3.2 Respiratory	failure	Gas	exchange	at	the	alveolus	occurs	by	diffusion	between	the	air	spaces	and	pulmonary	capillaries.	Oxygen	passes	from	inspired	air,	across	the	alveolar	epithelium	and	capillary	wall	into	the	blood	where	it	is	largely	carried	bound	to	haemoglobin.	Carbon	dioxide	-	a	highly	soluble	gas	–	diffuses	freely	along	its	concentration	gradient	from	blood	to	alveolus	(O'Driscoll	et	al.,	2008).	In	pneumonia,	the	alveolar	airspaces	become	engorged	with	inflammatory	exudate,	reducing	ventilation	and	compromising	gas	exchange.	Auto-regulatory	mechanisms	within	the	pulmonary	vasculature	attempt	to	redirect	blood	flow	to	ventilated	areas,	but	if	overcome	a	ventilation-perfusion	mismatch	occurs.	Since	blood	oxygen	content	is	limited	by	haemoglobin	concentration,	reduced	oxygen	uptake	in	one	area	may	not	be	compensated	for	by	increase	uptake	in	another,	a	substantial	ventilation-perfusion	mismatch	often	results	in	hypoxaemia	(Gea	
et	al.,	1991;	O'Driscoll	et	al.,	2008).		
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1.4 Defining,	diagnosing	and	classifying	pneumonia	
1.4.1 Pneumonia	and	other	lower	respiratory	tract	infections	The	term	lower	respiratory	tract	infection	(LRTI)	refers	to	any	infection	of	the	respiratory	tract	distal	to	the	larynx;	it	encompasses	pneumonia,	acute	and	chronic	bronchitis,	and	acute	exacerbations	of	COPD	and	bronchiectasis	(Woodhead	et	al.,	2011).	Whilst	each	of	these	specific	infections	give	rise	to	a	similar	clinical	presentation,	differentiation	is	important	since	their	microbial	aetiology	and	prognosis	-	and	hence	treatment	requirements	-	differ	markedly.		
Distinguishing	pneumonia	from	acute	bronchitis	is	a	common	diagnostic	dilemma.	Acute	bronchitis,	in	contrast	to	pneumonia,	is	a	typically	a	self-resolving	and	short-lived	illness,	for	which	antimicrobials	are	generally	not	effective	or	recommended	(Gonzales	et	al.,	2000;	Macfarlane	et	al.,	2001;	Smith	et	al.,	2014;	Wenzel	et	al.,	2006).	Amongst	adults	presenting	with	an	acute	LRTI	syndrome	in	a	community	setting,	acute	bronchitis	is	20-	to	30-times	more	common	than	pneumonia	(Macfarlane	et	al.,	1993;	Metlay	et	al.,	2003).	The	challenge	for	clinicians	is	to	accurately	identify	the	relatively	infrequent	cases	of	pneumonia,	avoiding	both	delayed	treatment	initiation	and	unnecessary	antimicrobial	use.		
1.4.2 Clinical	versus	radiological	diagnosis	At	a	pathological	level,	pneumonia	is	distinguished	from	the	other	LRTI	syndromes	by	the	presence	of	alveolar	inflammation.	Demonstration	of	a	new	infiltrate	on	a	chest	radiograph	is	typically	used	as	a	proxy	of	alveolar	inflammation	and,	in	the	context	of	a	compatible	clinical	presentation,	is	the	widely	accepted	diagnostic	standard	for	pneumonia	(Lim	et	al.,	2009;	Mandell	et	al.,	2007;	Metlay	et	al.,	2003;	Woodhead	et	al.,	2011).		
Radiographic	pneumonia	as	defined	by	a	plain	chest	radiograph,	however,	has	important	limitations	as	a	diagnostic	reference	standard.	Firstly,	plain	chest	radiography	has	limited	sensitivty.	Computerised	tomography	(CT)	scanning	reveals	pneumonic	changes	in	33-50%	more	patients	with	clinical	pneumonia	than	plain	chest	radiograph	(Claessens	et	al.,	2015;	Syrjala	et	al.,	1998).	The	development	of	radiographic	changes	may	lag	behind	clinical	features	and	may	alter	with	hydration	status	(Hagaman	et	al.,	2009;	Hash	et	al.,	2000).	Secondly,	inter-observer	agreement	for	the	recognition	of	consolidation	is	only	moderate	at	best,	and	for	patients	with	underlying	chronic	lung	disease	is	poor	(Albaum	et	al.,	1996;	Hopstaken	et	al.,	2004).	Thirdly,	confirmation	of	radiographic	pneumonia	does	not	necessarily	usefully	guide	treatment	decisions	since	it	does	not	reliably	distinguish	between	bacterial	and	viral	
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aetiologies	(Graffelman	et	al.,	2008).	In	a	recent	cohort	of	US	CAP	patients	with	radiographic	pneumonia,	an	isolated	viral	infection	accounted	for	more	than	half	of	the	cases	in	which	an	aetiology	was	determined	(Jain	et	al.,	2015).		
Many	studies	have	unsuccessfully	attempted	to	define	a	combination	of	clinical	features	that	accurately	and	consistently	identifies	individuals	with	radiographic	pneumonia	(Metlay	et	al.,	1997).	Auscultatory	findings	in	isolation	have	poor	diagnostic	precision	and	high	inter-observer	variation	(Hopstaken	et	al.,	2003;	Melbye	et	al.,	1992;	Wipf	et	
al.,	1999).	Specific	symptoms	such	as	lateral	chest	pain	and	severe	dyspnoea	have	good	specificity	for	pneumonia,	but	lack	sensitivity	(Melbye	et	al.,	1992).	In	community	studies	of	adults	with	presumed	LRTI,	only	around	one-third	of	those	with	pneumonia	will	be	identified	on	clinical	assessment	(van	Vugt	et	al.,	2013;	Woodhead	et	al.,	1987).	Although	studies	of	patients	presenting	to	hospital	emergency	departments	indicate	the	absence	of	any	vital	sign	abnormality	(tachycardia,	fever,	tachypnoea	and	hypoxaemia)	excludes	pneumonia	with	reasonable	sensitivity	(Khalil	et	al.,	2007;	Nolt	
et	al.,	2007;	O'Brien	et	al.,	2006).		
Despite	the	limitations	of	clinical	diagnosis,	many	patients	with	suspected	CAP	are	managed	in	community	settings	without	a	chest	radiograph.	The	presence	of	focal	signs	and/or	systemic	features	is	used	as	an	indicator	of	pneumonia,	hence	the	need	for	antimicrobial	treatment.	British	pneumonia	guidelines	advocate	starting	antibiotic	treatment	on	the	basis	of	a	clinical	diagnosis	for	patients	with	mild	severity	disease	not	requiring	hospitalisation	(Lim	et	al.,	2009).	US	pneumonia	guidelines	recommend	routine	chest	radiography	for	all	adult	patients	with	suspected	CAP	(Mandell	et	al.,	2007).	
1.4.3 Inflammatory	biomarkers	for	CAP	diagnosis	Inflammatory	biomarkers	may	serve	as	a	useful	adjunct	to	clinical	assessment.	Combining	values	of	procalcitonin	(PCT)	or	C-reactive	protein	(CRP)	with	a	standard	clinical	assessment	improves	accuracy	for	diagnosing	radiographic	CAP	(Muller	et	al.,	2007).	These	markers	may	also	be	used	to	define	the	need	for	antibacterial	therapy.	Using	a	PCT-guided	treatment	algorithm,	Christ-Crain	et	al.	demonstrated	that	antibacterial	use	may	safely	be	reduced	amongst	patients	presenting	to	hospital	with	LRTI	(Christ-Crain	et	al.,	2004;	Schuetz	et	al.,	2009).	In	radiographic	CAP	specifically,	antibacterial	therapy	may	be	withheld	or	substantially	shortened	on	the	basis	of	low	PCT	levels	(Christ-Crain	et	al.,	2006).	
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1.4.4 Diagnostic	considerations	in	sub-Saharan	Africa	In	sub-Saharan	Africa,	limitations	in	the	availability	of	both	adequately	trained	clinicians	and	diagnostic	facilities	further	compound	the	problems	associated	with	pneumonia	diagnosis.	In	community	settings,	initial	patient	assessment	will	be	made	by	lay-providers	or	first	level	health	care	workers	who	may,	for	example,	not	have	been	trained	to	perform	chest	auscultation	(World	Health	Organization,	2009).	Chest	radiography	would	be	reserved	for	patients	requiring	hospitalisation,	but	even	then	might	be	delayed	or	deliberately	restricted	for	those	failing	to	respond	to	treatment.	WHO	treatment	guidelines	indicate	that	in	adults	that	present	with	cough	or	difficulty	in	breathing	the	diagnosis	of	pneumonia	is	made	on	the	basis	of	fever,	tachypnoea	or	chest	pain	(World	Health	Organization,	2009,	2011c).	
In	high	prevalence	settings,	the	influence	of	HIV	on	pneumonia	aetiology	and	presentation	will	also	be	relevant	to	the	diagnostic	approach.	For	some	pathogens,	notably	M.	tuberculosis,	HIV	infection	alters	the	characteristic	radiographic	appearances	of	pulmonary	infection	(Dawson	et	al.,	2010).	For	opportunistic	pathogens	such	as	Pneumocystis,	the	radiographic	features	may	be	subtle	and	not	readily	appreciated	on	plain	chest	radiograph	(Richards	et	al.,	1996).	PCT	and	CRP	identify	severe	bacterial	infection	in	children	with	reasonable	accuracy	(area	under	receiver-operating	characteristic	curve	(AUROC)	0.81	and	0.86,	respectively)	and	may	help	to	distinguish	bacterial	from	viral	pneumonia	(Carrol	et	al.,	2009;	Diez-Padrisa	et	al.,	2010).	In	adults	with	radiographic	CAP,	PCT	levels	in	bacterial	CAP	are	approximately	5	times	higher	that	for	tuberculosis	(TB)	and	19	times	higher	that	for	Pneumocystis	
jirovecii	pneumonia	(PCP)	(Cilloniz	et	al.,	2014;	Nyamande	et	al.,	2006;	Schleicher	et	al.,	2005),	but	there	are	no	data	examining	the	ability	of	inflammatory	biomarkers	to	safely	define	antimicrobial	therapy	in	Africa.		
1.4.5 Pneumonia	classification	If	otherwise	unspecified,	a	diagnostic	label	of	‘pneumonia’	is	too	imprecise	to	be	clinically	useful	since	the	array	of	potentially	causative	organisms	is	very	broad.	Pneumonia	is	therefore	classified	on	the	basis	of	patient	characteristics	and	clinical	features	in	order	to	narrow	the	spectrum	of	likely	pathogens	and	direct	initial	empirical	treatment	(Ewig,	2014).	Pneumonia	is	typically	classified	on	the	basis	of	presumed	site	of	pathogen	acquisition	as	community-acquired	pneumonia	(CAP)	or	hospital-acquired	pneumonia	(HAP)(National	Clinical	Guideline	Centre,	2014).	This	simple	distinction	usefully	directs	clinical	management	since	the	pathogens	commonly	implicated	in	CAP	and	HAP	differ	markedly	(American	Thoracic	Society,	2005;	Jain	et	al.,	2015;	Torres	et	
al.,	2014;	Welte	et	al.,	2012).	Pneumonia	in	immunocompromised	patients,	including	in	
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HIV-positive	patients,	is	generally	considered	separately	(Lim	et	al.,	2009;	National	Clinical	Guideline	Centre,	2014).	This	so-called	‘pneumonia	triad’	of	CAP,	HAP	and	pneumonia	in	the	immunocompromised	has	formed	the	framework	for	studies	and	pneumonia	management	guidelines	in	well-resourced	settings	(Ewig,	2014;	Lim	et	al.,	2009;	Mandell	et	al.,	2007;	National	Clinical	Guideline	Centre,	2014).		
1.4.6 Classification	considerations	in	sub-Saharan	Africa	In	sub-Saharan	Africa,	the	impact	of	HIV	means	that	managing	CAP	in	immunocompromised	host	is	a	daily	reality.	The	challenge	for	pneumonia	management	guidelines	in	these	settings	is	to	appropriately	direct	care,	but	to	do	so	with	recourse	to	limited	diagnostic	laboratory	facilities	(World	Health	Organization,	2011c).	The	current	South	African	guidelines	advocate	using	a	radiological	classification	scheme	that	divides	patients	into	focal	and	diffuse	pneumonic	changes	(Feldman	et	al.,	2007a).	Giving	the	limitations	of	chest	radiography	discussed	above	(Claessens	et	al.,	2015;	Nyamande	et	al.,	2007b),	this	might	not	be	the	most	useful	approach	and	alternative	parameters	such	as	CD4	count,	ART	use	and	duration	of	symptoms	might	be	more	appropriate	(Benito	et	al.,	2012).		
1.4.7 CAP	and	TB	
M.	tuberculosis	is	commonly	identified	amongst	adults	presenting	with	CAP	in	sub-Saharan	Africa	(Nyamande	et	al.,	2007a;	Scott	et	al.,	2000).	The	terminology	used	to	describe	this	group	of	patients	is	inconsistent:	some	authors	distinguish	TB	from	CAP	(Aderaye,	1994a;	Koulla-Shiro	et	al.,	1997;	Sow	et	al.,	1996);	others	identify	TB	as	a	cause	of	non-responding	pneumonia	(Aderaye	et	al.,	2007;	Malin	et	al.,	1995;	Worodria	
et	al.,	2003);	whilst	others	report	TB	as	a	cause	of	CAP	without	further	distinction	(Albrich	et	al.,	2014b;	Fiberesima	et	al.,	2007;	Scott	et	al.,	2000).	
Pulmonary	TB	may	arise	as	a	result	of	progressive	disease	following	recent	acquisition	of	infection	or	reactivation	of	latent	infection	(Dheda	et	al.,	2016;	Getahun	et	al.,	2015).	For	TB	arising	from	reactivation	of	latent	infection,	the	community-acquired	paradigm	breaks	down,	however	it	can	still	cause	an	acute	respiratory	presentation	compatible	with	the	time-course	of	CAP	due	to	other	aetiologies	(Fiberesima	et	al.,	2007;	Scott	et	
al.,	2000).	In	this	sense	it	is	reasonable	to	attribute	causation	of	‘CAP’	to	M.	tuberculosis.	
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1.5 CAP	in	the	context	of	HIV	
1.5.1 Epidemiology	of	respiratory	infection	in	HIV	Respiratory	infections	are	a	leading	cause	of	morbidity	and	mortality	and	one	of	the	most	frequent	causes	of	hospitalisation	in	patients	living	with	HIV	(Benito	et	al.,	2012).	In	the	pre-ART	era,	the	incidence	of	CAP	was	35-fold	higher	in	HIV-infected	individuals	(Segal	et	al.,	2011).	Use	of	ART	and	co-trimoxazole	preventative	therapy	markedly	reduces,	but	does	not	abolish,	the	excess	risk.	Respiratory	infections	continue	to	be	a	major	burden	of	illness	in	patient	groups	with	limited	access	to	health	services	(Segal	et	
al.,	2011).	The	impact	of	HIV	status	on	acute	CAP	mortality	is	however	unclear.	Two	international	observational	studies	indicated	no	overall	impact	on	CAP	outcome	(Christensen	et	al.,	2005;	Malinis	et	al.,	2010).	In	bacteraemic	pneumococcal	CAP,	HIV	infection	with	reduced	CD4	count	was	associated	with	increased	mortality	(Feldman	et	
al.,	2007b).	
Whilst	HIV	infection	probably	increases	susceptibility	to	respiratory	infection	generally	(Feikin	et	al.,	2004;	Hirschtick	et	al.,	1995),	the	reported	impact	of	HIV	on	the	incidence	of	Streptococcus	pneumoniae,	TB	and	PCP	is	most	dramatic	and	thoroughly	described	(DeRiemer	et	al.,	2007;	Gilks	et	al.,	1996;	Munoz	et	al.,	1993;	Sonnenberg	et	al.,	2005).		
1.5.1.1 Streptococcus	pneumoniae	
Streptococcus	pneumoniae	is	the	commonest	cause	of	bacterial	pneumonia	in	HIV-positive	adults	(Cilloniz	et	al.,	2014).	In	the	pre-ART	era,	the	incidence	of	pneumococcal	pneumonia	was	increased	20-fold	and	that	of	invasive	pneumococcal	disease	(IPD)	by	as	much	as	100-fold	(Feikin	et	al.,	2004;	Hirschtick	et	al.,	1995).	
1.5.1.2 Mycobacterial	pathogens		TB	is	the	most	important	HIV-associated	opportunistic	infection	globally	and	is	the	leading	cause	of	HIV-associated	mortality	accounting	for	approximately	25%	of	such	deaths	(Lawn	et	al.,	2013b).	In	low-endemicity	settings,	most	cases	are	due	to	reactivation	of	latent	TB	infection	(LTBI)	where	the	risk	of	developing	TB	is	inversely	proportional	to	CD4	cell	count	and	remains	elevated	compared	to	HIV-negative	patients	even	at	CD4	counts	up	to	500	(Lawn	et	al.,	2009).	ART	curtails	the	risk	of	progression	from	LTBI,	but	even	with	robust	immune	recovery	the	risk	of	TB	remains	elevated	(Girardi	et	al.,	2005;	Lawn	et	al.,	2005).		
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1.5.1.3 Pneumocystis	jirovecii	pneumonia	The	overall	incidence	of	Pneumocystis	jirovecii	(formerly	P.	carinii)	pneumonia	(PCP)	amongst	patients	with	HIV	living	in	well-resourced	settings	has	fallen	dramatically	with	the	availability	of	effective	ART	(Furrer	et	al.,	1999;	Moore	et	al.,	1999).	However,	it	remains	the	commonest	opportunistic	infection	in	individuals	with	advanced	HIV	at	presentation	(Benito	et	al.,	2012;	Cilloniz	et	al.,	2014;	Serraino	et	al.,	2003).	Despite	being	a	ubiquitous	organism,	historically	the	reported	burden	of	PCP	in	HIV-infected	populations	in	sub-Saharan	Africa	has	been	by	contrast	low	(Abouya	et	al.,	1992;	Batungwanayo	et	al.,	1994;	Fisk	et	al.,	2003;	Wasserman	et	al.,	2013).	This	may	in	part	be	attributable	to	early	mortality	due	to	more	virulent	infections,	but	under-ascertainment	due	to	lack	of	access	to	sensitive	diagnostic	tests	is	also	likely	(Atzori	et	
al.,	1993;	Lowe	et	al.,	2013).	Recent	bronchoscopy	studies	from	African	centres	have	demonstrated	a	considerable	burden	of	PCP	amongst	HIV-infected	patients	with	features	of	respiratory	infection	(Aderaye	et	al.,	2007;	Hargreaves	et	al.,	2001;	Hartung	
et	al.,	2011;	Malin	et	al.,	1995;	Nyamande	et	al.,	2006;	Worodria	et	al.,	2003).	
1.5.2 Mechanisms	of	immunocompromise	Pneumonia	occurs	when	pulmonary	defence	mechanisms	are	overwhelmed	and	invading	microorganisms	proliferate	within	the	lung	parenchyma.	In	immunocompetent	patients,	despite	continual	exposure	of	the	upper	respiratory	tract	to	potentially	pathogenic	organisms,	pneumonia	is	actually	an	infrequent	occurrence	owing	to	the	effectiveness	of	the	intricate	system	of	host	defence	mechanisms	present	(see	section	1.3.1)(Wootton	et	al.,	2014).	Infections	that	established	latency	such	as	tuberculosis	are	held	in	check	by	an	effective	cellular	immune	response	(Getahun	et	al.,	2015).	
HIV	infection	is	characterised	by	a	combination	of	immune	suppression	and	chronic	inflammation	that	results	in	immune	exhaustion	and	multiple	defects	that	compromise	the	pulmonary	response	to	infection	(Huson	et	al.,	2015).	Even	in	early,	asymptomatic	infection	when	peripheral	blood	CD4	cell	counts	are	maintained,	persistent	inflammation	at	the	respiratory	mucosal	surfaces,	preferentially	depletes	mucosal	lymphocytes	and	increases	susceptibility	to	pathogen	colonisation	and	ingress	(Glennie	
et	al.,	2011;	Sepako	et	al.,	2014).	Alveolar	macrophage	phagocytic	and	pathogen	lysis	function	is	impaired	(Jambo	et	al.,	2014b).	In	addition	macrophage	pro-inflammatory	cytokine	response	to	infection	is	attenuated,	in	particular	CXCL8	production	is	reduced	leading	to	impaired	neutrophil	recruitment	(Gordon	et	al.,	2005).	Antigen-specific	cellular	and	humoral	responses	against	S.	pneumoniae,	M.	tuberculosis	and	influenza	are	
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also	impaired	and	only	partially	restored	by	ART	(Eagan	et	al.,	2007;	Jambo	et	al.,	2014a;	Jambo	et	al.,	2011;	Sepako	et	al.,	2014).	
1.5.3 Clinical	assessment	and	management	The	rational	approach	to	managing	pneumonia	in	HIV-infected	patients	depends	upon	the	degree	of	immunosuppression.	This	is	reasonably	assessed	by	the	peripheral	CD4	cell	count,	since	the	sequence	of	pulmonary	complications	parallels	the	depletion	of	CD4	cells	(Hirschtick	et	al.,	1995).	Increasingly	general	CAP	studies	are	including	HIV-positive	patients	established	on	ART	with	well-preserved	CD4	counts	(Jain	et	al.,	2015).		
In	patients	with	advanced	HIV,	the	assessment	of	apparent	CAP	is	complicated	by	the	broad	array	of	pathogens	potentially	implicated.	There	are	no	evidence-based	algorithms	that	define	the	best	sequence	of	investigations	to	achieve	an	aetiological	diagnosis	(Figure	1.1).	The	radiological	appearance	(diffuse	versus	focal	infiltrates)	is	frequently	used	to	guide	initial	management	and	direct	investigations,	although	the	relatively	lack	of	sensitivity	of	plain	chest	radiograph	in	immunocompromised	patients	should	be	considered	(Feldman	et	al.,	2007a;	Nyamande	et	al.,	2007b).	Reported	dyspnoea	and	hypoxaemia	may	also	indicate	PCP	in	favour	of	other	aetiologies	(Hargreaves	et	al.,	2001;	Malin	et	al.,	1995).	Substantially	elevated	inflammatory	biomarker	levels	(i.e.	PCT	or	CRP)	are	suggestive	of	bacterial	CAP	over	PCP	or	TB	(Cilloniz	et	al.,	2014;	Nyamande	et	al.,	2006;	Schleicher	et	al.,	2005).	In	highly	immunocompromised	patients,	early	bronchoscopy	for	diagnostic	sampling	is	often	recommended	in	well-resourced	settings,	particularly	if	response	to	empirical	treatment	is	inadequate	(Benito	et	al.,	2012).		
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Figure	1.1	 Diagnostic	algorithm	of	pneumonia	in	HIV-infected	patients	in	
well-resourced	setting.	Adapted	from	(Benito	et	al.,	2012).	CXR,	chest	radiograph;	CT,	computerised	tomography;	PCR,	polymerase	chain	reaction;	BAL,	bronchoalveolar	lavage;	TBLB,	transbronchial	lung	biopsy;	CMV,	cytomegalovirus;	MRSA,	methicillin	resistant	Staphylococcus	aureus;	MDR,	multi-drug	resistant;	VATS,	video-assisted	thoracoscopic	surgery	1	Proceed	to	induced	sputum	for	microscopy	and	culture	for	mycobacteria	if	standard	sputum	unavailable.		2	Rationalised	in	light	of	investigations.		
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1.6 Establishing	aetiological	diagnosis	in	CAP	CAP	may	be	caused	by	a	broad	array	of	pathogens.	In	well-resourced	settings,	the	spectrum	of	potential	pathogens	is	generally	well	defined	and	empirical	treatment	algorithms	are	devised	to	reliably	provide	adequate	antimicrobial	cover	(Lim	et	al.,	2009).	In	clinical	practice	the	use	of	extensive	aetiological	diagnostic	tests	is	reserved	for	patients	with	severe	disease	or	those	that	are	failing	to	improve	where	the	result	of	the	test	is	likely	to	influence	management.	Although,	even	with	extensive	testing	using	multiple	different	assays,	the	aetiology	of	CAP	may	be	established	in	fewer	than	half	of	patients	(Jain	et	al.,	2015).	
1.6.1 Standard	bacteriological	methods	Obtaining	adequate	specimens	from	the	site	of	infection	in	pneumonia	is	often	unachievable.	Instead	diagnosis	by	standard	bacteriological	methods	is	usually	based	on	blood	and	expectorated	sputum.	Blood	culture	is	highly	specific,	but	has	limited	sensitivity	particularly	in	patients	that	have	already	received	antimicrobial	treatment.	Rates	of	bacteraemia	as	low	as	6-7%	have	been	reported	in	recent	cohorts	of	hospitalised	CAP	(Charles	et	al.,	2008a;	Jain	et	al.,	2015).	In	practice,	blood	cultures	should	restricted	to	patients	with	high	severity	illness,	in	whom	they	are	likely	to	have	a	higher	yield	and	also	to	influence	management	(Waterer	et	al.,	2001c).	
Microscopy	and	culture	of	expectorated	sputum	specimens	offer	the	potential	of	specific	aetiological	diagnosis.	However,	specimens	are	frequently	contaminated	by	upper	airway	commensal	organisms,	many	of	which	themselves	are	potential	agents	of	CAP.	Pre-treatment	specimen	collection,	rapid	processing	and	screening	by	microscopy	to	assess	specimen	adequacy	may	help	(Bartlett,	2011).	Alternative	methods	to	obtain	lower	respiratory	tract	specimens	such	as	induced	sputum,	bronchoscopy	and	transthoracic	needle	aspiration	offer	improved	diagnostic	yields	but	are	invasive	and	are	rarely	performed	in	non-immunocompromised	CAP	patients	that	respond	adequately	to	empirical	treatment	(Bartlett,	2011).	
1.6.2 Serological	assays	Serological	assays	were	previously	the	mainstay	of	conventional	diagnosis	for	
Legionella,	Mycoplasma	pneumoniae,	Chlamydophila	spp.	and	respiratory	viral	pathogens	in	CAP.		There	was	large	selection	of	different	assays	available	with	variable	diagnostic	performance,	but	all	with	the	intrinsic	limitation	of	delayed	diagnosis	because	of	the	requirement	to	demonstrate	rising	antibody	titre	in	a	convalescent	specimen(Waterer	et	al.,	2001a).	With	the	increasing	availability	specific	molecular	
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diagnostics	tests	for	atypical	bacterial	and	viral	pathogens,	use	of	serological	assays	is	declining	(Jain	et	al.,	2015;	Johansson	et	al.,	2010;	Lim	et	al.,	2009).	
1.6.3 Rapid	diagnostic	antigen	based	tests	The	Alere	BinaxNOW	Streptococcus	pneumoniae	antigen	card	(BinaxNOW-SP)	is	a	point-of-care	immunochromatographic	test	that	detects	pneumococcal	C-polysaccharide	coat	protein	in	urine	(Kobashi	et	al.,	2007).	Sensitivity	and	specificity	for	the	diagnosis	of	pneumococcal	pneumonia	in	adults	are	74%	and	97%,	respectively	(Sinclair	et	al.,	2013).	In	practice,	when	used	in	conjunction	with	classical	microbiological	methods,	it	gives	an	incremental	improvement	of	around	13%	for	detection	of	pneumococcal	pneumonia	(Kobashi	et	al.,	2007).	It	has	poor	specificity	in	children	owing	to	high	rates	of	asymptomatic	nasal	carriage	of	S.	pneumoniae	(Adegbola	et	al.,	2001).	The	limited	available	data	in	adults	indicate	that	specificity	of	BinaxNOW-SP	is	not	affected	by	nasopharyngeal	colonisation	(Turner	et	al.,	2011).	However,	the	impact	of	concurrent	HIV	infection	and	colonisation	density	has	not	been	analysed.		
An	analogous	urine	antigen	test	is	now	widely	used	for	the	diagnosis	of	Legionella.	The	Alere	BinaxNOW	Legionella	urinary	antigen	card	has	sensitivity	of	80%	and	specificity	of	99%	for	the	detection	of	L.	pneumophila	serogroup	1	infection	(Den	Boer	et	al.,	2004;	Helbig	et	al.,	2001).	It	is	important	to	appreciate	that	infection	with	other	serogroups	or	
Legionella	species	will	not	be	detected.	However,	more	than	90%	of	Legionella	infections	are	caused	by	Legionella	pneumophila	and	amongst	these	over	80%	are	caused	by	serogroup	1	strains	(Diederen	et	al.,	2006).		
1.6.4 Molecular	tests	for	atypical	bacteria	and	viruses	Molecular	assays	based	on	multiplex	polymerase	chain	reaction	(PCR)	have	become	the	standard	modality	for	determining	the	presence	of	Mycoplasma	pneumoniae,	
Chlamydophila	spp.	and	respiratory	viral	pathogens	in	CAP.	A	variety	of	different	PCR	platforms	are	available.	For	Mycoplasma	pneumoniae	and	Chlamydophila	spp.,	use	of	sputum	specimens	rather	than	nasopharyngeal	or	oral	swabs	is	superior	(Cho	et	al.,	2012).	For	most	respiratory	viral	pathogens,	detection	is	superior	in	nasopharyngeal	specimens.	Use	of	PCR	assays	gives	an	incremental	improvement	in	sensitivity	over	standard	techniques	of	approximately	50%	for	M.	pneumoniae	and	respiratory	viruses	(Johansson	et	al.,	2010).	Although	definitively	ascribing	aetiological	significance	is	often	difficult	since	asymptomatic	nasopharyngeal	colonisation	is	well	recognised	for	many	respiratory	viruses	(Feikin	et	al.,	2012;	Jain	et	al.,	2015;	Pretorius	et	al.,	2012).	
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1.6.5 Diagnostic	tests	for	TB	The	gold-standard	diagnostic	test	for	pulmonary	TB	is	the	culture	of	pathogen	from	a	respiratory	tract	specimen.	Automated	liquid-based	culture	techniques	have	improved	the	speed	and	sensitivity	of	culture,	but	still	the	delay	to	results	is	up	to	three	weeks	and	too	long	to	form	the	basis	of	acute	treatment	decisions	(Cruciani	et	al.,	2004).	Until	recently,	smear	microscopy	and	chest	radiography	were	the	mainstay	investigations	for	the	acute	diagnosis	of	TB.	In	HIV-associated	TB,	however,	approximately	only	a	third	of	cases	are	smear-positive	and	many	have	only	very	subtle	changes	on	radiographs	(Perlman	et	al.,	1997;	Steingart	et	al.,	2006).		
The	last	decade	has	seen	renewed	momentum	in	the	area	of	TB	diagnostics	with	several	new	assays	being	developed	(Lawn	et	al.,	2013c;	McNerney	et	al.,	2011).	The	Cepheid	Xpert	MTB/RIF	platform	is	the	single-most	important	recent	advance.	This	fully	integrated	and	automated	diagnostics	platform	is	capable	of	identifying	
Mycobacterium	tuberculosis	complex	and	the	presence	of	mutations	conferring	rifampicin	resistance	in	unprocessed	sputum	specimens	in	less	than	two	hours	(Lawn,	2013;	Steingart	et	al.,	2013).	Following	WHO	endorsement	in	2010	the	Xpert	MTB/RIF	platform	has	been	rolled-out	to	many	low-	and	middle-income	countries	where	it	is	frequently	the	central	pillar	of	TB	diagnostics	(Lawn	et	al.,	2013c;	World	Health	Organization,	2014c).	Compared	to	sputum	culture,	Xpert	MTB/RIF	has	an	overall	sensitivity	of	88%	and	specificity	of	98%.	The	estimated	sensitivity	for	smear-positive	and	smear-negative	subgroups	was	98%	and	67%,	respectively	(Steingart	et	al.,	2013).	The	reported	sensitivity	of	Xpert	MTB/RIF	in	HIV-associated	TB	ranges	between	58%	and	92%	(median	84%),	but	consistently	gives	a	median	increment	in	sensitivity	over	smear	microscopy	of	approximately	30%	(Lawn	et	al.,	2013c).		
1.6.6 Diagnostic	tests	for	PCP	Historically,	definitive	diagnosis	of	PCP	has	relied	on	direct	visualisation	of	
Pneumocystis	organisms	of	bronchoalveolar	lavage	fluid	and	transbronchial	tissue	biopsy	specimens.	In	recent	years,	molecular	assays	have	begun	to	supersede	direct	visualisation	techniques	for	the	detection	of	Pneumocystis	jirovecii	(Durand-Joly	et	al.,	2005).	The	improved	sensitivity	of	molecular	assays	based	on	PCR	may	permit	the	use	of	non-invasive	specimens	(where	Pneumocystis	organisms	are	present	in	lower	concentrations)	such	as	expectorated	sputum	(Cruciani	et	al.,	2002),	nasopharyngeal	aspirates	(To	et	al.,	2013)	and	oral	washes	(Larsen	et	al.,	2004)	for	the	diagnosis	of	PCP.	However,	all	current	PCP	diagnostic	assays	are	reliant	on	a	robust	laboratory	infrastructure	that	is	lacking	in	many	low-resource,	high	HIV-burden	settings.		
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1.6.7 Diagnostic	approach	in	sub-Saharan	Africa	The	difficulties	of	managing	CAP	in	HIV-infected	patients	were	discussed	in	section	1.4.4.	The	additional	challenge	in	low-resource	settings	is	to	manage	this	complicated	group	of	patients	with	weak	or	limited	diagnostic	microbiology	laboratory	capabilities	(World	Health	Organization,	2011c).	The	optimal	diagnostic	strategy	in	this	setting	is	unclear	and	warrants	further	research.	The	use	of	point-of-care	and	other	rapid	diagnostic	tests	that	require	minimal	laboratory	infrastructure	to	perform	may	provide	a	feasible	adjunct	to	guide	the	management	of	pneumonia	in	low-resource	settings	(Aston,	2014;	Lawn,	2012;	Zar	et	al.,	2013).	
1.7 CAP	outcomes	and	therapeutic	endpoints	
1.7.1 Overview	The	outcome	of	CAP	has	often	been	described	simply	as	the	proportion	of	patients	that	die	within	a	defined	period.	Whilst	mortality	is	a	highly	relevant	and	objective	outcome	metric,	since	most	patients	with	CAP	do	not	die	it	does	not	provide	any	information	on	the	clinical	course	of	the	majority	of	patients.	Various	attempts	have	been	made	to	better	conceptualise	clinical	outcomes	in	patients	with	CAP	following	the	initiation	of	treatment.	Broadly	speaking,	patients	can	get	better	–	either	quickly	or	slowly	(i.e.	early	clinical	stability	or	delayed	clinical	stability),	get	worse	–	either	quickly	or	slowly	(i.e.	early	or	late	clinical	failure),	or	remain	largely	unchanged	(i.e.	non-responding	pneumonia)	(Aliberti	et	al.,	2014b;	Wiemken	et	al.,	2013).		
Early	categorisations	of	treatment	non-response	aimed	to	group	patients	into	distinct	clinical	phenotypes	for	which	a	list	of	most	likely	causes	could	be	defined	and	thus	provide	clinicians	with	a	framework	to	approach	further	diagnosis	and	management.	The	terms	used	were	descriptive	and	relied	heavily	on	radiographic	changes.	For	example,	delayed	clinical	and/or	radiographic	improvement	was	termed	‘slowly	resolving	pneumonia,’	persistent	radiographic	infiltrates	as	‘non-resolving	pneumonia’	and	rapid	clinical	deterioration	as	‘progressive	pneumonia’	(Arancibia	et	al.,	2000).	
More	recent	studies	have	sought	to	define	early	clinical	endpoints	that	are	more	objective	and	reproducible,	typically	based	on	physiological	criteria,	and	the	attainment	of	which	is	prognostically	significant,	in	that	they	themselves	reflect	a	meaningful	endpoint	(e.g.	mechanical	ventilation)	or	are	predictive	of	long-term	outcome	(e.g.	death)	(Barlow	et	al.,	2003).	Increasingly	surrogate	endpoints	such	as	attainment	(or	lack	of	attainment)	of	clinical	stability	or	clinical	failure	are	being	used	as	the	primary	outcomes	in	CAP	clinical	trials	since	they	permit	detection	of	treatment	effect	in	a	study	
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population	much	smaller	than	that	which	would	be	required	to	detect	differences	in	mortality	(Garin	et	al.,	2014;	Torres	et	al.,	2015).	
	
	
Figure	1.2	 Chronology	of	outcomes	for	hospitalised	patients	with	CAP.	Adapted	from	(Wiemken	et	al.,	2013).		
	
1.7.2 Mortality	endpoints	Mortality	data	are	usually	readily	obtainable	and	provide	an	objective	measure	of	pneumonia	outcome.	Mortality	at	day	30	post	diagnosis	is	the	most	commonly	used	time-point	and	is	the	outcome	upon	which	many	of	the	most	widely	recommended	pneumonia	severity	assessment	tools	are	based	(Fine	et	al.,	1997a;	Lim	et	al.,	2003).	In-hospital	mortality	data	may	be	more	easily	obtainable	in	some	settings	and	approximates	30-day	mortality	but	clearly	misses	early	post-discharge	mortality.		
These	relatively	short-term	outcomes	arguably	underestimate	that	true	impact	of	CAP.	Multiple	studies	have	highlighted	the	excess	mortality	amongst	short-term	CAP	survivors	that	persists	for	several	years.	The	crude	mortality	rate	at	5	years	following	an	episode	of	CAP	may	be	as	high	as	50%	in	apparent	CAP	survivors	(Kaplan	et	al.,	2003;	Koivula	et	al.,	1999;	Restrepo	et	al.,	2013;	Waterer	et	al.,	2004).		
Only	around	half	of	deaths	in	the	3-months	following	an	episode	of	pneumonia	are	directly	attributable	to	pneumonia	(i.e.	due	to	respiratory	failure,	severe	sepsis).	Most	of	the	remainder	are	attributable	to	complications	of	underlying	comorbid	illness.	The	
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majority	of	pneumonia-related	deaths	occur	within	the	first	30	days,	whilst	most	unrelated	deaths	occur	later	(Mortensen	et	al.,	2002).		
1.7.3 Treatment	failure	and	related	endpoints	Deterioration	following	the	initiation	of	treatment	-	termed	either	treatment	failure	or	clinical	failure	-	occurs	in	8-33%	of	hospitalised	CAP	patients	(Aliberti	et	al.,	2008;	Genne	et	al.,	2006;	Hoogewerf	et	al.,	2006;	Martin-Loeches	et	al.,	2014;	Menendez	et	al.,	2004b;	Roson	et	al.,	2004).	Some	authors	distinguish	treatment	failure	and	clinical	failure,	using	the	former	to	refer	to	a	presumed	lack	of	response	to	antimicrobial	therapy	and	the	latter	to	describe	clinical	deterioration	regardless	of	the	underlying	cause	(e.g.	treatment	failure,	super-imposed	infection,	exacerbation	of	comorbid	condition)	(Aliberti	et	al.,	2014b).	However,	this	distinction	is	not	consistently	made	and	treatment	failure	is	the	more	widely	used	term.	Even	after	adjustment	for	baseline	disease	severity,	treatment	failure	is	strongly	associated	with	an	increased	risk	of	further	complications,	prolonged	hospital	stay	and	subsequent	death	(Aliberti	et	al.,	2008;	Hoogewerf	et	al.,	2006;	Menendez	et	al.,	2004b;	Roson	et	al.,	2004).	Identified	risk	factors	for	treatment	failure	include:	age,	comorbid	illness,	raised	inflammatory	cytokines,	high	initial	disease	severity,	infection	with	specific	pathogens	(e.g.	Legionella	and	Gram-negative	bacteria)	and	discordant	antimicrobial	therapy	(Martin-Loeches	et	
al.,	2014;	Menendez	et	al.,	2008;	Menendez	et	al.,	2004b;	Roson	et	al.,	2004).	
Several	different	definitions	of	treatment	failure	of	varying	complexity	have	been	used	(Table	1.1).	Most	are	largely	based	on	physiological	variables	to	indicate	the	development	of	respiratory	failure	and/or	haemodynamic	instability.	Most	definitions	categorise	as	treatment	failure	as	early	or	late	depending	if	it	occurs	within	or	beyond	72	hours	of	treatment	initiation,	respectively.		
Several	authors	have	attempted	to	define	and	categorise	the	causes	of	treatment	failure	(Aliberti	et	al.,	2008;	Genne	et	al.,	2006;	Menendez	et	al.,	2004b;	Roson	et	al.,	2004).	Broadly,	early	treatment	failure	is	often	directly	pneumonia-related	and	commonly	due	to	progressive	respiratory	failure	and/or	severe	sepsis;	nosocomial	infection	and	other	iatrogenic	complications	(e.g.	drug	toxicities)	are	common	causes	of	late	treatment	failure;	acute	cardiovascular	events,	in	particular	acute	heart	failure,	myocardial	infarction,	arrhythmia	and	pulmonary	embolism	are	common	throughout	(Corrales-Medina	et	al.,	2011).	In	practice,	it	is	often	difficult	to	determine	the	cause	of	treatment	failure	and	multiple	simultaneous	mechanisms	may	be	implicated	(Aliberti	et	al.,	2014b;	Genne	et	al.,	2003).		
Introduction:	CAP	in	sub-Saharan	Africa	 21	
Rather	than	using	explicit	treatment	failure	criteria,	some	studies	have	simply	used	admission	to	an	intensive	care	unit	(ICU)	as	an	endpoint	to	describe	severe	pneumonia.	However	ICU	admission	practices	vary	widely	between	countries	and	institutions.	Actual	receipt	of	(or	requirement	for)	intensive	respiratory	or	vasopressor	support	is	a	more	objective	marker	of	CAP	severity	that	may	be	more	generalisable	across	settings	(Charles	et	al.,	2008b).		
1.7.4 Clinical	stability	and	related	endpoints	Attainment	of	clinical	stability	was	initially	proposed	as	a	pragmatic	clinical	endpoint	that	could	usefully	guide	management	decisions	in	hospitalised	CAP	patients	such	as	timing	of	switch	from	intravenous	to	oral	antibiotics	and	timing	of	discharge	from	hospital	(Akram	et	al.,	2013;	Mandell	et	al.,	2007;	Niederman	et	al.,	2001).	Several	definitions	of	clinical	stability	have	been	proposed	with	varying	emphasis	on	symptomatic	improvement,	physiological	observations	and	laboratory	parameters	(Table	1.2).	Although	varying	slightly	with	the	definition	used,	median	time	to	clinical	stability	ranges	from	2	to	4	days	and	is	related	to	initial	severity	of	pneumonia,	presence	of	comorbid	illness	and	antimicrobial	regimen	(Halm	et	al.,	1998;	Menendez	
et	al.,	2004a;	Ramirez	et	al.,	1995).	
Several	prospective	validation	studies	have	confirmed	the	prognostic	significance	of	clinical	stability	indicating	that	it	may	be	a	suitable	surrogate	endpoint	in	CAP	trials,	particularly	in	patient	groups	where	the	risk	of	mortality	is	low.	Once	clinical	stability	is	attained,	the	risk	of	in-hospital	mortality	or	deterioration	requiring	intensive	care	input	is	very	low	–	generally	less	than	1%	(Akram	et	al.,	2013;	Aliberti	et	al.,	2013;	Halm	et	al.,	1998).	Although	delayed	attainment	(i.e.	greater	than	3	days)	is	also	associated	with	subsequent	readmission	or	death	(Aliberti	et	al.,	2011).	Patients	discharged	from	hospital	without	attaining	clinical	stability	have	substantially	higher	rates	of	death	or	readmission	(Halm	et	al.,	2002).		
Simple	process	of	care	variables	such	as	time	to	intravenous	to	oral	antimicrobial	switch	have	been	used	to	describe	treatment	response	in	hospitalised	CAP	patients,	but	interpretation	is	hampered	by	marked	regional	and	individual	differences	in	clinical	practice.	Length	of	hospitalisation	similarly	will	vary	with	differences	in	style	of	practice,	as	well	as	with	bed	pressures	and	the	availability	of	social	care	services.	This	limits	its	usefulness	as	an	outcome	to	either	describe	the	severity	of	CAP	or	evaluate	the	effectiveness	of	a	treatment	intervention	(Barlow	et	al.,	2003)	
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l	deter
ioratio
n	withi
n	72	hr
s	of	tre
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,	2013;
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e	(<37
.8°C)	o
n	two	o
ccasion
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blood	p
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l	oral	in
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(Menen
dez	et	a
l.,	2004
a)	
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)	
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receivi
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PaO 2	–	
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	pressu
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l	blood
;	SpO 2	
–	oxyge
n	satur
ations	
by	puls
e	oxim
etry	
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1.7.5 Non-resolving	pneumonia	Non-resolving	(or	non-responding)	pneumonia	is	an	historic	term	that	is	poorly	defined.	Conceptually,	it	refers	to	the	subgroup	of	patients	with	CAP	who	despite	a	prolonged	period	(at	least	10	days)	of	antimicrobial	treatment	have	persistent	symptoms	and/or	radiographic	infiltrates	but	who	are	not	sufficiently	clinically	unstable	to	be	classified	as	early	treatment	failure	or	‘progressive	pneumonia’	(Arancibia	et	al.,	2000;	Low	et	al.,	2005).	It	overlaps	considerably	with	more	modern	definitions	of	late	treatment	failure	or	delayed	clinical	stability.	The	causes	of	non-resolving	pneumonia	include:	drug	resistant	pathogens	(e.g.	penicillin-resistant	S.	
pneumoniae);	pathogens	not	covered	by	empirical	antimicrobial	treatment	(e.g.	M.	
tuberculosis,	Pneumocystis	jirovecii);	infectious	complications	(e.g.	empyema,	endocarditis,	nosocomial	pneumonia);	non-infectious	processes	that	mimic	pneumonia	(e.g.	lung	cancer,	cryptogenic	organising	pneumonia).	Rather	than	an	objective,	reproducible	CAP	endpoint,	the	usefulness	of	term	non-resolving	pneumonia	is	to	describe	a	clinical	phenotype	with	a	recognised,	albeit	broad,	differential	diagnosis	that	prompts	physicians	to	undertake	further	diagnostic	procedures	(Low	et	al.,	2005;	Mandell	et	al.,	2007).		
1.7.6 Defining	severe	CAP	Defining	severe	CAP	in	a	clinically	useful	way	has	proved	to	be	a	major	challenge.	Intuitively,	death	following	an	episode	of	CAP	appears	to	be	a	robust	outcome	and	stratifying	acute	treatments	on	the	basis	of	the	risk	of	mortality	initially	seems	reasonable	(Lim	et	al.,	2009).	However,	since	up	to	half	the	deaths	in	the	first	90	days	following	an	episode	of	CAP	are	not	directly	due	to	pneumonia	–	and	as	such	probably	not	modifiable	by	acute	treatment	choices	(e.g.	parenteral	versus	oral	antibiotics;	combination	versus	monotherapy)	–	the	usefulness	of	this	endpoint	is	lessened	(Mortensen	et	al.,	2002).	Alternative	composite	endpoints	that	encompass	respiratory	failure,	haemodynamic	compromise	as	well	as	the	risk	of	early	death	may	prove	more	suitable	in	this	regard	(Chalmers,	2015;	Kolditz	et	al.,	2015).		
Current	data	describing	outcomes	of	pneumonia	in	sub-Saharan	Africa	are	largely	limited	to	in-hospital	mortality	alone.	Whether	the	risk	of	mortality	is	an	adequate	descriptor	of	severity	to	form	the	basis	for	acute	management	decisions	will	depend	upon	the	predominant	causes	of	death	and	the	extent	to	which	they	are	modifiable	by	targeted	early	interventions.		
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1.8 Prognostication	in	CAP	
1.8.1 Importance	of	prognostication	in	management	The	severity	of	illness	and	mortality	rate	of	CAP	is	highly	varied	ranging	from	a	nearly	asymptomatic,	spontaneously	resolving	infection	to	an	acute	fulminant	illness	complicated	by	respiratory	failure	and	severe	sepsis	with	a	mortality	rate	approaching	50%	(Welte	et	al.,	2012).	Determining	the	severity	of	disease	and	risk	of	adverse	outcome	is	therefore	crucial	to	informing	key	management	decisions	such	as	site	of	care	and	antimicrobial	therapy.	Clinical	judgement	alone	is	not	reliably	predictive	of	CAP	outcome;	physicians	may	both	over-	and	under-estimate	disease	severity	with	the	resulting	consequences	of	unnecessary	hospitalisation	and	broad-spectrum	antimicrobial	treatment	or	inadequate	treatment	and	delayed	admission	to	ICU	(Fine	et	
al.,	1997b;	Neill	et	al.,	1996;	Tang	et	al.,	1993).		
To	support	early	clinical	decisions,	multiple	CAP	severity	assessment	tools	have	been	developed	(Table	1.3).	These	tools,	that	are	all	simply	multivariable	prognostic	models,	combine	demographic,	clinical	and	laboratory	data	to	categorise	the	severity	of	CAP	on	the	basis	of	the	estimated	risk	of	a	specified	adverse	outcome	(e.g.	death,	ICU	admission	etc.)	(Sintes	et	al.,	2014).	In	the	following	section,	I	briefly	describe	the	methodology	used	to	derive	multivariable	prognostic	models	before	reviewing	in	more	detail	some	of	the	more	widely	used	CAP	severity	assessment	tools.			
1.8.2 Prognostic	models:		Derivation,	validation	and	evaluation	The	estimate	of	the	risk	or	probability	of	a	particular	outcome	is	rarely	based	on	a	single	predictor.	Multivariable	prognostic	models	combine	several	risk	factors	to	give	a	more	accurate	estimate	of	the	risk	of	the	outcome	and	have	been	widely	used	in	studies	of	CAP	prognosis	(Moons	et	al.,	2015).	The	process	of	deriving	a	prognostic	model	begins	by	specifying	a	priori	a	set	of	candidate	prognostic	factors	based	on	prior	studies	or	biological	plausibility.	The	aim	is	to	identify	those	factors	independently	associated	with	the	outcome	of	interest	and	then	to	define	the	simplest	(or	most	parsimonious)	model	that	adequately	predicts	the	outcome	of	interest.	Several	different	approaches	to	this	variable	selection	process	have	been	used	(e.g.	backwards	elimination,	forwards	stepwise	selection)	and	no	consensus	exists	on	the	best	method.	Selection	of	predictors	on	the	basis	of	significance	testing	as	is	commonly	performed	tends	to	produce	selection	bias	and	overly	optimistic	estimates	of	the	predictive	capability	of	the	model	as	a	result	of	overfitting	(i.e.	the	model	is	too	closely	adapted	to	the	data).	Many	studies	also	use	a	variable	screening	process	based	on	univariable	analysis	prior	to	deriving	the	multivariable	model	that	may	further	exacerbate	bias	(Royston	et	al.,	2009).	
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External	validation	is	therefore	essential	to	confirm	that	a	prognostic	model	performs	satisfactorily	for	patients	other	than	those	from	whose	data	it	was	derived	(Altman	et	
al.,	2009;	Collins	et	al.,	2015).		
The	two	key	measures	of	a	model’s	prognostic	capability	are	calibration	and	discrimination.	Calibration	refers	to	the	agreement	between	observed	outcomes	and	predictions;	ideally	observed	and	predicted	event	probabilities	should	agree	over	the	whole	range	of	probabilities.	Discrimination	refers	to	the	ability	of	a	prognostic	model	to	distinguish	between	who	will	and	will	not	develop	the	outcome	of	interest.	The	area	under	the	Receiver	Operating	Characteristic	(ROC)	curve	(or	the	equivalent	concordance	(c)	index)	is	the	most	commonly	used	measure	and	equates	to	the	probability	that	model	will	assign	a	higher	probability	of	the	outcome	event	to	patients	that	go	on	to	experience	it	(Altman	et	al.,	2000;	Altman	et	al.,	2009;	Royston	et	al.,	2009;	Steyerberg	et	al.,	2010).	These	measures	of	statistical	validity	do	not,	however,	equate	to	clinical	validity	since	the	requirements	for	calibration	and	discriminative	capability	will	vary	with	the	context	of	practice	(Altman	et	al.,	2000).		
The	usefulness	of	a	prognostic	model	in	clinical	practice	does	not	solely	relate	to	its	accuracy.	The	information	necessary	to	complete	the	model	must	be	readily	available	in	the	clinical	setting	in	which	it	is	to	be	used	(Moons	et	al.,	2009).	For	example,	models	to	direct	acute	patient	care	in	primary	care	settings	cannot	practically	be	reliant	on	laboratory	indices.	Similar	considerations	pertain	in	low-resource	settings	where	laboratory	indices	are	unavailable	or	delayed.		
The	underlying	assumption	in	prognostics	research	is	that	by	providing	an	objective	measure	to	improve	the	accuracy	of	estimates	of	outcome	(e.g.	risk	of	death),	clinicians’	decision-making	is	improved	and	consequently	patient	outcome.	Unfortunately,	this	aspect	of	prognostic	model	evaluation	is	often	lacking,	not	least	for	many	of	the	severity	assessment	tools	derived	for	CAP	(Moons	et	al.,	2009;	Steyerberg	et	al.,	2013).			
1.8.3 Prognostic	factors	in	CAP	Multiple	studies	have	assessed	risk	factors	for	adverse	outcome	in	CAP	and	dozens	of	putative	prognostic	factors	have	been	identified.	The	factors	consistently	identified	with	adverse	outcome	and	therefore	repeatedly	used	in	severity	assessment	tools	included:	advancing	age;	presence	of	comorbid	illness;	raised	respiratory	rate;	hypoxaemia	and	respiratory	failure;	low	blood	pressure;	confusion;	high	or	low	white	cell	count;	raised	urea;	multilobar	or	extensive	chest	radiograph	changes	(Fine	et	al.,	1996;	Lim	et	al.,	2009;	Lim	et	al.,	2000;	Neill	et	al.,	1996).	
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1.8.4 CAP	severity	assessment	tools	
1.8.4.1 Pneumonia	severity	index	Over	the	last	two	decades,	many	different	CAP	severity	assessment	tools	have	been	derived.	However,	only	a	handful	of	these	have	been	adequately	validated	and	fewer	still	are	widely	used	(Table	1.3).	The	Pneumonia	Severity	Index	(PSI)	is	the	archetypal	severity	assessment	tool	that	predicts	the	risk	of	30-day	mortality.	It	was	derived	and	validated	with	data	on	more	than	50,000	CAP	patients	across	a	large	network	of	US	hospitals	(Fine	et	al.,	1997a).	In	a	meta-analysis	of	33	cohorts,	it	had	good	to	excellent	discriminatory	capability	for	the	prediction	of	30-day	mortality	(Table	1.4)	(Chalmers	
et	al.,	2010).	It	is	particularly	good	at	identifying	patients	at	low-risk	of	death.	Several	impact	studies	have	demonstrated	that	by	using	PSI	to	guide	site-of-care	decisions,	the	proportion	of	patients	treated	in	the	community	can	be	safely	increased	(Aujesky	et	al.,	2008).	With	20	parameters,	however,	the	score	is	relatively	complex	to	calculate	and	difficult	to	use	in	a	busy	emergency	departments	(Lee	et	al.,	2007).	The	PSI	performs	less	well	at	predicting	ICU	admission	or	the	need	for	respiratory	or	vasopressor	support	(Chalmers	et	al.,	2011a).	Since	it	is	heavily	weighted	by	the	presence	of	age	and	comorbid	illness,	elderly	patients	tend	to	be	assigned	to	higher	risk	classes,	but	many	may	not	be	considered	for	ICU	care	(Sintes	et	al.,	2014).	Some	authors	have	suggested	PSI	underestimates	disease	severity	in	younger	patients	(Buising,	2008).		
1.8.4.2 CURB65	The	CURB65	score	was	also	developed	to	predict	30-day	mortality	(Lim	et	al.,	2003).	Despite	being	considerably	simpler	and	more	easily	remembered	than	the	PSI	-	being	composed	of	only	5	parameters	-	it	has	overall	comparable	prognostic	capability,	although	PSI	may	better	at	identifying	low-risk	patients	(Chalmers	et	al.,	2010)	(Table	1.4).	It	has	been	adopted	internationally,	and	is	incorporated	into	international	CAP	guidelines	for	severity	assessment	and,	by	extension,	a	basis	for	selecting	antimicrobial	therapy	(see	below)	(Lim	et	al.,	2009).	Use	of	CURB65	may	decrease	the	use	of	broad-spectrum	antimicrobials	without	compromising	safety	(Chalmers	et	al.,	2011b).	The	related	CRB65	score,	in	which	the	requirement	to	measure	urea	is	removed,	performs	comparably	and	may	be	used	to	assess	CAP	severity	in	primary	care	settings.	A	low	CURB65	does	not	necessarily	equate	to	suitability	for	community	management;	additional	severity	indicators	(e.g.	multilobar	consolidation,	acidosis)	or	social	circumstances	may	mandate	hospitalisation	(Choudhury	et	al.,	2011).	CURB65	notably	does	not	include	a	direct	assessment	of	oxygenation;	the	presence	of	hypoxaemia	amongst	patients	with	mild	pneumonia	as	defined	by	CURB65	is	associated	with	adverse	outcome	(Sanz	et	al.,	2011).	As	for	the	PSI,	CURB65	performs	less	well	in	
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predicting	ICU	admission	or	the	need	for	respiratory	or	vasopressor	support	(Chalmers	
et	al.,	2011a).		
Table	1.4	 Prognostic	performance	of	CAP	severity	assessment	tools	for	
mortality,	intensive	care	unit	(ICU)	admission,	mechanical	
ventilation/vasopressor	support	(MV/VS)	and	clinical	stability.	Performance	summarised	as	discriminative	capability	using	area	under	ROC	curve.	When	available,	result	of	meta-analysis	used	(indicated	by	*),	otherwise	range	of	reported	values	given.	
Score	
30-day	
mortality	
ICU	admission	 MV/VS	 Clinical	stability	PSI	 0.81*	 0.69*	 0.69-0.73	 0.65	CURB65	 0.80*	 0.69*	 0.62-0.73	 0.65	CRB65	 0.79*	 0.57-0.77	 0.71	 -	IDSA/ATS	2007	 0.78-0.88	 0.80-0.88	 0.85	 -	SMART-COP	 0.71-0.85	 0.72-0.87	 0.83	 -	SCAP	 0.75-0.78	 0.72-0.86	 0.75	 -	Sources:	30-day	mortality,	(Chalmers	et	al.,	2010;	Sintes	et	al.,	2014);	ICU	admission,	(Chalmers	
et	al.,	2011a;	Marti	et	al.,	2012);	MV/VS,	(Chalmers	et	al.,	2011c;	Charles	et	al.,	2008b);	clinical	stability	(Arnold	et	al.,	2010).		
1.8.4.3 Tools	predicting	ICU	requirement	In	recognition	that	the	likelihood	of	death	alone	is	an	inadequate	descriptor	of	the	severity	of	CAP,	a	series	of	alternative	tools	that	predict	ICU	admission	or	the	need	for	invasive	mechanical	respiratory	or	vasopressor	support	have	been	developed.	The	IDSA/ATS	2007	criteria	and	the	SMART-COP	score	are	the	most	widely	used	and	have	been	more	extensively	validated.	 
The	IDSA/ATS	2007	criteria	were	suggested	by	expert	committee	as	reasonable	indices	of	severe	CAP	for	which	ICU	admission	was	indicated	(Mandell	et	al.,	2007).	The	major	criteria	of	use	of	mechanical	ventilation	or	vasopressors	would	routinely	mandate	ICU	admission	and	as	such	are	not	strictly	predictive	of	requirement.	The	definition	of	severe	CAP	as	three	or	more	minor	criteria	has	been	shown	to	be	accurately	predictive	of	ICU	admission	and	requirement	for	respiratory	or	vasopressor	support,	as	well	as	30-day	mortality	(Chalmers	et	al.,	2011c).	Lim	et	al.	used	the	IDSA/ATS	2007	minor	criteria	to	identify	patients	with	severe	CAP	for	aggressive	emergency	department	resuscitation	and	reported	substantial	mortality	reduction	(Lim	et	al.,	2014).		
Recognising	that	ICU	admission	practices	vary	widely,	the	SMART-COP	score	was	specifically	developed	to	predict	requirement	for	intensive	respiratory	or	vasopressor	support	(Charles	et	al.,	2008b).	Validation	studies	indicate	comparable	performance	to	
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the	IDSA/ATS	2007	minor	criteria	for	the	prediction	of	ICU	admission	(Chalmers	et	al.,	2011c),	although	evidence	for	the	clinical	of	use	of	the	score	are	as	yet	lacking	(Sintes	et	
al.,	2014).	SMART-COP	was	derived	in	non-tropical	Australia.	A	single	study	showed	it	to	have	comparable	prognostic	accuracy	in	a	tropical	population	with	a	lower	average	patient	age	and	different	spectrum	of	causative	pathogens	(Robins-Browne	et	al.,	2012).	
1.8.5 Severity	assessment	tools	for	use	in	sub-Saharan	Africa	The	widely	used	CAP	severity	assessment	scores	were	universally	developed	in	well-resourced	settings	and	routinely	excluded	immunosuppressed	patients.	In	small	studies	from	well-resourced	settings,	PSI	and	CURB65	remain	reasonably	predictive	of	CAP	outcome	in	HIV-positive	patients	and	may	appropriately	guide	assessment	and	treatment	of	patients	with	CD4	cell	counts	of	at	least	200	cells/μL	(Almeida	et	al.,	2015;	Chew	et	al.,	2011;	Curran	et	al.,	2008;	Madeddu	et	al.,	2010).	Data	on	the	use	of	severity	assessment	tools	in	sub-Saharan	Africa	are	limited.	In	small	cohort	of	patients	from	Nigeria,	Mbata	et	al.	described	comparable	performance	of	CURB65	in	terms	of	sensitivity	and	specificity	to	that	previously	described	in	other	settings,	but	did	not	provide	an	overall	estimate	of	the	tests	discriminative	capability	(Mbata	et	al.,	2013).	Another	study	from	Ethiopia	described	increasing	mortality	rates	amongst	hospitalised	patients	with	CAP	with	increasing	CURB65	score	but	did	not	provide	any	further	analysis	(Ahmedtaha	et	al.,	2014).	In	a	large	well-characterised	cohort	of	patients	from	South	Africa,	Albrich	et	al.	found	no	correlation	of	CURB65	with	in-hospital	mortality	in	either	all	CAP	patients	or	those	with	confirmed	pneumococcal	pneumonia	(Albrich	et	
al.,	2014a).		
In	a	cohort	of	patients	with	clinically-defined	pneumonia	from	Malawi,	of	whom	80%	were	known	to	be	HIV-positive,	Birkhamshaw	et	al.	reported	that	a	novel	severity	score	based	on	the	presence	of	male	sex,	wasting,	inability	to	stand,	pyrexia/hypothermia	and	low	blood	pressure	outperformed	CRB65	in	predicting	in-hospital	mortality	had	moderate	discriminative	capability	(AUROC	0.87	vs.	0.65)	(Birkhamshaw	et	al.,	2013).	In	a	cohort	of	HIV-infected	patients	with	cough	for	greater	than	two	weeks	and	clinically	suspected	pneumonia,	Koss	et	al.	suggested	an	alternative	severity	assessment	tool	based	on	tachycardia,	tachypnoea,	hypoxaemia	and	low	CD4	count	(Koss	et	al.,	2015).	Neither	of	these	novel	tools	has	been	adequately	validated.		
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1.9 Antimicrobial	management	of	CAP	
1.9.1 Principles	of	antimicrobial	selection	Antimicrobial	therapy	is	fundamental	to	the	management	of	CAP.	(Lim	et	al.,	2009).	Antimicrobial	selection	in	CAP	is	usually	empirical	since	at	the	point	of	initial	assessment	the	pathogen	is	rarely	known	and	clinical	features	are	not	reliably	predictive	of	specific	pathogens.	Given	the	diverse	array	of	possible	pathogens,	selection	of	appropriate	antibiotics	is	challenging.	The	need	to	give	antimicrobial	cover	for	the	majority	of	potential	pathogens	must	be	weighed	against	the	consequences	of	unnecessary	use	of	broad-spectrum	agents	(e.g.	Clostridium	difficile-associated	diarrhoea,	antimicrobial	resistance).		
CAP	management	guidelines	(summarised	in	Table	1.5)	recommend	that	empirical	antimicrobial	treatment	be	selected	on	the	basis	of	disease	severity	and/or	site	of	care.	Whilst	S.	pneumoniae	is	the	commonest	cause	of	pneumonia	across	all	severity	groups,	
Staphylococcus	aureus,	Legionella	species	and	Enterobacteriaceae	are	over-represented	in	the	most	severely	unwell	patients.			
1.9.2 Antimicrobial	classes	used	in	treatment	of	CAP	
1.9.2.1 Penicillins	and	β-lactam	antibiotics	Penicillins	and	other	β-lactam	antibiotics	remain	the	backbone	of	the	treatment	of	CAP	of	all	severities	in	most	regions	of	the	world.	They	have	excellent	activity	against	S.	
pneumoniae	but	are	not	active	against	atypical	bacteria	(i.e.	Legionella	spp.,	
Chlamydophila	spp.,	Mycoplasma	pneumoniae).	Amoxicillin	is	the	preferred	oral	agent	because	of	its	good	oral	bioavailability	and	favourable	side	effect	profile.	Reduced	in	
vitro	susceptibility	to	β-lactams	is	widespread	in	S.	pneumoniae	isolates	and	very	common	in	several	global	regions	including	sub-Saharan	Africa	(Ginsburg	et	al.,	2013;	Hackel	et	al.,	2013).	However,	in	non-meningeal	infections,	the	clinical	impact	of	reduced	β-lactam	susceptibility	is	minimal	providing	adequate	doses	are	used	(Jinno	et	
al.,	2012).	The	increasing	prevalence	of	Haemophilus	influenzae	isolates	that	are	resistant	to	β-lactams	may	pose	greater	problems	and	needs	to	be	monitored	(Ginsburg	
et	al.,	2013;	Tristram	et	al.,	2007).	
1.9.2.2 Fluoroquinolones	Fluoroquinolones	have	a	broad	spectrum	of	antimicrobial	activity	against	bacteria	that	commonly	cause	CAP	including	atypical	pathogens	and	some	Enterobacteriaceae.	Concerns	over	the	lack	of	anti-pneumococcal	activity	of	older	fluoroquinolones	such	as	ciprofloxacin	have	largely	been	allayed	with	newer	agents	–	the	so-called	respiratory	
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fluoroquinolones	(i.e.	moxifloxacin,	levofloxacin,	gemifloxacin)	–	that	are	highly	active	against	S.	pneumoniae	including	isolates	that	are	resistant	to	multiple	other	classes	of	antimicrobial	(Peterson	et	al.,	2009).	They	have	excellent	oral	bioavailability	and	tissue	penetration	(Erard	et	al.,	2004;	Pletz	et	al.,	2011;	Yuan	et	al.,	2012).	Concerns	over	their	propensity	to	promote	Clostridium	difficile-associated	diarrhoea	and	the	potential	ecological	impact	of	their	widespread	use	on	the	emergence	of	antimicrobial	resistance	has	seen	them	relegated	to	second	line	agents	in	UK,	European	and	South	African	CAP	guidelines	(Feldman	et	al.,	2007a;	Hoffken	et	al.,	2010;	Lim	et	al.,	2009;	Spindler	et	al.,	2012;	Woodhead	et	al.,	2011)	
1.9.2.3 Macrolides	Macrolide	antibiotics	-	notably	azithromycin,	clarithromycin	and	erythromycin	-	are	widely	used	for	the	treatment	of	CAP.	They	act	by	inhibiting	bacterial	protein	synthesis	and	offer	broad-spectrum	cover	against	Gram-positive	and	atypical	bacteria	and	have	reasonable	oral	bioavailability	(Restrepo	et	al.,	2016).	In	addition	to	their	direct	antimicrobial	effect,	macrolides	exert	a	broad	array	of	immunomodulatory	and	anti-inflammatory	effects	that	may	contribute	to	their	clinical	efficacy	in	treating	CAP	(Kovaleva	et	al.,	2012;	Lorenzo	et	al.,	2015).	Safety	concerns	have	been	raised	recently	following	registry	data	studies	that	have	identified	an	apparent	excess	of	cardiovascular-related	deaths	following	the	use	of	azithromycin	and	clarithromycin	(Cheng	et	al.,	2015;	Ray	et	al.,	2012;	Wong	et	al.,	2016).	In	vitro	resistance	to	macrolide	in	both	S.	pneumoniae	and	Mycoplasma	pneumoniae	is	increasing	but	the	clinical	impact	is	not	clear	(Cilloniz	et	al.,	2015;	Jenkins	et	al.,	2009;	Principi	et	al.,	2013).
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1.9.3 Antimicrobial	therapy	by	CAP	severity	
1.9.3.1 Mild	severity	CAP	US	guidelines	diverge	from	those	from	other	regions	by	mandating	the	coverage	of	atypical	pathogens	in	all	patients	with	mild	pneumonia.	Macrolides	are	recommended	as	first	line	agents	and	fluoroquinolones	for	patients	with	comorbid	illness	or	recent	antimicrobial	use	(Mandell	et	al.,	2007).	Amoxicillin	is	the	preferred	first	line	agent	in	most	guidelines	with	other	antimicrobial	classes	reserved	for	patients	that	fail	to	respond.		
1.9.3.2 Moderate	severity	CAP	The	key	questions	of	whether	antimicrobial	coverage	for	atypical	bacterial	infection	is	required	for	all	hospitalised	patients	and,	if	so,	whether	a	macrolide-	or	fluoroquinolone-based	regimen	is	optimal	continue	to	be	hotly	debated	(An	et	al.,	2010;	File	et	al.,	1997;	Lee	et	al.,	2015;	Querol-Ribelles	et	al.,	2005;	Raz-Pasteur	et	al.,	2015;	Vardakas	et	al.,	2008;	Yuan	et	al.,	2012).	Meta-analyses	largely	based	on	observational	studies	have	yielded	contrasting	results.	Eliakim-Raz	et	al.	found	no	improvement	in	survival	or	clinical	success	with	the	use	of	atypical	bacterial	coverage	(Eliakim-Raz	et	
al.,	2012),	whilst	Nie	et	al.	found	that	macrolide	combination	was	associated	with	reduced	mortality	compared	to	β-lactam	use	alone	(Nie	et	al.,	2014).	Similarly,	Asadi	et	
al	found	that	macrolide	exposure	was	associated	with	a	reduced	mortality,	but	this	benefit	disappeared	when	the	analysis	was	restricted	studies	comparing	macrolides	against	other	guideline	concordant	regimens	(Asadi	et	al.,	2012).	Two	recent	multi-centre	randomised-controlled	trials	of	hospitalised	non-ICU	patients	designed	to	definitively	address	the	issue	of	macrolide	combination	treatment	yielded	contrasting	results:	one	indicated	that	β-lactam	monotherapy	was	non-inferior	to	β-lactam-macrolide	combination	in	terms	of	risk	of	90-day	mortality	(Postma	et	al.,	2015),	whilst	the	other	failed	to	demonstrate	non-inferiority	of	β-lactam	monotherapy	clinical	stability	at	7	days	(Garin	et	al.,	2014).		
In	the	absence	of	definitive	results,	antimicrobial	choices	are	based	on	local	epidemiological	considerations	(Gattarello,	2015;	Lee	et	al.,	2016).	High	rates	of	macrolide	resistance	in	S.	pneumoniae	isolates	lead	US	CAP	guidelines	to	recommend	fluoroquinolone	monotherapy	as	first	choice	(Mandell	et	al.,	2007).	In	other	regions,	fluoroquinolones	are	reserved	as	second	line	agents	because	of	concerns	over	their	propensity	to	promote	Clostridium	difficile-associated	diarrhoea	and	drive	antimicrobial	resistance	(Feldman	et	al.,	2007a;	Hoffken	et	al.,	2010;	Lim	et	al.,	2009;	Spindler	et	al.,	2012;	Woodhead	et	al.,	2011).	
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1.9.3.3 Severe	CAP	In	severe	CAP,	all	major	current	guidelines	recommend	combination	therapy	with	a	β-lactam	plus	either	a	macrolide	or	fluoroquinolone.	β-lactamase	stable	penicillins	(e.g.	co-amoxiclav)	or	3rd	generation	cephalosporins	(e.g.	ceftriaxone,	cefotaxime)	are	recommended	to	provide	additional	antimicrobial	cover	for	S.	aureus,	Enterobacteriaceae	and	β-lactamase	producing	Haemophilus	influenzae.	European,	US	German	and	Brazilian	guidelines	advocate	the	choice	of	β-lactam	in	severe	CAP	is	modified	on	the	basis	of	the	risk	of	infection	with	Pseudomonas	(Hoffken	et	al.,	2010;	Woodhead	et	al.,	2011).	
Observational	studies	and	a	recent	meta-analysis	indicate	that	the	use	of	macrolides	confers	a	survival	benefit	(Martin-Loeches	et	al.,	2010;	Restrepo	et	al.,	2009)	(Gattarello	et	al.,	2014;	Gattarello	et	al.,	2015;	Metersky	et	al.,	2007)	particularly	in	bacteraemic	pneumococcal	CAP	(Sligl	et	al.,	2014;	Waterer	et	al.,	2001b).	The	beneficial	effects	of	macrolides	remain	evident	in	patients	with	disease	caused	by	organisms	resistant	to	macrolides	indicating	the	potential	importance	of	an	anti-inflammatory	or	immunomodulatory	role	(Giamarellos-Bourboulis,	2008;	Lorenzo	et	al.,	2015;	Martin-Loeches	et	al.,	2010).	
1.9.4 Antimicrobial	considerations	in	sub-Saharan	Africa	In	any	setting,	CAP	is	a	very	common	indication	for	antimicrobial	use	and	the	implications	of	treatment	recommendations	in	terms	of	their	cost	and	ecological	impact	need	to	be	carefully	assessed.	In	resourced-limited	settings,	both	the	cost	of	the	drug	and	the	broader	implications	of	the	treatment	regimen	in	terms	of	the	impact	of	dosing	frequency	on	nursing	time	should	be	considered.	In	the	absence	of	robust	laboratory	infrastructure,	the	development	of	antimicrobial	resistance	may	go	unnoticed	until	widespread	treatment	failures	occur.	Unrestricted	antimicrobial	use	in	low-resource	settings	is	a	major	driver	in	the	global	emergence	and	spread	of	drug	resistant	bacteria	(Kariuki	et	al.,	2014;	Leopold	et	al.,	2014).	For	example,	macrolide	resistant	S.	
pneumoniae	isolates	have	emerged	and	rapidly	spread	in	South	Africa	(Wolter	et	al.,	2008).	The	widespread	use	of	azithromycin	for	trachoma	control	may	accelerate	spread	in	other	areas	of	the	continent	(Coles	et	al.,	2013).	Fluoroquinolones	have	potent	anti-tuberculous	activity	and	in	high	TB-burden	settings	empirical	use	of	fluoroquinolones	may	lead	to	delayed	diagnosis	of	pulmonary	TB	and	a	higher	risk	of	subsequently	developing	fluoroquinolone-resistant	TB	(Chang	et	al.,	2010;	Chen	et	al.,	2011).		
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In	severe	CAP,	treatment	guidelines	from	well-resourced	settings	advocate	initial	broad-spectrum	antimicrobials	to	cover	all	of	the	probable	pathogens	and	in	tandem	extended	microbiological	investigations	to	increase	the	chance	that	aetiology	is	established	and	the	antimicrobial	spectrum	may	be	narrowed	(Lim	et	al.,	2009).	This	approach	cannot	be	replicated	in	many	sub-Saharan	African	settings	where	microbiological	diagnostics	are	lacking,	hence	treatment	modifications	often	have	to	be	made	on	the	basis	of	clinical	response.	In	addition,	given	the	high	burden	of	TB	and	other	HIV-associated	opportunistic	infections,	broad	empirical	treatment	would	have	to	include	anti-tuberculous	treatment	and	cover	for	PCP.	A	step-up	approach	is	generally	used	in	deteriorating	patients	(World	Health	Organization,	2011c),	but	the	optimal	clinical	indicators	and	the	consequences	of	delayed	adequate	treatment	are	unknown.		
1.10 Supportive	management	of	CAP	Pneumonia	is	frequently	complicated	by	respiratory	failure	and	severe	sepsis	(Aliberti	
et	al.,	2014a).	Successful	management	of	severe	CAP	requires	not	only	effective	antimicrobial	therapy	to	remove	the	causal	pathogen,	but	supportive	care	to	maintain	adequate	tissue	perfusion	and	oxygenation.		
1.10.1 Managing	respiratory	failure	Hypoxaemia	is	common	feature	of	severe	CAP	and	is	independently	associated	with	increased	mortality	(Fine	et	al.,	1996;	Lim	et	al.,	2003).	Although	an	established	core	component	of	CAP	management,	there	is	little	empirical	data	that	directly	defines	the	indications	for	and	therapeutic	benefit	of	supplemental	oxygen	(Lim	et	al.,	2009;	Mandell	et	al.,	2007;	O'Driscoll	et	al.,	2008;	Wijesinghe	et	al.,	2012).	Hypoxaemia	is	generally	defined	as	oxygen	saturations	(SpO2)	<90%	(approximately	equivalent	to	arterial	oxygen	tension	of	60mmHg)	since	there	is	no	known	risk	of	hypoxic	tissue	injury	above	this	level	(Bowton	et	al.,	1994;	O'Driscoll	et	al.,	2008).	British	CAP	guidelines	advise	that	SpO2	should	be	maintained	within	a	target	range	of	94-98%	to	give	a	wide	margin	of	safety	above	the	90%	threshold.	In	resource-limited	settings,	where	supplemental	oxygen	provision	is	scare,	it	is	usually	reserved	for	patients	with	SpO2	<90%	(World	Health	Organization,	2011a).	Potential	adverse	consequences	of	excessive	oxygen	administration	are	increasingly	being	recognised	(Martin	et	al.,	2013).	Amongst	vulnerable	patients	such	as	those	with	advanced	COPD,	chest	wall	deformities	or	neuromuscular	disease,	excessive	oxygen	administration	exacerbates	V/Q	mismatch	and	reduces	ventilatory	drive,	resulting	in	hypercapnic	respiratory	failure	(O'Driscoll	et	al.,	2008).	Hyperoxaemia	itself	is	associated	with	increased	
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peripheral	vascular	resistance,	reduced	coronary	blood	flow	generation	of	reactive-oxygen	species	(e.g.	hydrogen	peroxide)	that	may	cause	direct	cellular	damage	(Martin	
et	al.,	2013).	
Around	25%	of	hospitalised	CAP	patients	develop	acute	hypoxaemic	respiratory	failure	and	approximately	10%	require	intubation	and	mechanical	ventilation	(Chalmers	et	al.,	2011a;	Charles	et	al.,	2008b;	Fine	et	al.,	1997a;	Lim	et	al.,	2000).	To	avoid	the	complications	associated	with	invasive	mechanical	ventilation	(i.e.	ventilator-associated	pneumonia,	ventilator-induced	lung	injury),	non-invasive	ventilation	(NIV)	techniques	are	increasingly	used	in	patients	with	respiratory	failure	(Ferrer	et	al.,	2015).	However,	in	contrast	to	other	causes	of	acute	respiratory	failure	such	as	acute	pulmonary	oedema	and	COPD	exacerbations,	NIV	has	not	been	consistently	beneficial	in	CAP.	Whilst	small	early	randomised	trials	showed	that	NIV	reduced	rates	of	intubation	and	duration	of	ICU	stay	(Confalonieri	et	al.,	1999),	subsequent	larger	observational	cohorts	indicate	that	NIV	fails	in	up	to	75%	(Carron	et	al.,	2010;	Murad	et	
al.,	2015).	The	benefit	of	NIV	in	CAP	is	largely	restricted	to	patients	with	underlying	cardiorespiratory	disease,	particularly	COPD,	and	immunosuppressed	patients	(Antonelli	et	al.,	2000;	Hilbert	et	al.,	2001).	NIV	should	be	used	very	cautiously	in	other	CAP	patients	since	delays	in	intubation	for	mechanical	ventilation	are	associated	with	increased	mortality	(Ferrer	et	al.,	2012;	Hraiech	et	al.,	2013).	Failure	to	improve	after	one	hour	of	NIV	is	predictive	of	subsequent	mortality	(Carrillo	et	al.,	2012;	Nicolini	et	
al.,	2016).		
1.10.2 Fluid	resuscitation	Respiratory	tract	infections,	particularly	pneumonia,	are	the	leading	cause	of	severe	sepsis.	Around	20-30%	of	hospitalised	CAP	patients	will	develop	severe	sepsis,	of	whom	around	a	quarter	will	die	(Aliberti	et	al.,	2014a;	Kellum	et	al.,	2007).	Adequate	fluid	resuscitation	to	correct	sepsis-induced	hypoperfusion	and	ameliorate	tissue	injury	is	central	to	effective	management	(Dellinger	et	al.,	2013).	Protocolised	fluid	resuscitation	to	achieve	specific	haemodynamic	targets	and/or	normalisation	of	plasma	lactate	-	termed	early	goal-directed	therapy	-	has	been	shown	to	improve	survival	(Rivers	et	al.,	2001).	Recent	randomised	controlled	trials	of	early	sepsis	have	called	into	question	the	additive	benefit	of	invasive	monitoring	following	adequate	initial	fluid	volume	resuscitation	(Mouncey	et	al.,	2015;	Peake	et	al.,	2014;	Yealy	et	al.,	2014).	The	direct	applicability	of	these	findings	to	sub-Saharan	Africa	setting	where	critical	care	facilities	are	not	available	is	uncertain.	The	FEAST	trial	of	fluid	resuscitation	strategies	in	children	with	severe	febrile	illness	found	higher	mortality	in	those	treated	with	aggressive	fluid	management	(Maitland	et	al.,	2012).	Similarly,	a	small	study	from	
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Zambia	of	a	simplified	early	goal-directed	therapy	protocol	for	adult	sepsis	was	stopped	early	because	of	high	overall	mortality	(Andrews	et	al.,	2014).		
1.11 Study	setting	
1.11.1 Malawi:	Country	background	Malawi	is	a	tropical,	landlocked	country	in	south-eastern	Africa	occupying	a	thin	strip	of	land	between	Zambia	and	Mozambique.	It	is	one	of	the	world’s	poorest	countries	with	a	per	capita	gross	domestic	product	(GDP)	of	only	$226	that,	in	contrast	to	the	rest	of	the	region	has	fallen	over	the	last	four	years.	Total	health	expenditure	is	8.3%	of	GDP,	equating	to	approximately	$19	per	person	per	annum	(World	Bank,	2015).		
It	is	one	of	sub-Saharan	Africa’s	most	densely	populated	countries	with	an	estimated	current	population	of	15.9	million	and	annual	growth	rate	of	2.8%;	45.3%	of	the	population	are	aged	less	than	15	years	(United	Nations	Statistics	Division,	2014).	Life	expectancy	at	birth	has	improved	considerably	over	the	last	decade;	from	a	nadir	of	46	in	2000	to	its	a	current	level	of	now	55	(United	Nations	Statistics	Division,	2014;	World	Bank,	2015).	On	the	United	Nations	human	development	index,	Malawi	is	ranked	174	of	the	187	countries	for	which	data	were	available	(United	Nations	Development	Programme,	2014).		
There	is	a	generalised	HIV	epidemic.	At	its	peak	in	1999,	HIV	prevalence	amongst	adults	aged	15-49	was	16.6%.	This	declined	steadily	to	10.3%	in	2013;	currently	there	are	approximately	1	million	people	living	with	HIV	in	Malawi.	National	ART	scale-up	began	in	2004	and	as	of	December	2013,	there	were	approximately	500,000	people	alive	on	ART	with	an	estimated	coverage	of	83%	of	eligible	individuals	(Government	of	Malawi,	2014;	Harries	et	al.,	2011).	
1.11.2 Queen	Elizabeth	Central	Hospital	Government-funded	healthcare	in	Malawi	is	delivered	via	a	three-tiered	system	consisting	of	community	health	centres,	district	hospitals	and	regional	central	hospitals.	Queen	Elizabeth	Central	Hospital	is	the	largest	hospital	in	Malawi	with	approximately	1200	beds	and	acts	as	a	district	level	facility	for	Blantyre	and	surrounding	areas	(population	approximately	1.2	million)	and	a	referral	facility	for	the	entire	Southern	Region.			
Patients	referred	to	QECH	are	initialled	assessed	in	the	Adult	Emergency	and	Trauma	Centre	(AETC)	by	a	clinical	officer	(non-physician	clinician	licensed	to	practice	independently	following	completion	of	3-year	diploma	course)	or	doctor;	those	
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requiring	medical	admission	are	initially	seen	by	the	medical	intern	or	registrar	and	then	generally	reviewed	by	a	consultant	within	24	hours.	Following	admission,	patients	are	seen	twice	weekly	on	consultant	ward	rounds	and	then	variably	at	other	times	by	interns,	clinical	officers	or	medical	students	depending	on	the	availability	of	staff.		
The	Department	of	Medicine	consists	of	two	single-sex	general	medical	wards	each	with	approximately	60	beds	and	a	mixed-sex	TB	ward	of	similar	size.	The	bed	capacity	on	the	general	wards	is	frequently	exceeded,	with	patient	numbers	of	greater	than	100	on	each	ward	not	uncommon;	when	there	are	insufficient	beds,	patients	are	accommodated	on	mattresses	on	the	floor.	Each	ward	also	has	a	6-bedded	high	dependency	unit	(HDU)	that	is	equipped	with	oxygen	concentrators	for	supplementary	oxygen	delivery.	
Each	ward	is	staffed	by	two	or	three	trained	nurses	supported	by	a	variable	number	of	student	nurses;	the	nursing	complement	does	not	alter	regardless	of	the	patient	load.	Most	personal	care	including	feeding,	washing	and	toileting	is	administered	by	a	‘guardian’	-	a	close	relative	or	friend	that	remains	with	the	patient	during	their	hospitalisation.	Nurses	generally	prioritise	drug	administration	and	performing	phlebotomy	for	investigations;	daily	measurement	of	physiological	observations	is	not	routine	outside	the	HDUs.		
Medical	care	at	QECH	is	provided	in	accordance	with	Malawi	national	treatment	guidelines,	but	is	frequently	hampered	by	stockouts	of	essential	medicines	such	as	antibiotics,	diuretics	and	insulin.	Supplemental	oxygen	is	available	for	only	approximately	one-third	of	hypoxic	patients	(Evans	et	al.,	2012).	The	available	laboratory	facilities	support	basic	haematological	and	biochemical	investigations	and	smear	microscopy	and	latterly	Xpert	MTB/RIF	for	diagnosis	of	tuberculosis,	but	similarly	are	often	disrupted	by	lack	of	reagents.		
1.11.3 Malawi-Liverpool-Wellcome	Trust	Clinical	Research	Programme		The	Malawi-Liverpool-Wellcome	Trust	Clinical	Research	Programme	(MLW)	was	established	in	1995	and	is	located	adjacent	to	the	QECH	campus.	Investigators	based	at	MLW	undertake	a	broad	portfolio	of	clinical	and	basic	science	research	with	many	projects	recruiting	patients	from	QECH.	Since	2000	it	has	provided	a	routine	diagnostic	microbiology	service	to	support	clinical	care,	offering	blood	and	cerebrospinal	fluid	culture	(http://www.mlw.medcol.mw/).	
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1.12 Thesis	synopsis	
1.12.1 Aims	and	objectives	The	overall	aim	of	this	PhD	is	to	determine	the	clinical	predictors	of	adverse	outcome	of	CAP	in	Malawian	adults.	The	intended	outputs	are	two	fold:	firstly,	to	improve	triage	assessment	of	CAP;	secondly,	to	identify	modifiable	risk	factors	for	poor	outcome	that	could	be	the	target	for	future	interventional	studies.	The	underlying	main	hypothesis	is	that	epidemiology	and	aetiology	of	CAP	in	Malawi	and	comparable	sub-Saharan	African	settings	is	markedly	different	to	that	seen	in	well-resourced	settings	and	accordingly	that:	clinical	predictors	of	adverse	outcome	are	different;	CAP-severity	assessment	tools	derived	in	well-resourced	settings	(e.g.	CURB65)	fail	to	predict	outcome	accurately;	empirical	therapy	recommendations	from	well-resourced	settings	would	fail	to	provide	adequate	antimicrobial	coverage	for	the	spectrum	of	pathogens	encountered.	
Key	research	questions	to	be	addressed	include:	1. What	are	the	patient	characteristics	and	clinical	features	of	CAP	in	adults	in	sub-Saharan	Africa	in	general	and	in	Malawi	in	particular?		2. What	are	the	common	microbial	causes	of	CAP	in	these	settings?	3. What	clinical	factors	evident	at	presentation	predict	adverse	outcome?	4. Do	CAP-severity	assessment	tools	derived	in	well-resourced	settings	accurately	identify	individuals	at	risk	of	adverse	outcome?	5. Are	there	potentially	modifiable	risk	factors	for	adverse	outcome	that	are	rational	targets	for	therapeutic	interventions	to	improve	CAP	outcome?	
This	thesis	sets	out	to	address	these	questions	in	the	following	studies:	
1. A	prospective	observational	study	of	adults	hospitalised	with	CAP	to	Queen	Elizabeth	Central	Hospital	called	the	Malawian	Lower	Respiratory	Tract	Infection,	Severity,	Aetiology	and	Outcome	(MARISO)	Study.	The	key	objectives	were:		a. To	determine	the	frequency	of	30-day	mortality	and	treatment	failure	in	adults	hospitalised	with	clinically	diagnosed	CAP;	b. To	identify	the	clinical	and	basic	diagnostic	laboratory	characteristics	associated	with	30-day	mortality	and	treatment	failure;	c. To	describe	the	microbial	aetiology	using	modern	diagnostic	modalities.		
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2. To	set	the	results	of	the	MARISO	study	in	a	broader	regional	context,	a	systematic	review	of	CAP	in	adults	in	sub-Saharan	Africa	was	completed.	The	key	objectives	were:		a. To	describe	aetiology;	b. To	estimate	mortality	rate;		c. To	identify	risk	factors	associated	with	death.		3. An	interim	analysis	of	the	MARISO	cohort	showed	that	hypoxaemia	was	predictive	of	mortality.	I	therefore	undertook	a	further	study	(Addressing	Hypoxaemia	in	adult	Pneumonia	(AHIP)	study)	to	assess	the	effectiveness	of	supplemental	oxygen	delivery	by	oxygen	concentrator	to	correct	hypoxaemia	in	CAP	patients	in	this	setting.	The	key	objectives	were:		a. To	determine	the	proportion	of	adults	hospitalised	with	CAP	that	are	hypoxaemic	at	presentation	that	attain	normoxaemia	with	supplemental	oxygen	delivered	by	concentrator	at	a	standard	flow-rate	of	5	L/min.		b. To	determine	what	proportion	of	those	who	fail	to	attain	normoxaemia	at	a	rate	of	5	L/min,	attain	normoxaemia	at	a	high	flow-rate	of	10	L/min.	
1.12.2 Thesis	overview	The	systematic	review	of	CAP	in	sub-Saharan	Africa	is	presented	in	chapter	2.	The	detailed	methods	of	the	MARISO	study	are	described	in	chapter	3	with	the	results	presented	in	the	two	following	chapters.	In	chapter	4,	I	describe	the	baseline	characteristics,	radiological	features	and	aetiology	of	the	MARISO	cohort.	In	chapter	5,	I	describe	the	clinical	outcomes	in	terms	mortality,	treatment	failure	and	clinical	stability	and	present	the	results	of	multivariable	analyses	examining	risk	factors	for	adverse	outcome.	The	background,	methods	and	results	of	the	AHIP	study	are	presented	in	chapter	6.	In	the	final	chapter	I	discuss	the	preceding	results	in	light	of	recent	data	from	other	settings	to	suggest	how	outcomes	from	CAP	in	Malawi	and	other	comparable	settings	may	be	improved	and	outline	the	immediate	research	priorities	in	this	area.		
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2 Aetiology	and	outcome	of	community-acquired	pneumonia	
in	adults	in	sub-Saharan	Africa:	A	systematic	review	
2.1 Introduction	Pneumonia	is	the	commonest	cause	of	infectious	disease-related	death	globally	(Lopez	
et	al.,	2006).	The	burden	of	disease	in	African	adults	is	high,	particularly	in	sub-Saharan	Africa	where	pneumonia	is	the	among	the	commonest	reason	for	adult	hospitalisation	(SanJoaquin	et	al.,	2013)	and	the	cause	of	200,000	deaths	each	year	(Scott	et	al.,	2012).	Effective	management	of	community-acquired	pneumonia	(CAP)	requires	accurate	assessment	of	disease	severity	followed	by	prompt	initiation	of	appropriate	empirical	antimicrobials.	The	former	aspect	requires	awareness	of	key	prognostic	factors	that	independently	predict	outcome	and	the	latter	knowledge	of	the	likely	causal	pathogens	based	on	local	epidemiology	(Lim	et	al.,	2009;	Mandell	et	al.,	2007).	To	date,	neither	aspect	has	been	systematically	reviewed	in	CAP	cohorts	from	sub-Saharan	Africa.		
Severity	assessment	of	CAP	is	challenging	since	mortality	rates	for	CAP	vary	markedly	with	the	population	studied	(Welte	et	al.,	2012).	In	well-resourced	settings,	CAP	outcomes	have	been	studied	extensively	and	the	main	risk	factors	for	adverse	outcome	defined	and	often	consolidated	into	readily	usable	clinical	assessment	tools	(Charles	et	
al.,	2008b;	Fine	et	al.,	1996;	Lim	et	al.,	2003;	Welte,	2012).	Outcomes	are	influenced	substantially	by	patient	demographics	and	underlying	comorbidities	(Fine	et	al.,	1997a;	Lim	et	al.,	2003).	Compared	to	well-resourced	settings,	CAP	populations	from	sub-Saharan	Africa	are	likely	to	have	markedly	different	demographic	and	comorbidity	profiles	(Etyang	et	al.,	2013;	Lopez	et	al.,	2006;	Murray	et	al.,	2012).	As	such	the	clinical	factors	predictive	of	mortality	in	well-resourced	settings	may	not	apply	in	CAP	cohorts	in	sub-Saharan	Africa.	
The	aetiology	of	adult	CAP	has	also	been	extensively	studies	in	well-resourced	settings	in	Europe,	North	America,	Asia	and	Australia	and	summarised	in	several	systematic	reviews	(Charles	et	al.,	2008a;	Ewig	et	al.,	2009;	Peto	et	al.,	2014;	Torres	et	al.,	2014;	Welte	et	al.,	2012).	Whilst	most	cases	of	CAP	are	attributable	to	a	relatively	narrow	spectrum	of	pathogens,	these	studies	highlight	significant	regional	variations	in	CAP	aetiology	that	have	important	therapeutic	implications.	In	high	burden	settings,	like	sub-Saharan	Africa	(World	Health	Organization,	2015a),	tuberculosis	(TB)	may	account	for	a	substantial	proportion	of	acute	pneumonic	presentations	(Peto	et	al.,	2014).	CAP	aetiology	in	sub-Saharan	Africa	is	also	likely	to	differ	as	a	result	of	the	impact	of	HIV	
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that	renders	individuals	susceptible	to	opportunistic	pathogens	(e.g.	Pneumocystis	
jirovecii)(Benito	et	al.,	2012).		
In	this	chapter,	I	present	the	methodology	and	results	of	a	systematic	review	summarising	the	published	literature	on	the	aetiology	and	outcome	of	CAP	in	adults	in	sub-Saharan	Africa.	
2.2 Objectives	To	summarise	and	appraise	research	that	reports	the	aetiology	and	outcome	of	CAP	in	adults	in	sub-Saharan	Africa.	Specifically:	to	estimate	the	mortality	rate;	to	identify	risk	factors	associated	with	death	and	to	quantify	the	strength	of	association;	and	to	summarise	the	aetiology.		
2.3 Contributors	to	this	chapter	I	devised	the	study,	wrote	the	review	protocol,	reviewed	all	titles,	extracted	all	data	and	performed	the	analyses.	Professor	Charles	Feldman	(University	of	Witwatersrand,	South	Africa)	independently	reviewed	all	titles	and	corroborated	study	selection.	Professor	Paul	Garner	(Liverpool	School	of	Tropical	Medicine,	UK)	advised	on	the	development	of	the	study	methodology	and	analysis.	Victoria	Lutje	(search	strategist)	helped	to	develop	the	search	terms	and	performed	the	database	searches.			
2.4 Methods	The	study	was	conducted	according	to	MOOSE	guidelines	(meta-analysis	of	observational	studies	in	epidemiology)(Stroup	et	al.,	2000).	
2.4.1 Search	strategy	The	search	consisted	of	three	components:	firstly,	a	search	term	for	“pneumonia”	or	“respiratory	tract	infection”;	secondly,	a	geographical	term	listing	all	the	countries	in	sub-Saharan	Africa	along	with	“sub-Saharan	Africa”	and	the	relevant	MeSH	terms	for	Central,	Western,	Eastern	and	Southern	Africa;	and	thirdly,	limits	excluding	non-human	and	child	or	infant	studies.	The	following	electronic	databases	were	searched:	Medline	(via	OVID	from	1st	January	1960);	Embase	(via	OVID	from	1st	January	1960);	Science	Citation	Index	Expanded	and	Conference	Proceedings	Citation	Index	(Web	of	Science);	CINAHL	(EBSCOhost);	CAB	abstracts	and	Global	Health	(CABI,	Web	of	Science);	Scopus;	African	Index	Medicus.	Studies	published	prior	to	1960	were	not	considered	for	inclusion	because	of	the	non-systematic	manner	in	which	data	are	often	presented	in	reports	from	this	era	and	the	lack	of	comparability	of	microbiological	methods	used	to	
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determine	aetiology.	A	full	list	of	the	searches	terms	used	for	each	database	is	included	in	Appendix	A.	No	restrictions	of	language	or	publication	status	were	applied	to	the	electronic	searches.	Non-English	studies	were	translated	using	Google	Translate	(Google	Inc.;	California,	USA;	available	at:	https://translate.google.co.uk).	The	search	results	were	merged	using	citation	management	software	(Endnote	X5,	Thomson	Reuters)	and	duplicate	references	removed.	The	reference	lists	of	included	articles	were	subsequently	hand	searched	for	additional	relevant	articles.		
I	reviewed	all	titles	and	extracted	data	from	all	papers.	A	second	reviewer	(Professor	Charles	Feldman)	independently	reviewed	all	titles	and	corroborated	study	selection.	Disagreements	over	study	eligibility	were	resolved	by	discussion.	
2.4.2 Inclusion	criteria	Studies	that	described	the	mortality	rate	and/or	aetiological	profile	of	CAP	in	adults	(aged	12	years	or	older)	resident	in	any	sub-Saharan	African	country	were	included.	Clinical	trials	and	observational	studies	including	cohort	and	case-control	studies,	and	case	series	of	25	or	more	individuals	were	included.	Additional	abstracts	or	conference	reports	were	included	provided	they	contained	sufficient	detail	to	demonstrate	they	met	the	other	eligibility	criteria.	Multicentre	studies	encompassing	sites	outside	of	Africa	were	only	included	if	the	data	for	patients	recruited	in	Africa	were	presented	separately.	
2.4.3 Exclusion	criteria	Review	articles	and	small	case	series	with	fewer	than	25	participants	were	excluded.	Similarly	for	studies	that	presented	aetiology	or	mortality	data	only	as	subgroups	(e.g.	by	HIV	status),	subgroups	with	fewer	than	25	participants	were	excluded.	Studies	that	were	not	specifically	focused	on	CAP	such	as	surveillance	studies	or	service	improvement	surveys	that	analysed	records	or	patient	registers	were	also	excluded	because	of	possible	lack	of	precision	of	CAP	diagnosis.	Studies	that	did	not	provide	an	adequate	description	of	the	microbiological	techniques	used	to	assign	aetiology	were	excluded	from	the	aetiological	analysis.		
2.4.4 CAP	case-definition	To	produce	a	broad	and	inclusive	review	that	comprehensively	summarised	available	data,	a	precise	CAP	case	definition	was	not	mandated;	studies	were	included	regardless	of	whether	they	used	a	clinical	or	radiological	case	definition	of	CAP.	However	to	ensure	that	the	data	related	to	populations	with	acute	CAP,	studies	that	recruited	patients	with	nosocomial	infection	or	studies	that	selected	patients	for	recruitment	on	
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the	basis	of	prolonged	duration	of	symptoms,	failure	to	improve	with	initial	treatment	or	clinical	suspicion	of	PCP	or	TB	were	excluded.	Studies	describing	the	aetiology	and	outcome	of	severe	acute	respiratory	infection	(SARI)	without	otherwise	specifying	pneumonia	were	also	excluded;	similarly	studies	focusing	on	influenza-like	illness	(ILI)	were	excluded.		
2.4.5 Data	extraction	I	independently	reviewed	each	article	and	extracted	data	using	a	standardised	paper	form	that	was	designed	and	piloted	for	this	review.		Data	extracted	included:	details	of	the	study	size,	design,	population	and	dates	of	completion;	patient	demographics	and	recorded	medical	comorbidities;	definition	of	CAP	used;	physiological	and	laboratory	indices	of	disease	severity;	types	and	results	of	investigations	to	determine	aetiology;	frequency	of	mortality	and	other	relevant	clinical	endpoints.	Data	on	the	risk	of	bias	assessment	of	the	second	reviewer	(Professor	Charles	Feldman)	are	also	presented.	The	template	for	data	extraction	is	shown	in	Appendix	A.		
2.4.6 Risk	of	bias	assessment	In	the	absence	of	a	generally	accepted	tool	for	observational	studies,	criteria	adapted	from	the	Cochrane	Collaboration	Tool	to	Assess	Risk	of	Bias	in	Cohort	Studies	were	used	to	assess	the	risk	of	bias	and	quality	of	studies	included	in	this	review	(Cochrane	Collaboration,	2014)(see	Appendix	A).	The	risk	of	bias	for	each	of	the	three	analyses	–	mortality,	risk	factors	and	aetiology	–	was	considered	separately	for	each	study.	For	the	mortality	analysis,	studies	were	considered	to	have	a	low	risk	of	bias	if	each	of	the	following	criteria	were	satisfied:	a	radiographic	definition	of	CAP	was	used;	patient	recruitment	was	not	restricted	to	specific	groups	defined	by	age,	comorbidity	or	disease	aetiology;	patient	follow-up	was	greater	than	90%.	For	the	mortality	risk	factors	analysis,	studies	were	regarded	to	have	a	low	risk	of	bias	if	the	following	additional	criteria	were	met:	prognostic	factor	data	was	collected	prospectively	using	standardised	methods	and	was	available	in	at	least	90%	of	patients	analysed;	the	extent	of	missing	outcome	data	was	insufficient	to	have	a	clinically-relevant	impact	on	reported	associations;	statistical	analysis	was	performed	according	to	pre-specified	methods	with	all	outcomes	being	reported	and	appropriate	adjustment	made	for	confounding	variables.	For	the	aetiology	analysis,	studies	were	considered	to	have	a	low	risk	of	bias	if	clinical	specimen	collection	was	systematic	and	reasonably	complete	and	the	laboratory	techniques	used	were	adequately	described.		
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2.4.7 Statistical	analysis	For	each	study	demographic	data	was	summarised	as	the	proportion	of	male	patients	and	mean	age	with	standard	deviation.	When	unavailable	mean	age	and/or	standard	deviation	were	estimated	from	the	median,	interquartile	interval	and	range	(Wan	et	al.,	2014).	The	overall	frequency	of	common	comorbid	illnesses	across	all	studies	was	estimated	by	meta-analysis.	Mortality	rates	were	directly	extracted	and	95%	confidence	intervals	calculated.	Estimated	overall	mortality	rates	by	clinical	setting	were	estimated	by	meta-analysis.	When	data	on	specific	potential	prognostic	factors	were	provided	their	association	with	mortality	was	estimated	by	calculating	univariable	odds	ratios	(ORs)	with	95%	confidence	intervals.	Aetiological	data	was	tabulated	with	the	prevalence	of	specific	pathogens	reported	as	proportions.	Weighted	mean	proportions	for	each	main	pathogen	were	calculated	using	data	from	all	studies	and	only	those	with	low	risk	of	bias.	The	inter-observer	variability	of	the	risk	of	bias	assessment	between	the	two	reviewers	was	assessed	by	calculating	percentage	agreement	and	kappa	coefficient	with	estimated	95%	confidence	intervals.		
2.5 Results	
2.5.1 Summary	of	literature	search	The	literature	search	yielded	3546	citations	after	duplicates	were	removed,	of	which	200	were	reviewed	in	full-text	and	44	included	in	the	review	(Figure	2.1).	A	further	26	potentially	relevant	citations	were	identified	through	searching	the	reference	lists	of	the	included	studies;	17	were	reviewed	in	full	and	an	additional	9	included	in	the	review.	The	53	reports	described	47	studies:	39	studies	were	included	in	the	mortality	analysis,	of	which	18	were	also	included	in	the	mortality	risk	factors	analysis;	30	studies	were	included	in	the	aetiology	analysis.		
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Figure	2.1	 Flow	diagram	of	study	selection	for	systematic	review		
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2.5.2 Characteristics	of	included	studies	
2.5.2.1 Distribution	The	47	studies	were	performed	in	15	countries	(Table	2.1).	The	geographical	distribution	across	sub-Saharan	Africa	was	uneven;	studies	from	South	Africa	(12	studies),	Kenya	(6	studies),	Nigeria	(5	studies)	and	Côte	d’Ivoire	(5	studies)	accounted	for	half	of	the	total	included.	Within	countries,	most	studies	were	conducted	in	major	urban	centres.	11	studies	were	completed	prior	to	1990.	A	further	15	were	completed	prior	to	2000.	
2.5.2.2 Design	and	setting	The	majority	of	studies	were	hospital-based,	mainly	recruiting	patients	from	general	ward	or	emergency	department	settings.	Three	studies	restricted	recruitment	to	patients	admitted	to	high	dependency	units	(HDU)	or	intensive	care	units	(ICU)(Feldman	et	al.,	1995;	Hartung	et	al.,	2011;	Potgieter	et	al.,	1992);	only	two	studies	were	community	based	(Gilks	et	al.,	1996;	Mwachari	et	al.,	2006).		
Most	studies	were	prospective	observational	studies	in	design.	The	median	number	of	patients	included	was	100	(interquartile	range:	81-121);	22	studies	included	fewer	than	100	patients	(Table	2.1).	All	studies	combined	included	6184	patients.	
2.5.2.3 Patient	selection	A	pneumonia	case	definition	was	explicitly	stated	in	all	but	10	studies,	but	in	these,	requirement	for	radiographic	confirmation	was	implied.	Only	three	studies	recruited	patients	based	solely	on	a	clinical	case	definition	(Birkhamshaw	et	al.,	2013;	Gordon	et	
al.,	2002;	Harries	et	al.,	1988b).	Other	exclusion	criteria	used	included:	prolonged	symptom	duration	(Albrich	et	al.,	2012;	Fiberesima	et	al.,	2008;	French	et	al.,	2002;	Mwachari	et	al.,	2006;	Ouedraogo	et	al.,	2010;	Scott	et	al.,	2000;	Zoubga	et	al.,	2000);	recent	hospitalisation	(Birkhamshaw	et	al.,	2013;	Onyedum	et	al.,	2011;	Rakotoson	et	
al.,	2010);	prior	antibiotic	use	(Coulibaly	et	al.,	1986;	Domoua	et	al.,	1993;	Koffi	et	al.,	2001)	and	severe	illness	(Coulibaly	et	al.,	1986;	Harries	et	al.,	1988b;	Mwachari	et	al.,	2006).	
HIV	testing	was	performed	in	25	of	the	studies	overall	and	24	of	the	36	completed	after	1990	(Table	2.3).	Five	studies	focused	specifically	on	HIV-positive	patients	(Domoua	et	
al.,	1993;	Gilks	et	al.,	1996;	Schleicher	et	al.,	2005;	Sire	et	al.,	2010;	Vray	et	al.,	2008)	whilst	two	specifically	restricted	analysis	to	HIV-negative	patients	(Fiberesima	et	al.,	2008;	Sow	et	al.,	1996).		
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Studies	varied	in	the	way	they	dealt	with	patients	with	TB.	15	studies	specifically	excluded	all	patients	with	TB	including	both	those	identified	at	presentation	and	those	diagnosed	subsequently	during	their	work-up.	Several	other	studies	excluded	patients	with	evidence	of	TB	at	presentation	(typically	on	the	basis	of	positive	smear	microscopy)	but	then	performed	systematic	TB	diagnostic	testing	on	enrolled	patients	and	presented	the	results	in	their	aetiological	descriptions	(Albrich	et	al.,	2012;	Fiberesima	et	al.,	2008;	Mwachari	et	al.,	2006;	Sire	et	al.,	2010;	Vray	et	al.,	2008).		
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ri
od
	
M
et
ho
do
lo
gy
	
Po
pu
la
ti
on
	
Pn
eu
m
on
ia
	c
as
e	
de
fin
it
io
n	
D
em
og
ra
ph
ic
s	
An
al
ys
es
	
%
m
al
e	
Ag
e	
	
(Vray	e
t	a
l.,	
2008)	
Centra
l	Africa
n	
Repub
lic,	
Bangui
	
Sep	20
02	–	
Dec	20
05	M
ulticen
tre,	pro
spectiv
e,	
observ
ational
	study	
HIV-po
sitive	p
atients
	≥18	yr
s	hospi
talised
	
with	pn
eumon
ia;	n=1
01.		
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	termi
nal	
AIDS	
Clinica
l	featur
es	of	pn
eumon
ia	with
	
radiog
raphic	
feature
s	comp
atible	
with	in
fection
:	focal	o
r	diffus
e	
opaciti
es;	lym
phaden
opathy
	
34.7	
Med.	3
4;	IQR	
29-40	
Mortal
ity,	
aetiolo
gy	
(Coulib
aly	
et
	a
l.,	1986
)	Cote
	d’Ivoir
e,	
Abidja
n	
1986a ;
	5	
month
s	S
ingle	ce
ntre,	
prospe
ctive,	n
on-
compa
rative	c
linical	
trial	H
ospital
ised	pa
tients	w
ith	acu
te	pres
umed	
bacteri
al	pneu
monia;
	n=47.	
	
Ex
cl
us
io
ns
:	prior	
antibio
tics;	se
vere	sh
ock;	
penicil
lin	alle
rgy;	co
ncurre
nt	men
ingitis	
Clinicia
n	diagn
osis	wi
th	radi
ologica
l	
confirm
ation;	n
ot	othe
rwise	
specifi
ed	
72.3	
Range	
16-57	
Aetiolo
gy	
(Domo
ua	et	
al
.,	1993
)	Co
te	d’Ivo
ire,	
Abidja
n	
Jan	–	O
ct	
1990	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
HIV-po
sitive	p
atients
	with	a
cute	
pneum
onia;	n
=70.	
Ex
cl
us
io
ns
:	prior	
antibio
tics	
Su
bg
ro
up
s:	hosp
italised
	patien
ts,	n=5
8;	
outpat
ients,	n
=12	(ex
cluded
).	
Clinicia
n	diagn
osis	wi
th	radi
ologica
l	
confirm
ation;	n
ot	othe
rwise	
specifi
ed	
-	
33;	ran
ge	
22-59	
Mortal
ity,	
aetiolo
gy	
(Koffi	e
t	a
l.,	
1997)	
Cote	d’
Ivoire,	
Abidja
n	
Jan	199
4	–	
March	
1995	S
ingle	ce
ntre,	
retrosp
ective	
case	se
ries	Ad
ults	ho
spitalis
ed	with
	presum
ed	
bacteri
al	pneu
monia;
	n=96.	
	
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	
confirm
ed/sus
pected
	PCP;	H
IV	statu
s	
unknow
n	
Releva
nt	sym
ptoms	
with	po
sitive	
auscult
atory	f
indings
	and	
radiog
raphic	
confirm
ation		
71.9	
31.5;	r
ange	
15-45	
Mortal
ity,	
progno
stics	
(Koffi	e
t	a
l.,	
2001)	
Cote	d’
Ivoire,	
Abidja
n	
April	1
998	
–	Oct	1
999	S
ingle	ce
ntre,	
retrosp
ective	
case	se
ries	Ad
ults	ho
spitalis
ed	with
	presum
ed	
bacteri
al	pneu
monia;
	n=100
.		
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	pre-
hospita
l	antibi
otics;	d
eath	<7
2	hour
s	of	
admiss
ion	
Clinica
l	featur
es	with
	radiog
raphic	
consol
idation
	and	ne
utroph
ilia.	
57.0	
-	
Mortal
ity	
(Horo	
et
	a
l.,	
2009)	
Cote	d'
Ivoire,	
Abidja
n	
2009a ;
	12	
month
s	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	cohort
	
study	
Patient
s	≥15	y
rs	hosp
italised
	with	
(presu
med	ba
cterial)
	CAP;	n
=50.		
Ex
cl
us
io
ns
:	TB;	H
IV	statu
s	unkn
own;	
interst
itial	sh
adowin
g	on	CX
R;	unab
le	to	
afford	
investi
gations
	
Su
bg
ro
up
s:	HIV-
positiv
e,	n=29
;	HIV-
negativ
e,	n=21
	
Clinica
l	featur
es	with
	radiog
raphic	
alveola
r	conso
lidation
	and	
leucocy
tosis	o
r	eleva
ted	CR
P.	
-	
40.8		 HIV-po
s.,	
38.2		 HIV-ne
g.,	
44.5	
Mortal
ity,	
progno
stics	
	
CA
P	
in
	a
du
lts
	in
	su
b-
Sa
ha
ra
n	
Af
ri
ca
:	a
	sy
st
em
at
ic
	re
vi
ew
	
57	
Re
fe
re
nc
e	
Co
un
tr
y;
	
re
gi
on
	
St
ud
y	
pe
ri
od
	
M
et
ho
do
lo
gy
	
Po
pu
la
ti
on
	
Pn
eu
m
on
ia
	c
as
e	
de
fin
it
io
n	
D
em
og
ra
ph
ic
s	
An
al
ys
es
	
%
m
al
e	
Ag
e	
	
(Adera
ye,	
1994a,
	
1994b
)	
Ethiop
ia,	Add
is	
Ababa	
Aug	19
87	–	
July	19
89	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Consec
utive	p
atients
	≥14	yr
s	hospi
talised
	
with	CA
P;	n=11
0.		
Su
bg
ro
up
s:	HIV-
positiv
e,	n=9;
	HIV-
negativ
e,	n=10
1.	
Acute	i
llness	w
ith	rad
iologic
al	
pulmon
ary	sha
dowing
	
56.3		 HIV-po
s.,	
77.8		 HIV-ne
g.,	
54.5	
35;	ran
ge	
14-75	
	
HIV-po
s.,	
30.5±8
.1		
HIV-ne
g.,	
35.5±1
5.4	
Mortal
ity,	
progno
stics,	
aetiolo
gy	
(Ahme
dtaha	
et
	a
l.,	2014
)	Ethi
opia,	Ji
mma	M
arch	20
08	
–	Feb	2
009	S
ingle	ce
ntre,	
retrosp
ective,	
observ
ational
	study	
Consec
utive	p
atients
	≥15	yr
s	hospi
talised
	
with	CA
P;	n=10
4.		
Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
71.2	
<44,	66
.3%	M
ortality
,	
progno
stics	
(Slack	
et
	a
l.,	
1976)	
Kenya,
	Nairob
i	1976
a 	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
Adults
	presen
ting	to
	hospit
al	eme
rgency
	
depart
ment	a
nd	med
ical	filt
er	clini
c	with	
acute	p
neumo
nia;	n=
105.	
	
Acute	h
istory	w
ith	com
patible
	
sympto
ms,	po
sitive	a
usculta
tory	
finding
s	and	r
adiogr
aphic	
confirm
ation	
72.4	
Comm
onest	
age	gro
up	
20-30	
yrs	
Mortal
ity,	
aetiolo
gy	
(Scott	e
t	a
l.,	
2000)	
Kenya,
	Coast	
Provin
ce	
March	
1994	
–	May	1
996	Si
ngle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Consec
utive	p
atients
	≥15	yr
s	hospi
talised
	
with	ac
ute	pne
umonia
;	n=281
.		
Su
bg
ro
up
s:	HIV-
positiv
e,	n=14
7;	HIV-
negativ
e,	n=13
4	
Acute	i
llness	(
≤14	da
ys)	wit
h	≥2	
respira
tory	sy
mptom
s	and	
pulmon
ary	con
solidat
ion	on	
CXR		
63.0	
15-24,	
23%;		
25-34,	
40%;		
35-44,	
22%;		
45-54,	
8%;		
55-85,	
8%	
Mortal
ity,	
progno
stics,	
aetiolo
gy	
(Frenc
h	et	
al
.,	2002
)	Ke
nya,	Na
irobi	
2002a 	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
Consec
utive	a
dults	h
ospital
ised	wi
th	
pneum
ococca
l	pneum
onia;	n
=122.		
Su
bg
ro
up
s:	HIV-
positiv
e,	n=60
;	HIV-
negativ
e,	n=62
	
Acute	(
≤28	da
ys)	feb
rile	res
pirator
y	
illness	
with	LR
T	signs
	and	
parenc
hymal	
abnorm
ality	on
	CXR	
and	S.	p
ne
um
on
ia
e	isolat
ed	in	b
lood	
or	lung
	aspira
te.		
72.1		 HIV-po
s.,	
66.7		 HIV-ne
g.,	
77.4	
HIV-po
s.,	
med.	3
1;	
range	1
9-54	
HIV-ne
g.,	
med.	3
0;	
range	1
6-71	M
ortality
,	
progno
stics	
(Odera
	e
t	
al
.,	2009
)	
	
Kenya,
	Nairob
i	Mar
ch	–	 June	20
07	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
,	case-
contro
l	study
	
Patient
s	≥18	y
rs	adm
itted	w
ith	pro
visiona
l	
diagno
sis	of	p
neumo
nia;	n=
120.	Ai
ms	to	
identif
y	risk	f
actors	
for	Leg
io
ne
lla
	
pneum
onia	
Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
60.8	
38.7	
Aetiolo
gy	
(Rakot
oson	
et
	a
l.,	2010
)	Mad
agasca
r,	
Antana
narivo
	Sep
	2006	–
	
Aug	20
07	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Patient
s	≥16	y
rs	hosp
italised
	with	C
AP;	
n=96.		 Exclusi
on
s:	posit
ive	AFB
	smear
;	prior	
hospita
lisation
	within
	7	days
	
Clinica
l	featur
es	with
	radiog
raphic	
consol
idation
	and	ei
ther	
neutro
philia	o
r	eleva
ted	CR
P/ESR.
	61.
5	
41.8;	r
ange	
16-90	
Mortal
ity	
	
CA
P	
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	a
du
lts
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	su
b-
Sa
ha
ra
n	
Af
ri
ca
:	a
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st
em
at
ic
	re
vi
ew
	
58	
Re
fe
re
nc
e	
Co
un
tr
y;
	
re
gi
on
	
St
ud
y	
pe
ri
od
	
M
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ho
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lo
gy
	
Po
pu
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ti
on
	
Pn
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m
on
ia
	c
as
e	
de
fin
it
io
n	
D
em
og
ra
ph
ic
s	
An
al
ys
es
	
%
m
al
e	
Ag
e	
	
(Harrie
s	et	
al
.,	1988
b)	M
alawi,	 Lilongw
e	
May	–	 August
	
1986	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
Hospit
alised	a
dults	w
ith	clin
ically	d
efined	
lobar	p
neumo
nia;	n=
100.		
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	prior	
pulmon
ary	TB
;	comp
licating
	diseas
e;	
severe
	illness
	
Compa
tible	cl
inical	f
eature
s	with	
unilate
ral	che
st	signs
	
74.0	
34;	ran
ge	
14-76	
Mortal
ity	
(Gordo
n	et	
al
.,	2002
)	M
alawi,	 Blanty
re	
Oct	19
97	–	
March	
1999	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Consec
utive	a
dult	pa
tients	h
ospital
ised	
with	IP
D;	n=2
17.	Sub
set	dia
gnosed
	with	
pneum
onia,	n
=92.	
Focal	c
hest	sig
ns	in	p
atient	w
ith	
pneum
ococca
l	bacte
raemia
	
57.6	
33.9	
Mortal
ity,	
progno
stics	
(Birkh
amsh
aw	et	a
l.,	
2013)	
Malaw
i,	
Blanty
re	
Feb	–	 March	
2010	S
ingle	ce
ntre,	
retrosp
ective,	
observ
ational
	study	
All	pat
ients	h
ospital
ised	wi
th	a	cli
nical	
diagno
sis	of	a
cute	LR
TI;	n=2
40.		
Ex
cl
us
io
ns
:	know
n	malig
nancy;
	prior	
hospita
lisation
	within
	14	day
s;	illne
ss	
duratio
n	>21	d
ays	
Clinicia
n	prim
ary	dia
gnosis	
of	
LRTI/C
AP	plu
s	≥2	re
cognise
d	signs
	
and	sy
mptom
s	of	CA
P	
48.3	
Med.	3
7;	IQR	
29-48;
	range	
16-85	
Mortal
ity,	
progno
stics	
(Bos	et
	a
l.,	
2014)	
Mozam
bique,	
Beira	
April	–
	June	
2010	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
Patient
s	≥16	y
rs	pres
enting	
to	eme
rgency
	
room	w
ith	LRT
I;	n=17
7.	86	w
ith	
pneum
onia	
LRTI	d
efined	
by	feve
r	plus	≥
1	
relevan
t	symp
tom;	pn
eumon
ia	by	
radiog
raphic	
confirm
ation		
45.2	
16-45,	
85%	
Aetiolo
gy	
(Sofow
ora	
et
	a
l.,	1973
)	Nige
ria,	Iba
dan	19
69	–	 1971	
Single	
centre,
	
retrosp
ective,	
observ
ational
	study	
Consec
utive	p
atients
	≥15	yr
s	with	
pneum
onia;	n
=88.	
Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
56.8	
20-45,	
75%;	
range	1
5-65	M
ortality
,	
aetiolo
gy	
(Awun
or-
Renner
,	
1979)	
Nigeria
,	Zaria	
1979a 	
Single	
centre,
	
retrosp
ective,	
observ
ational
	study	
Adults
	hospit
alised	w
ith	pne
umonia
;	n=73.
		
Ex
cl
us
io
ns
:	prior	
antibio
tics;	‘re
luctant
	to	
cooper
ate’	
Releva
nt	sym
ptoms	
with	po
sitive	
auscult
atory	f
indings
	and	
radiog
raphic	
confirm
ation		
63.0	
30.1;	r
ange	
12-60	
Mortal
ity,	
aetiolo
gy	
(Fibere
sima	
et
	a
l.,	2007
,	
2008)	
Nigeria
,	Port	
Harcou
rt	
May	20
02	–	
April	2
003	M
ulticen
tre,	pro
spectiv
e,	
observ
ational
	study	
Consec
utive	p
atients
	≥15	yr
s	hospi
talised
	
with	CA
P;	n=54
.		
Ex
cl
us
io
ns
:	Know
n	HIV-p
ositive
;	know
n	TB;	
COPD;	
illness	
duratio
n	>14	d
ays	
Clinica
l	featur
es	with
	radiog
raphic	
consol
idation
	
55.6	
38.1±1
7.6	
Mortal
ity,	
aetiolo
gy	
(Onyed
um	
et
	a
l.,	2011
)	Nige
ria,	Enu
gu	Jul
y	2003
	–	
July	20
08	S
ingle	ce
ntre,	
retrosp
ective	
case	se
ries	H
ospital
ised	pa
tients	≥
18	yrs	
with	fin
al	
diagno
sis	of	p
neumo
nia;	n=
160.		
Ex
cl
us
io
ns
:	recen
t	prior	
hospita
lisation
	or	
hospita
lised	>
48	hou
rs;	CXR
	unava
ilable	
≥2	rele
vant	sy
mptom
s	with	
positiv
e	
auscult
atory	f
indings
	and	
radiog
raphic	
confirm
ation		
55.0	
52.9±1
9.0	
Mortal
ity,	
progno
stics	
(Mbata
	e
t	
al
.,	2013
)	N
igeria,	
Enugu	
Dec	20
08	–	
June	20
09	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Consec
utive	p
atients
	≥18	yr
s	with	
CAP	
seen	in
	emerg
ency	d
epartm
ent	or	
medica
l	
outpat
ients;	n
=80.	
Acute	r
espirat
ory	illn
ess	(≥2
	
sympto
ms)	wi
th	acut
e	infiltr
ates	on
	
CXR	
48.8	
56±18
	
Mortal
ity,	
progno
stics	
CA
P	
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	a
du
lts
	in
	su
b-
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ca
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	re
vi
ew
	
59	
Re
fe
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e	
Co
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tr
y;
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on
	
St
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M
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gy
	
Po
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on
	
Pn
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e	
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fin
it
io
n	
D
em
og
ra
ph
ic
s	
An
al
ys
es
	
%
m
al
e	
Ag
e	
	
(Sow	e
t	a
l.,	
1996)	
Repub
lic	of	
Guinea
,	
Conakr
y	
March	
1992	
–	Marc
h	
1993	
Multice
ntre,	p
rospec
tive,	
observ
ational
	study	
Patient
s	≥15	y
rs	diag
nosed	
with	CA
P;	
n=218
.	
Ex
cl
us
io
ns
:	HIV-p
ositive
;	TB;	no
socom
ial	
pneum
onia	
Compa
tible	re
spirato
ry	sym
ptoms	
with	fe
ver	and
	new	d
ensitie
s	on	CX
R		79.4
	
38±16
	
Mortal
ity	
(Sire	et
	a
l.,	
2010)	 	
Senega
l,	Daka
r	June
	2003	–
	
Dec	20
04	M
ulticen
tre,	pro
spectiv
e,	
observ
ational
	study	
HIV-po
sitive	p
atients
	≥18	yr
s	hospi
talised
	
with	pn
eumon
ia;	n=7
0.		
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	termi
nal	
AIDS	
Clinica
l	featur
es	of	pn
eumon
ia	with
	
radiog
raphic	
feature
s	comp
atible	
with	in
fection
:	focal	o
r	diffus
e	
opaciti
es;	lym
phaden
opathy
	
55.7	
Med.	3
9;	IQR	
32-47	
Mortal
ity,	
aetiolo
gy	
(Prout
	e
t	a
l.,	
1983)	
South	A
frica,	
Cape	T
own	
Feb	–	J
une	
1980	
Single	
centre,
	
retrosp
ective,	
observ
ational
	study	
Consec
utive	a
dults	w
ith	acu
te	pneu
monia	
presen
ting	to
	the	em
ergenc
y	unit;	
n=81.		
Ex
cl
us
io
ns
:	altern
ative	fi
nal	dia
gnosis;
	
inadeq
uate	fo
llow-up
	data.		
Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
67.9	
39;	ran
ge	
14-85	
Mortal
ity,	
aetiolo
gy	
(Maart
ens	
et
	a
l.,	1994
)	Sout
h	Afric
a,	
Cape	T
own	
July	19
87	–	
July	19
88	S
ingle	ce
ntre,	
retrosp
ective	
case	se
ries	Ad
ults	ho
spitalis
ed	with
	CAP;	n
=92.		
Ex
cl
us
io
ns
:	pulmo
nary	T
B;	adva
nced	
immun
osuppr
ession;
	serolo
gy	spec
imen	
unavai
lable	
Acute	r
espirat
ory	illn
ess	wit
h	
compa
tible	sh
adowin
g	on	CX
R	
56.5	
43.4	
Aetiolo
gy	
(Feldm
an	et	
al
.,	1996
)	So
uth	Afr
ica,	
Johann
esburg
	199
6a 	
Single	
centre,
	
prospe
ctive,	
observ
ational
	case-
contro
l	study
	
Patient
s	hospi
talised
	with	C
AP.		
Su
bg
ro
up
s:	Gene
ral	war
ds,	n=4
7;	ICU,
	n=19	
(exclud
ed)	
Acute,	
pyrexia
l	LRTI,
	acquir
ed	in	th
e	
commu
nity	an
d	assoc
iated	w
ith	
clinica
l	and	ra
diologi
cal	evid
ence	of
	
consol
idation
	
ICU	89
.5		
Ward	6
6.0	IC
U,	rang
e	
18-62	
	
Ward,	
range	
15-71	
Mortal
ity,	
progno
stics,	
aetiolo
gy	
(Feldm
an	et	
al
.,	1999
)	So
uth	Afr
ica,	
Johann
esburg
	199
9a ;	2	yr
s	Singl
e	centr
e,	
retrosp
ective,	
observ
ational
	study	
Consec
utive	a
dult	pa
tients	w
ith	
bactera
emic	p
neumo
coccal	
pneum
onia;	
n=112
.		
Su
bg
ro
up
s:	HIV-
positiv
e,	n=31
;	HIV-
negativ
e,	n=81
	
Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
73.9		 HIV-po
s.,	
58.3		 HIV-ne
g.,	
79.6	
37.7		 HIV-po
s.,	
32.8±2
.9		
HIV-ne
g.,	
39.6±1
.7	
Mortal
ity,	
progno
stics	
(Mpe	e
t	a
l.,	
2001)	
South	A
frica,	
Medun
sa	
2001a ;
	12	
month
s	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Consec
utive	a
dults	h
ospital
ised	wi
th	CAP
;	
n=123
.		
Ex
cl
us
io
ns
:	TB	
Acute,	
pyrexia
l	LRTI	
acquire
d	in	the
	
commu
nity	wi
th	clini
cal	and
	
radiolo
gical	ev
idence
	of	
consol
idation
	
40.8	
Range	
13-85	
Mortal
ity,	
aetiolo
gy	
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du
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ha
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re
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D
em
og
ra
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al
ys
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(Chara
lamb
ous	et	
al
.,	
2003)	
South	A
frica,	
Free	St
ate	
Feb	19
98	–	
Feb	19
99	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	cohort
	
study	
Gold	m
iners	a
dmitte
d	to	co
mpany
	hospit
al	
with	ba
cterial	
pneum
onia;	n
=108	w
ith	124
	
episod
es	of	pn
eumon
ia.		
Ex
cl
us
io
ns
:	confir
med	TB
.		
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bg
ro
up
s:	HIV-
positiv
e,	n=11
9;	HIV-
negativ
e,	n=5	
Clinica
l	featur
es	with
	radiog
raphic	
confirm
ation	a
nd	eith
er	path
ogen	
isolatio
n	or	sa
tisfacto
ry	resp
onse	to
	
treatm
ent	
100	
<30,	9.
3%;		
30-39,	 46.3%
;		
40-49,	 39.8%
;		
>50,	4.
6%	
Mortal
ity,	
aetiolo
gy	
(Schlei
cher	
et
	a
l.,	2005
)	Sout
h	Afric
a,	
Johann
esburg
	Jan	2
001	–	 Oct	20
03	S
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ntre,	
prospe
ctive,	
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ational
,	case-
contro
l	study
	
Hospit
al	HIV-
positiv
e	patie
nts	wit
h	CAP;
	
n=67:	C
ases	-	c
onfirm
ed	pne
umoco
ccal	
CAP,	n=
33	(dat
a	prese
nted);	
contro
ls	-	
confirm
ed	pulm
onary	T
B,	n=34
.	
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l	featur
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eumon
ia	and	
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enia	an
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XR	
51.5	
32.5±1
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et
	a
l.,	 2007a)
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frica,	
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	study	
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	≥18	yr
s	hospi
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0.		
Ex
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us
io
ns
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hiectas
is,	inte
rstitial
	lung	
disease
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hial	car
cinoma
	
Su
bg
ro
up
s:	HIV-
positiv
e,	n=31
1;	HIV-
negativ
e,	n=71
	
Compa
tible	re
spirato
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ptoms	
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l	CXR	w
ith	new
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te	or	co
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37.4	
33;	ran
ge	
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ity,	
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stics,	
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gy	
(Xaba	e
t	a
l.,	
2014)	
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frica,	
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a	
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2	S
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	cohort
	
study	
Random
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	≥	13	y
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diagno
sed	wit
h	CAP;
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Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
67.5	
43.6;	r
ange	
14-89	
Mortal
ity	
(Albric
h	et	
al
.,	2012
;	
Albrich
	e
t	
al
.,	2014
a;	
Albrich
	e
t	
al
.,	2014
b)	So
uth	Afr
ica,	
Soweto
	
Dec	20
05	–	
Sep	20
07	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Patient
s	≥18	y
rs	hosp
italised
	with	a
cute	
pneum
onia;	n
=370.		
Ex
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us
io
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:	Know
n	TB	
Su
bg
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s:	HIV-
positiv
e,	n=28
0	
Releva
nt	acut
e	(≤14	
days)	s
ympto
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with	po
sitive	a
usculta
tory	fin
dings	
and	rad
iograp
hic	con
firmati
on		
41.8		 HIV-po
s.,	
37.1	
38.4±1
2.2		
HIV-po
s.,	
36.5±9
.7	
Mortal
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stics,	
aetiolo
gy	
(Roe,	1
968)	U
ganda,
	Jinja	
March	
1966	
–	Aug	1
967	S
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ective	
case	se
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mitted
	with	r
adiolog
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neumo
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Clinicia
n	diagn
osis;	no
t	other
wise	
specifi
ed	
78.2	
-	
Mortal
ity,	
aetiolo
gy	
(Yoshim
ine	
et
	a
l.,	2001
)	Ugan
da,	 Kampa
la	
Nov	19
96	–	
March	
1998	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
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s	≥18	y
rs	adm
itted	w
ith	CAP
;	n=99.
		
Su
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ro
up
s:	HIV-
positiv
e,	n=74
;	HIV-
negativ
e,	n=25
	
New	pu
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CXR	
with	co
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ures	or
	
elevate
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	cell	co
unt	or	
CRP	
65.7		 HIV-po
s.,	
66.2		 HIV-ne
g.,	
64.0	
34.2		 HIV-po
s.,	
33.2±9
.8		
HIV-ne
g.,	
37.2±2
1.2	
Aetiolo
gy	
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(El-Am
in,	
1978)	
Zambia
,	
Solwez
i	
Jan	–	O
ct	
1976	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
All	pat
ients	w
ith	pre
sumed
	bacter
ial	
pneum
onia;	n
=109	
Not	oth
erwise
	specifi
ed;	all	
patient
s	
had	rad
iograp
hic	con
firmati
on	
54.1	
34.4;	r
ange	
20-65	
Aetiolo
gy	
H
ig
h	
de
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	o
r	
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te
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iv
e	
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re
	u
ni
t	s
tu
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es
	
(Hartu
ng	et	
al
.,	2011
)	M
alawi,	 Blanty
re	
Feb	–	S
ep	
2006	
Single	
centre,
	
prospe
ctive,	
observ
ational
	study	
Patient
s	≥18	y
rs	with
	clinica
l	diagn
osis	of	
severe
	pneum
onia;	n
=51.		
Ex
cl
us
io
ns
:	positi
ve	AFB
	smear
;	unsui
table	
for	bro
nchosc
opy	
Clinica
l	featur
es	with
	radiog
raphic	
abnorm
ality	co
nsisten
t	with	
infectio
n	
54.9	
35;	ran
ge	
17-88	
Mortal
ity,	
progno
stics,	
aetiolo
gy	
(Potgie
ter	
et
	a
l.,	1992
)	Sout
h	Afric
a,	
Cape	T
own	
Jan	198
7	–	
Dec	19
89	S
ingle	ce
ntre,	
prospe
ctive,	
observ
ational
	study	
Patient
s	with	
a	diagn
osis	of	
acute	
pneum
onia	ad
mitted
	to	ICU
;	n=178
.	Data	
extract
ed	for	t
he	sub
set	of	9
5	with	
CAP.		
Ex
cl
us
io
ns
:	TB;	m
ajor	im
munoc
ompro
mise	C
linical	
(incl.	p
yrexia,
	cough
,	
purule
nt	sput
um,	cra
ckles,	b
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al	
breath
ing),	
leucocy
tosis/n
eutrop
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nd	
infiltra
te	on	C
XR	
64.2	
47;	ran
ge	
13-84	
Mortal
ity,	
aetiolo
gy	
(Feldm
an	et	
al
.,	1989
;	
Feldma
n	et	
al
.,	1995
)	So
uth	Afr
ica,	
Johann
esburg
	Jan	1
982	–	 Dec	19
92	S
ingle	ce
ntre,	
retrosp
ective,	
observ
ational
	study	
Consec
utive	p
atients
	admitt
ed	to	IC
U	with
	
severe
	CAP;	n
=259.		
Mortal
ity	risk
	factors
	descri
bed	in	
subset
	
of	73	w
ith	loba
r	CAP	
Ex
cl
us
io
ns
:	TB.		
Acute	L
RTI	wi
th	clini
cal	and
	
radiolo
gical	ev
idence
	of	pulm
onary	
consol
idation
	
77.2	
43.9;	r
ange	
14-75	
Mortal
ity,	
progno
stics,	
aetiolo
gy	
AFB	–	a
cid	fast
	bacilli
;	CAP	–
	comm
unity-a
cquired
	pneum
onia;	C
RP	-	C-
reactiv
e	prote
in;	CXR
	–	ches
t	radio
graph;
	ESR	–	
erythro
cyte	se
diment
ation	r
ate;	IPD
	–	Inva
sive	
pneum
ococca
l	diseas
e;	LRT	
–	lowe
r	respi
ratory	
tract;	L
RTI	–	l
ower	r
espirat
ory	tra
ct	infec
tion;	M
ed.	–	M
edian;	
IQR	–	i
nterqu
artile	r
ange;	T
B	–	tub
erculos
is	
a 	Study
	period
	not	sta
ted;	pu
blicatio
n	year	
used.		
b 	Consi
dered	t
he	prim
ary	ref
erence
	for	stu
dies	de
scribed
	in	mul
tiple	re
ports;	
used	fo
r	subse
quent	c
itation
s.		
.
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2.5.2.4 Assessment	of	the	risk	of	bias	The	risk	of	bias	was	considered	for	the	mortality,	prognostics	and	aetiology	analyses	separately	(Table	2.2).		
Of	the	39	studies	included	in	the	mortality	analysis	11	were	assessed	to	have	a	low-risk	of	bias	on	the	basis	of	my	assessment.	The	most	common	reason	studies	were	judged	to	have	high	risk	of	bias	was	inadequate	CAP	case	definition	–	either	non-radiographic	or	not	clearly	defined.	Inter-observer	agreement	with	the	second	reviewer	was	fair	(agreement	65.7%;	kappa	0.37;	95%	CI:	0.11-0.63).	
Only	two	of	the	18	studies	included	in	the	risk	factors	for	mortality	analysis	were	judged	overall	to	have	a	low	risk	of	bias	(Albrich	et	al.,	2014a;	Scott	et	al.,	2000)	on	the	basis	of	my	assessment.	The	two	most	common	reasons	for	studies	being	assessed	as	having	a	high	risk	of	bias	were	lack	of	prospective,	systematically	collected	data	on	putative	risk	factors	and	a	failure	to	control	for	confounding	variables	in	statistical	analysis.	Inter-observer	agreement	with	the	second	reviewer	was	perfect	(agreement	100%;	kappa	1.00).	
For	studies	included	in	the	aetiological	analysis,	12	of	30	studies	were	considered	to	have	a	low	risk	of	bias	on	the	basis	of	my	assessment.	Inter-observer	agreement	with	the	second	reviewer	was	slight	(agreement	66.7%;	kappa	0.12).	
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Table	2.2	 Risk	of	bias	assessment.	Green,	red	and	orange	fields	indicate	a	low,	high	and	unclear	risk	of	bias,	respectively.	Grey	for	non-applicable	fields	in	bold	in	the	three	right-most	columns	indicate	the	overall	risk	of	bias	for	the	specified	analysis	(See	section	2.5.6	and	Appendix	A	for	further	details).		 	 Key	indicator	domains	 Analyses	
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Community-based	studies	(Gilks	et	al.,	1996)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Mwachari	et	al.,	2006)	 Kenya	 		 		 		 		 		 		 		 		 		 		
Hospital-based	studies	(Zoubga	et	al.,	2000)	 Burkina	Faso	 		 		 		 		 		 		 		 		 		 		(Ouedraogo	et	al.,	2010)	 Burkina	Faso	 		 		 		 		 		 		 		 		 		 		(Koulla-Shiro	et	al.,	1994)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Koulla-Shiro	et	al.,	1997)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Yone	et	al.,	2012)	 Cameroon	 		 		 		 		 		 		 		 		 		 		(Vray	et	al.,	2008)	 CAR	 		 		 		 		 		 		 		 		 		 		(Coulibaly	et	al.,	1986)	 Cote	d'Ivoire	 		 		 		 		 		 		 		 		 		 		(Domoua	et	al.,	1993)	 Cote	d'Ivoire	 		 		 		 		 		 		 		 		 		 		(Koffi	et	al.,	1997)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Koffi	et	al.,	2001)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Horo	et	al.,	2009)	 Cote	d’Ivoire	 		 		 		 		 		 		 		 		 		 		(Aderaye,	1994a)	 Ethiopia	 		 		 		 		 		 		 		 		 		 		(Ahmedtaha	et	al.,	2014)	 Ethiopia	 		 		 		 		 		 		 		 		 		 		(Slack	et	al.,	1976)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Scott	et	al.,	2000)	 Kenya	 		 		 		 		 		 		 		 		 		 		(French	et	al.,	2002)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Odera	et	al.,	2009)	 Kenya	 		 		 		 		 		 		 		 		 		 		(Rakotoson	et	al.,	2010)	 Madagascar	 		 		 		 		 		 		 		 		 		 		(Harries	et	al.,	1988a)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Gordon	et	al.,	2002)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Birkhamshaw	et	al.,	2013)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Bos	et	al.,	2014)	 Mozambique	 		 		 		 		 		 		 		 		 		 		(Sofowora	et	al.,	1973)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Awunor-Renner,	1979)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Fiberesima	et	al.,	2008)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Onyedum	et	al.,	2011)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Mbata	et	al.,	2013)	 Nigeria	 		 		 		 		 		 		 		 		 		 		(Sow	et	al.,	1996)	 Rep.	of	Guinea	 		 		 		 		 		 		 		 		 		 		(Sire	et	al.,	2010)	 Senegal	 		 		 		 		 		 		 		 		 		 		(Prout	et	al.,	1983)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Maartens	et	al.,	1994)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Feldman	et	al.,	1996)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Feldman	et	al.,	1999)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Mpe	et	al.,	2001)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Charalambous	et	al.,	2003)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Schleicher	et	al.,	2005)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Nyamande	et	al.,	2007a)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Xaba	et	al.,	2014)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Albrich	et	al.,	2012)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Roe,	1968)	 Uganda	 		 		 		 		 		 		 		 		 		 		(Yoshimine	et	al.,	2001)	 Uganda	 		 		 		 		 		 		 		 		 		 		(El-Amin,	1978)	 Zambia	 		 		 		 		 		 		 		 		 		 			
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High-dependency	or	intensive	care	unit	studies	(Hartung	et	al.,	2011)	 Malawi	 		 		 		 		 		 		 		 		 		 		(Potgieter	et	al.,	1992)	 South	Africa	 		 		 		 		 		 		 		 		 		 		(Feldman	et	al.,	1995)	 South	Africa	 		 		 		 		 		 		 		 		 		 		
	
2.5.3 Patient	characteristics	
2.5.3.1 Demographics	34	of	the	42	studies	describing	the	sex	distribution	of	recruited	patients	reported	a	male	majority	(Table	2.1).	The	median	proportion	of	males	recruited	was	61%	(interquartile	range	(IQR):	54-71%).	Based	on	28	studies	that	presented	sufficient	information,	the	estimated	age	was	38.3	years	(95%	CI:	36.4-40.2).	
2.5.3.2 Comorbid	illness	The	most	commonly	reported	comorbidity	was	HIV	(Table	2.3).	In	the	24	studies	reporting	HIV	status,	the	mean	proportion	of	patients	infected	was	55.0%	(IQR:	34.6-75.0).	Previous	TB	and	lung	disease	were	reported	in	11.2%	(IQR:	7.2-19.7;	6	studies)	and	10.8%	(IQR:	4.0-13.7%;	13	studies),	respectively.	Four	studies	reported	the	proportion	of	patients	with	any	comorbid	illnesses;	the	median	proportion	was	44.9%	(IQR:	37.4-55.8%).	Approximately	28%	(IQR:	15.0-34.5%;	16	studies)	of	all	patients	reported	being	current	smokers.	There	was	marked	heterogeneity	between	studies	for	the	proportions	of	patients	affected	for	nearly	all	comorbid	conditions.		
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ye,	199
4a;	Ahm
edtaha
	e
t	a
l.,	2014
;	Albric
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2.5.4 Mortality	Amongst	general	hospital	inpatient	populations	mortality	rates	ranged	from	0	–	22.7%	(Table	2.4).		The	overall	estimated	median	mortality	rate	was	9.8%	(IQR:	4.1-18.7%).	The	median	mortality	rate	was	similar	in	the	11	studies	with	a	low	risk	of	bias	at	9.8%	(IQR:	2.6-13.4%;	range	1.9-17%).	In	the	three	studies	of	HDU	or	ICU	populations,	mortality	rates	ranged	from	21.6-45.2%	(Feldman	et	al.,	1995;	Hartung	et	al.,	2011;	Potgieter	et	al.,	1992)	with	a	median	of	32.6%	(IQR:	).	Neither	of	the	two	community-based	studies	reported	on	mortality	(Gilks	et	al.,	1996;	Mwachari	et	al.,	2006).	Only	nine	studies	specifically	defined	the	time-point	following	admission	at	which	mortality	was	recorded.	
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Table	2.4	 CAP	mortality	by	study	setting	and	grouped	by	country.		
	 	
Citation	 Country	 Mortality	
time	point	
No.	deaths/	
patients	
Mortality	rate	
(95%	CI)	
Hospital-based	studies	(Zoubga	et	al.,	2000)	 Burkina	Faso	 Inpatient	 10/106	 9.4		(3.9-15.0)	(Ouedraogo	et	al.,	2010)	 Burkina	Faso	 Inpatient	 52/239	 21.8		(16.5-27.0)	(Koulla-Shiro	et	al.,	1994)	 Cameroon	 Inpatient	 0/43	 0		(0-4.3)	
(Koulla-Shiro	et	al.,	1997)	 Cameroon	 Inpatient	 7/91	 7.7		(2.2-13.2)	(Yone	et	al.,	2012)	 Cameroon	 Inpatient	 13/106	 12.3		(6.0-18.5)	(Vray	et	al.,	2008)	 CAR	 21	days	 15/95	 15.8		(8.5-23.1)	(Domoua	et	al.,	1993)	 Cote	d’Ivoire	 Inpatient	 12/52	 23.1		(11.6-34.5)	(Koffi	et	al.,	1997)	 Cote	d’Ivoire	 Inpatient	 5/96	 5.2		(0.8-9.7)	(Koffi	et	al.,	2001)	 Cote	d’Ivoire	 Inpatient	 5/100	 5.0		0.7-9.3)	(Horo	et	al.,	2009)	 Cote	d'Ivoire	 3	days	 3/50	 6.0		(0-12.6)	
(Aderaye,	1994a)	 Ethiopia	 6-8	weeks	 11/110	 10.0		(4.4-15.6)	(Ahmedtaha	et	al.,	2014)	 Ethiopia	 Inpatient	 21/104	 20.2		(12.5-27.9)	
(Slack	et	al.,	1976)	 Kenya	 Inpatient	 2/105	 1.9		(0-4.5)	
(Scott	et	al.,	2000)	 Kenya	 3	weeks	 25/255	 9.8		(6.2-13.5)	(French	et	al.,	2002)	 Kenya	 Inpatient	 12/122	 9.8		(4.6-15.1)	
(Rakotoson	et	al.,	2010)	 Madagascar	 Inpatient	 2/96	 2.1		(0-4.9)	(Harries	et	al.,	1988b)	 Malawi	 Inpatient	 1/100	 1.0		(0-3.0)	(Gordon	et	al.,	2002)	 Malawi	 Inpatient	 18/92	 19.6		(11.5-27.7)	(Birkhamshaw	et	al.,	2013)	 Malawi	 Inpatient	 43/235	 18.3		(13.4-23.2)	(Sofowora	et	al.,	1973)	 Nigeria	 Inpatient	 20/88	 22.7		(14.0-31.5)	(Awunor-Renner,	1979)	 Nigeria	 Radiological	resolution	 0/73	 0		(0-2.5)	(Fiberesima	et	al.,	2008)	 Nigeria	 21	days	 4/53	 7.5		(0-14.7)	(Onyedum	et	al.,	2011)	 Nigeria	 Inpatient	 19/160	 11.9		(6.9-16.9)	
(Mbata	et	al.,	2013)	 Nigeria	 30	days	 12/80	 15.0		(7.2-22.8)	(Sow	et	al.,	1996)	 Rep.	of	Guinea	 Inpatient	 13/218	 6.0		(2.8-9.1)	(Sire	et	al.,	2010)	 Senegal	 21	days	 13/68	 19.1		(9.8-28.5)	(Prout	et	al.,	1983)	 South	Africa	 Inpatient		(min.	14	days)	 3/81	 3.7		(0-7.8)	
(Feldman	et	al.,	1996)	 South	Africa	 Inpatient	 1/47	 2.1		(2.0-6.3)	(Feldman	et	al.,	1999)	 South	Africa	 Inpatient	 4/94	 4.3		(0-8.3)	
(Mpe	et	al.,	2001)	 South	Africa	 Inpatient	 15/123	 12.2		(6.4-18.0)	(Charalambous	et	al.,	2003)	 South	Africa	 Inpatient		(min.	14	days)	 5/124	 4.0		(0.1-7.5)	
(Schleicher	et	al.,	2005)	 South	Africa	 Inpatient	 1/33	 3.0		(0-8.9)	
(Nyamande	et	al.,	2007a)	 South	Africa	 Inpatient	 73/430	 17.0		(13.4-20.5)	(Xaba	et	al.,	2014)	 South	Africa	 Inpatient	 39/200	 19.5		(14.0-25.0)	
(Albrich	et	al.,	2012)	 South	Africa	 Inpatient	 52/357	 14.6		(10.9-18.2)	(Roe,	1968)	 Uganda	 Inpatient	 2/97	 2.1		(0-4.9)		 	 	 Median,	%	(IQR)	Overall	 	 	 9.8	 (4.1-18.7)	Low	risk	of	bias	studies	 	 	 9.8	 (2.6-13.4)	
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2.5.5 Risk	factors	for	mortality	The	description	of	risk	factors	for	mortality	was	poor;	only	two	studies	had	a	low	risk	of	bias	(Table	2.2).	A	formal	meta-analysis	of	morality	risk	factors	was	not	attempted	in	view	of	the	limited	data	available,	variability	in	how	risk	features	were	defined	(e.g.	different	blood	pressure	or	respiratory	rate	thresholds	to	define	abnormality)	and	the	inability	to	adequately	account	for	confounding	factors.	A	narrative	summary	of	the	available	data	is	provided.		
2.5.5.1 Demographic	Five	studies	investigated	the	association	between	sex	and	Malawi.	In	a	large	cohort	from	Malawi,	Birkhamshaw	et	al.	reported	significantly	greater	inpatient	mortality	amongst	males	in	multivariable	analysis	(aOR	2.64;	95%	CI:	1.07-6.51).	This	finding	was	not	replicated	in	any	of	the	other	four	studies	(Feldman	et	al.,	1995;	Hartung	et	al.,	2011),	including	two	with	low	risk	of	bias	(Albrich	et	al.,	2012;	Scott	et	al.,	2000).		
The	relationship	between	age	and	risk	of	mortality	was	described	in	five	studies.	There	was	no	consistent	association	with	advancing	age:	two	studies	described	increased	risk	(Ahmedtaha	et	al.,	2014;	Scott	et	al.,	2000),	one	reduced	risk	(Birkhamshaw	et	al.,	2013),	and	two	others	found	no	significant	association	(Albrich	et	al.,	2012;	Hartung	et	
al.,	2011).		
2.5.5.2 Comorbid	illnesses	The	relationship	between	mortality	and	HIV	status	was	examined	in	14	studies	ranging	in	size	from	50	to	430	patients.	None	demonstrated	a	significant	association;	estimated	effect	sizes	ranged	from	OR	0.52	(95%	CI:	0.28-0.94)	to	OR	4.44	(95%	CI:	0.49-41.25).	The	two	studies	with	low	risk	of	bias	estimated	the	OR	for	mortality	at	1.23	(95%	CI:	0.49-3.13)(Scott	et	al.,	2000)	and	0.84	(95%	CI:	0.33-2.15),	respectively.(Albrich	et	al.,	2012).Three	other	studies	examined	the	impact	of	any	underlying	comorbid	illness	(including	HIV)	on	mortality,	but	again,	none	demonstrated	a	significant	association.	(Ahmedtaha	et	al.,	2014;	Feldman	et	al.,	1995;	Mbata	et	al.,	2013).		
Citation	 Country	 Mortality	
time	point	 No.	deaths/	patients	 Mortality	rate	(95%	CI)	
High-dependency	or	intensive	care	unit	studies	(Hartung	et	al.,	2011)	 Malawi	 Inpatient	 11/51	 21.6		(10.3-32.9)	(Potgieter	et	al.,	1992)	 South	Africa	 Inpatient	 28/95	 29.5		(20.3-38.6)	(Feldman	et	al.,	1995)	 South	Africa	 Inpatient	 117/259	 45.2		(39.1-51.2)		 	 	 Median,	%	(IQR)	Overall	 	 	 29.5	 (25.6-37.4)	
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2.5.5.3 Clinical	features	Whilst	variably	defined,	hypotension	was	consistently	associated	with	mortality	in	the	three	cohorts	of	general	ward	patients	in	it	was	assessed	with	effect	sizes	ranging	from	aOR	3.72	(95%:	1.51-9.13)	to	OR	10.4	(95%	CI:	1.8-60.6)(Birkhamshaw	et	al.,	2013;	Feldman	et	al.,	1996;	Gordon	et	al.,	2002).	Neither	of	the	two	studies	from	HDU	settings	reported	a	significant	association	of	reduced	blood	pressure	with	mortality	(Feldman	et	
al.,	1995;	Hartung	et	al.,	2011).	
The	association	of	tachypnoea	(defined	as	a	respiratory	rate	greater	than	30	breaths/minute)	with	mortality	was	examined	in	three	studies	(Ahmedtaha	et	al.,	2014;	Birkhamshaw	et	al.,	2013),	one	of	which	reported	an	increased	risk	of	death	but	with	very	wide	confidence	intervals	(OR	10.89;	95%	CI:	1.23-96.08)(Feldman	et	al.,	1996).	Two	additional	studies	found	no	difference	in	mean	baseline	respiratory	rates	between	patients	who	died	and	those	who	survived	(Feldman	et	al.,	1995;	Hartung	et	
al.,	2011).	A	study	from	Kenya,	however,	found	self-reported	dyspnoea	was	strongly	associated	with	mortality	(OR	4.04;	95%	CI:	1.34-12.14)	(Scott	et	al.,	2000).		
Four	studies	examined	the	association	of	heart	rate	with	mortality	(Feldman	et	al.,	1996;	Feldman	et	al.,	1995;	Hartung	et	al.,	2011;	Scott	et	al.,	2000).	Only	Scott	et	al.	found	a	significant	association	with	tachycardia	(aOR	1.64	for	every	10	beats/min	above	90	beats/min)(Scott	et	al.,	2000).		
Oxygen	saturations	were	only	measured	in	two	studies	from	Malawi	and	neither	identified	a	significant	association	with	mortality	(Birkhamshaw	et	al.,	2013;	Hartung	et	
al.,	2011).	A	single	study	from	Malawi	examined	the	effect	of	temperature	and	found	in	multivariable	analysis	that	an	abnormal	temperature	(either	high	or	low)	was	associated	with	increased	mortality	risk	(Birkhamshaw	et	al.,	2013).	
Both	of	the	two	studies	that	analysed	the	risk	of	mortality	with	cachexia	found	significant	associations	(Birkhamshaw	et	al.,	2013)	aOR	6.61;	95%	CI:	2.61-16.70.	(Nyamande	et	al.,	2007a)	RR	3.02;	P<0.001.	Non-ambulatory	status	was	associated	with	mortality	in	multivariable	analysis	(aOR	2.46;	95%	CI:	1.26-4.82)(Birkhamshaw	et	al.,	2013).	
2.5.5.4 Radiological	features	The	single	study	with	low	risk	of	bias	that	presented	data	on	radiographic	changes	described	an	approximate	4-fold	increase	in	mortality	with	multilobar	consolidation	compared	to	unilobar	involvement	(OR	4.50;	95%	CI:	1.65-13.5)	(Scott	et	al.,	2000).	Neither	the	general	ward	(Feldman	et	al.,	1996)	nor	the	ICU	cohort	(Feldman	et	al.,	
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1995)	from	South	Africa	demonstrated	a	significant	relationship	of	multilobar	involvement	with	morality.	Birkhamshaw	et	al.,	in	a	cohort	from	Malawi,	found	no	association	of	either	multizonal	or	bilateral	radiographic	changes	with	mortality,	although	chest	radiographs	were	available	for	analysis	in	only	61%	of	patients	(Birkhamshaw	et	al.,	2013).	
2.5.5.5 Laboratory	indices	A	single	study	from	Malawi	found	in	univariable	analysis	haemoglobin	was	lower	in	non-survivors	(Hartung	et	al.,	2011).	Three	of	four	studies	described	an	association	of	white	cell	count	with	mortality:	two	showed	reduced	white	cell	count	in	non-survivors	(Feldman	et	al.,	1996;	Feldman	et	al.,	1995);	one	other	showed	an	abnormal	white	cell	count	(either	high	(i.e.	>18;	OR	7.33;	95%	CI:	1.2-42.9)	or	low	(i.e.	<4;	OR	5.79;	95%	CI:	1.43-27.4)	was	associated	with	mortality	(Scott	et	al.,	2000).		
Three	studies	reported	on	the	relationship	of	biochemical	parameters	with	mortality	(Feldman	et	al.,	1996;	Feldman	et	al.,	1995;	Nyamande	et	al.,	2007a).	Two	described	significant	reduction	in	serum	albumin	and/or	serum	protein	in	non-survivors	(Feldman	et	al.,	1995;	Nyamande	et	al.,	2007a).	An	association	of	elevated	creatinine	and	urea	with	mortality	was	described	in	one	and	two	studies,	respectively	(Feldman	et	
al.,	1996;	Feldman	et	al.,	1995).		
2.5.5.6 Severity	assessment	tools	The	performance	of	CURB65	in	predicting	mortality	was	described	in	two	studies.	In	a	cohort	of	88	patients	from	Nigeria,	30-day	mortality	rose	with	CURB65	and	at	a	threshold	score	of	3	or	more,	sensitivity	and	specificity	were	80%	and	97%,	respectively	(Mbata	et	al.,	2013).	Albrich	et	al.	in	a	cohort	of	280	HIV-infected	patients	from	South	Africa	found	CURB65	was	not	a	useful	discriminator	of	in-hospital	mortality	(Albrich	et	al.,	2012).	CRB65	(the	abbreviated	version	of	CURB65	that	does	not	require	laboratory	urea	measurement)	showed	only	moderate	discriminative	capability	(i.e.	CRB65	≥2:	sensitivity	36%;	specificity	81%;	positive	predictive	value	30%;	negative	predictive	value	85%;	AUROC	0.65)	for	predicting	inpatient	mortality	in	a	cohort	of	patients	from	Malawi	(Birkhamshaw	et	al.,	2013).		
CAP	in	adults	in	sub-Saharan	Africa:	a	systematic	review	 71	
2.5.6 Clinical	specimens	and	microbiological	techniques	The	clinical	specimens	collected	and	the	microbiological	techniques	used	to	define	CAP	aetiology	are	summarised	in	Table	2.5.	A	combination	of	blood	and	expectorated	sputum	culture	were	performed	in	16	of	the	30	studies	included	in	the	analysis.	Four	studies	used	only	sputum	microscopy	and	culture	(El-Amin,	1978;	Mwachari	et	al.,	2006;	Roe,	1968;	Sofowora	et	al.,	1973).	The	adequacy	of	sputum	quality	control	procedures	was	difficult	to	assess.	Results	were	rarely	disaggregated	by	site	of	pathogen	isolation;	thus	it	was	not	possible	to	consistently	identify	aetiologies	assigned	on	the	basis	of	sputum	analysis	alone	versus	those	where	an	isolate	was	obtained	from	a	sterile	site.			
Several	studies	used	more	invasive	techniques	to	obtain	lower	respiratory	specimens:	four	studies	collected	tracheobronchial	aspirates;	six	studies	collected	bronchoalveolar	(BAL)	specimens.	However,	specimen	collection	was	often	not	systematic	(Domoua	et	
al.,	1993;	Feldman	et	al.,	1995)	or	restricted	to	a	limited	subset	of	patients	related	to	their	ability	to	tolerate	the	procedure	(Hartung	et	al.,	2011)	or	because	of	lack	of	response	to	initial	therapy	(Nyamande	et	al.,	2007a;	Ouedraogo	et	al.,	2010;	Potgieter	et	
al.,	1992).	Transthoracic	needle	aspiration	was	systematically	used	in	two	studies	as	an	alternative	approach	to	obtaining	lower	respiratory	tract	specimens	(Aderaye,	1994a;	Scott	et	al.,	2000).	
17	studies	included	at	least	one	method	of	TB	diagnostic	testing,	but	in	eight	was	smear	microscopy	alone.	Testing	for	atypical	bacterial	pathogens	was	performed	in	nine	studies	using	serological	methods.	An	additional	four	studies	used	urinary	antigen	testing	to	identify	Legionella	pneumophila	infection	(Mpe	et	al.,	2001;	Odera	et	al.,	2009;	Sire	et	al.,	2010;	Vray	et	al.,	2008).	Molecular	PCR-based	diagnostic	methods	were	only	used	in	two	studies	(Albrich	et	al.,	2012;	Hartung	et	al.,	2011).	
Several	studies	deliberately	used	a	restricted	array	of	diagnostics	only	capable	of	detecting	specific	pathogens	of	interest:	S.	pneumoniae	(Albrich	et	al.,	2012;	Bos	et	al.,	2014),	L.	pneumophila	(Odera	et	al.,	2009)	or	other	atypical	pathogens	(Maartens	et	al.,	1994).			
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6;	Hart
ung	et	
al.,	201
1;	Kou
lla-Shir
o	et	al.
,	1997;
	Mpe	e
t	al.,	
2001;	N
yaman
de	et	a
l.,	2007
a;	Oued
raogo	e
t	al.,	20
10;	Pot
gieter	e
t	
al.,	199
2;	Prou
t	et	al.,
	1983;	
Scott	e
t	al.,	20
00;	Sir
e	et	al.,
	2010;	
Slack	e
t	al.,	19
76;	Vra
y	et	al.,
	2008)
	
Sputum
	Gram	
stain	
16	(53
)	
	
(Adera
ye,	199
4a;	Alb
rich	et	
al.,	201
2;	Char
alambo
us	et	al
.,	2003
;	
Feldma
n	et	al.
,	1996;
	Feldm
an	et	a
l.,	1995
;	Koulla
-Shiro	
et	al.,	
1994;	M
wachar
i	et	al.,	
2006;	N
yaman
de	et	a
l.,	2007
a;	Potg
ieter	et
	
al.,	199
2;	Prou
t	et	al.,
	1983;	
Roe,	19
68;	Sir
e	et	al.,
	2010;	
Slack	e
t	al.,	
1976;	S
ofowor
a	et	al.,
	1973;	
Vray	et
	al.,	200
8;	Yosh
imine	e
t	al.,	
2001)	
Sputum
	cultur
e	
21	(70
)	
	
(Albric
h	et	al.
,	2012;
	Awuno
r-Renn
er,	197
9;	Bos	
et	al.,	2
014;	
Charal
ambou
s	et	al.,
	2003;	
El-Ami
n,	1978
;	Feldm
an	et	a
l.,	1996
;	
Feldma
n	et	al.
,	1995;
	Fibere
sima	et
	al.,	200
8;	Gilks
	et	al.,	1
996;	
Koulla-
Shiro	e
t	al.,	19
97;	Ko
ulla-Sh
iro	et	a
l.,	1994
;	Mwac
hari	et
	al.,	
2006;	N
yaman
de	et	a
l.,	2007
a;	Potg
ieter	et
	al.,	199
2;	Prou
t	et	al.,
	
1983;	R
oe,	196
8;	Sire	
et	al.,	2
010;	Sl
ack	et	a
l.,	1976
;	Sofow
ora	et	
al.,	197
3;	Vray
	et	al.,	2
008;	Yo
shimin
e	et	al.,
	2001)
	
Sputum
	AFB	
micros
copy	
16	(53
)	
	
(Adera
ye,	199
4a;	Alb
rich	et	
al.,	201
2;	Char
alambo
us	et	al
.,	2003
;	
El-Ami
n,	1978
;	Fiber
esima	e
t	al.,	20
08;	Gil
ks	et	al
.,	1996
;	Hartu
ng	
et	al.,	2
011;	K
oulla-S
hiro	et
	al.,	199
4;	Mwa
chari	e
t	al.,	20
06;	
Nyama
nde	et	
al.,	200
7a;	Roe
,	1968;
	Scott	e
t	al.,	20
00;	Sir
e	et	al.,
	
2010;	S
lack	et
	al.,	197
6;	Sofo
wora	e
t	al.,	19
73;	Vra
y	et	al.,
	2008)
	
Sputum
	mycob
acteria
l	
culture
	
7	(23)	
	
(Chara
lambou
s	et	al.,
	2003;	
Gilks	e
t	al.,	19
96;	Mw
achari	
et	al.,	
2006;	S
cott	et	
al.,	200
0;	Sire	
et	al.,	2
010;	V
ray	et	a
l.,	2008
;	
Yoshim
ine	et	a
l.,	2001
)	
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Sp
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t		
St
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s	
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g	
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e,
		
n	
(%
)	
Ad
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on
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	d
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ls
	
Ci
ta
ti
on
s	
Transt
horacic
	needle
	
aspirat
ion	
2	(7)	
Bacter
ial	mic
roscop
y	and	c
ulture,
	pneum
ococca
l	antige
n	
detecti
on,	AFB
	smear
	micros
copy	(b
oth	stu
dies);	
mycob
acteria
l	cultur
e	(1	stu
dy).	
(Adera
ye,	199
4a;	Sco
tt	et	al.
,	2000)
	
Trache
obronc
hial	
aspirat
e	
4	(13)	
Gram	s
tain	an
d	cultu
re	(all	
studies
);	AFB	
micros
copy,	
pneum
ococca
l	and	H
.	i
nf
lu
en
za
e	antig
en	dete
ction	(
1	
study)
.	
(Coulib
aly	et	a
l.,	1986
;	Domo
ua	et	a
l.,	1993
;	Feldm
an	et	a
l.,	1995
;	
Potgiet
er	et	al
.,	1992
)	
Bronch
oalveo
lar	
lavage	
6	(20)	
Investi
gations
:	bacte
rial	mi
crosco
py	and
	cultur
e	(6	
studies
);	fung
al	micr
oscopy
	and	cu
lture	(5
	studie
s);	
mycob
acteria
l	micro
scopy	a
nd	cult
ure	(4	
studies
);	P.	
jirovec
ii	IF	(4
	studie
s);	Leg
io
ne
lla
	IF	(2	s
tudies)
;	
multip
lex	PCR
	for	aty
pical	b
acteria
	and	vi
ruses	(
1	study
).	(Har
tung	et
	al.,	201
1;	Nyam
ande	e
t	al.,	20
07a;	Ou
edraog
o	et	al.
,	
2010;	P
otgiete
r	et	al.,
	1992;	
Sire	et	
al.,	201
0;	Vray
	et	al.,	2
008)	
Pleura
l	fluid	
3	(10)	
Investi
gations
:	Gram
	stain	a
nd	cult
ure	(2	
studies
);	
pneum
ococca
l	antige
n	detec
tion	(2
	studie
s).	
(Adera
ye,	199
4a;	Kou
lla-Shir
o	et	al.
,	1994;
	Ouedr
aogo	e
t	al.,	20
10)	
Pneum
ococca
l	urine
	
antigen
	test	
7	(23)	
Other	s
tudies	
tested	
for	pne
umoco
ccal	an
tigen	in
:	sera	(
5	
studies
),	sputu
m/bro
nchial	
aspirat
e	(3	stu
dies),	p
leural	
fluid	(1
	study)
,	transt
horacic
	needle
	aspira
te	(2	st
udies).
	(Ade
raye,	1
994a;	A
lbrich	e
t	al.,	20
14a;	Bo
s	et	al.,
	2014;	
Nyama
nde	
et	al.,	2
007a;	S
cott	et	
al.,	200
0;	Sire	
et	al.,	2
010;	V
ray	et	a
l.,	2008
)	
Legion
ella	uri
ne	
antigen
	test	
5	(17)	
	
(Mpe	e
t	al.,	20
01;	Ny
amand
e	et	al.,
	2007a
;	Odera
	et	al.,	2
009;	Si
re	et	
al.,	201
0;	Vray
	et	al.,	2
008)	
Serolog
y	
9	(30)	
Pathog
ens:	Le
gi
on
el
la
	spp.	(4
	studie
s);	M.	p
ne
um
on
ia
e	(9	
studies
);	C.	pn
eu
m
on
ia
e	(5	stu
dies);	C
.	p
si
tt
ac
i	(3	stu
dies);	
C.
	b
ur
ne
tt
i	(4	stu
dies);	r
espirat
ory	vir
uses	(3
	studie
s).	
(Adera
ye,	199
4a;	Fel
dman	e
t	al.,	19
96;	Fel
dman	e
t	al.,	19
95;	
Koulla-
Shiro	e
t	al.,	19
97;	Ma
artens	
et	al.,	1
994;	N
yaman
de	et	a
l.,	
2007a;
	Potgie
ter	et	a
l.,	1992
;	Prout
	et	al.,	1
983;	Sc
ott	et	a
l.,	2000
)	
Molecu
lar	
2	(7)	
Multip
lex	PCR
	for	aty
pical	b
acteria
	and	re
spirato
ry	
viruses
	on	nas
ophary
ngeal	a
spirate
	with	S
.	p
ne
um
on
ia
e	
colonis
ation	d
ensity	
(1	stud
y)	or	o
n	BAL	
(1	stud
y).		
(Albric
h	et	al.
,	2012;
	Hartun
g	et	al.,
	2011)
	
AFB	–	a
cid-fas
t	bacill
i;	BAL	
–	bron
choalv
eolar	la
vage;	I
F	–	imm
unoflu
oresce
nce;	PC
R	–	pol
ymeras
e	chain
	reactio
n	
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Ta
bl
e	
2.
6	
Ae
ti
ol
og
y	
of
	C
AP
	b
y	
H
IV
	s
ta
tu
s	
in
	h
os
pi
ta
lis
ed
	p
at
ie
nt
s.
	Percen
tages	r
efer	to
	the	pr
oportio
n	of	pa
tients	w
ith	spe
cific	pa
thogen
	identif
ied;	
patient
s	may	h
ave	mo
re	than
	one	pa
thogen
	and	to
tals	ma
y	excee
d	100%
.	Overa
ll	weig
hted	av
erage	c
ombin
es	data
	for	HIV
-positi
ve,	HIV
-negati
ve	and
	HIV	
mixed/
unknow
n	studi
es.	Stud
ies	wit
h	low	r
isk	of	b
ias	sho
wn	in	b
old.	-	in
dicates
	releva
nt	diag
nostic	
test	no
t	perfo
rmed	a
nd	?	th
at	data
	not	av
ailable
	or	
propor
tion	is	
unclea
r.	Qual
ifying	i
nforma
tion	pr
ovided
	where
	possib
le	in	fin
al	colu
mn	and
	indica
ted	by	
*	or	^.	
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ta
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	p
at
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ge
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en
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S.	pneumoniae	
H.	influenzae	
S.	aureus	
K.	pneumoniae	
Other	Gram- negative	bacillia	
P.	aeruginosa	
M.	pneumoniae	
C.	pneumoniae	
Legionella	spp.	
Viruses	
M.	tuberculosis	
None		identified	
H
IV
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os
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	all	bac
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1993)	
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00
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M
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ra
la
m
bo
us
	
et
	a
l.,
	2
00
3)
	
So
ut
h	
Af
ri
ca
	
11
9	
31
	
8	
3	
4	
1	
2	
-	
-	
-	
-	
Ex
cl
.	
52
	
	
(N
ya
m
an
de
	e
t	
al
.,	
20
07
a)
c 	
So
ut
h	
Af
ri
ca
	
31
1	
20
	
3	
5	
1	
3	
1	
?*
	
?*
	
<1
	
-	
23
	
?*
	
C.
	n
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*	Not	r
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V	statu
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eu
m
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ia
e	~14%
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m
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e	~4%
;	None	
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ied		~4
8%	
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t	a
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20
12
)	
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0	
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nostics
	tests;	^
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sma	
or	vira
l	infect
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H
IV
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S.	pneumoniae	
H.	influenzae	
S.	aureus	
K.	pneumoniae	
Other	Gram- negative	bacillia	
P.	aeruginosa	
M.	pneumoniae	
C.	pneumoniae	
Legionella	spp.	
Viruses	
M.	tuberculosis	
None		identified	
H
IV
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eg
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t	a
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20
00
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en
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(Fibere
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	a
l.,	
2008)g
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South	A
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llu
s	spp.	3
%;	Chi
cken	p
ox	1%;
	Anaer
obes	1
%	
*	Not	r
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d	by	HI
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m
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m
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m
in
e	
et
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U
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only	
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All	stud
ies	
3056	
27	
3	
5	
3	
5	
2	
7	
5	
2	
7	
14	
-		
a 	Includ
es	Ente
robact
eriacea
e	and	l
actose	
non-fe
rmente
rs,	but	
not	Ha
em
op
hi
lu
s	i
nf
lu
en
za
e,	Klebs
ie
lla
	p
ne
um
on
ia
e,	Pseu
do
m
on
as
	a
er
ug
in
os
a,	Mora
xe
lla
	c
at
ar
rh
al
is
	or	
atypica
l	patho
gens.		
b 	Exclu
ded	pa
tients	w
ith	pos
itive	AF
B	smea
r	on	sp
ontane
ously	e
xpecto
rated	s
putum
	specim
en.		
c 	266	p
atients
	under
went	m
ore	ext
ended	
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2.5.7 Aetiology	Unless	otherwise	stated	the	narrative	summary	of	results	in	this	section	is	based	on	studies	with	low	risk	of	bias	for	aetiology	analysis.	Figures	quoted	may	vary	from	those	presented	in	Tables	2.6	and	2.7	if	an	aggregate	rather	HIV-status-specific	estimate	is	used.	
2.5.7.1 Streptococcus	pneumoniae	
Streptococcus	pneumoniae	was	the	most	commonly	identified	pathogen	amongst	hospitalised	patients	accounting	for	approximately	one-quarter	of	all	CAP	cases.	The	proportion	of	CAP	attributable	to	S.	pneumoniae	was	higher	amongst	HIV-negative	patients	(34%	vs.	26%),	although	the	estimate	for	HIV-negative	patients	is	numerically	dominated	by	a	single	cohort	(Scott	et	al.,	2000).	A	similar	overall	proportion	of	pneumococcal	pneumonia	was	seen	in	the	studies	from	HDU	and	ICU	settings	(Hartung	
et	al.,	2011).	Amongst	the	six	studies	with	low	risk	of	bias	that	included	pneumococcal	urinary	antigen	testing,	proportions	with	pneumococcal	CAP	ranged	from	3-46%	(Albrich	et	al.,	2012;	Bos	et	al.,	2014;	Nyamande	et	al.,	2007a;	Scott	et	al.,	2000;	Sire	et	
al.,	2010;	Vray	et	al.,	2008).	One	study	from	South	Africa	incorporated	a	new	diagnostic	assay	based	on	the	density	of	pneumococcal	nasopharyngeal	colonisation	and	found	54%	of	CAP	was	attributable	to	S.	pneumoniae	(Albrich	et	al.,	2012).		
2.5.7.2 Mycobacterium	tuberculosis	Overall	Mycobacterium	tuberculosis	was	the	second	most	commonly	identified	pathogen.	In	studies	with	low	risk	of	bias	that	did	not	specifically	exclude	TB,	it	was	identified	in	19%.	Rates	in	the	HIV-positive	group	(20%)	were	almost	double	those	of	the	HIV-negative	group	(11%).	The	proportion	of	cases	attributable	to	TB	was	similar	in	the	two	studies	that	restricted	recruitment	to	patients	with	illness	duration	of	less	than	14	days	(13%	(Scott	et	al.,	2000)	and	25%	(Albrich	et	al.,	2012)).	The	four	studies	that	used	microscopy	and	mycobacterial	culture	of	BAL	specimens	identified	TB	in	13-29%	of	patients	(Hartung	et	al.,	2011;	Nyamande	et	al.,	2007a;	Sire	et	al.,	2010;	Vray	et	
al.,	2008).		
2.5.7.3 Other	bacterial	pathogens	Amongst	general	hospital	inpatients,	Haemophilus	influenzae,	Staphylococcus	aureus	and	Klebsiella	pneumoniae	accounted	for	4%,	4%	and	2%	of	CAP	cases,	respectively.	The	relative	proportion	of	cases	due	to	each	pathogen	did	not	vary	substantially	with	HIV	status.	The	overall	combined	data	from	HDU	or	ICU	settings	indicated	that	
Klebsiella	pneumoniae	occurred	more	frequently	in	severely	ill	patients	(15%),	
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although	this	increase	was	most	notable	in	the	two	studies	from	South	Africa	(Feldman	
et	al.,	1995;	Potgieter	et	al.,	1992).			
Overall	Pseudomonas	aeruginosa	was	uncommon,	accounting	for	only	1-2%	of	cases.	However,	there	was	substantial	variation	and	in	two	studies	Pseudomonas	was	identified	in	more	than	10%	of	cases	(Sire	et	al.,	2010;	Sofowora	et	al.,	1973).		
The	combined	group	of	other	Gram-negative	bacteria	that	included	Enterobacteriaceae	and	lactose	non-fermenters	accounted	for	approximately	5%	cases	and	did	not	vary	markedly	with	disease	severity.	Studies	varied	in	the	extent	to	which	the	specific	pathogens	within	this	group	were	reported	separately.	Amongst	HIV-positive	patients,	infection	with	nontyphoidal	Salmonella	(NTS)	species	(S.	enterica	serovar	Enteritidis	and	S.	enterica	serovar	Typhimurium)	was	noted	(Domoua	et	al.,	1993;	Scott	et	al.,	2000).		
2.5.7.4 Atypical	bacteria	Diagnostic	testing	for	atypical	bacterial	pathogens	was	limited	(Table	2.6);	the	estimates	of	the	proportion	of	CAP	attributable	of	Mycoplasma	pneumoniae	and	
Chlamydophila	pneumoniae	presented	in	Table	2.7	were	each	based	on	data	from	less	than	1000	patients.	With	the	exception	of	a	study	from	Malawi	that	used	a	multiplex	PCR	assay	on	BAL	fluid	(Hartung	et	al.,	2011),	diagnostic	testing	was	based	on	serological	diagnosis.	Overall	M.	pneumoniae	and	C.	pneumoniae	accounted	for	8%	and	2%	of	CAP,	respectively.		
Testing	for	Legionella	pneumophila	was	more	comprehensive	(Table	2.6).	In	cohorts	from	Kenya	and	South	Africa,	that	systematically	used	the	BinaxNOW	L.	pneumophila	urinary	antigen	test,	Legionella	was	identified	in	9%	and	2%	respectively	(Mpe	et	al.,	2001;	Odera	et	al.,	2009).	Legionella	accounted	for	approximately	2%	of	cases	in	both	general	inpatient	and	high	dependency	settings.		
2.5.7.5 Respiratory	viruses	Diagnostic	testing	for	respiratory	viruses	was	performed	in	six	studies,	but	systematically	in	only	two	(Hartung	et	al.,	2011;	Scott	et	al.,	2000).	Using	serological	testing	alone,	a	viral	aetiology	was	found	in	6%	of	a	Kenyan	CAP	cohort;	influenza	was	the	most	commonly	identified	virus	(Scott	et	al.,	2000).	Using	a	multiplex	PCR	assay	on	BAL	specimens,	similar	overall	rates	of	viral	disease	were	identified	in	a	Malawian	cohort	with	a	mixed	array	of	virus	including	influenza,	parainfluenza,	respiratory	syncytial	and	rhinovirus	but	most	frequently	as	a	co-pathogen	with	bacterial	or	
Pneumocystis	pneumonia	(Hartung	et	al.,	2011).	The	cases	of	viral	disease	identified	by	
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Prout	et	al.	in	a	South	African	cohort	were	also	mainly	as	co-pathogens	with	bacterial	pneumonia	(Prout	et	al.,	1983).	
2.5.7.6 Other	causes	Immunofluorescence	staining	of	BAL	fluid	for	Pneumocystis	jirovecii	was	performed	in	four	studies.	Three	of	these	studies	conducted	in	Central	African	Republic,	Senegal	and	South	Africa	recruited	general	hospital	inpatient	cohorts	of	HIV-infected	individuals	and	identified	P.	jirovecii	in	2%,	2%	and	12%,	respectively	(Nyamande	et	al.,	2006;	Sire	
et	al.,	2010;	Vray	et	al.,	2008).	The	fourth	study	conducted	in	Malawi	recruited	a	predominantly	HIV-infected	cohort	(94%)	admitted	to	the	high	dependency	unit	found	27%	of	patients	to	have	confirmed	or	probable	PCP	(Hartung	et	al.,	2011).	The	latter	study	also	identified	a	primary	or	associated	diagnosis	of	pulmonary	Kaposi	sarcoma	in	16%	of	patients.	
2.6 Discussion	This	is	the	first	systematic	review	of	CAP	in	adults	in	sub-Saharan	Africa.	It	highlights	important	differences	in	the	epidemiology,	aetiology	and	outcome	of	CAP	in	sub-Saharan	Africa	compared	to	other	global	regions	that	are	relevant	to	disease	assessment	and	management.		
2.6.1 Epidemiology	This	review	highlights	that	CAP	populations	in	sub-Saharan	Africa	are	dominated	by	young	patients.	This	is	in	marked	contrast	to	well-resourced	settings	where	the	burden	of	CAP,	particularly	in	hospitalised	cohorts,	is	in	elderly	patients	(Ewig	et	al.,	2009;	Fine	
et	al.,	1996;	Welte	et	al.,	2012).	Although	there	are	no	high	quality	adult	CAP	incidence	data	from	sub-Saharan	Africa,	the	observed	predominance	of	young	adults	in	CAP	cohorts	is	likely	to	reflect	the	true	burden	of	disease	in	the	population	and	probably	relates	both	to	the	underlying	population	age	structure	and	the	dominant	impact	of	HIV	on	CAP	incidence	(Benito	et	al.,	2012;	Feikin	et	al.,	2004;	Gilks	et	al.,	1996;	Oxford	Institute	of	Population	Ageing,	2015;	Segal	et	al.,	2011).		
HIV	was	the	dominant	comorbid	condition,	present	in	around	half	of	CAP	patients.	Much	of	the	excess	risk	of	CAP	associated	with	HIV	infection	is	preventable	with	anti-retroviral	therapy	(ART)	and	co-trimoxazole	preventative	therapy	(Kohli	et	al.,	2006;	Sullivan	et	al.,	2000;	Suthar	et	al.,	2015).	To	date,	ART	has	been	started	in	more	than	9	million	patients	in	sub-Saharan	Africa	(World	Health	Organization,	2014b).	Continued	efforts	to	increase	ART	rollout	coupled	with	strategies	for	HIV	prevention	and	early	
CAP	in	adults	in	sub-Saharan	Africa:	a	systematic	review	 81	
diagnosis	represent	important	opportunities	to	markedly	reduce	the	burden	of	adult	CAP	in	the	region.		
In	contrast	to	HIV,	other	chronic	comorbid	conditions	such	as	COPD,	heart	failure	and	ischaemic	heart	disease	-	which	are	very	common	in	hospitalised	CAP	cohorts	from	well-resourced	settings	and	are	an	important	driver	of	CAP-related	mortality	(Musher	
et	al.,	2007;	Welte	et	al.,	2012)	-	are	currently	present	in	a	small	minority	of	patients.	The	relative	importance	of	these	conditions	is	likely	to	increase	as	life	expectancies	across	sub-Saharan	Africa	increase	(Mathers	et	al.,	2006;	World	Health	Organization,	2014a).		
2.6.2 Mortality	The	median	mortality	rates	in	general	hospital	ward	and	HDU/ICU	patients	were	9.8%	and	29.5%,	respectively,	but	rates	varied	markedly	between	cohorts.	Variations	in	outcome	are	expected	given	differences	in	demographic	and	comorbidity	profile,	disease	aetiology	and	management	including	the	availability	of	higher	level	care.	Although,	observed	mortality	differences	could	be	in	part	artifactual	and	related	to	differences	in	the	duration	of	follow-up	which	for	most	cohorts	was	not	standardised.		
The	overall	mortality	rates	are	comparable	to	those	reported	in	well-resourced	settings	in	Europe	and	US	(Ewig	et	al.,	2009;	Welte	et	al.,	2012;	Yu	et	al.,	2012).	The	extent	to	which	mortality	is	preventable	with	optimised	management	may	differ	between	these	settings.	In	well-resourced	settings,	a	substantial	proportion	of	total	CAP-related	deaths	occurs	in	elderly	individuals	as	a	result	of	decompensated	comorbid	conditions,	many	of	whom	have	limitations	on	the	treatment	interventions	(e.g.	do	not	attempt	resuscitation	orders)	(Bauer	et	al.,	2013;	Chalmers,	2015;	Wunderink,	2015).	Mortality	may	be	more	readily	preventable	in	younger	cohorts	with	limited	cardiopulmonary	comorbidity.	Further	studies	are	required	to	define	the	pattern	of	treatment	response	and	causes	of	mortality	following	CAP	in	sub-Saharan	Africa.		
The	assessment	of	risk	factors	for	mortality	was	poor.	18	studies	reported	the	relationship	of	mortality	to	at	least	one	candidate	risk	factor.	Formal	meta-analysis	was	not	undertaken.	The	observed	association	of	hypotension	and	multilobar	consolidation	with	mortality	is	consistent	with	previous	studies	from	other	settings	(Charles	et	al.,	2008b;	Fine	et	al.,	1996).	General	clinical	status	variables	such	as	cachexia	and	inability	to	stand	that	are	not	widely	used	in	well-resourced	contexts	were	also	associated	with	mortality	(Birkhamshaw	et	al.,	2013;	Nyamande	et	al.,	2007a).	Inability	to	stand	has	also	been	identified	as	an	independent	risk	factor	for	mortality	in	other	unselected	acute	medical	in-patient	populations	in	Africa	(Rylance	et	al.,	2009;	Wheeler	et	al.,	
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2013).	It	may	be	useful	as	a	component	of	a	rapid	assessment	or	triage	tool,	but	its	accuracy	needs	to	be	assessed	in	prospective	studies.		
The	lack	of	consistent	association	between	age	and	mortality	risk	is	notable.	Only	two	of	five	studies	described	increasing	mortality	with	advancing	age.	In	studies	from	high-income	settings	the	increased	risk	of	mortality	with	advancing	age	becomes	apparent	after	the	age	of	40	(Ewig	et	al.,	2009;	Fine	et	al.,	1997a).	Given	the	size	and	age	distribution	of	many	cohorts,	the	power	to	detect	an	association	with	advancing	age	might	be	limited.		
There	was	no	evidence	of	an	association	between	HIV	status	and	mortality.	Previous	studies	of	the	impact	of	HIV	on	CAP	outcome	from	other	settings	have	yielded	variable	results.	Two	international	observational	studies	indicated	no	overall	impact	on	CAP	outcome	(Christensen	et	al.,	2005;	Malinis	et	al.,	2010).	In	bacteraemic	pneumococcal	CAP,	HIV	infection	with	reduced	CD4	count	is	associated	with	increased	mortality	(Feldman	et	al.,	2007b).	The	implication	for	a	resource-limited,	sub-Saharan	African	context	is	that	the	presence	of	HIV	alone	should	not	be	used	as	the	basis	for	rationing	care	on	the	presumption	of	substantially	worse	prognosis.		
2.6.3 Aetiology	In	keeping	with	studies	from	other	global	regions,	Streptococcus	pneumoniae	was	the	most	commonly	identified	organism	across	all	clinical	settings,	accounting	for	approximately	27%	of	cases.	Based	on	the	spectrum	of	diagnostic	modalities	used,	this	is	likely	to	be	a	substantial	underestimate	of	the	true	prevalence	(Jokinen	et	al.,	2010;	Said	et	al.,	2013).	Future	studies	will	be	required	to	monitor	changes	in	CAP	aetiology	following	the	widespread	introduction	of	infant	pneumococcal	conjugate	vaccination	in	Africa	(Bar-Zeev	et	al.,	2015).		
These	data	highlight	the	major	importance	of	Mycobacterium	tuberculosis	as	a	cause	of	acute	CAP	in	a	sub-Saharan	African	setting.	Given	the	limited	array	of	TB	diagnostic	tests	used	in	many	of	the	studies	and	their	limited	sensitivity	for	HIV-associated	TB	in	particular	(Lawn	et	al.,	2013c),	the	overall	estimate	of	19%	is	likely	to	considerably	underestimate	the	true	frequency.	In	post	mortem	series,	TB	is	the	most	prominent	cause	of	death	of	HIV-infected	patients	with	respiratory	infection	(Bates	et	al.,	2013).	A	recent	study	from	South	Africa	using	an	array	of	conventional	and	molecular	diagnostic	tests	identified	TB	in	one-third	of	all	acutely	hospitalised	HIV-infected	adults	(Lawn	et	
al.,	2015).	The	optimal	strategy	for	identifying	TB	in	patients	presenting	with	acute	illness	in	low-resource	settings,	including	the	use	of	new	rapid	or	point	of	care	assays	
CAP	in	adults	in	sub-Saharan	Africa:	a	systematic	review	 83	
(e.g.	Xpert	MTB/RIF,	urinary	lipoarabinomannan)	is	the	focus	of	intense	investigation	(Peter	et	al.,	2016;	Theron	et	al.,	2014).		
The	frequencies	of	atypical	and	Gram-negative	enteric	bacteria	are	important	considerations	when	deciding	upon	appropriate	empirical	antibacterial	therapy.	In	this	review,	the	reported	frequency	of	disease	caused	by	atypical	bacterial	pathogens	(i.e.	
M.	pneumoniae,	C.	pneumoniae,	Legionella	spp.)	was	comparable	to	that	seen	in	other	global	regions	(Charles	et	al.,	2008a;	Torres	et	al.,	2014).	However	diagnostic	testing	was	often	not	systematic	and	relied	on	serological	testing	rather	than	newly	developed	more	sensitive	molecular	assays.	The	necessity	of	antimicrobial	cover	for	atypical	bacterial	pathogens	amongst	hospitalised	adults	is	still	unclear	–as	it	is	in	well-resourced	settings	(Garin	et	al.,	2014;	Postma	et	al.,	2015)	–	and	further	studies	are	needed.		
The	prevalence	of	CAP	caused	by	individual	species	of	Gram-negative	enteric	bacteria	was	often	not	reported	separately.	Amongst	HIV-positive	patients,	a	significant	proportion	of	patients	presenting	with	CAP	have	infection	with	NTS	(Domoua	et	al.,	1993;	Scott	et	al.,	2000).	These	organisms	(S.	enterica	serovar	Enteritidis	and	S.	enterica	serovar	Typhimurium)	are	the	commonest	cause	of	bacteraemia	in	sub-Saharan	Africa	(Reddy	et	al.,	2010).	Whether	this	represents	true	Salmonella	pneumonia	or	disease	caused	by	an	undetected	co-pathogen	in	patients	with	invasive	salmonellosis	is	unclear,	but	the	necessity	to	consider	modifying	empirical	antimicrobial	therapy	is	the	same	regardless	(Feasey	et	al.,	2012).		
	Klebsiella	pneumoniae	–	typically	implicated	as	a	cause	of	hospital-acquired	pneumonia	in	well-resourced	setting	–	was	identified	in	2-3%	of	hospitalised	patients	and	up	to	15%	of	patients	in	high	dependency	settings,	although	the	latter	estimation	was	dominated	by	studies	from	South	Africa	(Feldman	et	al.,	1995;	Potgieter	et	al.,	1992).	This	finding	also	has	implications	for	empirical	antibiotic	therapy,	particularly	for	those	patients	with	severe	disease	or	that	fail	to	improve	on	first	line	therapy.		
Given	the	high	prevalence	of	HIV,	the	potential	for	CAP	attributable	to	opportunistic	pathogens	in	sub-Saharan	Africa	is	clear.	P.	jirovecii	was	identified	in	2-12%	of	patients	in	general	hospital	cohorts	(Nyamande	et	al.,	2006;	Sire	et	al.,	2010;	Vray	et	al.,	2008)	and	27%	of	patients	in	the	single	study	of	high	dependency	unit	patients	(Hartung	et	al.,	2011).	Diagnosis	of	P.	jirovecii	pneumonia	(PCP)	is	difficult.	It	is	not	reliably	distinguished	from	other	causes	of	pneumonia	on	clinical	or	radiological	grounds	and	microbiological	confirmation	has	historically	relied	on	microscopy	of	invasively	obtained	lower	respiratory	tract	specimens	that	are	often	unobtainable	in	low-resource	
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settings	(Malin	et	al.,	1995).	Recently	developed	highly	sensitive	PCR	assays	may	permit	the	use	of	more	readily	obtained	clinical	specimens	(e.g.	expectorated	sputum,	nasopharyngeal	aspirate)(Cruciani	et	al.,	2002;	To	et	al.,	2013).		
The	contribution	of	viruses	to	the	aetiology	of	CAP	has	not	been	adequately	addressed	by	the	studies	included	in	this	review.	Only	five	studies	included	diagnostic	tests	for	respiratory	viruses	of	which	only	two	used	modern	molecular	diagnostic	assays.	In	a	recent	multicentre	study	of	hospitalised	adults	with	CAP	in	the	US,	rhinovirus	was	the	most	commonly	identified	pathogen	(Jain	et	al.,	2015).	Further	studies	are	needed	to	define	the	burden	of	viral	pathogens	and	their	relationship	with	other	pneumonia	pathogens.		
2.6.4 Notable	excluded	studies	The	eligibility	criteria	for	this	systematic	review	were	devised	to	capture	studies	that	described	acute	CAP	populations	to	give	results	that	were	generalisable	to	unselected	adults	presenting	de	novo	with	acute	pneumonic	illness.	Studies	that	included	children	younger	than	12	years	were	excluded.	A	large	observational	study	of	502	patients	with	lobar	pneumonia	in	Zambia	that	included	children	however	found	similar	results:	mortality	occurred	in	4%	and	associated	with	advanced	age,	leucopaenia,	multilobar	involvement,	hypothermia	and	hypotension;	S.	pneumoniae	and	tuberculosis	were	the	commonest	causes	(Allen,	1984).	
Studies	that	selected	patients	on	the	basis	of	failure	of	response	to	first-line	treatment,	prolonged	symptoms	(e.g.	more	than	2	or	3	weeks)	or	that	attempted	to	enrich	the	cohort	for	particular	pathogens	were	excluded.	Okwera	et	al	studied	HIV-infected,	AFB-smear	negative	recurrent	pulmonary	TB	suspects	in	Uganda	with	symptoms	for	two	or	more	weeks	and	identified	bacterial	and	PCP	in	27%	and	7%	respectively,	with	TB	only	confirmed	in	18%	(Okwera	et	al.,	2013).	Another	study	from	Uganda	in	a	similar	population	that	also	included	analysis	of	BAL	specimens	found	P.	jirovecii	to	be	the	commonest	cause	of	disease,	present	in	39%	(Worodria	et	al.,	2003).	Two	acute	pneumonia	cohort	studies	from	Ethiopia	and	Zimbabwe	were	excluded	because	they	specifically	selected	patients	with	‘atypical’	or	diffuse	radiographic	changes.	Both	found	that	approximately	one-third	of	cases	were	each	caused	by	PCP	and	TB	with	the	remainder	attributable	to	bacteria,	Kaposi’s	sarcoma	or	other	opportunistic	infections	(Aderaye	et	al.,	2007;	Malin	et	al.,	1995).		
Studies	that	specifically	recruited	patients	with	SARI	as	defined	by	the	World	Health	Organisation	were	also	excluded.	The	SARI	case	definition	-	currently,	acute	respiratory	infection	with	reported	or	measured	fever,	cough,	onset	within	last	10	days	and	
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requirement	for	hospitalisation	-	is	designed	to	facilitate	standardised	reporting	of	respiratory	illness	and	is	mainly	used	for	viral	pathogen	surveillance	(World	Health	Organization,	2013b).	A	large	SARI	surveillance	project	in	rural	Kenya	that	was	excluded	from	this	review	found	a	similar	spectrum	of	aetiologies	in	hospitalised	patients	(23%	pneumococcal	disease;	3%	NTS;	7%	influenza	A;	8%	respiratory	syncytial	virus)	and	comparable	30-day	mortality	at	6%	(Feikin	et	al.,	2012).	
2.6.5 Strengths	and	limitations	This	review	has	provided	an	inclusive	and	comprehensive	summary	of	the	published	literature	describing	the	aetiology	and	outcome	of	CAP	in	sub-Saharan	Africa.	The	search	strategy	was	broad	and	specifically	aimed	to	access	the	African	literature	including	that	from	Francophone	countries	by	using	databases	such	as	CAB	abstracts	and	Global	Health	(CABI,	Web	of	Science)	and	African	Index	Medicus.	The	decision	to	restrict	inclusions	to	studies	describing	acute	CAP	presentations	was	deliberate	but	resulted	in	the	exclusion	of	several	high	quality	studies.	As	such,	this	review	does	not	provide	specific	data	to	address	the	important	question	of	what	is	the	aetiology	and	outcome	of	pneumonia	amongst	adults	that	fails	to	respond	to	initial	narrow-spectrum	antibacterial	therapy.		
The	criteria	used	to	assess	the	risk	of	bias	and	quality	of	the	studies	in	the	review	were	adapted	from	those	used	in	the	Cochrane	Collaboration	Tool	to	Assess	Risk	of	Bias	in	Cohort	Studies	and	as	such	were	not	validated.	Several	of	the	criteria,	in	particular	those	used	to	assess	the	risk	of	bias	for	the	aetiology	analysis,	were	subjective	as	demonstrated	by	the	poor	agreement	between	the	assessors.	Assessing	the	methodological	quality	of	non-randomised	studies	is	complicated	by	the	range	of	study	designs	used	and	the	varying	approaches	adopted	to	adjust	for	confounding.			Numerous	tools,	scales	and	checklists	have	been	developed	for	this	purpose	(Deeks	et	
al.,	2003).	The	Downs	scale,	for	example,	lists	27	questions	to	assess	reporting,	external	validity,	bias	and	confounding.	The	Newcastle-Ottawa	Scale	uses	a	simple	scoring	system	to	assess	studies	across	eight	domains	including	representativeness	of	cohort	and	appropriateness	of	analyses.	The	inter-rate	reliability	of	the	tool	has	been	established	and	it	is	recommended	for	use	in	systematic	reviews	(Deeks	et	al.,	2003;	Wells	et	al.,	2014).		
Additional	limitations	and	potential	for	bias	of	this	review	relate	mainly	to	the	quality	of	the	data	of	the	included	studies.	Many	studies	were	small	and/or	retrospective.	Some	studies	did	not	describe	the	CAP	case	definition	used	and	as	such	their	generalisability	is	difficult	to	infer.	The	included	studies	were	almost	universally	conducted	in	large	
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urban	hospitals	and	as	such	might	not	be	representative	of	other	settings.	In	terms	of	the	aetiological	data,	many	of	the	included	studies	relied	heavily	on	microscopy	and	culture	of	spontaneously	expectorated	sputum	that	is	particularly	susceptible	to	contamination;	fewer	than	half	described	robust	techniques	for	assessing	the	quality	of	sputum	specimens.	Only	a	small	number	of	studies	used	more	invasively	obtained	specimens	such	as	bronchoalveolar	specimens	and	peripheral	lung	aspirates.	Shortcomings	in	laboratory	testing	were	further	compounded	by	incomplete	and	non-systematic	specimen	collection	evident	in	many	studies.		
2.6.6 Future	research	The	description	of	CAP	outcome	in	sub-Saharan	Africa	in	studies	conducted	to	date	has	largely	been	limited	to	inpatients	mortality	rate	alone.	Data	from	well-resourced	settings	highlight	the	persistently	elevated	risk	of	death	for	at	least	one	year	following	an	episode	of	CAP	(Koivula	et	al.,	1999;	Waterer	et	al.,	2004).	Long-term	follow	up	data	from	sub-Saharan	Africa	are	needed	to	estimate	the	true	impact	of	CAP	on	survival.	Data	from	well-resourced	settings	also	indicate	that	only	half	of	all	deaths	following	an	episode	of	CAP	are	directly	attributable	to	pneumonia	itself	(Mortensen	et	al.,	2002).	Further	detailed	prospective	observational	studies	are	also	needed	to	define	the	cause	of	death	following	CAP	to	develop	appropriate	management	strategies.	
The	relative	lack	of	high	quality	data	describing	risk	factors	for	adverse	outcome	in	CAP	needs	to	be	addressed.	These	data	are	necessary	to	improve	prognostication	and	risk	stratification	in	CAP	patients.	CAP	severity	assessment	tools	(e.g.	CURB65,	pneumonia	severity	index)	should	be	prospectively	assessed	to	determine	their	accuracy	and	utility	in	guiding	CAP	management	sub-Saharan	African	populations.		
The	potential	spectrum	of	pathogens	implicated	in	CAP	in	sub-Saharan	Africa	is	broad	–	particularly	for	HIV-infected	patients	–	but	laboratory	infrastructure	to	support	advanced	microbiological	investigations	is	often	lacking.	The	utility	of	recently	developed	rapid	or	point-of-care	diagnostic	tests	(e.g.	Xpert	MTB/RIF,	urinary	lipoarabinomannan)	to	effectively	direct	antimicrobial	management	in	CAP	should	be	examined.		
2.7 Conclusions	The	major	burden	of	CAP	in	sub-Saharan	Africa	is	in	working	age	adults	and	associated	mortality	is	considerable.	HIV	-	the	main	driver	of	CAP	in	this	region	-	is	preventable	and	treatable:	substantial	reductions	in	the	burden	of	CAP	may	be	achievable	with	continued	rollout	of	antiretroviral	therapy	across	the	continent.	Further	research	is	
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required	to	determine	the	risk	factors	predictive	of	adverse	outcome	in	CAP	to	both	improve	prognostication	and	identify	opportunities	for	intervention.	After	S.	
pneumoniae,	Mycobacterium	tuberculosis	is	amongst	the	most	commonly	identified	pathogens:	strategies	to	improve	early	detection	and	treatment	are	needed.		
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3 Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	
Aetiology	and	Outcome	(MARISO)	Study:	Aims,	design	and	
methodology.	
3.1 Introduction		Local	surveillance	data	from	Malawi	show	that	pneumonia	is	the	commonest	reason	for	adult	hospitalisation	in	Malawi	(SanJoaquin	et	al.,	2013).	However,	there	are	limited	recent	data	from	prospective	studies	describing	the	outcome	and	aetiology	of	community-acquired	pneumonia	(CAP)	in	either	Malawi	or	comparable	sub-Saharan	Africa	settings.		
I	hypothesised	that	the	epidemiology	and	aetiology	of	CAP	in	Malawi	would	be	markedly	different	to	that	seen	in	well-resourced	settings	and	accordingly	that	clinical	predictors	of	adverse	outcome	would	be	different	and	empirical	therapy	recommendations	from	well-resourced	settings	would	fail	to	provide	adequate	antimicrobial	coverage	for	the	spectrum	of	pathogens	encountered.		
The	MARISO	study	was	a	prospective	observational	study	of	adults	with	clinically	diagnosed	CAP	admitted	to	Queen	Elizabeth	Central	Hospital	(QECH),	Blantyre,	Malawi.	The	broad	aim	was	to	describe	the	clinical	features,	aetiology	and	outcome	of	CAP	in	adults	in	Malawi	with	a	view	to	identifying	the	key	risk	factors	for	adverse	outcome.	
3.2 Objectives	i) To	determine	the	frequency	of	30-day	mortality	and	treatment	failure	amongst	adults	hospitalised	with	clinically	diagnosed	CAP	in	Blantyre,	Malawi	and	to	identify	the	clinical	and	laboratory	characteristics	associated	with	these	poor	outcomes.	
ii) To	describe	the	microbial	aetiology	of	clinically	diagnosed	CAP	using	microbiological	culture,	serological	and	molecular	techniques.		
iii) To	determine	the	median	time	to	clinical	stability	adults	hospitalised	with	clinically	diagnosed	CAP	
iv) To	determine	the	utility	of	inflammatory	biomarkers	in	predicting	30-day	mortality	and	treatment	failure	in	adults	hospitalised	with	clinically	diagnosed	CAP.	
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3.3 Integration	with	other	respiratory	infection	studies	The	MARISO	study	was	one	of	several	concurrently	recruiting	projects	based	at	QECH	focusing	on	the	clinical	epidemiology	and	aetiology	of	respiratory	infection.	Recruitment	to	the	MARISO	study	was	nested	within	that	of	the	Burden	and	Severity	of	HIV-associated	Influenza	(BASH-FLU)	Study	(Principal	Investigator:	Dr	Antonia	Ho).	This	case-control	study	recruited	adults	with	mild	(influenza-like	illness)	and	severe	(hospitalised	LRTI)	influenza-associated	respiratory	illness	to	determine	the	association	of	HIV	with	disease	severity.	The	eligibility	criteria	used	to	define	hospitalised	LRTI	were	aligned	with	that	of	the	MARISO	study;	patients	recruited	to	the	BASH-FLU	study	were	invited	to	participate	in	the	MARISO	study	that	involved	more	detailed	assessment	and	follow-up.		
Recruitment	to	the	MARISO	study	also	integrated	with	that	of	the	existing	severe	acute	respiratory	infection	(SARI)	surveillance	programme	at	QECH	that	aimed	to	describe	the	local	epidemiology	of	respiratory	viral	infections.	Latterly,	some	patients	recruited	to	MARISO	were	invited	to	participate	in	the	Acute	Infection	of	the	Respiratory	Tract	(AIR)	study	(Principal	Investigator:	Dr	Hannah	Jary);	a	case-control	study	investigating	the	impact	of	exposure	to	indoor	air	pollution	on	the	risk	of	developing	pneumonia.		
Recruitment	to	the	studies	was	performed	by	an	integrated	respiratory	infection	research	clinical	study	team.	Laboratory	and	clinical	data	were	shared	between	the	respective	studies.	Recruitment	was	carefully	coordinated	so	that	there	was	no	duplication	of	clinical	specimen	sampling	and	burden	on	participants	was	minimised.		
3.4 Contributors	to	the	MARISO	Study	Patient	recruitment	and	follow-up	was	performed	by	the	integrated	respiratory	infection	clinical	research	study	team	made	up	of	clinical	officers	and	research	nurses.	I	and	the	principal	investigators	of	the	BASH-FLU	and	AIR	studies,	Dr	Antonia	Ho	and	Dr	Hannah	Jary,	provided	direct	oversight	of	recruitment	by	regularly	attending	the	study	ward	rounds	and	confirmed	the	eligibility	of	patients	for	recruitment	and	assured	the	quality	of	clinical	data	collection.	For	study	participants	that	could	not	be	reached	after	hospital	discharge,	community	follow-up	was	undertaken	by	two	study	field	workers.		
Clinical	specimens	for	haematology,	biochemistry	and	bacteriology	tests	were	processed	in	the	MLW	Clinical	Diagnostic	Laboratory	under	the	supervisions	of	the	laboratory	managers,	Brigitte	Denis	and	George	Selemani.	Nasopharyngeal	aspirate	specimens	for	molecular	respiratory	pathogen	diagnostic	testing	were	processed	at	the	MLW	Molecular	Laboratory	under	the	supervision	of	senior	laboratory	technician,	
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Mavis	Menyere.	Specimens	for	mycobacterial	microscopy	and	culture	and	Xpert	MTB/RIF	testing	were	process	at	the	College	of	Medicine	Tuberculosis	Research	Laboratory	under	the	supervision	of	its	manager,	Aaron	Mdolo.	
Chest	radiographs	were	photographed	by	Antonia	Ho,	Hannah	Jary	or	myself.	The	chest	radiograph	interpreting	proforma	was	developed	by	Dr	Sarah	Heath	under	my	supervision	as	part	of	Masters	research	project.	Reading	and	grading	of	the	radiographs	was	performed	by	two	UK	based	radiologists,	Dr	Elizabeth	Joekes	and	Dr	Simon	Greenwood,	and	by	myself.		
I	designed	the	case	record	forms	(CRFs)	used	for	the	capture	of	clinical	data	in	conjunction	with	Dr	Ho.	We	also	shared	the	tasks	of	CRF	scanning,	clinical	data	verification	and	cleaning	processes.		
I	developed	the	statistical	analysis	plan	and	undertook	all	analyses	myself	with	the	guidance	of	Professor	Brian	Faragher.	
3.5 Study	design	The	MARISO	study	was	a	prospective	observational	cohort	study.	
3.6 Clinical	endpoints	i. 30-day	mortality:	death	on	or	before	the	30th	day	following	hospital	admission.	
ii. 90-day	mortality:	death	on	or	before	the	90th	day	following	hospital	admission.	
iii. Treatment	failure	was	defined	as	clinical	deterioration	with	death,	respiratory	failure	(mechanical	ventilation	or	oxygen	saturations	<90%	without	supplemental	oxygen),	haemodynamic	instability	(systolic	blood	pressure	<90mmHg	or	fall	by	≥40mmHg	from	baseline)	or	persistence/reappearance	of	fever	(≥38°)	at	72	hours	following	the	commencement	of	antimicrobial	treatment	(Menendez	et	al.,	2008;	Menendez	et	al.,	2004b).		
iv. Clinical	stability	was	defined	as	the	achievement	of	all	the	following	parameters:	temperature	≤	37.2°C;	heart	rate	≤100	beats	per	minute;	respiratory	rate	≤24	breaths	per	minute;	systolic	blood	pressure	≥90mmHg;	and	oxygen	saturations	≥90%	without	supplemental	oxygen	(Halm	et	al.,	1998;	Menendez	et	al.,	2004a).	
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3.7 Ethical	approval	The	study	protocol	was	independently	reviewed	and	approved	by	the	Research	Ethics	Committee	of	both	the	University	of	Malawi	College	of	Medicine	(Protocol	No.	P.11/12/1309)	and	the	Liverpool	School	of	Tropical	Medicine	(Protocol	No.	13.02).	
3.8 Setting	The	study	was	conducted	at	Queen	Elizabeth	Central	Hospital,	Blantyre,	Malawi	(see	section	1.11.2).	Recruitment	commenced	on	15th	May	2013	and	continued	until	31st	January	2015.	Participant	follow-up	was	completed	by	28th	May	2015.	
3.9 Study	participants	The	study	recruited	hospitalised	adults	with	clinically	diagnosed	pneumonia.		
3.9.1 Inclusion	criteria	All	of	the	following	had	to	be	present:	
• Adults	(aged	18	years	or	over)	
• Reported	or	recorded	fever	(≥38°C)	
• Reported	cough	or	chest	pain	or	breathlessness	or	haemoptysis		
• Crepitations	or	pleural	rub	or	bronchial	breathing	or	percussive	dullness	or	diminished	breath	sounds	on	clinical	examination	
3.9.2 Exclusion	criteria	
• Pre-admission	diagnosis	of	terminal	illness	(e.g.	metastatic	malignancy,	terminal	AIDS)	
• Current	anti-tuberculous	treatment	
• Admitted	to	hospital	more	than	24	hours	previously	
• Symptoms	for	greater	than	14	days	
• Prior	hospitalisation	within	last	4	weeks	
• Suspected	co-existent	meningitis	
• Prior	participation	in	the	study	
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3.10 Recruitment	procedures	Patients	were	recruited	in	AETC	and	the	adult	medical	wards.1	In	AETC,	the	study	nurses	were	based	at	the	triage	station	on	weekdays	between	8am	and	3pm.	All	patients	with	any	features	of	respiratory	illness	or	infection	were	referred	to	the	study	clinical	officers	for	formal	screening	against	the	eligibility	criteria	listed	above.	The	study	team	also	toured	the	medical	wards	each	morning2	to	identify	patients	admitted	within	the	previous	24	hours	not	previously	seen	in	AETC	and	screened	all	those	with	features	of	respiratory	illness	or	infection.	Patient	eligibility	was	determined	by	direct	interview	of	the	patient	and/or	their	guardian	and	if	necessary	by	reference	to	the	medical	notes.	The	physical	examination	to	determine	eligibility	was	performed	by	the	study	clinical	officer.		
Potentially	eligible	patients	who	were	willing	to	consider	participation	in	the	study	were	given	written	and	verbal	information	(in	either	English	or	Chichewa	according	to	their	preference)	that	provided	an	overview	of	the	study	and	its	objectives	and	describing	the	study	procedures	and	associated	risks	and	benefits.	Written	informed	consent	was	obtained	by	a	study	team	member	from	the	patient	or,	in	the	case	of	incapacity,	by	proxy	from	their	accompanying	guardian.		
3.11 Clinical	assessment	
3.11.1 Medical	history	For	each	participant,	the	study	clinical	officer	completed	a	thorough	clinical	assessment	using	standardised	reporting	forms	(included	in	Appendix	B).	The	medical	history	included	details	of	the	present	illness,	past	medical	and	drug	history,	demographic	details,	social	history	and	information	about	household	characteristics.	Information	was	obtained	via	direct	questioning	of	the	study	participant	(or	accompanying	guardian)	and	by	reference	to	medical	notes	and	health	passport.			
3.11.2 Physical	examination	The	initial	physical	examination	consisted	of	cardiovascular,	upper	and	lower	respiratory	tract	and	abdominal	examinations.	The	examination	findings	were	reported	as	the	presence	or	absence	of	pre-specified	features,	rather	than	a	non-directed	description	of	findings.	Level	of	consciousness	was	assessed	using	the	AVPU	scale	(Kelly	et	al.,	2004).	Using	this	simplified	tool	patients	are	assessed	as	“Alert”,	“Responsive	to	voice”,	“Responsive	to	pain”	or	“Unresponsive.”	In	lieu	of	a	validated																																									 																					1	Recruitment	was	initially	restricted	to	the	AETC.	Ward-based	recruitment	began	in	May	2014	to	allow	the	recruitment	of	patients	admitted	overnight.		2	Ward-based	recruited	was	extended	to	weekends	from	August	2014.	
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cognitive	assessment	tool	that	is	not	available	in	Malawi,	the	presence	of	confusion	was	determined	using	three	standardised	questions	assessing	orientation	in	time,	place	and	person.	For	patients	able	to	stand,	weight	and	height	were	measured	using	mechanical	floor	scales	(seca	761;	seca,	Birmingham,	UK)	and	a	wall-mounted	measuring	tape	(seca	206;	seca,	Birmingham,	UK).		
3.11.3 Measurement	of	physiological	observations	The	study	team	measured	temperature,	blood	pressure,	heart	rate,	respiratory	rate	and	oxygen	saturations	at	the	point	of	recruitment.3	Physiological	observations	were	measured	at	rest	and	in	accordance	with	a	detailed	standardised	operating	procedure,	using	study-specific	equipment:	temperature	(Welch	Allyn	SureTemp	Plus	thermometer	using	an	oral	probe;	Welch	Allyn,	Buckinghamshire,	UK);	blood	pressure	(A&D	UA767	Digital	Blood	Pressure	Monitor;	A&D	Instruments,	Abingdon,	UK);	oxygen	saturations	(CMS50DL	Pulse	Oximeter	or	CMS60C	Pulse	Oximeter;	Contec	Medical	Systems,	Qinhuangdao,	China).	Heart	rate	was	read	from	the	pulse	oximeter	unless	there	was	a	discrepancy	of	greater	than	5	beats/minute	with	the	reading	on	the	sphygmomanometer	in	which	case	it	was	counted	manually.	Respiratory	rate	was	counted	by	direct	chest	visualisation	over	the	course	of	a	full	60	seconds.	
3.11.4 Chest	radiograph	A	plain	posteroanterior	chest	radiograph	was	requested	for	all	study	participants	at	the	point	of	enrolment.	Radiographs	were	performed	in	the	Department	of	Radiology,	QECH	using	standard	techniques.	During	the	period	of	the	study,	there	was	no	functional	portable	radiograph	machine	available	at	QECH;	consequently,	radiographs	were	not	performed	in	clinically	unstable	patients	that	could	not	be	safely	transferred	to	the	radiology	department.	
3.12 Clinical	management	Patient	management	was	directed	by	the	clinical	team.	Patients	recruited	by	the	study	team	in	AETC	prior	to	review	by	the	clinical	team	were	commenced	on	treatment	in	accordance	with	local	guidelines	for	the	management	of	pneumonia.	The	diagnostic	work-up	undertaken	as	part	of	the	study	was	far	more	detailed	than	routinely	available	at	QECH;	the	study	team	ensured	that	clinically	relevant	results	were	made	available	to	the	clinical	team	to	aid	management	decisions.		
																																								 																					3	For	patients	recruited	from	the	medical	wards,	the	observations	recorded	on	admission	documented	by	the	AETC	triage	team	were	used	for	the	baseline	assessment.		
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3.13 Clinical	specimen	collection		At	the	point	of	enrolment,	a	25ml	venous	blood	specimen	was	obtained	for	the	following	investigations:	aerobic	blood	culture,	full	blood	count,	urea,	creatinine,	HIV	test	and	CD4	cell	count.	Serum	specimens	were	stored	for	delayed	inflammatory	biomarker	and	acute	atypical	bacteria	serological	assays.4	A	capillary	blood	specimen	was	obtained	for	point-of-care	glucose	measurement	(Accu-Chek	Aviva;	Roche,	UK)	and	malaria	antigen	test	(First	Response	Malaria	Ag.	pLDH/HRP2	Combo	Card	Test;	Premier	Medical	Corporation,	Daman,	India).	For	patients	with	productive	cough,	two	spontaneously	expectorated	sputum	specimens	were	collected	for	mycobacterial	smear	microscopy	and	culture	and	Xpert	MTB/RIF	assay	(Cepheid;	Sunnyvale,	California,	US).	A	nasopharyngeal	aspirate	specimen	was	collected	for	molecular	testing	for	influenza	viruses	(CDC	Human	Influenza	RT-PCR	diagnostic	panel;	CDC	Influenza	Division,	Atlanta,	Georgia,	US)	and	a	real-time	PCR	multiplex	assay	for	33	respiratory	pathogens	(FTD	Respiratory	Pathogens	33;	Fast-Track	Diagnostics,	Luxembourg).	A	urine	specimen	was	collected	for	pneumococcal	urinary	antigen	testing	(BinaxNOW	
Streptococcus	pneumoniae	antigen	card;	Alere,	Massachusetts,	USA)	and	additional	aliquots	were	stored.	For	patients	with	a	clinically	and	radiologically	apparent	pleural	effusion,	diagnostic	thoracocentesis	was	performed.	Pleural	fluid	specimens	were	sent	for	Gram-stain	microscopy	and	aerobic	culture,	mycobacterial	smear	microscopy	and	culture,	and	pneumococcal	antigen	testing	(BinaxNOW	Streptococcus	pneumoniae	antigen	card).	
For	surviving	inpatients,	a	further	venous	blood	specimen	was	collected	at	day	3	and	a	serum	specimen	stored	for	repeated	measurement	of	inflammatory	biomarkers.	This	specimen	was	omitted	for	patients	known	to	have	a	haemoglobin	concentration	of	less	than	8	g/dl.	A	convalescent	serum	specimen	was	obtained	at	approximately	six	weeks	following	enrolment	for	repeated	serological	assays.	 	
																																								 																					4	Specimens	for	acute	and	convalescent	serology	were	collected	for	approximately	the	second	half	of	the	patient	cohort	recruited	from	12th	May	2014	onwards.	
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Table	3.1	 Clinical	specimens	collected	and	investigations	performed	in	
MARISO	study	
	Clinical	specimen	and	investigation	
Venous	blood	Full	blood	count	 Urea		HIV	test	 Creatinine	CD4	cell	count	 Atypical	bacteria	serology	Aerobic	blood	culture	 Inflammatory	biomarker	assays	
Finger	prick	capillary	blood	Glucose	 Malarial	rapid	diagnostic	test	
Urine	BinaxNOW	Streptococcus	pneumoniae	antigen	test	
Nasopharyngeal	aspirate	Multiplex	molecular	assays	for	influenza	viruses	and	other	respiratory	pathogens	
Sputum	AFB	smear	microscopy	and	mycobacterial	culture	 Cepheid	Xpert	MTB/RIF	
Pleural	fluid	AFB	smear	microscopy	and	mycobacterial	culture	 BinaxNOW	Streptococcus	pneumoniae	antigen	test	Gram	stain,	microscopy	and	aerobic	bacteriological	culture	
3.14 Patient	follow-up	Study	participants	were	reviewed	on	a	daily	basis	each	morning.	Level	of	consciousness	and	orientation,	temperature,	blood	pressure,	heart	rate,	respiratory	rate	and	oxygen	saturations	were	measured	daily	up	to	14	days	following	hospital	admission.5	The	clinical	team	were	promptly	informed	of	markedly	abnormal	findings	that	required	immediate	intervention.	At	the	point	of	hospital	discharge	or	inpatient	death,	the	study	team	reviewed	the	clinical	notes	and	recorded	details	of	treatment	administered	and	discharge	diagnosis	as	determined	by	the	clinical	team.		
Patients	surviving	to	discharge	were	contacted	at	30-days	and	90-days	post	admission	to	determine	vital	status	and	hospital	readmission.	Two	attempts	were	made	to	obtain	
																																								 																					5	Observation	rounds	were	completed	once	daily	in	the	morning.	For	patients	recruited	on	the	medical	wards,	the	first	day	post-admission	(termed	day	1)	observations	were	completed	at	the	time	of	recruitment	if	more	than	12	hours	had	elapsed	since	the	time	of	admission.	
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this	information	by	phone	call	to	the	patient	or	their	guardian;	if	unsuccessful	field	workers	visited	the	patient’s	home.6		
3.15 Clinical	specimen	processing	Tuberculosis	diagnostic	tests	were	performed	at	the	College	of	Medicine	Tuberculosis	Research	Laboratory.	All	other	specimen	processing	and	investigations	were	performed	at	MLW	Clinical	Diagnostic	and	Molecular	Laboratories	which	has	an	internal	quality	assurance	programme	with	external	quality	control.	These	tests	were	done	by	a	designated	trained	technician.	
3.15.1 Haematology	Full	blood	count	was	performed	on	whole	blood	specimens	using	a	Beckman	Coulter	HmX	Haematology	Analyser	(Beckman	Coulter,	California,	USA).	CD4	cell	counts	were	measured	according	to	standard	protocols	using	either	a	Becton	Dickinson	FACSCount	(Becton	Dickinson,	California,	USA)	or	Partec	CyFlow	CD4	Analyser	(Sysmex	Partec,	Görlitz,	Germany).	
3.15.2 Biochemistry	Whole	blood	specimens	for	biochemical	assays	were	centrifuged	within	24	hours	of	collection.	Urea	and	creatinine	concentrations	were	measured	in	serum	specimens	using	a	Beckman	Coulter	AU480	Chemistry	Analyser	(Beckman	Coulter,	California,	USA).		
3.15.3 Blood	culture	Blood	cultures	were	performed	using	standard	aerobic	bottles	in	the	BacT/ALERT	3D	automated	system	(bioMérieux,	Marcy-L’Etoile,	France)	as	previously	described	(Everett	et	al.,	2011;	Feasey	et	al.,	2014).	All	isolates	were	identified	using	standard	diagnostic	procedures	(Barrow	et	al.,	1993).	Coagulase-negative	Staphylococci,	Bacillus	spp.,	Micrococcus	spp.	and	diphtheroids	were	considered	as	contaminants.		
3.15.4 HIV	test	HIV	testing	was	performed	on	whole	blood	specimens	using	rapid	diagnostic	test	kits	in	a	serial	testing	pathway	in	accordance	with	WHO	guidelines	(World	Health	Organization,	2004).	Initial	screening	was	performed	using	the	Alere	Determine	HIV-1/2	Ag/Ab	Combo	assay	(Alere,	Massachusetts,	USA);	negative	results	were	reported	and	positive	results	prompted	confirmatory	testing	using	the	Uni-Gold	Recombinogen																																									 																					6	Telephone	follow-up	alone	was	used	for	the	first	100	patients	but	there	was	substantial	loss	to	follow-up	so	a	protocol	amendment	to	permit	home	follow-up	via	field	worker	was	made.		
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HIV-1/2	test	(Trinity	Biotech,	Co	Wicklow,	Ireland).	If	results	were	discrepant	a	second	confirmatory	test	was	performed	using	a	different	assay	(Bioline	HIV-1/2	3.0;	Standard	Diagnostics,	Gyeonggi-do,	Republic	of	Korea).	
3.15.5 Respiratory	pathogen	multiplex	PCR	The	nasopharyngeal	aspirates	were	divided	into	aliquots	and	stored	at	-80°C	in	Universal	Transport	Medium	(Copan,	Brescia,	Italy).	These	were	batch-tested	for	influenza	viruses	by	real-time	reverse	transcription	polymerase	chain	reaction	(qRT-PCR).	Total	nucleic	acids	were	extracted	from	300μl	aliquots	of	each	specimen	with	the	Qiagen	BioRobotÒ	Universal	System	using	the	QIAamp	One-For-All	nucleic	acid	kit	(Qiagen,	Manchester,	UK).	5	or	10	μL	of	nucleic	acid	extract	was	used	in	each	qRT-PCR	reaction.	Both	the	CDC	Human	Influenza	RT-PCR	diagnostic	panel	(CDC	Influenza	Division)	detecting	influenza	A	and	B	and	influenza	A	subtypes	H1,	H3	and	H5,	and	the	FTD	respiratory	pathogens	33	kit	(Fast-track	Diagnostics,	Luxembourg)	detecting	influenza	A,	B	and	C,	coronaviruses	OC43,	NL63,	HKU1	and	229E,	parainfluenza	viruses	1-4;	respiratory	syncytial	viruses	(RSV)	A	and	B;	enterovirus;	human	metapneumovirus;	rhinovirus;	adenovirus;	bocavirus;	parechovirus;	cytomegalovirus	(CMV);	Bordetella	pertussis;	Chlamydia	pneumoniae;	Haemophilus	influenzae;	Klebsiella	
pneumoniae;	Legionella	spp;	Moraxella	catarrhalis;	Pneumocystis	jirovecii,	Salmonella	species,	Staphylococcus	aureus	and	Streptococcus	pneumoniae	were	used,	in	combination	with	the	AgPath	one-step	RT-PCR	reagents	(Applied	Biosystems,	Foster	City,	California,	USA).	PCR	conditions	were	according	to	the	manufacturer’s	instructions.	Appropriate	negative	and	positive	control	specimens	were	run	alongside	each	reaction.	Samples	with	cycle	threshold	(Ct)-value	<40	were	recorded	as	positive.		
3.15.6 BinaxNOW®	Streptococcus	pneumoniae	Antigen	Card	The	BinaxNOW®	Streptococcus	pneumoniae	Antigen	Card	(Alere,	Massachusetts,	USA)	is	a	lateral	flow	rapid	immunochromatographic	assay	for	the	detection	of	pneumococcal	C-polysaccharide	coat	protein	in	the	urine	of	patients	with	pneumonia.	The	assay	was	performed	in	accordance	with	the	manufacturer’s	instructions	(Alere,	2015).	Briefly,	the	test	kit	swab	was	submerged	in	the	urine	sample	and	inserted	into	the	specimen	window	of	the	assay	cartridge,	followed	by	three	drops	of	the	assay	reagent.	The	test	was	read	visually	in	ambient	light	at	15	minutes.	An	identical	procedure	was	used	for	the	pleural	fluid	specimens.			
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3.15.7 Tuberculosis	diagnostic	tests	
3.15.7.1 Smear	microscopy	Sputum	and	pleural	fluid	microscopy	were	performed	according	to	standard	procedures.	Briefly,	the	most	viscous	part	of	the	sputum	specimen	was	aspirated	and	expelled	onto	a	dry	glass	slide,	spread	to	make	a	thin	smear	and	stained	using	the	Auramine	O	method.	Pleural	fluid	specimens	were	concentrated	by	centrifugation	at	2800	rpm	for	10	minutes	prior	to	smear	preparation.	Smear	specimens	were	each	examined	twice	by	two	independent	readers	using	LED	fluorescence	microscopy	and	reported	according	to	standard	criteria;	discordant	results	prompted	review	by	a	third	reader.	All	sample	smears	graded	as	scanty,	1+,	2+,	and	3+	were	defined	as	smear-positive.	
3.15.7.2 Mycobacterial	culture	Mycobacterial	culture	was	performed	according	to	standard	procedures	using	the	BACTEC	MGIT	960	Mycobacterial	Detection	System	(Becton	Dickinson	Diagnostic	Systems,	Sparks,	Maryland,	USA)	as	previously	described	(Feasey	et	al.,	2013;	Tortoli	et	
al.,	1999).	Briefly,	following	decontamination	in	sodium	hydroxide	and	concentration	by	centrifugation,	sputum	and	pleural	fluid	specimens	were	inoculated	into	mycobacterial	growth	indicator	tubes	(MGIT)	tubes	and	incubated	at	37°C	in	the	BACTEC	MGIT	automated	liquid	culture	system	for	up	to	44	days.	Cultured	isolates	identified	as	acid-fast	bacilli	on	ZN	microscopy	were	positively	confirmed	as	
Mycobacterium	tuberculosis	complex	by	microscopic	cording	and	MPT-64	lateral	flow	assay	(Capilia;	TAUNS	Laboratories,	Numazu,	Japan).	Acid-fast	bacilli	(AFB)	isolates	that	were	negative	on	either	confirmatory	test	were	inoculated	onto	plain	Löwenstein-Jensen	(LJ)	media	and	incubated	at	25°C,	37°C	and	45°C	and	onto	paranitrobenzoic	acid	(PNB)	and	incubated	at	37°C.	Isolates	that	grew	on	LJ	media	at	37°C	only	were	classified	as	M.	tuberculosis.	Those	that	grew	at	25°C	or	45°C	or	on	PNB	were	classified	as	nontuberculous	mycobacteria	and	not	speciated	further.	Positive	cultures	that	did	not	reveal	AFB	on	microscopy	were	re-cultured	using	a	stored	aliquot	of	the	primary	specimen;	if	the	same	result	was	obtained,	they	were	classified	as	contaminants	or	false	positives.		
3.15.7.3 Cepheid	Xpert	MTB/RIF	The	Cepheid	Xpert	MTB/RIF	assay	(Cepheid,	Sunnyvale,	California,	USA)	is	a	self-contained,	fully	integrated,	automated	rapid	diagnostic	system	that	uses	nested	real-time	PCR	to	detect	M.	tuberculosis	genomic	DNA	in	sputum	and	other	clinical	specimens	(Lawn	et	al.,	2013c).	The	assay	was	performed	in	accordance	with	the	manufacturer’s	
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instructions	(Cepheid,	2015).	Briefly,	unprocessed	sputum	specimens	were	mixed	with	the	dedicated	assay	Sample	Reagent	and	incubated	at	room	temperature	for	15	minutes.	The	liquefied	specimen	was	then	loaded	into	the	Xpert	MTB/RIF	test	cartridge	and	inserted	into	the	GeneXpert	machine	for	processing.		
3.16 Chest	radiograph	photography	and	reporting	Plain	chest	radiograph	films	were	photographed	on	a	light-box	using	a	standard	light-reflex	digital	camera	mounted	on	a	tripod	in	a	darkened	room.	Several	high-resolution	photographs	at	a	range	of	exposure	settings	were	taken	of	each	radiograph	to	compensate	for	some	of	the	variability	in	penetration	of	the	original	radiograph.	All	study	radiograph	reports	were	generated	by	review	of	the	set	of	digital	images	rather	than	the	original	radiograph.	
Chest	radiographs	were	reported	independently	by	two	UK-based	radiologists	(Dr	Elizabeth	Joekes	and	Dr	Simon	Greenwood)	and	myself.	All	reporters	were	blinded	to	demographic	and	clinical	data	at	the	time	of	reporting.	Radiographs	were	reported	using	a	standardised	form	developed	specifically	for	the	study	(see	Appendix	A).	The	form	was	accompanied	with	guidance	notes	containing	definitions	for	radiological	features	based	on	the	Fleischner	Society:	Glossary	of	terms	for	thoracic	imaging	(Hansell	et	al.,	2008).	The	form	was	piloted	using	a	small	number	of	non-study	radiographs	to	ensure	consistency	of	application	of	the	agreed	definitions.		
The	reporting	form	was	based	on	fixed,	categorical	responses.	Parenchymal	abnormalities	were	categorised	as	consolidation,	reticulonodular	change,	miliary	appearance	and	cavitation.	Consolidation	was	further	characterised	in	terms	of	its	quality	(confluent	or	patchy),	extent	(segmental,	lobar	or	multifocal)	and	distribution	(lower,	mid-	and/or	upper	zone,	or	diffuse).		
A	consensus	report	was	used	for	the	main	analyses.	If	there	was	disagreement	between	the	three	reporters,	the	majority	opinion	was	used.	Radiographic	pneumonia	was	defined	as	the	presence	of	consolidation	or	other	parenchymal	abnormality	(including	reticulonodular	change,	cavitation	or	miliary	appearance)	or	pleural	effusion	(Jain	et	
al.,	2015).	Multilobar	consolidation	was	not	specifically	reported	on	the	form.	Consolidation	was	considered	to	be	multilobar	if	characterised	as	diffuse,	present	in	two	or	more	non-contiguous	lung	zones	regardless	of	extent	or	present	in	two	or	more	contiguous	lung	zones	and	characterised	as	multifocal.	Multifocal	consolidation	within	a	single	lung	zone	was	not	classified	as	multilobar.	
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3.17 Data	management	Study	participants	were	assigned	a	unique	study	number	at	the	time	of	recruitment,	under	which	all	data	were	captured.	The	clinical	data	were	collected	in	paper-based	CRFs	and	subsequently	converted	to	electronic	form	using	Intelligent	Character	Recognition	scanning	software	(TeleForm;	Cardiff	Software	Developers,	Cardiff,	UK).	Following	verification	the	data	were	exported	to	a	Microsoft	Access	database	(Microsoft	Corporation,	Redmond,	Washington,	USA).	Data	were	exported	to	a	Microsoft	Excel	spreadsheet	(Microsoft	Corporation,	Redmond,	Washington,	USA)	and	subsequently	to	Stata	12	(StataCorp	LP,	College	Station,	Texas,	USA)	for	cleaning	and	analysis.		
Prior	to	scanning	the	CRFs	were	checked	by	the	clinical	team	and	again	by	Dr	Antonia	Ho	or	myself.	Discrepancies	were	queried	and	addressed;	where	possible	missing	fields	were	completed	although	frequently	the	patient	had	already	been	discharged.	The	TeleForm	software	automatically	scans	each	CRF	twice;	any	discrepant	values	or	values	outwith	a	range	pre-specified	by	the	user	are	highlighted	for	manual	review.	Further	certain	essential	fields	containing,	for	example,	identifiers	or	key	outcome	variables	were	set	for	mandatory	manual	review.		
The	study	database	was	hosted	on	the	secure	MLW	server;	access	was	restricted	to	the	respiratory	infection	team	lead	investigators	and	the	MLW	data	management	and	information	technology	groups.	The	corresponding	paper	records	were	held	securely	at	MLW	in	a	locked	office.	These	records	were	pseudo-anonymised,	identifiable	by	study	number	and	initials	only.	The	paper	record	containing	the	demographic	data	and	contact	details	of	the	participants	necessary	for	follow-up	were	held	separately	from	the	other	CRFs	in	a	secure	locked	cabinet	only	accessible	to	study	team	members.	
3.18 Analysis	
3.18.1 Sample	size	considerations	The	intended	analytic	approach	was	to	generate	a	multivariable	logistic	regression	model	to	identify	factors	independently	predictive	of	treatment	failure	and	death.	When	using	multivariable	logistic	regression,	in	order	to	avoid	‘over-fitting’	and	type	I	(i.e.	false	positive)	errors,	a	minimum	number	of	10	events	per	predictor	variable	is	recommended	(Peduzzi	et	al.,	1996).	Assuming	a	treatment	failure	rate	of	15%,	a	sample	size	of	433	would	give	65	outcome	events	that	should	allow	the	inclusion	of	at	least	6	predictor	variables	in	a	stable	multivariable	model.	In	univariable	analyses,	this	sample	size	would	give	approximately	80%	power	to	detect	factors	that	are	associated	
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with	treatment	failure	with	odds	ratio	of	2.2	or	greater.	In	order	to	mitigate	the	effects	of	missing	data	and	incomplete	follow-up,	I	planned	to	recruit	an	additional	15%	to	give	a	target	study	patient	population	of	500.		
3.18.2 Statistical	methods	The	statistical	methods	applicable	to	specific	analyses	are	describes	in	detail	in	each	of	the	respective	results	chapters.	All	statistical	analyses	were	conducted	using	Stata	version	12.1	(StataCorp;	Texas,	US).	
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4 Clinical	characteristics,	microbial	aetiology	and	radiological	
features	of	community-acquired	pneumonia	in	Malawi:	A	
prospective	observational	cohort	
4.1 Introduction	The	clinical	characteristics	and	aetiology	of	pneumonia	in	adults	in	Malawi,	and	sub-Saharan	Africa	more	generally,	are	poorly	described.	With	the	exception	of	several	cohorts	from	South	Africa	(Albrich	et	al.,	2012;	Nyamande	et	al.,	2007a),	the	available	studies	of	acute	CAP	in	sub-Saharan	Africa	are	either	small	(Fiberesima	et	al.,	2008;	Hartung	et	al.,	2011;	Horo	et	al.,	2009;	Vray	et	al.,	2008),	retrospective	(Birkhamshaw	
et	al.,	2013;	Onyedum	et	al.,	2011;	Ouedraogo	et	al.,	2010),	completed	prior	to	the	HIV	era	or	roll-out	of	ART	(Scott	et	al.,	2000;	Yoshimine	et	al.,	2001)	or	only	used	a	restricted	panel	of	investigations	to	define	aetiology	(Bos	et	al.,	2014;	Odera	et	al.,	2009).		
The	Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	Aetiology	and	Outcome	(MARISO)	Study	was	a	prospective	observational	study	of	adults	hospitalised	with	clinically	diagnosed	community-acquired	pneumonia	(CAP)	to	Queen	Elizabeth	Central	Hospital,	Blantyre,	Malawi	between	May	2013	and	January	2015.	Study	participants	underwent	a	standardised	clinical	assessment	and	laboratory	work-up	encompassing	classical	microbiological	and	molecular	diagnostic	techniques	to	define	disease	aetiology.	
4.2 Objectives	In	this	chapter	I	describe	the	baseline	characteristics,	microbial	aetiology	and	radiological	features	of	the	patient	cohort.	Clinical	outcomes	and	severity	assessment	will	be	described	in	chapter	5.		
4.3 Contributors	to	this	chapter	The	MARISO	study	was	one	of	several	prospective	observational	studies	of	respiratory	tract	infection	occurring	concurrently	at	Queen	Elizabeth	Central	Hospital.	The	individuals	that	contributed	to	data	collection	are	summarised	in	section	3.3.	I	have	performed	all	analyses	undertaken	in	this	chapter	independently.		
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4.4 Methods		
4.4.1 Patient	recruitment	and	assessment	The	methods	relevant	to	this	chapter	are	described	in	full	in	chapter	3.	Briefly,	patients	with	features	of	respiratory	illness	or	infection	were	screened	within	24	hours	of	admission.	Consenting	patients	with	clinically	diagnosed	CAP	as	defined	by	the	presence	of	reported	or	recorded	fever,	a	relevant	respiratory	symptom	and	focal	chest	signs	were	recruited	(see	section	3.1.1	for	full	eligibility	criteria).	Patients	underwent	a	standardised	clinical	assessment	consisting	of	comprehensive	medical	history,	targeted	physical	examination	and	measurement	of	physiological	observations	(see	section	3.13).	
Plain	posteroanterior	chest	radiographs	were	performed	as	early	as	possible	after	hospital	admission	and	independently	reported	by	two	radiologists	and	myself	using	a	standardised	form	(section	3.14	and	3.18).	Radiographic	pneumonia	was	defined	as	the	presence	of	consolidation	or	other	parenchymal	abnormality	(including	reticulonodular	change,	cavitation	or	miliary	appearance)	or	pleural	effusion	(Jain	et	
al.,	2015).	
4.4.2 Clinical	specimen	collection	Blood	was	collected	for	aerobic	culture,	HIV	testing,	malaria	rapid	diagnostic	antigen	test	and	basic	haematological	and	biochemical	analysis	(section	3.15).	Non-induced	sputum	was	collected	for	mycobacterial	microscopy	and	culture	and	Xpert	MTB/RIF	assay	(Cepheid;	Sunnyvale,	California,	USA).	Urine	was	collected	for	pneumococcal	antigen	testing	(BinaxNOW	Streptococcus	pneumoniae	antigen	card;	Alere,	Massachusetts,	USA).	Nasopharyngeal	aspirate	(NPA)	was	obtained	for	molecular	testing	for	influenza	viruses	(CDC	Human	Influenza	RT-PCR	diagnostic	panel;	CDC	Influenza	Division,	Atlanta,	Georgia,	US)	and	a	real-time	PCR	multiplex	assay	for	33	respiratory	pathogens	(FTD	Respiratory	Pathogens	33;	Fast-Track	Diagnostics,	Luxembourg).	When	available	pleural	fluid	specimens	were	collected	for	aerobic	culture,	mycobacterial	smear	microscopy	and	culture,	and	pneumococcal	antigen	testing.	Diagnostic	criteria	for	detection	of	specific	microbial	aetiologies	are	listed	in	table	4.1	
4.4.3 Statistical	analysis	The	demographic	features	of	enrolled	and	excluded	patients	were	compared	using	χ2	test	and	Mann-Whitney	U	test	for	categorical	and	continuous	variables,	respectively.	The	impact	of	an	altered	case	definition	of	the	demographics	of	the	cohort	was	
Clinical	characteristics,	aetiology	and	radiology	of	CAP	in	Malawi	 104	
estimated.	Differences	in	baseline	characteristics	by	HIV	status,	presence	of	radiographic	pneumonia,	symptom	duration	and	timing	of	recruitment	with	respect	to	admission	were	explored	by	univariable	logistic	regression.	The	relationship	of	baseline	parameters	with	antimicrobial	and	supportive	treatment	was	examined	by	logistic	regression.	The	impact	of	HIV	on	pathogen	prevalence	was	assessed	by	comparing	the	proportion	of	HIV-positive	and	HIV-negative	patients	with	each	pathogen	by	χ2	test	and	calculating	odds	ratios	with	95%	confidence	intervals.	The	relationship	between	radiographic	change	and	pathogen	prevalence	was	assessed	by	comparing	the	proportion	of	those	with	and	without	radiographic	pneumonia	for	each	pathogen	controlling	for	the	effect	of	HIV	status;	χ2	test	was	used	and	weighted	odds	ratios	with	95%	confidence	intervals	calculated	directly	by	the	Mantel-Haenszel	method	or	estimated	by	logistic	regression.	The	inter-observer	variability	of	chest	radiograph	interpretation	between	the	three	readers	was	assessed	by	calculating	average	percentage	agreement	and	kappa	coefficient	with	estimated	95%	confidence	intervals.	The	kappa	coefficient	was	interpreted	as	follow:	<0,	poor	agreement;	0-0.2,	slight	agreement;	0.21-0.4,	fair	agreement;	0.41-0.6,	moderate	agreement;	0.61-0.8,	substantial	agreement;	0.81-1.0,	almost	perfect	agreement.		 	
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Table	4.1	 Diagnostic	criteria	for	specific	microbial	aetiologies	in	MARISO	
study	
Organism	 Diagnostic	criteria	
Streptococcus	pneumoniae	 Positive	blood	or	pleural	fluid	culture;	positive	BinaxNOW	S.	pneumoniae	antigen	card	on	either	urine	or	pleural	fluid	
Mycoplasma	pneumoniae	
Chlamydophila	pneumoniae	
Legionella	spp.	
Positive	result	in	NPA	specimen	on	FTD	33	PCR	assaya	
Other	bacteria	 Positive	blood	or	pleural	fluid	culture	
Mycobacterium	tuberculosis	 Positive	sputum	or	pleural	fluid	culture;	positive	Xpert	MTB/RIF	assay	on	sputum;	positive	AFB	smear	microscopy	of	sputum	or	pleural	fluid	(if	results	absent	for	sputum	culture	and	Xpert	MTB/RIF)	Nontuberculous	mycobacteria	 Positive	sputum	or	pleural	fluid	culture	Influenza	 Positive	result	in	NPA	specimen	CDC	Influenza	PCRb	Adenovirus	Bocavirus	Coronavirus	Enterovirus	Metapneumovirus	Parainfluenza	Parechovirus	Rhinovirus	Respiratory	syncytial	virus	
Positive	result	in	NPA	specimen	on	FTD	33	PCR	assaya	
a	FTD	Respiratory	Pathogens	33	real-time	PCR	multiplex	assay	–	Also	detected	influenza,	
Pneumocystis	jirovecii,	Streptococcus	pneumoniae,	Haemophilus	influenzae,	Staphylococcus	
aureus,	Moraxella	catarrhalis,	Bordetella	spp.,	Klebsiella	pneumoniae,	Salmonella	spp.	but	results	not	analysed		b	CDC	Human	Influenza	RT-PCR	diagnostic	panel	
4.5 Results	
4.5.1 Screening	and	recruitment	Between	13th	May	2013	and	31st	January	2015,	1711	adult	patients	were	screened	for	inclusion	in	the	study.	Of	489	eligible	patients,	472	(97%)	were	enrolled	and	459	(94%)	were	included	in	the	analysis	(Figure	4.1).	Due	to	the	lack	of	radiograph	developer	solutions,	patient	recruitment	was	temporarily	suspended	between	28th	October	and	6th	November	2013.	Staffing	and	logistical	issues	also	necessitated	temporary	suspension	of	recruitment	from	16th	December	2013	to	6th	January	2014	and	16th	December	2014	to	4th	January	2015.	
There	was	a	male	preponderance	in	both	the	excluded	and	analysed	populations	(57%	and	62%,	respectively;	Table	4.2).	Compared	to	the	excluded	patients,	the	analysed	population	was	1	year	younger	overall	(median	age	34.6	vs.	35.6	years;	P=0.02),	
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although	this	difference	was	only	significant	for	males	(median	age	35.4	vs.	36.8	years;	
P<0.01;	Figure	4.2	and	Table	4.2).		
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Figure	4.1	 CONSORT	diagram	of	screening,	recruitment	and	follow-up	in	
MARISO	cohort.		 	
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Figure	4.2	 Age	and	sex	distribution	of	screened	and	enrolled	population	in	
the	MARISO	cohort;	displayed	as	opposing	overlaid	histograms.		
Table	4.2	 Comparison	of	the	demographics	of	excluded	and	enrolled	
populations.	Proportions	of	males	compared	by	χ2	test;	age	distributions	compared	using	Mann-Whitney	U	test;	odds	ratios	(with	95%	confidence	intervals)	for	enrolment	in	each	age	quartile	estimated	by	logistic	regression.		 Excludeda	(n=1246)	 Analysed	(n=459)	 Comparative	statistics	OR	(95%	CI)	 P	Male	(n/%)b	 708	(56.8)	 285	(62.1)	 1.24	(1.00-1.56)	 0.05	Median	age	(IQR)	 35.6	(29.6-46.0)	 34.6	(29.6-41.9)	 -	 0.02	Males		 36.8	(31.2-46.6)	 35.4	(30.6-41.4)	 -	 0.009	Females		 34.0	(27.5-45.1)	 32.7	(27.7-42.1)	 -	 0.32	Age	quartiles	(n/%)c	 	 	 	 	≤29	 304	(72.7)	 114	(27.3)	 1	 -	30-34	 260	(69.7)	 113	(30.3)	 1.16	(0.85-1.58)	 0.36	35-44	 335	(70.2)	 142	(29.8)	 1.13	(0.84-1.51)	 0.41	≥45	 347	(79.4)	 90	(20.6)	 0.69	(0.51-0.95)	 0.02	OR	–	odds	ratio;	NS	–	non-significant	a	Includes	8	ineligible	patients	erroneously	recruited;	6	patients	that	withdrew	or	with	lost	records	not	presented.	b	Column	percentage	c	Row	percentage	 	
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Illness	duration	greater	than	14	days,	lack	of	focal	chest	signs	and	absence	of	fever	(either	reported	or	measured)	were,	respectively,	the	three	commonest	reasons	for	ineligibility	(Figure	4.1).	Prolonged	symptom	duration	and	lack	of	focal	chest	signs	frequently	co-existed	(Figure	4.3).	If	the	symptom	duration	criterion	were	removed,	at	least	an	additional	338	patients	would	have	been	eligible	for	recruitment.	Had	these	patients	been	included	the	expanded	hypothetical	cohort	of	797	patients	would	have	had	broadly	similar	demographic	characteristics	(male	sex	512/797	(64.2%);	median	age	35.8	(IQR:	29.6-46.8)).	The	reasons	for	exclusion	varied	with	both	age	and	sex	(Table	4.3).	Absence	of	fever	(χ2test	for	trend,	P<0.0001)	and	inability	to	give	consent	(χ2test	for	trend,	P=0.049)	were	more	common	reasons	for	exclusion	in	the	oldest	quartile	(patients	≥45	years).	Male	patients	were	more	likely	to	be	excluded	on	the	basis	of	prolonged	illness	duration	(OR	1.78;	95%	CI:	1.38-2.29)	and	having	features	of	terminal	illness	(OR	4.62;	95%	CI:	1.02-42.67),	whilst	females	were	more	likely	to	lack	focal	chest	signs	(OR	0.62;	95%	CI:	0.48-0.81).	
	
Figure	4.3	 Inter-relationship	of	main	reasons	for	exclusion	from	MARISO	
cohort.	Proportional	Venn	diagram	showing	relationship	of	the	three	most	frequent	reasons	for	ineligibility	for	participation:	illness	duration	greater	than	14	days;	lack	of	focal	chest	signs;	absent	fever.	Percentages	refer	to	proportion	of	all	excluded	patients	for	whom	reason	for	exclusion	is	known	(n=1079;	88%	of	all	excluded	patients).				
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Over	the	21	months	of	recruitment,	a	median	of	74	patients	was	screened	and	22	patients	recruited	each	calendar	month	(Figure	4.4).	During	the	first	13	months	of	the	study,	patient	recruitment	only	occurred	during	weekdays.	From	14th	June	2014	recruitment	was	extended	to	weekends;	the	number	of	patients	screened	increased	significantly	(monthly	median:	116	vs.	59;	P=0.04),	but	without	corresponding	increase	in	recruitment	(monthly	median:	25	vs.	21;	P=0.18)	(i.e.	the	proportion	of	screened	patients	who	were	recruited	fell	from	32.6%	to	21.8%).	Extension	of	screening	to	weekends	however,	only	made	a	modest	impact	on	the	total	numbers	of	patients	screened;	a	median	of	15	(IQR:	11-19)	patients	were	screened	at	weekends	each	month	and	3	(IQR:	2-5)	recruited.	The	proportion	of	patients	recruited	did	not	vary	depending	on	whether	screening	occurred	on	weekdays	or	at	weekends.	Comparing	patients	that	were	screened	before	and	after	7th	June	2014,	the	only	significant	change	in	reasons	for	exclusion	was	that	the	proportion	of	patients	that	were	excluded	for	being	in	hospital	greater	than	24	hours	fell	(23/460	(5.0%)	vs.	11/618	(1.8%);	P	=	0.003).	There	was	no	obvious	seasonal	variation	in	the	rate	of	recruitment,	although	it	is	not	possible	to	robustly	assess	this	given	the	study	duration	of	less	than	2	years.		
	
Figure	4.4	 MARISO	study	patient	screening	and	enrolment	by	month.	Patient	recruitment	was	temporarily	suspended	between	28th	October	and	6th	November	2013,	16th	December	2013	and	6th	January	2014,	and	16th	December	2014	and	4th	January	2015	(see	section	4.3	for	further	details).	Recruitment	was	extended	to	include	weekends	from	14th	June	2014.	 	
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Most	patients	were	recruited	immediately	upon	presentation	to	hospital	with	initial	assessment	and	management	being	undertaken	by	the	study	team.	The	median	time	from	hospital	admission	to	recruitment	was	1.75	hours	(IQR:	0.5-18.4).	162	(35.3%)	patients	were	recruited	the	day	following	the	day	of	admission	and	188	(41%)	recruited	more	than	4	hours	after	presentation.		
4.5.2 Baseline	characteristics	
4.5.2.1 Demographic	and	social	characteristics	The	baseline	characteristics	of	the	459	patients	included	in	the	analysis	are	summarised	in	Tables	4.4	–	4.8.	There	was	a	marked	male	preponderance	(285;	62%)	and	the	median	age	was	34.6	years	(IQR:	29.6-41.9).	50	(11%)	of	patients	were	current	smokers;	an	additional	20	(15%)	reported	smoking	previously.	122	(27%)	reported	regular	consumption	of	alcohol	(i.e.	drinking	at	least	once	a	week),	although	exact	quantification	of	alcohol	consumption	is	precluded	by	the	wide	variation	of	alcohol	concentration	in	the	commonly	consumed	locally-brewed	beers	and	spirits	and	uncertainty	over	volumes.	
A	basic	assessment	of	socioeconomic	status	was	undertaken	by	enquiring	of	details	of	employment	status,	educational	attainment,	food	security	and	water	usage	(Table	4.4).	Nearly	one-third	(137;	30%)	of	patients	were	in	regular	paid	employment;	an	additional	third	(152,	33%)	described	themselves	as	self-employed.	164	(36%)	had	attended	secondary	school,	but	only	52	(12%)	had	attained	a	school-leavers	qualification.	More	than	half	(237;	52%)	reported	frequent	or	occasional	difficulties	in	obtaining	sufficient	food	and	these	patients	had	lower	median	body	mass	index	(19.3	
vs.	20.6;	P<0.0001;	see	Table	4.8).	The	vast	majority	of	patients	obtained	water	from	a	communal	borehole/well	(128;	28%)	or	standpipe	(247;	54%).	In	keeping	with	previous	reports	of	cooking	fuel	use	in	urban	Blantyre,	charcoal	(298;	65%),	and	to	a	lesser	extent,	firewood	(117;	26%),	were	the	predominant	fuel	sources	for	cooking	(Fullerton	et	al.,	2009).			
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Table	4.4	 Demographics	and	social	characteristics	of	MARISO	cohort.	Data	presented	as	number	and	proportion	of	total	episodes	(n=459)	unless	indicated	by	*	where	median	and	interquartile	range	are	shown.	Denominator	adjusted	where	data	are	unavailable.	
Characteristic	 No.	(%)	of	episodes	Male	sex	 285/459	 (62.1)	Age*	 34.6	 (29.6-41.9)	Current	smoker	 50/457	 (10.9)	Regular	alcohol	intake	 122/456	 (26.8)	Employment	status	Paid	employment	Self-employed	Unemployed	Other	
	157/455	152/455	120/455	26/455	
	(34.1)	(33.4)	(26.4)	(5.7)	Highest	educational	level	attended	None	Primary	Secondary	Higher	
	45/451	242/451	152/451	12/451	
	(10.0)	(53.7)	(33.7)	(2.7)	Water	source	River	Borehole/well	Public	tap/standpipe	Piped	to	dwelling	
	3/458	128/458	247/458	80/458	
	(0.7)	(28.0)	(53.9)	(17.5)	Difficulty	obtaining	food	Often	Sometimes	Never	
	35/458	202/458	221/458	
	(7.6)	(44.1)	(48.3)	Main	cooking	fuel	Firewood	Charcoal	Paraffin	Electricity	
	117/458	298/458	6/458	37/458	
	(25.6)	(65.0)	(1.3)	(8.1)		 	
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4.5.2.2 Comorbid	illness	HIV	status	was	determined	in	453	(99%)	patients;	355	(78%)	were	HIV-positive,	of	whom	124	(35%)	were	newly	diagnosed	at	presentation	(Table	4.5).	CD4	cell	counts	were	measured	on	admission	as	a	crude	estimate	of	the	degree	of	immunosuppression;	results	were	available	in	315	(89%).	Median	CD4	count	was	100	cells/mm3	(IQR:	44-193);	246	(78%)	had	CD4	counts	of	<200	cells/mm3.	Antiretroviral	therapy	(ART)	coverage	amongst	patients	with	prior	diagnosis	of	HIV	was	83%	(189/227)	and	53%	(189/355)	overall.	There	was	a	trend	to	higher	median	CD4	counts	in	those	patients	receiving	ART,	but	this	difference	was	not	statistically	significant	(106	vs.	76;	P=0.10).	In	the	absence	of	convalescent	CD4	counts	or	HIV	viral	load	measurements,	it	was	not	possible	to	definitively	diagnose	ART	failure	(World	Health	Organization,	2013a).	Data	on	the	use	of	co-trimoxazole	preventative	therapy	(CPT)	was	available	in	only	188	(81.4%)	of	the	known	HIV-positive	patients,	of	whom	151	(80.3%)	reported	current	use.	
The	presence	of	other	chronic	medical	comorbid	conditions	was	determined	by	direct	questioning	of	the	patient	and	by	reference	to	their	health	passport.	In	contrast	to	HIV,	other	comorbidities	were	reported	infrequently;	overall,	only	31	(7%)	patients	reported	a	non-HIV	chronic	comorbid	condition.	Chronic	lung	disease	–	which	included	asthma,	COPD	and	bronchiectasis	–	was	reported	by	15	(3%)	patients.	Reported	chronic	lung	disease	did	not	correlate	with	current	or	previous	smoking	(OR	1.28;	95%	CI:	0.34-4.09).			
Prior	pneumonia	-	defined	as	a	history	of	a	syndrome	compatible	with	a	lower	respiratory	tract	infection	reviewed	in	a	health	care	facility	and	treated	with	antibiotics	–	was	common	(108/457;	24%)	and	associated	with	HIV	(OR	2.91;	95%	CI:	1.46-6.30).	In	addition,	84	(18%)	of	patients	reported	a	prior	history	of	tuberculosis,	which	again	was	associated	with	HIV	(OR	3.49;	95%	CI:	1.54-9.29)	
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Table	4.5	 HIV	and	other	comorbid	illness	of	MARISO	cohort.	Data	presented	as	number	and	proportion	of	patients	unless	indicated	by	*	where	median	and	interquartile	range	are	shown.	Data	relating	specifically	to	HIV-positive	patients	indicated	by	†.	Denominator	adjusted	where	data	are	unavailable.	
Characteristic	 No.	(%)	of	episodes*	HIV	positive	Newly	diagnosed†	 355/453	124/355	 (78.4)	(34.9)	CD4	cell	count	(cells/mm3)†	All	HIV-positive*	Known	HIV-positive*	On	ART*	Not	on	ART*	Newly	diagnosed	HIV-positive*	
	99	100	106	90	93	
	(44-193)	(44-196)	(45-203)	(43-164)	(42.5-178.5)	CD4	<200	cells/mm3†	On	ART*	Not	on	ART*	
246/315	125/169	121/146	 (78.1)	(74.0)	(82.9)	ART	use	on	admission†	All	HIV-positive	Known	HIV-positive	
	189/355	189/227	 	(53.2)	(83.3)	ART	duration		<3	months†	3-12	months	>12	months	
	34/157	35/157	89/157	
	(21.7)	(22.3)	(56.1)	CPT	use	on	admission†	All	HIV-positive	Known	HIV-positive	
	151/355	151/188	 	(42.5)	(80.3)	Any	other	comorbid	condition	 31/451	 (6.9)	Chronic	lung	diseasea	 15/452	 (3.3)	Chronic	heart	diseaseb	 3/452	 (0.7)	Hypertension	 8/452	 (1.8)	Cancer	 5/452	 (1.1)	Chronic	kidney	disease	 1/452	 (0.2)	Liver	disease	 1/452	 (0.2)	Stroke	 5/452	 (1.1)	Epilepsy	 1/452	 (0.2)	Dementia	 2/452	 (0.4)	Previous	tuberculosisc	 84/458	 (18.3)	Previous	pneumonia	in	last	5	yearsd	 108/457	 (23.6)	Pregnancy	 2/174	 (1.2)	ART	–	antiretroviral	therapy;	CPT	–	co-trimoxazole	preventative	therapy	a	Chronic	lung	disease	includes	asthma,	COPD	and	bronchiectasis	b	Chronic	heart	disease	includes	congestive	cardiac	failure,	cor	pulmonale	and	dilated	cardiomyopathy	c	Any	previous	episode	of	treated	tuberculosis	regardless	of	site	and	confirmation	d	Any	prior	episode	within	the	last	5	years	of	a	syndrome	compatible	with	lower	respiratory	tract	infection	reviewed	in	a	healthcare	facility	and	treated	with	antibiotics		
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4.5.2.3 Prior	treatment	The	median	duration	of	symptoms	prior	to	presentation	was	7	days	(IQR:	5-12;	Table	4.6).	However,	reported	symptom	duration	was	not	smoothly	distributed	and	clustered	around	3,	7	and	14	days;	24%	of	patients	reported	symptoms	for	exactly	14	days.	283	(62%)	patients	had	been	seen	at	some	form	of	healthcare	facility	prior	to	the	current	attendance	at	hospital.	The	majority	(230/283;	81%)	had	attended	a	primary	health	centre,	in	keeping	with	the	standard	referral	practice	in	operation	at	QECH	whereby	all	but	severely	unwell	patients	must	be	referred.	Prior	review	was	not	associated	with	longer	duration	of	symptoms	(7	days	vs.	7	days;	P=0.11).	280	(62%)	patients	had	used	antibiotics	(excluding	co-trimoxazole	prophylactic	treatment)	in	the	two	weeks	prior	to	presentation.	Prior	use	of	antimalarials	was	also	common	(79/457;	17%).	Whilst	attendance	at	traditional	healers	was	rare	(2/283;	0.7%),	40	(9%)	patients	reported	use	of	traditional	remedies	although	these	were	not	further	characterised.		
Table	4.6	 Healthcare	utilisation	and	prior	treatment	of	MARISO	cohort.	Data	presented	as	number	and	proportion	of	patients	unless	indicated	by	*	where	median	and	interquartile	range	are	shown.	Denominator	adjusted	where	data	are	unavailable.	
Characteristic	 No.	(%)	of	episodes*	Pre-admission	symptom	duration*	1-3	days	4-7	days	8-10	days	11-14	days	
7	63/457	214/457	50/457	130/457	
(5-12)	(13.8)	(46.8)	(10.9)	(28.5)	Travel	time	to	hospital	<1	hour	1-2	hours	>2	hours	
	114/455	245/455	96/455	
	(25.0)	(53.9)	(21.1)	Prior	review	Primary	health	centre	Private	clinic	Other	hospital	Pharmacy	Traditional	healer	
283/458	230/283	49/283	7/283	1/283	2/283	
(61.8)	(81.2)	(17.3)	(2.5)	(0.4)	(0.7)	Prior	treatment	Antibiotics	Antimalarials	Traditional	remedies	
	280/455	79/457	40/456	
	(61.5)	(17.3)	(8.8)			 	
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4.5.2.4 Clinical	features		The	reported	symptoms	and	clinical	examination	features	evident	at	presentation	are	summarised	in	Table	4.7.	The	symptoms	that	formed	a	component	of	the	clinical	case	definition	–	fever,	cough,	dyspnoea	and	chest	pain	–	were	all	present	in	almost	all	patients.	Despite	the	short	maximal	symptom	duration	of	14	days,	weight	loss	was	frequently	reported	(277/458;	61%).	Similarly,	night	sweats	were	also	commonly	reported	(299/457;	65%).	
Audible	crepitations	were	the	most	frequently	detected	focal	chest	sign	(387/457;	85%).	79	(17%)	patients	had	clinical	evidence	of	pleural	effusion.	Cutaneous	or	palatal	Kaposi’s	sarcoma	was	present	in	3%	(14/458)	but	did	not	associate	with	clinical	pleural	effusion.	Acute	confusion	as	assessed	by	orientation	in	time,	place	and	person	was	judged	to	be	present	in	only	5	patients	(1%).	Inability	to	stand	-	a	feature	previously	used	as	a	global	assessment	of	illness	severity	in	low-resource	settings	-	was	present	in	87	(19%)	(Rylance	et	al.,	2009).			
Haemoptysis	was	reported	more	frequently	amongst	patients	with	radiographic	pneumonia	(21.2%	vs.	10.6%;	P=0.02)	(see	section	4.5.4).	Amongst	the	recorded	respiratory	examination	features,	only	clinically	detected	pleural	effusion	was	significantly	associated	with	radiographic	pneumonia	(22.5%	vs.	5.8%;	P	<0.0001).	
Weight	loss	(227/354	(64.1%)	vs.	46/98	(46.9)),	oral	thrush	(28/354	(7.9%)	vs.	0/98	(0%))	and	lymphadenopathy	(40/355	(11.3%)	vs.	2/98	(2.0%))	were	present	more	frequently	in	HIV-infected	patients.	However,	amongst	HIV-infected	patients,	the	clinical	presentation	did	not	vary	with	the	use	of	ART.	As	reported	earlier,	there	was	substantial	missing	data	on	the	use	of	CPT.	Clubbing	(6/37	(16.2%)	vs.	7/151	(4.6%))	and	confusion	(2/37	(5.4%)	vs.	1/150	(0.7%))	were	present	more	frequently	in	patients	not	taking	CPT,	but	there	was	no	difference	in	the	recorded	respiratory	features.		
Physiological	observations	were	considered	as	absolute	values	and	as	proportion	of	patients	with	a	significant	abnormality	using	thresholds	described	in	previous	validated	CAP	severity	assessment	tools	(Table	4.8)(Charles	et	al.,	2008b;	Fine	et	al.,	1997a;	Lim	et	al.,	2003).	Hypotension	(systolic	blood	pressure	<90	mmHg	or	diastolic	blood	pressure	≤60	mmHg),	tachycardia	(≥125	beats/min)	and	tachypnoea	(≥30	breaths/min)	were	present	in	35%	(160/454),	38%	(176/458)	and	48%	(213/446)	of	patients,	respectively.	Hypoxaemia	as	defined	by	peripheral	oxygen	saturations	of	<90%	was	present	in	16%	(73/449).	Tachypnoea	(≥30	breaths/min)	was	neither	a	sensitive	(61.1%;	95%	CI:	48.9%-72.4%)	nor	specific	(54.9%;	95%	CI:	49.6%-60.0%)	
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marker	for	the	presence	of	hypoxaemia.	Using	a	body	mass	index	threshold	of	<18.5	kg/m2,	30%	(132/444)	of	patients	were	underweight	(World	Health	Organization,	1995).	A	similar	proportion	(26%;	118/451)	were	classified	as	underweight/undernourished	using	a	mid-upper	arm	circumference	threshold	of	<230mm	(Tang	et	al.,	2013).	
For	patients	recruited	from	the	medical	wards	on	the	day	following	admission,	the	physiological	observations	recorded	at	presentation	by	the	routine	AETC	triage	staff	were	used	for	analysis.	The	median	recorded	respiratory	rate	was	lower	in	this	group	(27	vs.	30;	P	<0.0001)	than	for	patients	recruited	directly	from	AETC	whose	initial	observations	were	measured	by	the	study	team.	There	was	no	significant	difference	in	temperance,	blood	pressure,	heart	rate	or	oxygen	saturations.		
The	median	haemoglobin	concentration	was	11.0	g/dL	(IQR:	9.0-12.8).	Using	the	WHO	recommended	threshold	of	8	g/dL,	17%	(74/449)	of	patients	had	severe	anaemia	(World	Health	Organization,	2011b).	Pallor	identified	on	clinical	examination	had	excellent	specificity	(97.1%;	CI:	94.8%-98.5%)	but	poor	sensitivity	for	the	diagnosis	of	severe	anaemia	(21.6%;	CI:	12.9%-32.7%).	Urea	and	creatinine	were	elevated	in	an	estimated	30%	and	17%	of	patients,	respectively,	however	in	the	absence	of	baseline	or	interval	values,	determining	whether	this	reflects	acute	kidney	injury	is	not	possible.		Concurrent	malaria	was	detected	in	only	2%	(8/436).		
The	systemic	inflammatory	response	syndrome	(SIRS)	criteria7	of	tachycardia,	tachypnoea,	fever	or	hypothermia,	and	high	or	low	white	blood	are	used	to	rapidly	identify	patient	with	potentially	severe	infection.	SIRS	was	present	in	396	(91%)	patients	in	the	MARISO	cohort.	Severe	sepsis8	–	defined	as	the	presence	of	SIRS	with	evidence	of	organ	dysfunction	(i.e.	hypotension,	respiratory	failure,	confusion,	renal	dysfunction,	thrombocytopenia,	jaundice)	-	was	present	in	179/412	(43%).		
Since	prolonged	symptom	duration	was	the	commonest	reason	for	exclusion	from	the	cohort,	the	relationship	between	reported	symptom	duration	and	clinical	features	at	presentation	was	examined	(Table	4.9).	Patients	with	reported	symptom	duration	of	8-14	days	compared	to	1-7	days	were	more	likely	to	be	male	and	to	report	weight	loss	
																																								 																					7	Systemic	inflammatory	response	syndrome	(SIRS)	defined	as	≥2	of:	temperature	<36°C	or	>38°C;	heart	rate	>90/min;	respiratory	rate	>20/min;	white	blood	cell	<4	or	>12	x	109	cells/L	(Bone	et	al.,	1992).	8	Severe	sepsis	was	defined	as	the	presence	of	SIRS	response	with	≥1	of	the	followings	signs	of	organ	dysfunction:	systolic	blood	pressure	<90	mmHg	or	mean	arterial	blood	pressure	<65	mmHg;	altered	mentation;	creatinine	>164	μmol/L;	platelet	count	<100	x	109/L;	respiratory	rate	>40/min;	jaundice	(Andrews	et	al.,	2014)	adapted	from	(Vincent	et	al.,	1996).	
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and	night	sweats.	Recorded	physiological	observations	and	the	proportion	with	radiographic	pneumonia	did	not	differ	substantially.		
4.5.3 Antimicrobial	and	supportive	management	Details	of	the	initial	antibiotic	treatment	regimen	were	available	in	435/459	(94.8%).	Whilst	overall	13	different	initial	antibiotic	regimens	were	used,	ceftriaxone	monotherapy	(n=306;	70.3%)	and	combination	treatment	with	penicillin	and	chloramphenicol	(n=100;	23.0%)	accounted	for	more	than	93%.	An	additional	10	(2.3%)	patients	received	ceftriaxone	in	combination	with	other	agents	and	9	received	(2.0%)	penicillin	monotherapy.	Only	2	patients	(0.5%)	received	atypical	bacterial	infection	antimicrobial	cover	in	the	form	of	erythromycin	(n=1)	or	doxycycline	(n=1)	in	their	initial	treatment	regimen.	Only	4	(1.2%)	patients	were	initially	treated	solely	with	oral	antibiotics.	The	use	of	a	ceftriaxone-based	(n=316;	72.6%)	versus	an	alternative	antibiotic	regimen	(n=119;	27.4%)	did	not	vary	with	sex,	age,	symptom	duration,	HIV	status	or	oxygen	saturations,	but	was	more	common	amongst	patients	with	low	systolic	blood	pressure	(<90mmHg,	67/80	(83.8%)	vs.	≥90mmHg,	246/351	(71.9%);	P	=	0.02).	
242	(79.1%)	of	patients	with	initial	empirical	ceftriaxone	therapy	completed	treatment	course	with	ceftriaxone	monotherapy	for	a	median	duration	of	5	days	(IQR:	3-7)	without	a	subsequent	oral	agent.	45	(14.7%)	of	patients	initially	treated	with	ceftriaxone	monotherapy	were	stepped	down	to	oral	therapy	after	a	median	duration	of	ceftriaxone	of	5	days	(IQR:	2-7).	Amoxicillin	alone	was	used	in	33	patients	(10.8%);	a	single	agent	with	atypical	cover	in	10	(3.3%);	or	a	combination	of	both	in	2	(0.7%).	
Of	the	100	patients	initially	commenced	on	penicillin	and	chloramphenicol,	67	(67%)	stayed	on	this	regimen	throughout	the	treatment	course	for	a	median	duration	of	4	days	(IQR:	3-6).	23	(23%)	were	switched	to	a	treatment	regimen	containing	ceftriaxone.	
Intravenous	fluids	were	commenced	at	the	time	of	initial	assessment	in	278	(62.8%)	of	patients	for	whom	data	was	available.	Intravenous	fluids	were	started	more	frequently	in	patients	with	low	systolic	blood	pressure	(<90mmHg	,	70/81	(86.4%)	vs.	≥90mmHg	,	205/357	(57.4%);	P	<0.0001)	and	low	saturations	(<90%,	58/73	(79.5%)	vs.	≥90%,	215/360	(59.7%);	P	=	0.002).	
Details	on	oxygen	administration	were	available	in	439	(95.6%)	patients.	Oxygen	was	commenced	on	initial	assessment	in	56	(12.8%)	patients,	including	43/70	(61.4%)	of	those	with	oxygen	saturations	of	less	than	90%	at	presentation.	
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There	was	no	significant	differences	in	antimicrobial	selection,	recorded	oxygen	or	intravenous	fluid	use	between	patients	recruited	on	the	day	of	admission,	whose	initial	management	was	usually	overseen	by	the	study	team,	and	those	recruited	from	the	medical	wards	on	the	day	following	admission	whose	initial	management	was	undertaken	by	the	routine	clinical	team.	
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Table	4.7	 Clinical	features	at	presentation	of	MARISO	cohort	stratified	by	
radiographic	appearance.	Data	presented	as	number	and	proportion	of	patients.	Denominator	adjusted	where	data	are	unavailable.	
Characteristic	
No.	(%)	of	episodes	
Overall	
No	radiographic	
pneumonia	
Radiographic	
pneumonia	
P	
Respiratory	symptoms	Cough	Sputum	production	Dyspnoea	Chest	pain	Haemoptysis	Rhinorrhoea	Sore	throat	
	451/458	357/458	440/458	449/457	84/457	75/458	111/458	
	(98.5)	(78.0)	(96.1)	(98.3)	(18.4)	(16.4)	(24.2)	
	102/104	82/104	98/104	101/104	11/104	22/104	30/104	
	(98.1)	(78.9)	(94.2)	(97.1)	(10.6)	(21.2)	(28.9)	
	312/317	242/317	306/317	311/316	67/316	49/317	72/317	
	(98.4)	(76.3)	(96.5)	(98.4)	(21.2)	(15.5)	(22.7)	
	0.81	0.60	0.30	0.40	0.02	0.18	0.21	
Respiratory	examn	features	Crepitations	Bronchial	breathing	Pleural	rub	Pleural	effusion	Wheeze	
	387/457	167/458	128/457	79/457	17/458	
	(84.7)	(36.4)	(28.0)	(17.3)	(3.7)	
	93/104	39/104	32/104	6/104	7/104	
	(89.4)	(37.5)	(30.8)	(5.8)	(6.7)	
	258/315	111/316	84/315	71/315	9/317	
	(81.9)	(35.1)	(26.7)	(22.5)	(2.8)	
	0.07	0.66	0.42	<0.0001	0.07	
Other	symptoms	Fever	Weight	loss	Night	sweats	Collapse	Myalgia	Headache	Skin	rash	Diarrhoea	Nausea	and	vomiting	
	457/458	277/458	299/457	8/457	371/458	217/458	36/458	75/456	73/457	
	(99.8)	(60.5)	(65.4)	(1.8)	(81.0)	(47.4)	(7.9)	(16.5)	(16.0)	
	104/104	65/104	63/104	3/104	87/104	58/104	7/104	25/104	22/103	
	(100)	(62.5)	(60.6)	(2.9)	(83.7)	(55.8)	(6.7)	(24.0)	(21.4)	
	316/317	192/317	208/316	5/316	254/317	143/317	26/317	43/315	44/317	
	(99.7)	(60.6)	(65.8)	(1.6)	(80.1)	(45.1)	(8.2)	(13.7)	(13.9)	
	0.57	0.73	0.33	0.40	0.43	0.06	0.63	0.01	0.07	
Other	examn	features	Confusion/disorientation	Inability	to	stand	Pallor	Oral	thrush	Jaundice	Clubbing	Lymphadenopathy	Peripheral	oedema	Kaposi’s	sarcoma	Hepatomegaly	Splenomegaly	Murmur	
	5/458	87/459	27/458	28/458	3/457	27/459	43/459	14/456	14/458	22/457	16/456	2/457	
	(1.1)	(19.0)	(5.9)	(6.1)	(0.7)	(5.9)	(9.4)	(3.1)	(3.1)	(4.8)	(3.5)	(0.4)	
	3/104	20/104	8/104	8/104	1/103	7/104	16/104	3/103	2/104	3/103	3/103	0/103	
	(2.9)	(19.2)	(7.7)	(7.7)	(1.0)	(6.7)	(15.4)	(2.9)	(1.9)	(2.9)	(2.9)	(0)	
	5/316	51/317	14/316	16/315	2/316	16/317	22/317	8/315	11/316	16/315	10/315	2/316	
	(1.6)	(16.1)	(4.4)	(5.1)	(0.6)	(5.1)	(6.9)	(2.5)	(3.5)	(5.1)	(3.2)	(0.6)	
	0.40	0.46	0.20	0.32	0.72	0.51	0.009	0.84	0.43	0.36	0.89	0.42	
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Table	4.8	 Physiological	observations	and	laboratory	results	at	presentation	
of	MARISO	cohort.	Data	summarised	as	median	and	interquartile	range	and	also	in	
italics	as	number	and	proportion	significantly	abnormal	using	accepted	thresholds.	Denominator	adjusted	where	data	are	unavailable.	
Characteristic	
Median	(IQR)	
No.	(%)	of	episodes	
Physiological	observations	 	 	Temperature	(°C)	<35	or	≥40	 37.9	14/459	 (37.1-38.9)	(3.1)	Systolic	blood	pressure	(mmHg)	<90	 106	86/454	 (93-121)	(18.9)	Diastolic	blood	pressure	(mmHg)	≤60	 68	143/454	 (59-78)	(31.5)	Systolic	<90	and/or	diastolic	blood	pressure	≤60	(mmHg)	 	160/454	 	(35.2)	Heart	rate	(beats/min)	≥125	 118	176/458	 (102-132)	(38.4)	Respiratory	rate	(breaths/min)	≥30		 29	213/446	 (26-34)	(47.8)	Oxygen	saturations	(%)	≤90	<90	
95	
101/449	
73/449	 (91-98)	(22.5)	(16.3)	Body	mass	index	(kg/m2)	<18.5	 19.9	132/444	 (18.2-21.8)	(29.7)	Mid-upper	arm	circumference	(mm)	<230mm	 250	118/451	 (220-260)	(26.2)	
Laboratory	results	 	 	Haemoglobin	(g/dL)	<8	 11	74/449	 (9.0-12.8)	(16.5)	White	blood	cells	(x	109	cells/L)	<4	or	>15	 7.7	128/448	 (5.0-11.4)	(28.6)	Platelets	(x	109	cells/L)	<100	 201	77/449	 (127-304)	(17.2)	Urea	(mmol/L)	>7	 4.8	137/450	 (3.3-8.0)	(30.4)	Creatinine	(μmol/L)	>120	 76	76/448	 (59-100)	(17.0)	Glucose	(mmol/L)	≥11.1	 5.6	5/401	 (4.9-6.4)	(1.2)	Positive	malaria	rapid	antigen	test	 	 8/436	 (1.8)		
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Table	4.9	 Baseline	characteristics,	clinical	features	and	physiological	
observations	stratified	by	reported	symptom	duration	in	MARISO	cohort.	Data	summarised	as	median	and	interquartile	range	or	in	italics	as	number	and	proportion.	Denominator	adjusted	where	data	are	unavailable.		
Characteristic	 Symptoms	1-7	days	 Symptoms	8-14	days	 P	Male	sex	 159/277	 (57.4)	 124/180	 (68.9)	 0.013	Age	 35.0	 (29.1-41.9)	 34.5	 (30.0-41.3)	 0.96	HIV	positive	 219/275	 (79.6)	 135/176	 (76.7)	 0.46	Crepitations	 237/276	 (85.9)	 149/176	 (83.2)	 0.45	Bronchial	breathing	 106/277	 (38.2)	 61/179	 (34.1)	 0.37	Pleural	effusion	 29/276	 (10.5)	 49/179	 (27.4)	 <0.0001	Weight	loss	 145/277	 (52.4)	 132/180	 (73.3)	 <0.0001	Night	sweats	 167/277	 (60.3)	 131/179	 (73.2)	 0.005	Inability	to	stand	 57/277	 (20.6)	 29/180	 (16.1)	 0.23	Pallor	 14/277	 (5.1)	 12/179	 (6.7)	 0.46	Temperature	(°C)	 38.0	 (37.2-39.0)	 37.8	 (37.0-38.8)	 0.03	Systolic	BP	(mmHg)	 105	 (92-122)	 106	 (94-117)	 0.82	Diastolic	BP	(mmHg)	 68	 (59-79)	 68	 (60-77)	 0.90	Heart	rate	(/min)	 118	 (102-132)	 120	 (103-132)	 0.49	Respiratory	rate	(/min)	 30	 (26-34)	 28	 (24-34)	 0.05	Oxygen	saturations	(%)	 95	 (91-98)	 95	 (92-98)	 0.59	Radiographic	pneumonia	 194/255	 (76.1)	 122/165	 (73.9)	 0.62		
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Table	4.10	 Initial	and	final	summary	antimicrobial	treatment	regimens	
Initial	treatment	
group	
n	 Detailed	initial	regimen	 n	 Final	treatment	summary	 n	
Ceftriax.		 306	 -	 	 Ceftriax.	Ceftriax.	&	Amox.	Ceftriax.	&	Atypical	Pen.	&	Chloram.	Ceftriax.	&	Gent.	&	Atypical	Ceftriax.,	Amox.	&	Atypical	Ceftriax.,	Pen.	&	Chloram.	Ceftriax.	&	Gent.	
242	33	10	5	3	2	2	1	Ceftriax.-based	combination		 10	 Ceftriax.,	Pen.	&	Chloram.	Ceftriax.	&	Atypical	Ceftriax.	&	Co-trimox.	Ceftriax.	&	Metronid.	Ceftriax.	&	Pen.	
5	2	1	1	1	
Ceftriax.	Pen.	&	Chloram.	Ceftriax.,	Pen.	&	Chloram.	Ceftriax.	&	Amox.	Ceftriax.	&	Pen.	Pen.,	Chloram.	&	Amox.	
3	2	2	1	1	1	Pen.	&	Chloram.	 100	 -	 	 Pen.	&	Chloram.	Ceftriax.,	Pen.	&	Chloram.	Ceftriax.	Pen.,	Chloram.&	Amox.	Ceftriax.	&	Amox.	Pen.,	Chloram.,	Amox.	&	Atypical	Ceftriax.,	Pen.,	Chloram.	&	Amox.	Ceftriax.,	Pen.	&	Gent.	
67	10	7	6	3	2	1	1	Amox.	 4	 -	 	 Amox.	Amox.	&	Ceftriax.,	 3	1	Other	 15	 Pen.		Chloram.	Pen.,	Chloram.	&	Metronid.	Pen.	&	Co-trimox.	
9	3	2	1	
Ceftriax.	Ceftriax.,	Pen.	&	Chloram.	Pen.	&	Chloram.	Ceftriax.,	&	Atypical	Pen.,	Chloram.	&	Amox.	Pen.,	Chloram.	&	Atypical	
8	2	2	1	1	1	Amox.	–	Amoxicillin;	Ceftriax.	–	Ceftriaxone;	Chloram.	–	Chloramphenicol;	Co-trimox	–	Co-trimoxazole;	Gent.	–	Gentamicin;	Metronid.	–	Metronidazole;	Pen.	–	Pencillin;	
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4.5.4 Aetiology	
4.5.4.1 Specimen	collection	Blood	for	culture	was	obtained	in	450	of	the	459	patients	(98%),	urine	for	pneumococcal	antigen	detection	from	433	(94%)	and	a	nasopharyngeal	aspirate	(NPA)	for	multiplex	respiratory	pathogen	PCR	panel	from	455	(99%;	Table	4.9).	Overall	322	(70%)	patients	submitted	a	sputum	specimen	for	mycobacterial	diagnostic	testing.	A	result	for	smear	microscopy	was	available	in	305	(66%);	valid	results	for	Xpert	MTB/RIF	and	mycobacterial	cultures	were	available	in	308	(67%)	and	273	(59%),	respectively.	Pleural	fluid	sampling	was	performed	in	35	patients	(8%).	Results	for	bacterial	culture	of	pleural	fluid	were	available	in	31	(89%),	for	pneumococcal	antigen	detection	in	urine	or	pleural	fluid	in	31	(89%),	and	for	smear	microscopy	and	mycobacterial	culture	in	35	(100%).	Overall	at	least	one	potential	pathogen	was	identified	in	310	(68%)	patients	or,	if	the	results	for	Legionella	spp.	are	discounted	(see	below),	in	278	(61%).		
Table	4.11	 Organism	identification	by	specimen	type	and	diagnostic	test	
stratified	by	HIV	status.	Data	presented	as	number	and	proportion	of	specimens	positive	for	specific	organism.	
Organism	
All	
(n=459)	
HIV-positive	
(n=355)	
HIV-negative	
(n=98)	
Blood	cultures	
S.	pneumonia	 5/450	 (1.1)	 4/350	 (1.1)	 1/94	 (1.1)	
S.	typhi	 9/450	 (2.0)	 3/350	 (0.9)	 5/94	 (5.3)	
S.	Typhimurium	 6/450	 (1.3)	 6/350	 (1.7)	 0/94	 (0)	
S.	Enteritidis	 1/450	 (0.2)	 1/350	 (0.3)	 0/94	 (0)	
S.	aureus	 2/450	 (0.4)	 1/350	 (0.3)	 1/94	 (1.1)	
E.	coli	 2/450	 (0.4)	 2/350	 (0.6)	 0/94	 (0)	
E.	cloacae	 1/450	 (0.2)	 1/350	 (0.3)	 0/94	 (0)	
Pleural	fluid	culture	
S.	typhi	 1/31	 (3.2)	 1/19	 (5.3)	 0/11	 (0)	
M.	tuberculosis	 7/35	 (20.0)	 4/22	 (18.2)	 2/12	 (16.7)	
S.	pneumoniae	antigen	test	Urine	 95/433	 (21.9)	 67/333	 (20.1)	 28/94	 (29.8)	Pleural	fluid	 3/31	 (9.7)	 1/20	 (5)	 2/10	 (20)	
Sputum	mycobacterial	diagnostic	tests	AFB	smear	microscopy	 36/305	 (11.8)	 30/241	 (12.4)	 6/60	 (10.0)	
Sputum	culture	
M.	tuberculosis	 60/273	 (22.0)	 54/217	 (24.9)	 6/52	 (11.5)	NTM	 8/273	 (2.9)	 5/217	 (2.3)	 3/52	 (5.8)	Xpert	MTB/RIF	 56/308	 (18.2)	 46/244	 (18.9)	 10/60	 (16.7)		 	
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Organism	
All	
(n=459)	
HIV-positive	
(n=355)	
HIV-negative	
(n=98)	
Multiplex	PCR	on	nasopharyngeal	aspirate	Adenovirus	 35/455	 (7.7)	 30/355	 (8.5)	 5/98	 (5.1)	Bocavirus	 13/455	 (2.9)	 13/355	 (3.6)	 0/98	 (0)	
C.	pneumoniae	 2/455	 (0.4)	 0/355	 (0)	 2/98	 (2)	Coronavirus	HKU	 3/455	 (0.7)	 3/355	 (0.9)	 0/98	 (0)	Coronavirus	229	 19/455	 (4.2)	 16/355	 (4.5)	 3/98	 (3.1)	Coronavirus	43	 6/455	 (1.3)	 6/355	 (1.7)	 0/98	 (0)	Coronavirus	63	 5/455	 (1.4)	 5/355	 (1.4)	 0/98	 (0)	Enterovirus	 5/455	 (1.1)	 5/355	 (1.4)	 0/98	 (0)	Influenza	A	 19/454	 (4.2)	 13/354	 (3.7)	 5/98	 (5.1)	Influenza	B	 21/454	 (4.6)	 17/354	 (4.8)	 4/98	 (4.1)	
Legionella	spp.	 84/455	 (18.5)	 62/355	 (17.5)	 20/98	 (20.4)	Metapneumovirus	 9/455	 (2)	 8/355	 (2.3)	 1/98	 (1.0)	
M.	pneumoniae	 6/455	 (1.3)	 6/355	 (1.7)	 0/98	 (0)	Parainfluenza	1	 2/455	 (0.4)	 1/355	 (0.3)	 1/98	 (1.0)	Parainfluenza	2	 6/455	 (1.3)	 6/355	 (1.7)	 0/98	 (0)	Parainfluenza	3	 7/455	 (1.5)	 7/355	 (2)	 0/98	 (0)	Parainfluenza	4	 3/455	 (0.7)	 2/355	 (0.6)	 0/98	 (0)	Parechovirus	 5/455	 (1.1)	 5/355	 (1.4)	 0/98	 (0)	Rhinovirus	 17/455	 (3.7)	 15/355	 (4.2)	 2/98	 (2)	RSV	 8/455	 (1.8)	 4/355	 (1.1)	 3/98	 (3.1)	NTM	–	nontuberculous	mycobacteria;	RSV	–	respiratory	syncytial	virus	
	
4.5.4.2 Bacteria	At	least	one	potential	bacterial	pathogen	was	identified	in	182	(40%)	patients	or,	if	the	results	for	Legionella	spp.	are	discounted	(see	below),	in	125	(28%).		Overall,	26	patients	(6%)	were	bacteraemic	with	a	significant	organism:	Salmonella	typhi	(9	patients);	nontyphoidal	Salmonella	(NTS)(7);	S.	pneumoniae	(6);	Gram-negative	enteric	bacteria	(3);	Staphylococcus	aureus	(2).	A	further	12	(3%)	yielded	contaminants:	coagulase-negative	Staphylococci	(8);	Micrococcus	spp.	(2);	Bacillus	spp.	(2).		
Streptococcus	pneumoniae	was	the	most	commonly	identified	pathogen	overall	being	present	in	98	(21%;	Table	4.10).	Of	these	92	(94%)	were	identified	by	detection	of	pneumococcal	urinary	antigen	alone,	3	(3%)	by	both	blood	culture	and	urinary	antigen,	2	(2%)	by	blood	culture	alone,	and	1	(1%)	by	antigen	detection	in	pleural	fluid	alone.	Whilst	70%	patients	with	pneumococcal	disease	were	HIV	positive,	pneumococcal	aetiology	was	more	common	in	HIV-negative	patients	(30/98	(31%)	vs.	68/355	(19%);	
P=0.01).	
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Salmonella	spp.	were	the	most	commonly	identified	pathogens	in	blood	culture.	One	additional	case	of	S.	typhi	was	identified	on	pleural	fluid	culture.		S.	typhi	was	identified	more	frequently	in	HIV-negative	patients	(5/94	(5%)	vs.	3/350	(1%);	P=0.01).	All	7	cases	of	NTS	infection	(S.	Typhimurium,	6	cases;	S.	Enteritidis,	1	case)	occurred	in	HIV-positive	patients.		
Legionella	spp.	were	identified	by	PCR	in	84/455	(18%)	of	nasopharyngeal	aspirate	specimens.	This	prevalence	greatly	exceeds	that	reported	in	previous	studies	of	adult	CAP	from	either	sub-Saharan	Africa	(see	chapter	2)	or	other	settings	(Charles	et	al.,	2008a;	Jain	et	al.,	2015;	Peto	et	al.,	2014;	Torres	et	al.,	2014).	Pending	further	confirmatory	testing	the	validity	of	this	result	is	unclear	and	as	such	has	not	been	included	in	combined	aetiological	analyses.		
Infection	with	other	‘atypical’	bacterial	pathogens	was	uncommon;	only	6/455	(1%)	cases	of	Mycoplasma	pneumoniae	and	2/455	(0.4%)	cases	of	Chlamydia	pneumoniae	were	identified	overall.	No	association	of	atypical	bacterial	infection	with	HIV-status	was	detected.	
4.5.4.3 Mycobacteria	Infection	with	Mycobacterium	tuberculosis	(TB)	was	determined	on	the	basis	of	sputum	AFB	smear	microscopy	and	mycobacterial	culture,	Xpert	MTB/RIF	assay	and	for	those	with	an	aspirated	pleural	effusion,	pleural	fluid	smear	microscopy	and	mycobacterial	culture.	Mycobacterial	blood	cultures	were	not	performed.	The	result	of	a	TB	diagnostic	test	performed	on	a	sputum	specimen	was	available	in	71%	(326/459)	of	the	whole	patient	cohort.	Overall,	TB	was	identified	in	75	patients,	representing	23%	of	those	that	submitted	a	sputum	specimen	and	16%	of	the	overall	cohort.	TB	was	confirmed	by	culture	in	65	(87%):	sputum	(n=65);	pleural	fluid	(n=7);	both	(n=2).	In	the	absence	of	a	valid	culture	result,	TB	was	diagnosed	on	the	basis	of	Xpert	MTB/RIF	alone	in	8	patients,	sputum	microscopy	in	1	and	pleural	fluid	microscopy	in	1.	Using	a	positive	culture	as	reference	standard,	sputum	Xpert	MTB/RIF	sensitivity	was	68.4%	(95%	CI:	54.8%-80.1%)	and	specificity	was	95.6%	(95%	CI:	91.8%-98.0%);	smear	microscopy	sensitivity	was	52.5%	(95%	CI:	39.3%-65.4%)	and	specificity	was	99.1%	(95%	CI:	96.6%-99.9%).	
Overall	64	(86%)	of	patients	with	TB	were	HIV-positive.	TB	was	identified	in	25%	(64/257)	of	HIV-positive	patients	compared	to	16%	(10/64)	of	HIV-negative	patients,	although	this	difference	was	not	statistically	significant	(OR	1.79;	95%	CI:	0.84-4.17).		
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Nontuberculous	mycobacteria	infection	was	identified	in	3%	(8/273)	of	patients	on	the	basis	of	sputum	culture;	sputum	smear	microscopy	was	negative	in	all	but	one	case.		
4.5.4.4 Viruses	Influenza	viruses	(encompassing	influenza	A	and	influenza	B)	were	the	most	commonly	identified	viral	pathogens	(Table	4.10).	Overall	influenza	was	found	in	9%	(40/454)	patients;	influenza	A	and	B	occurred	with	approximately	equal	frequency.	75%	(30/40)	of	patients	with	influenza	were	HIV	positive;	influenza	did	not	associate	with	HIV	status.	
Adenovirus	(35/455;	8%)	and	coronaviruses	(31/455;	7%)	were	the	two	next	most	commonly	identified	viral	pathogens;	86%	(30/35)	and	90%	(28/31),	respectively,	were	HIV	positive.	Rates	of	identification	did	not	significantly	vary	with	HIV	status.		
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4.5.4.5 Co-infection	Co-infection	relationships	were	investigated	in	the	307	(67%)	patients	from	whom	a	complete	set	of	investigations	was	performed	(i.e.	blood	culture,	pneumococcal	urine	antigen	testing,	sputum	mycobacterial	culture	and/or	Xpert	MTB/RIF,	nasopharyngeal	aspirate	multiplex	PCR).	In	view	of	the	uncertainties	over	their	accuracy,	results	for	
Legionella	spp.	were	excluded	from	this	analysis	
In	this	subset	at	least	one	potential	pathogen	was	identified	in	206	(67%)	patients.	The	overall	pattern	of	pathogens	was	similar	to	that	describe	in	the	overall	cohort	with	S.	
pneumoniae	(73/307;	24%),	M.	tuberculosis	(68/307;	22%)	and	influenza	(31/307;	10%)	being	the	most	commonly	identified	pathogens.	Overall	a	single	organism	was	identified	in	139	(45%):	single	bacterial	pathogen	in	45	(15%);	single	virus	in	50	(16%);	single	mycobacterial	infection	in	44	(14%;	Figure	4.7).	In	the	patients	with	multiple	identified	organisms,	the	combination	of	a	bacterial	viral	co-infection	was	most	frequently	observed	(28/307;	9%),	followed	by	a	mycobacterial	viral	co-infection	in	18	(6%).	
Amongst	the	73	patients	with	S.	pneumoniae,	it	was	present	as	sole	pathogen	in	40	(55%)	patients	and	in	combination	with	M.	tuberculosis	in	7	(10%),	adenovirus	in	7	(10%),	influenza	in	6	(8%)	and	rhinovirus	in	6	(8%;	Table	4.11).	M.	tuberculosis	occurred	as	a	sole	pathogen	in	42	(62%)	patients	and	in	co-infection	was	most	commonly	detected	with	adenovirus	(8/68;	12%),	S.	pneumoniae	(7/68;	10%)	and	parainfluenza	viruses	(4/68;	6%).	Influenza	was	detected	as	in	isolation	in	19	(61%)	patients	and	in	co-infection	was	most	commonly	associated	with	S.	pneumoniae	(6/31;	19%),	coronavirus	(3/31;	10%)	and	M.	tuberculosis	(2/31;	6%).	
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Figure	4.5	 Bacterial,	viral	and	mycobacterial	infection	in	isolation	and	
combination	in	MARISO	cohort.	Analysis	restricted	to	307	patients	with	results	available	for	blood	culture,	pneumococcal	urine	antigen	testing,	sputum	mycobacterial	culture	and/or	Xpert	MTB/RIF,	nasopharyngeal	aspirate	multiplex	PCR.		 	
15%$
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14%$
2%$9%$
3%$6%$2%$
33%$
Single$bacterial$pathogen$Single$viral$pathogen$Single$mycobacterial$pathogen$Viral<viral$co<detection$Bacterial<viral$co<detection$Bacterial<mycobcaterial$co<detection$Mycobcaterial<viral$co<detection$Bacterial<mycobcaterial<viral$co<detection$No$pathogen$detected$
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Table	4.13	 Matrix	showing	co-infection	combinations	in	MARISO	cohort.	Analysis	restricted	to	307	patients	with	complete	results	available	for	blood	culture,	pneumococcal	urine	antigen	testing,	sputum	mycobacterial	culture	and/or	Xpert	MTB/RIF,	nasopharyngeal	aspirate	multiplex	PCR.	Shaded	squares	indicate	mono-infection.		
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4.5.5 Radiology	features	
4.5.5.1 Overview	A	chest	radiograph	was	available	for	review	in	421	(91.7%)	patients.	Radiographs	were	unavailable	for	analysis	due	to:	early	death	in	14;	hospital	discharge	without	radiograph	in	10	(including	at	least	4	where	radiographs	were	not	possible	due	to	the	lack	of	processing	chemicals);	discharge	prior	to	photograph	in	8;	unknown	reason	in	5.		
Each	radiograph	was	independently	assessed	by	three	readers	(two	radiologists	and	myself);	a	consensus	view	based	on	the	majority	opinion	of	the	three	readers	was	used	to	define	the	presence	of	specific	radiological	features	for	use	in	analysis	(see	sections	3.14	and	3.18	for	detailed	methods).	Radiographic	pneumonia	-	defined	as	the	presence	of	consolidation	or	other	parenchymal	abnormality	or	pleural	effusion	-	was	identified	in	322	(77%),	297	(71%)	and	314	(75%)	patients,	respectively,	by	the	three	readers	giving	a	consensus	value	of	317	(76%).	Applying	a	more	restrictive	definition	of	radiographic	pneumonia	based	on	parenchymal	abnormalities	alone,	the	proportion	with	radiographic	pneumonia	was	67%.	There	was	substantial	agreement	between	the	three	reporters	for	the	identification	of	radiographic	pneumonia	(kappa	coefficient	0.71;	95%	CI:	0.65-0.78).		
Consolidation	was	identified	in	251	(60%)	patients.	Inter-reader	agreement	was	substantial	for	the	presence	of	consolidation	(kappa	0.65;	95%	CI:	0.59-0.70),	but	only	moderate	for	its	quality	(kappa	0.46;	95%	CI:	0.37-0.55)	and	extent	(kappa	0.49;	95%	CI:	0.42-0.55).	Multilobar	involvement	was	present	in	73/250	(29%)	of	those	with	consolidation.	Other	parenchymal	abnormalities	such	as	reticulonodular	change	(35/418;	8%),	cavitation	(20/418;	5%)	and	miliary	appearance	(2/417;	0.5%)	were	less	common	and	inter-reader	agreement	was	moderate	at	best.	Pleural	effusion	was	identified	in	118/417	(28%)	with	substantial	inter-reader	agreement	(kappa	0.49;	95%	CI:	0.42-0.55).	The	presence	of	pleural	effusion	was	the	sole	grounds	of	defining	radiographic	pneumonia	in	38/322	(12%).	
The	proportion	of	patients	with	radiographic	pneumonia	did	not	vary	with	HIV	status	(HIV-positive	247/324	(76%)	vs.	HIV-negative	66/91	(73%);	P=0.47).	Similarly	the	frequencies	of	the	following	features	did	not	associate	with	HIV	status:	any	parenchymal	abnormality	(222/318	(70%)	vs.	57/90	(63%);	P=0.24);	consolidation	(199/317	(63%)	vs.	49/90	(54%);	P=0.15);	cavitation	(15/321	(5%)	vs.	5/91	(5%);	
P=0.75);	reticulonodular	change	(27/321	(8%)	vs.	8/91	(9%);	P=0.91);	pleural	effusion	(93/319	(29%)	vs.	23/91	(25%);	P=0.47).	Amongst	HIV-positive	patients,	the	frequencies	of	the	following	features	did	not	alter	with	CD4	count:	radiographic	
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pneumonia	(CD4	<200	cells/mm3	176/225	(78%)	vs.	CD4	≥	200	cells/mm3	49/64	(77%),	P=0.78);	consolidation	(139/219	(63%)	vs.	39/64	(61%),	P=0.71);	cavitation	(10/223	(4%)	vs.	4/64	(6%),	P=0.56);	reticulonodular	change	(17/223	(8%)	vs.	6/64	(9%),	P=0.65);	pleural	effusion	(64/221	(29%)	vs.	18/64	(28%),	P=0.90).			
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4.5.5.2 Radiological	features	by	aetiology	In	this	cohort	of	patients	with	clinically	defined	pneumonia	the	relationship	of	aetiology	with	radiological	change	was	investigated	(Table	4.13).	The	overall	rankings	of	the	most	commonly	identified	organisms	in	the	subgroup	of	patients	with	radiographic	pneumonia	reflected	those	of	the	whole	cohort	with	S.	pneumoniae	(83/317;	26%),	M.	tuberculosis	(58/232;	25%)	and	influenza	(25/313;	8%)	being	identified	most	frequently.	In	the	subgroup	lacking	radiographic	pneumonia,	M.	
tuberculosis	(13/70;	19%)	and	influenza	(11/103;	11%)	were	the	most	frequently	identified	pathogens.	Having	controlled	for	any	effect	of	HIV,	detection	of	S.	pneumoniae	was	positively	associated	with	radiological	pneumonia	(83/317	(26%)	vs.	9/104	(9%);	OR	3.93;	95%	CI:	1.86-8.29).	Both	S.	typhi	(2/309	(1%)	vs.	8/103	(8%);	OR	0.09;	95%	CI:	0.02-0.48)	and	NTS	(1/309	(<1%)	vs.	5/103	(5%)	OR	0.06;	95%	CI:	0.01-0.53)	were	negatively	associated	with	the	presence	of	radiographic	pneumonia.	The	relative	abundance	of	all	other	organisms	did	not	vary	significantly	with	the	presence	of	radiological	change.		
The	radiographic	appearance	of	the	three	commonest	organisms	(S.	pneumoniae,	M.	
tuberculosis	and	influenza)	was	analysed	in	more	detail	(Table	4.14).	For	patients	with	radiographic	pneumonia,	confluent	consolidation	was	associated	with	S.	pneumoniae	(OR	2.41;	95%	CI:	1.29-4.51)	and	patchy	consolidation	with	M.	tuberculosis	(OR	2.12;	95%	CI:	1.06-4.29).	Multilobar	involvement	(OR	2.37;	95%	CI:	1.23-4.56),	reticulonodular	change	(OR	3.98;	95%	CI:	1.74-9.12)	and	mediastinal	lymphadenopathy	(OR	4.91;	95%	CI:	1.77-13.64)	were	more	common	with	M.	
tuberculosis	infection.	Pleural	effusion	was	common	across	all	aetiologies.	There	were	no	significant	associations	between	specific	radiological	features	and	influenza.	As	described	above,	inter-observer	agreement	was	substantial	for	identification	of	pleural	effusion,	moderate	for	consolidation	quality	and	multilobar	involvement,	fair	for	mediastinal	lymphadenopathy	and	only	slight	for	reticulonodular	change	(Table	4.12).		
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Table	4.16	 Description	of	radiological	appearance	for	three	commonest	
causal	organisms:	S.	pneumoniae,	tuberculosis	and	influenza.	Analysis	restricted	to	patients	with	radiographic	pneumonia.	
Radiographic	feature	
Organism	
S.	pneumoniae	
(n=82)	
M.	tuberculosis	
(n=58)	
Influenza	
(n=25)	Any	parenchymal	abnormality	 79	 (96.3)	 50	 (86.2)	 25	 (100)	Consolidation	 75	 (91.5)	 47	 (81.0)	 20	 (80.0)	Quality	 	 	 	 	 	 	Confluent	 56	 (75.7)	 21	 (47.7)	 10	 (55.6)	Patchy	 18	 (24.3)	 23	 (52.3)	 8	 (44.4)	Extent	 	 	 	 	 	 	Segmental	 13	 (18.8)	 5	 (11.4)	 3	 (20)	Lobar	 29	 (42.0)	 12	 (27.3)	 5	 (33.3)	Multifocal	 27	 (39.1)	 27	 (61.4)	 7	 (46.7)	Multilobar	 23	 (28.4)	 22	 (37.9)	 4	 (18.2)	Cavitation	 2	 (2.4)	 6	 (10.3)	 0	 (0)	Reticulonodular	change	 5	 (6.0)	 14	 (24.1)	 4	 (16)	Miliary	appearance	 0	 (0)	 0	 (0)	 0	 (0)	Pleural	effusion	 26	 (31.3)	 23	 (40.4)	 7	 (28.0)	Mediastinal	lymphadenopathy	 3	 (3.7)	 10	 (17.2)	 2	 (8.3)	
4.6 Discussion	
4.6.1 Study	recruitment	The	broad	objective	of	the	MARISO	study	was	to	recruit	a	cohort	representative	of	patients	hospitalised	with	acute	CAP	in	Malawi.	Of	1711	patients	with	features	of	respiratory	illness	or	infection	that	were	screened,	only	489	were	assessed	as	eligible	with	the	clinical	case	definition	of	CAP	used.	The	primary	reason	for	non-eligibility	was	prolonged	symptom	duration	(>2	weeks),	present	in	more	than	a	third	of	excluded	patients.	Delayed	presentation,	in	particular	in	male	patients,	may	reflect	that	the	study	was	completed	in	a	referral	hospital	setting	where	prior	review	in	primary	care	was	mandated	or	other	barriers	to	healthcare-seeking	behaviour	present	in	Malawi	(e.g.	transportation	costs).	Also,	women	were	more	frequently	excluded	for	lack	of	chest	signs	and	older	patients	for	absent	fever.	The	case	definition	of	pneumonia	used	may	substantially	impact	the	demographic	composition	of	study	cohorts	and,	by	extension,	the	aetiological	spectrum	and	outcome.		
The	proportion	of	screened	patients	who	were	recruited	varied	over	the	course	of	the	study	with	a	notable	fall	in	June	2014	as	screening	numbers	increased.	The	explanation	for	this	is	not	immediately	clear	and	can	only	be	speculated	because	of	the	limited	information	available	about	non-recruited	patients.	However,	it	is	possible	that	in	an	
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attempt	to	maximise	recruitment	the	study	team	screened	more	broadly	(i.e.	interpreted	the	screening	criterion	of	features	of	respiratory	illness	or	infection	more	liberally)	whilst	continuing	to	comply	the	eligibility	criteria	consistently.	
4.6.2 Baseline	characteristics		The	study	population	was	predominantly	young,	male	and	HIV-positive.	The	age	profile	reflects	that	of	acute	adult	medical	admissions	to	QECH,	but	is	on	average	younger	than	the	local	community;	adults	aged	30	to	40	years	make	up	27%	of	the	urban	population	of	southern	Malawi	compared	to	44%	of	the	study	cohort	(National	Statistical	Office	of	Malawi,	2008;	SanJoaquin	et	al.,	2013).	The	male	preponderance,	however,	is	not	observed	in	overall	admission	figures	and	has	not	been	seen	in	other	recent	local	cohorts	of	sepsis	(Waitt	et	al.,	2015),	meningitis	(Scarborough	et	al.,	2007)	or	tuberculosis	(Feasey	et	al.,	2013).	A	male	preponderance	is	a	consistent	finding	of	CAP	cohorts	in	both	sub-Saharan	Africa	(Aderaye,	1994a;	Albrich	et	al.,	2014a;	Birkhamshaw	et	al.,	2013;	Nyamande	et	al.,	2007a;	Scott	et	al.,	2000)	and	well-resourced	settings	(Ewig	et	al.,	2009;	Gutierrez	et	al.,	2006)	and	reflects	a	genuine	increased	incidence	in	men,	although	the	reasons	for	this	are	incompletely	understood.	
The	high	rate	of	HIV	is	consistent	with	the	overall	prevalence	of	HIV	amongst	medical	inpatients	at	QECH	(SanJoaquin	et	al.,	2013),	comparable	to	that	of	other	CAP	cohorts	from	the	region	and	reflects	its	role	as	a	key	driver	of	pneumonia	incidence	(Aderaye,	1994a;	Albrich	et	al.,	2014a;	Birkhamshaw	et	al.,	2013;	Nyamande	et	al.,	2007a;	Scott	et	
al.,	2000).	More	than	one-third	of	HIV	infected	patients	were	newly	diagnosed	at	presentation	and	disease	was	typically	advanced	(median	CD4	cell	count	of	100	cells/mm3).	These	data	suggest	that	there	are	still	considerable	gains	to	be	made	in	reducing	CAP	incidence	through	earlier	diagnosis	and	treatment	of	HIV.	The	impact	of	the	recent	shift	in	to	WHO	policy	to	recommending	universal	ART	upon	diagnosis	of	HIV	(regardless	of	CD4	count)	should	be	observed	(Siedner	et	al.,	2015;	World	Health	Organization,	2015b).	
In	keeping	with	previous	CAP	cohorts	from	sub-Saharan	Africa,	other	chronic	comorbid	conditions	such	as	COPD,	congestive	heart	failure,	and	cerebrovascular	disease	were	rarely	reported,	presumably	reflecting	the	age	profile	of	patients	(Feldman	et	al.,	1995;	Koulla-Shiro	et	al.,	1997;	Onyedum	et	al.,	2011).	By	contrast,	in	well-resourced	settings	typically	more	than	two-thirds	of	hospitalised	CAP	patients	are	over	65	and	more	than	half	have	chronic	cardiopulmonary	or	neurological	comorbidities	(Ewig	et	al.,	2009;	Gutierrez	et	al.,	2006;	Jackson	et	al.,	2004).	Differences	in	demographics	and	comorbidity	profile	mean	that	strategies	for	CAP	prevention,	severity	assessment	and	
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management	need	to	be	locally	adapted.	Severity	assessment	tools	derived	in	well-resourced	settings	that	predict	CAP	mortality	and	give	weight	to	advanced	age	and	comorbid	illness	are	unlikely	to	be	accurate	in	Malawi	(Albrich	et	al.,	2014a;	Fine	et	al.,	1997a).		
4.6.3 Aetiology	Using	a	combination	of	blood	culture,	pneumococcal	urinary	antigen	testing,	multiplex	PCR	on	nasopharyngeal	aspirate	and	TB	diagnostic	tests	on	sputum	and	pleural	fluid,	a	potentially	causal	organism	was	identified	in	61%	of	patients.	This	yield	is	comparable	to	other	recent	high	quality	pneumonia	aetiology	studies	(Charles	et	al.,	2008a;	Johansson	et	al.,	2010).	A	recent	CDC	study	of	adult	pneumonia	in	the	US	identified	a	potential	causative	organism	in	only	38%	of	patients	(Jain	et	al.,	2015).		
Streptococcus	pneumoniae	was	commonest	organism	identified,	present	in	21%	overall.	This	is	comparable	to	the	27%	reported	in	a	recent	South	African	cohort	of	HIV-infected	adults	that	used	similar	diagnostic	tests	(Albrich	et	al.,	2012).	Higher	proportions	have	been	obtained	with	more	invasive	sampling	techniques	(e.g.	percutaneous	transthoracic	needles	aspirates)(Scott	et	al.,	2000).	Pneumococcal	pneumonia	occurred	more	frequently	in	HIV	negative	patients.	Given	the	strong	positive	association	between	HIV	and	pneumococcal	disease	this	result	initially	appears	counter-intuitive	(Gilks	et	al.,	1996),	but	has	also	been	observed	in	recent	South	African	cohort	(Albrich	et	al.,	2012).	Potential	explanations	include:	differential	under-ascertainment	of	S.	pneumoniae;	aggressive	disease	course	leading	to	early	(pre-recruitment)	death;	relatively	higher	burden	of	other	opportunistic	pathogens.	
Nearly	all	cases	of	pneumococcal	infection	were	based	on	a	positive	BinaxNOW	S.	
pneumoniae	urinary	antigen	test;	only	1%	of	patients	had	pneumococcal	bacteraemia.	This	may	reflect	under-ascertainment	as	a	result	of	high	rates	of	pre-presentation	antibiotic	use	(Jokinen	et	al.,	2010).	Alternatively,	it	may	indicate	a	genuine	shift	to	less	invasive	pneumococcal	serotypes,	perhaps	as	an	indirect	result	of	universal	infant	pneumococcal	vaccination	(Bar-Zeev	et	al.,	2015).	BinaxNOW	S.	pneumoniae	has	poor	specificity	in	children	because	of	high	rates	of	asymptomatic	nasopharyngeal	carriage	of	S.	pneumoniae	(Adegbola	et	al.,	2001).	Limited	data	indicate	that	specificity	in	adults	is	not	compromised	by	nasopharyngeal	colonisation	(Boulware	et	al.,	2007;	Sinclair	et	
al.,	2013;	Turner	et	al.,	2011).	The	combined	effect	of	nasopharyngeal	colonisation	and	HIV-infection	on	test	accuracy	has	not	been	examined.	
M.	tuberculosis	was	overall	the	second	most	commonly	identified	organism.	Traditional	teaching	has	attuned	clinicians	to	suspecting	pulmonary	TB	in	patients	with	prolonged	
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symptoms	-	typically	a	cough	for	longer	than	2	weeks	(World	Health	Organization,	2013c).	These	results	highlight	the	high	prevalence	of	TB	in	patients	with	CAP	and	short	reported	illness	duration.	Previous	CAP	studies	in	the	region	have	consistently	identified	a	substantial	burden	of	TB	when	adequate	diagnostic	tests	have	been	performed	(Hartung	et	al.,	2011;	Nyamande	et	al.,	2007a;	Scott	et	al.,	2000;	Vray	et	al.,	2008).	Recent	studies	from	South	Africa,	Zambia	and	Malawi	using	rigorous	TB	diagnostic	algorithms	with	intensive	specimen	collection	estimate	that	up	to	one-third	of	all	HIV-positive	acute	medical	inpatients	have	TB	(Bates	et	al.,	2012;	Gupta	et	al.,	2015;	Lawn	et	al.,	2015).	A	post	mortem	series	of	medical	inpatients	in	Zambia	found	TB	in	62%	with	concurrent	pyogenic	pneumonia	present	in	approximately	one	third	(Bates	et	al.,	2015).		
Improved	diagnostic	tests	for	TB	that	facilitate	early	treatment	are	urgently	needed.	In	many	low-resource	settings,	TB	diagnosis	is	still	largely	reliant	on	smear	microscopy	and	chest	radiography	despite	their	limited	diagnostic	accuracy	.	The	development	and	rollout	of	the	Xpert	MTB/RIF	platform	represents	a	major	step	forward	in	TB	diagnostics	in	low-resource	settings	(Lawn	et	al.,	2013c).	However,	as	seen	in	this	cohort,	sputum	specimens	are	frequently	unobtainable	in	acutely	unwell	patients.	New	diagnostic	modalities	based	on	urine	specimens	(e.g.	Alere	Determine	urinary	lipoarabinomannan	assay)	show	some	promise	to	improving	outcomes	(Peter	et	al.,	2016).		
Invasive	salmonellosis	was	the	commonest	cause	of	bacteraemic	disease.	Whether	these	cases	were	true	pneumonic	disease	directly	attributable	to	Salmonella	spp.	or	primarily	bacteraemic	diseases	with	pulmonary	features	due	to	other	pathogens	is	uncertain.	It	is	notable	that	most	patients	with	invasive	salmonellosis	lacked	radiographic	change.	NTS	is	the	commonest	cause	of	bacteraemia	in	African	adults	and	up	to	30%	of	patients	have	an	apparent	focal	lower	respiratory	tract	infection	(Feasey	
et	al.,	2012).	In	a	cohort	of	Kenyan	adults	with	radiographic	pneumonia,	invasive	
Salmonella	infection	was	present	in	4%	of	HIV-infected	patients	(Scott	et	al.,	2000).	Regardless	of	the	exact	nature	of	infection,	the	therapeutic	implications	of	the	need	for	broader	spectrum	antibacterials	are	the	same.		
The	burden	of	so-called	atypical	bacterial	infections	(including	Legionella	spp.,	
Mycoplasma	pneumoniae	and	Chlamydophila	spp.)	in	sub-Saharan	Africa	is	poorly	described.	The	low	prevalence	of	infection	with	Mycoplasma	pneumoniae	and	
Chlamydophila	pneumoniae	observed	in	the	current	study	based	on	multiplex	PCR	of	NPA	specimens	is	consistent	with	previous	studies	based	on	serology	that	estimated	
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prevalence,	respectively,	at	0-9%	and	0-21%	(Koulla-Shiro	et	al.,	1997;	Maartens	et	al.,	1994;	Nyamande	et	al.,	2007a;	Prout	et	al.,	1983;	Scott	et	al.,	2000).		
The	multiplex	PCR	detected	Legionella	spp.	in	19%.	The	primers	and	probes	used	in	the	FTD	33	kit	have	been	designed	to	target	the	16S	rRNA	gene	of	L.	pneumophila	and	L.	
longbeachae.	Validation	experiments	by	the	manufacturer	report	excellent	(100%)	specificity	although	sequence	analysis	by	BLAST	predicts	possible	cross	reactivity	with	
L.	worsleiensis,	which	has	been	implicated	as	a	rare	cause	of	nosocomial	pneumonia	(Berger	et	al.,	2006).	Previous	studies	from	Kenya	and	South	Africa	estimated	
Legionella	prevalence	in	CAP	patients	at	2-9%	based	on	BinaxNOW	L.	pneumophila	urinary	antigen	assay	(Mpe	et	al.,	2001;	Odera	et	al.,	2009).	The	substantial	difference	may	be	due	to	infection	with	non-serogroup	1	L.	pneumophila	or	non-pneumophila	species	that	are	not	detected	by	the	urinary	antigen	test.	There	is	considerable	geographical	variation	in	the	predominance	of	particular	Legionella	species	and	serogroups	(Isenman	et	al.,	2016;	Waterer	et	al.,	2001a).	In	a	recent	CAP	cohort	from	rural	Thailand,	for	example,	legionellosis	was	identified	by	serological	methods	in	5%	of	patients,	with	all	cases	caused	by	L.	longbeachae	(Phares	et	al.,	2007).		
There	are	possible	reasons	for	false	positive	results	that	require	further	investigation.	The	automated	PCR	process	used	the	Qiagen	QIAamp	One-For-All	nucleic	acid	extraction	kit.	Previous	reports	have	suggested	that	the	silica-gel	membrane	component	of	the	extraction	columns	produced	by	this	company	may	be	contaminated	with	Legionella	species	during	the	manufacturing	process	(Evans	et	al.,	2003;	van	der	Zee	et	al.,	2002).	It	is	unclear	whether	this	problem	has	been	addressed	in	current	versions	of	the	extraction	kit.	All	samples	were	however	run	alongside	a	negative	control	of	manufacturer	provided	nuclease	free	water	that	should	have	identified	contamination	during	the	extraction	step.	In	analysing	the	PCR	curves,	no	cut-off	value	of	cycle	thresholds	was	applied;	all	specimens	with	evidence	of	an	amplification	curve	within	the	40	cycles	of	the	reaction	were	reported	as	positive.	Amplification	artefacts	or	non-specific	cross-reactivity	at	high	cycle	threshold	values	may	account	for	some	of	the	positive	results.	
Respiratory	viruses	were	frequently	detected	with	influenza,	adenovirus	and	coronavirus	being	most	common.	Viral	detection	was	more	common	than	described	in	previous	dedicated	CAP	cohorts	from	sub-Saharan	Africa,	presumably	reflecting	the	increased	sensitivity	of	molecular	detection	methods	compared	to	serological	or	viral	culture	techniques	(Aderaye,	1994a;	Prout	et	al.,	1983;	Scott	et	al.,	2000).	Whether	the	isolated	viruses	were	the	primary	pathogen,	were	permissive	to	the	action	of	the	co-pathogen	or	were	simply	bystanders	is	uncertain.	In	severe	acute	respiratory	illness	
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(SARI)	surveillance	in	Kenya,	influenza	and	rhinovirus/enterovirus	were	each	identified	in	23%,	adenovirus,	RSV	and	parainfluenza	each	in	approximately	7%	and	human	metapneumovirus	(hMPV)	in	3%;	when	compared	against	asymptomatic	controls	however,	only	influenza,	RSV	and	hMPV	were	associated	with	clinical	disease	(Feikin	et	al.,	2012).	Rhinovirus,	RSV,	influenza	and	adenovirus	were	similarly	most	frequently	detected	in	South	African	SARI	surveillance	(Pretorius	et	al.,	2012).	A	recent	US	CAP	cohort	that	used	a	similar	multiplex	PCR	assay	of	upper	respiratory	tract	specimens	found	one	or	more	viruses	in	23%	of	patients;	rhinovirus,	influenza	and	human	metapneumovirus	were	most	common	(Jain	et	al.,	2015).	The	finding	of	high	frequencies	of	viral	infection	is	in	keeping	with	previous	studies,	but	further	work	is	needed	to	define	their	contribution	to	clinical	disease	in	this	setting	and	also	whether	this	may	be	mitigated	by	vaccination	or	treatment	strategies.		
4.6.4 Radiological	features	In	contrast	to	most	studies	of	CAP,	this	study	used	a	clinical	rather	than	radiological	definition	of	pneumonia.	This	approach	was	used	for	several	reasons.	Firstly,	to	recruit	a	study	population	that	was	representative	of	that	treated	as	CAP	in	low-resource	settings	where	chest	radiography	may	not	routinely	available	or	is	used	selectively	in	patients	that	deteriorate.	Secondly,	to	avoid	selection	bias	given	the	lack	of	portable	radiography	facilities	at	QECH	that	may	hamper	chest	radiography	in	the	sickest	patients.	Thirdly,	recognising	that	although	commonly	used	as	the	gold	standard	to	diagnose	CAP,	plain	chest	radiography	has	inherently	limited	sensitivity	and	specificity,	particularly	in	advanced	immunosuppression	(Claessens	et	al.,	2015;	Nyamande	et	al.,	2007b;	Syrjala	et	al.,	1998).		
Using	a	broad	definition	that	included	pleural	effusion,	radiographic	pneumonia	was	identified	in	76%.	However,	the	usefulness	of	plain	chest	radiography	for	directing	therapy	appears	limited.	Using	a	simple	binary	classification	(i.e.	presence	or	absence),	radiographic	pneumonia	was	positively	associated	with	S.	pneumoniae,	negatively	associated	with	Salmonella	spp.,	but	had	no	bearing	on	the	likelihood	of	detecting	any	other	organism.	The	analysis	of	patterns	of	radiographic	change	to	infer	aetiology	was	compromised	by	inter-observer	variability	in	interpretation.	Reticulonodular	change	and	mediastinal	lymphadenopathy	were	most	strongly	associated	with	TB,	but	agreement	for	identifying	these	features	was	only	fair	or	slight.	South	African	CAP	guidelines	recommend	a	management	algorithm	for	HIV-positive	patients	based	on	the	presence	of	diffuse	infiltrates	or	focal	consolidation	(Benito	et	al.,	2012;	Feldman	et	al.,	2007a).	The	current	findings	indicate	that	this	recommendation	could	not	be	applied	consistently	by	clinicians	and	may	be	of	limited	value.		
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Variability	in	chest	radiograph	interpretation	is	well	recognised	and	is	accentuated	by	differences	in	reader	experience	and	training	(Albaum	et	al.,	1996;	Moncada	et	al.,	2011;	Sakurada	et	al.,	2012).	Standardised	reading	protocols	and	computer-assisted	diagnosis	may	improve	the	consistency	of	radiographic	interpretation	(Breuninger	et	
al.,	2014;	Pinto	et	al.,	2013),	but	radiological	features	are	rarely	sufficiently	characteristic	to	accurately	differentiate	between	CAP	of	different	aetiologies	and	are	a	questionable	basis	for	therapeutic	decisions	(Assefa	et	al.,	2011).	
How	best	to	characterise	and	manage	patients	with	a	clinical	diagnosis	of	CAP	but	lacking	radiographic	change	(24%	of	patients	in	this	study)	is	unclear	and	has	received	scant	attention.	These	patients	may	have	pneumonia	that	is	not	appreciable	on	plain	chest	radiograph	or	an	alternative	-	non-pneumonia	-	diagnosis.	In	a	CAP	cohort	from	Canada,	patients	lacking	radiological	change	were	older	and	had	a	different	microbiological	spectrum	of	disease	(Basi	et	al.,	2004).	In	well-resourced	settings,	chest	tomography	scanning	is	often	used	in	immunosuppressed	patients	with	a	clinical	impression	of	pneumonia	but	negative	plain	chest	radiography	(Benito	et	al.,	2012).	Potential	options	for	further	evaluation	in	a	resource-limited	setting	include	an	interval	chest	radiograph,	chest	ultrasound	(Cortellaro	et	al.,	2012;	Reissig	et	al.,	2012)	and	inflammatory	biomarkers	(Pfister	et	al.,	2014;	Schuetz	et	al.,	2009).		
4.6.5 Strengths	and	limitations	The	MARISO	study	is	the	largest	prospective	observational	study	of	acute	CAP	in	hospitalised	adults	in	sub-Saharan	Africa,	outside	of	South	Africa,	conducted	in	the	last	thirty	years.	Patients	were	recruited	according	to	a	case	definition	reflective	of	that	used	in	clinical	practice	in	low-resource	settings	and	were	thoroughly	characterised	and	prospectively	observed	with	minimal	loss	to	follow-up.	The	panel	of	microbiological	investigations	used	to	identify	causal	pathogens	was	broad	and	with	the	exception	of	sputum	specimens	for	mycobacterial	investigations,	specimen	collection	was	reasonably	complete.		
There	are	several	important	limitations.	There	is	potential	for	selection	bias	in	the	study	population	that	was	entirely	recruited	at	a	single	central,	teaching	hospital.	Restriction	of	patient	recruitment	to	weekdays	in	the	early	phase	of	the	study	may	further	compound	any	bias.	Although	reflective	of	clinical	practice,	the	use	of	a	clinical	case	definition	based	on	clinical	signs	is	likely	to	miss	a	substantial	proportion	with	radiographic	CAP	(Hopstaken	et	al.,	2003;	van	Vugt	et	al.,	2013).	The	medical	history	of	the	patients	was	based	on	that	recorded	in	the	health	passports.	Given	limitations	in	access	to	care	and	lack	of	availability	of	diagnostics,	under-diagnosis	of	comorbid	
Clinical	characteristics,	aetiology	and	radiology	of	CAP	in	Malawi	 145	
conditions	is	possible.	The	study	relied	on	spontaneously	expectorated	sputum	specimens	for	TB	diagnostics	and	up	to	30%	failed	to	produce	a	specimen.	At	most	a	single	specimen	for	culture	and	Xpert	MTB/RIF	was	sent,	meaning	that	the	burden	of	TB	is	probably	underestimated.	The	diagnostic	panel	for	detecting	other	opportunistic	pathogens,	in	particular	PCP	and	cytomegalovirus	was	lacking.	Further,	the	lack	of	a	healthy	control	population	limits	interpretation	of	the	significance	of	the	results	of	multiplex	PCR	panel,	in	particular	for	respiratory	viruses.		
4.6.6 Future	research	The	current	results	suggest	opportunities	for	CAP	prevention	that	should	be	evaluated	in	future	studies.	HIV	infection	was	highly	prevalent.	Whether	the	occurrence	of	CAP	represented	delayed	initiation	of	ART	or	ART	failure	should	be	investigated	in	longitudinal	studies.	The	potential	role	of	exposure	to	indoor	air	pollution	as	a	modifiable	cause	of	CAP	is	the	focus	of	a	current	case-control	study	based	at	QECH	(Jary	
et	al.,	2015).	CAP	due	to	S.	pneumoniae	and	influenza	is	potentially	preventable	with	vaccination	(Bonten	et	al.,	2015;	French	et	al.,	2010;	Madhi	et	al.,	2011).	Serotype-specific	urinary	antigen	assays	that	are	able	to	define	pneumococcal	serotype	in	CAP	in	the	absence	of	bacterial	isolate	have	recently	been	developed	(Pride	et	al.,	2012;	Sheppard	et	al.,	2011).	Defining	the	serotype	distribution	of	adult	pneumococcal	CAP	would	complement	current	surveillance	studies	monitoring	the	effect	of	universal	infant	PCV	vaccination	(Bar-Zeev	et	al.,	2015).		
A	more	comprehensive	understanding	of	CAP	aetiology	is	required	to	support	empirical	therapy	decisions.	This	study	highlighted	the	large	burden	of	TB,	but	also	exposed	the	difficulties	of	diagnosis	based	on	sputum	specimens	alone.	The	role	of	new	urine	based	diagnostic	methods	(e.g.	urine	lipoarabinomannan,	urine	Xpert	MTB/RIF)	should	be	investigated	(Lawn	et	al.,	2013a;	Peter	et	al.,	2012;	Peter	et	al.,	2016).	Questions	remain	about	the	burden	of	PCP	amongst	HIV-positive	patients	with	acute	CAP	in	this	setting	(Lowe	et	al.,	2013).	New	tests	based	on	quantitative	PCR	of	nasopharyngeal	aspirates	and	detection	of	fungal	antigens	in	serum	that	remove	the	need	for	invasively-obtained	lower	respiratory	tract	specimens	should	be	evaluated	(Durand-Joly	et	al.,	2005;	Karageorgopoulos	et	al.,	2013;	To	et	al.,	2013).		
The	need	to	include	antimicrobial	cover	for	atypical	bacteria	in	empirical	treatment	is	also	unresolved.	Additional	investigation	to	confirm	the	high	detection	rate	of	
Legionella	spp.	by	the	multiplex	PCR	assay	is	needed.	In	the	first	instance,	the	multiplex	PCR	data	will	be	re-examined	to	identify	the	proportion	that	occurred	at	high	cycle-threshold	values,	possible	suggestive	of	non-specific	amplification.	The	potential	role	of	
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contamination	during	the	extraction	process	will	be	further	examined.	Stored	nasopharyngeal	specimens	are	available	for	repeat	processing.	BinaxNOW	Legionella	urinary	antigen	testing	will	be	performed	on	stored	urine	specimens,	although	this	will	not	address	the	potential	role	of	non-serogroup	1	L.	pneumophila	or	non-pneumophila	species.	Convalescent	serum	specimens	are	available	in	88	patients	for	serological	testing.	Indirect	immunofluorescence	antibody	testing	can	distinguish	between	L.	
pneumophila	serogroups	and	non-pneumophila	species,	although	cross	reactivity	has	been	reported	and	seroconversion	may	be	attenuated	in	highly	immunocompromised	patients	(Ditommaso	et	al.,	2008;	Mercante	et	al.,	2015).					
4.7 Conclusions	The	major	burden	of	hospitalised	community-acquired	pneumonia	in	Malawi	is	in	young,	HIV-positive	patients	and	is	most	commonly	caused	by	S.	pneumoniae,	tuberculosis	and	influenza.	The	epidemiology	and	aetiology	of	disease	differs	markedly	from	that	seen	in	well-resourced	settings;	accordingly	strategies	for	prevention,	assessment	and	treatment	should	be	locally	adapted.	There	are	potentially	substantial	gains	to	be	made	in	the	prevention	of	CAP	through	early	HIV	diagnosis	and	initiation	of	ART	and	vaccination.	Further	studies	are	required	to	define	how	to	optimally	use	basic	laboratory	and	radiological	investigations	to	diagnose	CAP	and	to	make	best	use	of	available	therapies.		
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5 Risk	factors	for	30-day	mortality	and	treatment	failure	in	
adults	with	community-acquired	pneumonia	in	Malawi:	A	
prospective	observational	cohort	
5.1 Introduction		Community-acquired	pneumonia	(CAP)	varies	in	severity	from	a	mild,	short-lived	illness	that	settles	with	little	or	no	treatment	to	an	acute,	fulminant	disease	complicated	by	respiratory	failure	and	severe	sepsis	(Welte	et	al.,	2012).	Understanding	the	determinants	of	outcome	is	crucial.	Firstly,	accurately	assessing	CAP	outcome	allows	early	aggressive	treatment	to	be	initiated	in	those	at	risk	of	deterioration	or,	conversely,	avoidance	of	unnecessary	treatment	or	prolonged	hospitalisation	in	those	with	mild	disease.	Secondly,	it	identifies	opportunities	for	therapeutic	innovation	to	improve	outcome.	In	the	setting	of	limited	resources,	identifying	factors	most	strongly	associated	with	adverse	outcome	provides	a	rational	basis	on	which	to	target	interventions.		
Data	describing	the	outcome	of	CAP	in	sub-Saharan	Africa	are	limited	and	as	such	the	risk	factors	for	adverse	outcome	are	poorly	described.	CAP	in	sub-Saharan	Africa	differs	from	that	seen	in	many	well-resourced	settings	in	terms	of	aetiology	and	the	demographics	and	comorbidity	profile	of	the	patients	affected	(see	chapters	2	and	4).	The	same	risk	factors	therefore	cannot	be	assumed	to	apply.	CAP	severity	assessment	tools	(e.g.	CURB65,	PSI,	SMART-COP)	aid	physicians	in	making	early	management	decisions	by	estimating	the	risk	of	adverse	outcome	increased	(Aujesky	et	al.,	2008;	Chalmers	et	al.,	2011b;	Charles	et	al.,	2008b).	These	tools	have	almost	exclusively	been	derived	in	CAP	populations	from	well-resourced	settings.	Their	prognostic	performance	in	sub-Saharan	Africa	is	largely	unknown	(Aliberti	et	al.,	2014a).		
As	described	previously,9	the	Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	Aetiology	and	Outcome	(MARISO)	Study	was	a	prospective	observational	study	of	adults	hospitalised	with	clinically	diagnosed	CAP	to	Queen	Elizabeth	Central	Hospital.	The	broad	aim	was	to	describe	the	clinical	features,	aetiology	and	outcome	of	CAP	in	adults	in	Malawi	with	a	view	to	identifying	the	key	risk	factors	for	adverse	outcome.	
																																								 																					9	The	baseline	characteristics,	radiological	features	and	aetiology	of	the	MARISO	cohort	have	been	described	in	detail	in	chapter	4.	Unless	required	for	clarity	of	the	current	analysis,	the	results	will	not	be	repeated.		
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5.2 Objectives	In	this	chapter	I	describe	the	outcome	of	CAP	in	Malawi	in	terms	of	30-day	mortality,	treatment	failure	and	clinical	stability	and	present	analyses	that	identify	the	clinical	and	basic	diagnostic	laboratory	characteristics	associated	with	these	outcomes.	I	also	describe	the	accuracy	of	existing	CAP	severity	assessment	tools	for	predicting	30-day	mortality	(CURB65	and	CRB65	(Lim	et	al.,	2003);	SMART-CO	(Charles	et	al.,	2008b);	IDSA/ATS	2007	minor	criteria	(Mandell	et	al.,	2007);	SWAT-Bp	(Birkhamshaw	et	al.,	2013))	and	the	derivation	of	a	novel	severity	assessment	tool	based	on	clinical	characteristics	evident	at	presentation.		
5.3 Contributors	to	this	chapter	As	described	in	section	3.3,	the	MARISO	study	was	a	one	of	several	prospective	observational	studies	of	respiratory	tract	infection	occurring	concurrently	at	Queen	Elizabeth	Central	Hospital.	The	individuals	that	contributed	to	data	collection	are	summarised	in	that	section.		
I	have	performed	all	analyses	undertaken	in	this	chapter.	Professor	Brian	Faragher	(Liverpool	School	of	Tropical	Medicine)	advised	on	the	development	of	the	analysis	methodology	and	interpretation.		
5.4 Methods	
5.4.1 Patient	recruitment	and	assessment	The	methods	of	the	MARISO	study	are	described	in	full	in	chapter	3.	Briefly,	patients	with	features	of	respiratory	illness	or	infection	were	screened	within	24	hours	of	admission.	Consenting	patients	with	clinically	diagnosed	CAP	as	defined	by	the	presence	of	reported	or	recorded	fever,	a	relevant	respiratory	symptom	and	focal	chest	signs	were	recruited	(see	section	3.1.1	for	full	eligibility	criteria).	Patients	underwent	a	standardised	clinical	assessment	consisting	of	comprehensive	medical	history,	targeted	physical	examination	and	measurement	of	physiological	observations	(see	section	3.13).	Plain	posteroanterior	chest	radiographs	were	performed	as	early	as	possible	after	hospital	admission	and	independently	reported	by	two	radiologists	and	myself	using	a	standardised	form	(section	3.14	and	3.18).	Radiographic	pneumonia	was	defined	as	the	presence	of	consolidation	or	other	parenchymal	abnormality	(including	reticulonodular	change,	cavitation	or	miliary	appearance)	or	pleural	effusion	(Jain	et	
al.,	2015).	Blood	was	collected	for	HIV	testing	and	basic	haematological	and	biochemical	analysis	(section	3.15).	In	addition,	blood,	urine	and	respiratory	tract	
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specimens	were	collected	for	microbiological	investigations	to	determine	disease	aetiology	(section	3.15).		
5.4.2 Clinical	endpoints	Patients	were	followed	through	their	hospital	admission	with	daily	physiological	observations	recorded	for	up	to	14	days.	Following	discharge	patients	were	followed-up	by	telephone,	or	where	necessary	by	field	worker	visit,	to	determine	vital	status	at	30	and	90	days	post	admission.	The	clinical	endpoints	were	defined	as	follows:		
i. 30-day	mortality:	death	on	or	before	the	30th	day	following	hospital	admission.	
ii. 90-day	mortality:	death	on	or	before	the	90th	day	following	hospital	admission.	
iii. Treatment	failure	was	defined	as	clinical	deterioration	with	death,	respiratory	failure	(mechanical	ventilation	or	oxygen	saturations	<90%	without	supplemental	oxygen),	haemodynamic	instability	(systolic	blood	pressure	<90mmHg	or	fall	by	≥40mmHg	from	baseline)	or	persistence/reappearance	of	fever	(≥38°)	at	72	hours	following	the	commencement	of	antimicrobial	treatment	(Menendez	et	al.,	2008;	Menendez	et	al.,	2004b).		
iv. Clinical	stability	was	defined	as	the	achievement	of	all	the	following	parameters:	temperature	≤	37.2°C;	heart	rate	≤100	beats	per	minute;	respiratory	rate	≤24	breaths	per	minute;	systolic	blood	pressure	≥90mmHg;	and	oxygen	saturations	≥90%	without	supplemental	oxygen	(Halm	et	al.,	1998;	Menendez	et	al.,	2004a).	
5.4.3 Statistical	methods	Candidate	risk	factors	for	adverse	outcome	were	selected	a	priori	based	on	a	review	of	the	literature	(Birkhamshaw	et	al.,	2013;	Fine	et	al.,	1996;	Lim	et	al.,	2009;	Lim	et	al.,	2000;	Neill	et	al.,	1996;	Scott	et	al.,	2000).	Univariable	analyses	were	performed	using	logistic	regression	to	explore	associations	between	these	risk	factors	and	(a)	30-day	mortality,	(b)	treatment	failure	and	(c)	death	within	24	hours.	Multivariable	logistic	regression	analyses	were	performed	in	stages	using	all	variables	that	had	prevalence	of	at	least	5%	and	for	which	data	were	available	in	more	than	95%	of	patients.	Firstly,	preliminary	analyses	were	performed	to	identify	variables	showing	multicollinearity	that	were	then	excluded.	Secondly,	two	intermediate	models	were	generated	in	which	clinical	and	laboratory	variables	were	grouped	together.	A	backwards	elimination	procedure	was	used	with	removal	of	variables	that	had	P	>0.2.	Variables	retained	in	these	intermediate	models	were	combined	in	a	full	model	and	the	backwards	
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elimination	procedure	was	repeated	using	P	>0.1	to	derive	a	final	multivariable	model	(Moons	et	al.,	2015;	Steyerberg	et	al.,	2013).	Age,	sex	and	HIV	status	were	retained	in	all	models	regardless	of	P	value.	Subgroup	analyses	of	HIV-infected	patients	(both	overall	and	those	known	to	be	infected	at	admission)	and	those	with	radiographic	pneumonia	were	completed.	The	impact	of	delayed	recruitment	(i.e.	using	baseline	observations	extracted	from	clinical	notes	rather	than	directly	obtained	by	the	study	team)	on	multivariable	models	for	each	of	the	endpoints	was	examined.		
The	clinical	stability	endpoint	was	analysed	in	patients	surviving	to	discharge.	Time	to	clinical	stability	was	measured	in	whole	days	from	the	date	of	admission	to	the	date	of	the	first	occurrence	of	clinical	stability.	Kaplan-Meier	analyses	were	performed	to	identify	baseline	variables	associated	with	delayed	clinical	stability.	Survival	curves	were	compared	by	log-rank	test.		
A	severity	assessment	tool	was	derived	based	on	the	clinical	features	shown	to	be	associated	with	30-day	mortality.	Continuous	variables	were	dichotomized	at	standard	thresholds	to	form	binary	indicator	variables.	The	backwards	elimination	process	was	repeated	using	P	>0.1.	As	a	strategy	to	avoid	overfitting,	1000	bootstrap	replications	of	the	selection	procedure	were	performed	and	only	those	variables	present	in	at	least	60%	of	the	replications	were	included	in	the	final	multivariable	model	(Austin	et	al.,	2004).	A	simplified	tool	was	derived	by	assigning	points	based	on	the	strength	of	association	of	individual	variables	with	mortality:	1	point	for	variables	with	a	β	coefficient	of	≤1.2	and	2	points	if	β	coefficient	of	>1.2	(Han	et	al.,	2016;	Moons	et	al.,	2015;	Steyerberg	et	al.,	2013).	The	prognostic	performance	of	the	tool	was	compared	against	that	of	existing	CAP	severity	assessment	tools	by	calculating	sensitivity,	specificity,	positive	and	negative	predictive	values,	positive	and	negative	likelihood	ratios	and	area	under	the	receiver-operating	characteristic	curve	(with	95%	confidence	intervals).	Subgroup	analyses	were	performed	to	assess	prognostic	performance	in	HIV-infected	patients	(both	overall	and	those	known	to	be	infected	at	admission)	and	in	delayed	recruitment	patients.	In	exploratory	analyses,	the	effect	of	altering	the	thresholds	at	which	heart	rate,	respiratory	rate,	oxygen	saturation	and	systolic	blood	pressure	were	dichotomized	to	form	binary	indicator	variables	was	examined.	The	severity	assessment	tool	was	re-derived	based	on	thresholds	that	maximized	Youden’s	index	for	each	of	the	component	parameters.	Population	attributable	fractions	for	mortality	were	calculated	for	potentially	modifiable	parameters.	All	statistical	analyses	were	conducted	using	Stata	version	12.1	(StataCorp;	Texas,	US).	
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5.5 Results	
5.5.1 Recruitment	and	follow-up	The	baseline	characteristics	and	details	of	the	screened	and	recruited	population	are	detailed	in	the	previous	chapter	(sections	4.3	and	4.4)	and	summarised	in	figure	5.1.	Of	the	472	patients	initially	recruited,	data	from	459	was	available	for	analysis.	Outcome	at	hospital	discharge,	at	30-days	and	at	90	days	was	determined	in	457	(99.6%),	439	(95.6%)	and	418	(91.1%),	respectively.	The	response	to	treatment	at	72	hours	was	determined	in	454	(98.9%)	patients.	Amongst	the	408	patients	surviving	to	hospital	discharge,	the	daily	observation	record	was	adequate	in	399	(97.8%)	to	determine	the	attainment	of	clinical	stability.	Overall	patient	outcomes	are	summarised	in	table	5.1	and	described	in	detail	in	the	following	sections.			
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Figure	5.1	 CONSORT	diagram	of	screening,	recruitment	and	follow-up	in	
MARISO	cohort.	 	
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Refused%consent%n=17%Not%interested%(n=7)%Fear%of%participation%(n=5)%No%time%(n=1)%Not%stated/unknown%(n=4)%
Analysed%n=459%
Not%analysed%n=13%Not%eligible%(n=8)%Records%missing%(n=3)%Withdrew%(n=2)%
Discharge%outcome%n=457%
Day%30%outcome%n=439%
Day%90%outcome%n=418%
Lost%to%follow?up%n=2%Absconded%(n=2)%
Lost%to%follow?up%n=18%
Lost%to%follow?up%n=21%
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Table	5.1	 Summary	of	patient	outcomes	in	MARISO	cohort.	Treatment	failure	defined	as	death	or	hypotension,	hypoxia	or	fever	at	72	hours	post	admission;	clinical	stability	endpoint	attained	if	normal	temperature,	heart	rate,	respiratory	rate,	systolic	blood	pressure	and	oxygen	saturations	recorded	on	single	day.	
Outcome	 No.	(%)	of	episodes	Inpatient	mortalitya	 51/457	 (11.2)	Day	30	mortalitya	 64/439	 (14.6)	Day	90	mortalitya	 87/418	 (20.8)	Treatment	failure	at	72	hoursb	Death	All	non-death	treatment	failurec	Systolic	BP	<90	or	fall	≥40	mmHg	Oxygen	saturations	<90%	Temperature	≥38°C	
109/454	16/454	93/454	60/454	32/454	26/454	
(24.0)	(3.5)	(20.5)	(13.2)	(7.1)	(5.7)	Clinical	stability	attainedd	Survivors	to	discharge	All	patientse	
	242/399	254/451	 	(60.7)	(56.3)	
a	Vital	status	missing	at	discharge	in	2,	at	day	30	in	20,	and	at	day	90	in	41.		b	Data	missing	for	5	patients.	c	Components	of	non-death	treatment	failure	exceed	total	since	hypotension,	hypoxia	and	fever	may	coexist.		d	Data	missing	for	8	patients.	e	Clinical	stability	attained	in	12	patients	that	subsequently	died	prior	to	hospital	discharge.				
5.5.2 30-day	mortality	
5.5.2.1 Overall	cohort	64	(14.6%)	of	the	439	patients	followed	to	30	days	died.	Of	these,	51	(79.7%)	died	during	hospitalization,	including	15	(23.4%)	within	24	hours	of	admission,	16	(25%)	within	the	first	3	days	and	31	(48.4%)	within	the	first	7	days	following	admission.	A	further	23	patients	died	between	day	30	and	day	90,	giving	an	overall	90	day	mortality	rate	of	20.8%	(87/418).	Amongst	patients	surviving	to	day	30,	the	mortality	rate	over	the	following	60	days	was	6.5%	(23/354).		
The	association	of	the	candidate	clinical	risk	factors	to	30-day	mortality	is	shown	in	table	5.2.	Seven	variables	were	retained	in	the	final	multivariable	analysis	as	independently	predictive	of	mortality:	male	sex	(aOR	2.57;	95%	CI:	1.23-5.39);	pre-presentation	symptom	duration	(aOR	1.11	per	day	increase;	95%	CI	1.02-1.20);	inability	to	stand	(aOR	4.28;	95%	CI:	2.14-8.57);	heart	rate	(aOR	1.02	per	beat/minute	rise;	95%	CI:	1.00-1.04);	oxygen	saturations	(aOR	0.95	per	%	rise;	95%	CI:	0.92-0.98);	white	cell	count	(aOR	0.91	per	109/L	rise;	95%	CI:	0.84-0.98);	haemoglobin	(aOR	0.90	per	g/dL	rise;	95%	CI:	0.80-1.01).	Reduced	blood	pressure	was	associated	with	30-day	
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mortality	in	univariable	analysis	and	in	the	intermediate	multivariable	model	of	clinical	predictors,	but	was	eliminated	from	the	final	multivariable	model.	Confusion	was	strongly	associated	with	mortality	in	univariable	analysis	(OR	9.15;	95%	CI:	1.50-55.87),	but	was	identified	in	only	5	(1%)	patients,	hence	excluded	from	multivariable	analysis.	Neither	age	nor	any	underlying	comorbid	illness,	including	HIV	status,	was	found	to	be	significantly	associated	with	30-day	mortality.	
162	(35.3%)	patients	were	recruited	from	the	medical	wards	on	the	day	following	admission	(see	section	4.5.2.4).	Baseline	observations	in	this	subgroup	were	obtained	by	the	AETC	triage	staff	rather	than	the	dedicated	study	team	and	the	median	respiratory	rate	was	lower	(27	vs.	30;	P	<0.0001)	(see	section	4.5.2.4).	Delayed	recruitment	was	not	associated	with	mortality	(26/159	(16.4%)	vs.	38/280	(13.6%);	OR	1.24;	95%	CI:	0.72-2.14).	Adjustment	for	delayed	recruitment	in	the	multivariable	analysis	did	not	affect	the	variables	retained	in	the	final	model	or	their	effect	size.		
5.5.2.2 Radiographic	pneumonia	Of	the	305	patients	with	radiographic	pneumonia	followed	to	30	days,	31	(10.2%)	died.	After	controlling	for	age,	sex	and	HIV	status,	radiographic	pneumonia	was	associated	with	a	reduced	risk	of	30-day	mortality	(aOR	0.47;	95%	CI:	0.24-0.92).	In	this	subgroup,	elevated	heart	rate	(aOR	1.03	per	beat/minute	rise;	95%	CI:	1.00-105),	inability	to	stand	(aOR	2.81;	95%	CI:	1.08-7.30)	and	reduced	white	cell	count	(aOR	0.87	per	109/L	rise;	95%	CI:	0.78-0.98)	were	associated	with	30-day	mortality	(Table	5.3).	Multilobar	consolidation	(OR	4.21;	95%	CI:	1.73-10.24),	but	not	pleural	effusion	or	cavitation	was	associated	with	mortality.	There	was	no	association	of	oxygen	saturations	with	mortality	in	this	subgroup.	There	was	an	unexpected	association	of	reduced	respiratory	rate	and	mortality	(aOR	0.94	per	breath/minute	rise;	95%	CI:	0.89-1.00),	but	the	absolute	difference	in	respiratory	rate	was	small	and	clinically	insignificant	(30	(IQR:	26-33)	vs.	30	(26-34)).		
5.5.2.3 HIV-infected	patients	Of	the	342	patients	with	HIV-infection	followed	to	30	days,	54	(15.8%)	died.	With	the	exception	of	haemoglobin,	the	independent	associations	with	mortality	in	this	subgroup	were	the	same	as	the	cohort	overall	(Table	5.4):	male	sex	(aOR	2.48;	95%	CI:	1.03-5.99);	symptom	duration	(aOR	1.17	per	day	increase;	95%	CI:	1.06-1.29);	heart	rate	(OR	1.02	per	beat/minute	rise;	95%	CI:	1.00-1.04);	oxygen	saturations	(OR	0.96	per	%	rise;	95%	CI:	0.92-0.99);	inability	to	stand	(OR	5.7;	95%	CI:	2.45-13.40);	white	cell	count	(OR	0.83	per	109/L	rise;	95%	CI:	0.74-0.93).	Median	CD4	cells	were	overall	lower	in	patients	that	died	(54	(IQR:	25-137)	vs.	102	(49-193);	P=0.03),	but	were	not	
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associated	with	increased	of	mortality	in	multivariable	analysis.	
The	ability	of	reported	HIV	status	to	stratify	patients	into	risk	groups	was	explored.	310	patients	reported	a	previous	HIV	test,	of	whom,	231	(74.5%)	were	positive	and	222	followed	to	30-days.	Of	the	77	patients	whose	last	reported	HIV	test	was	negative,	31	(40.3%)	were	subsequently	diagnosed	HIV-positive.	30-day	mortality	amongst	known	HIV-positive	patients	was	significantly	higher	compared	to	all	other	patients	(40/222	(18.0%)	vs.	24/217	(11.1%);	P	=	0.04).	In	this	group,	ART	use	did	not	associate	with	30-day	mortality	(33/180	(18.3)	vs.	6/38	(15.8%);	P	=	0.82).	There	was	a	non-significant	trend	towards	reduced	30-day	mortality	in	patients	using	co-trimoxazole	preventative	treatment	(CPT),	although	numbers	were	small	and	there	was	considerable	missing	data	in	this	analysis	(21/147	(14.3)	vs.	9/36	(25.0%);	P	0.13).	In	the	222	known	HIV-positive	patients,	the	independent	associations	with	mortality	were:	male	sex	(aOR	5.19;	95%	CI:	1.53-17.56);	symptom	duration	(aOR	1.16	per	day	increase;	95%	CI:	1.03-1.32);	oxygen	saturations	(aOR	0.96	per	%	rise;	95%	CI:	0.92-1.00);	inability	to	stand	(aOR	8.96;	95%	CI:	3.15-25.52);	white	cell	count	(aOR	0.83;	95%	CI:	0.73-0.95).		
5.5.2.4 Treatment	related	factors	The	association	of	initial	treatment	components	with	30-day	mortality	was	explored	(table	5.5).	Oxygen	use	on	admission	was	strongly	associated	with	increase	mortality	in	univariable	analysis	in	the	cohort	overall	(crude	OR	3.85;	95%	CI:	2.03-7.29),	but	stratified	analyses	indicated	this	was	due	to	confounding	with	hypoxaemia.	Intravenous	fluid	use	was	not	associated	with	mortality.	Although,	information	on	both	oxygen	provision	and	intravenous	fluid	use	was	limited	to	binary	variables	alone	with	no	data	available	on	concentrations	use	or	volume	administered,	respectively.	Antimicrobial	selection	–	classified	as	ceftriaxone	based	regimen	or	other	–	was	not	associated	with	mortality.	Use	of	agents	with	atypical	bacterial	cover	was	very	infrequent	and	insufficient	for	stratified	analysis	to	explore	differences	in	outcome.			
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5.5.3 Treatment	failure	Treatment	failure	occurred	in	109	(24.0%)	patients,	including	16	who	died	within	the	first	72	hours	following	hospitalization	(Table	5.1).	Amongst	patients	surviving	to	day	3,	persistent	hypotension	(60/456;	13.2%)	was	the	commonest	factor	indicating	treatment	failure.	The	relationship	of	treatment	failure	to	30-day	outcome	is	illustrated	in	figure	5.3.	Non-death	treatment	failure	(i.e.	persistent	hypotension,	hypoxia	or	fever	at	72	hours)	was	associated	with	mortality	at	day	30	(OR	3.45;	95%	CI:	1.81-6.58);	the	sensitivity	and	specificity	for	predicting	30-day	mortality	were	45.5	(30.4-61.2%)	and	80.5%	(76.2-84.4%),	respectively.		
	
	
Figure	5.2	 30-day	mortality	stratified	by	treatment	response	at	day.	The	association	of	the	candidate	risk	factors	with	treatment	failure	is	shown	in	table	5.5.	Despite	efforts	to	identify	potentially	collinear	variables,	the	final	multivariable	had	large	standard	errors	suggestive	of	multicollinearity.	Four	variables	predictive	of	treatment	failure	were	retained	in	the	final	model:	HIV	infection	(aOR	2.74;	95%	CI:	1.28-5.87);	oxygen	saturations	(aOR	0.93	per	%	rise;	95%	CI:	0.89-0.96);	inability	to	stand	(aOR	2.34;	95%	CI:	1.31-4.21);	body	mass	index	(aOR	0.86	per	kg/m2	rise;	95%	CI:	0.78-0.94).	In	contrast	to	the	analysis	for	30-day	mortality,	male	sex	was	not	significantly	associated	with	treatment	failure	(aOR	1.20;	95%	CI:	0.71-2.05).	After	controlling	for	clinical	and	demographic	features,	no	laboratory	parameter	was	found	to	be	independently	associated	with	treatment	failure.		
Delayed	recruitment	was	not	associated	with	treatment	failure	(45/161	(28.0%)	vs.	63/293	(21.5%);	OR	1.42;	95%	CI:	0.91-2.21).	Adjustment	for	delayed	recruitment	in	the	multivariable	analysis	did	not	affect	the	variables	retained	in	the	final	model	or	their	effect	size.	
Analysed)n=454%
Treatment)response)n=345%
Lost)to)follow3up)n=19%Dead)n=24% Alive)n=302%Dead)n=31% Alive)n=78%
Treatment)failure)n=109%
Dead)n=16% Alive)n=93%
Day)3)
Day)30%
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Treated	failure	was	identified	in	72	(22.9%)	of	314	patients	with	radiographic	pneumonia.	There	was	no	overall	association	between	the	presence	of	radiographic	pneumonia	and	the	risk	of	treatment	failure	(aOR	1.02;	95%	CI:	0.58-1.80).	Amongst	the	subset	of	patients	with	radiographic	pneumonia,	HIV	infection	(aOR	2.58;	95%	CI:	1.05-6.35),	reduced	oxygen	saturations	(aOR	0.92	per	%	rise;	95%	CI:	0.88-0.96)	and	reduced	body	mass	index	(aOR	0.79	per	kg/m2	rise;	95%	CI:	0.69-0.91)	predicted	treatment	failure	(Table	5.6).	There	was	no	association	between	the	presence	of	specific	radiological	features	(i.e.	multilobar	involvement,	pleural	effusion,	cavitation)	and	the	risk	of	treatment	failure.		
Treatment	failure	occurred	in	96	(27.3%)	of	the	subgroup	of	352	patients	with	HIV-infection.	As	for	the	overall	cohort,	reduced	oxygen	saturations	(aOR	0.91	per	%	rise;	95%	CI:	0.87-0.95),	reduced	body	mass	index	(aOR	0.85	per	kg/m2	rise;	95%	CI:	0.76-0.96)	and	inability	to	stand	(aOR	2.45;	95%	CI:	1.23-4.87)	predicted	treatment	failure	(Table	5.7).	There	was	no	significant	association	between	CD4	cell	count	and	the	risk	of	treatment	failure.			
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ntinuo
us	vari
ables	(
in	itali
cs
)	show
n	as	m
edian	a
nd	inte
rquart
ile	rang
e.	Anal
yses	co
lumns	
show	r
isk	
ratios	w
ith	95%
	confid
ence	in
tervals
.	Univa
riable	a
nd	mul
tivaria
ble	ana
lyses	b
y	logist
ic	regr
ession.
	For	co
ntinuo
us	vari
ables	o
dds	rat
io	(OR)
	indica
tes	
change
	in	risk
	of	mor
tality	w
ith	uni
t	increa
se	in	va
riable.	
Ch
ar
ac
te
ri
st
ic
	
Tr
ea
tm
en
t	r
es
po
nd
er
s	
(n
=3
45
)	
Tr
ea
tm
en
t	f
ai
lu
re
	
(n
=1
09
)	
O
ut
co
m
e	
un
kn
ow
n	
(n
=5
)	
U
ni
va
ri
ab
le
	a
na
ly
si
s	
M
ul
ti
va
ri
ab
le
	a
na
ly
si
s	
O
R	
(9
5%
	C
I)
	
P	
aO
R	
(9
5%
	C
I)
	
P	
Male	se
x	
207/34
5	(60
.0)	
74/109
	(67.9
)	
4/5	(
80)	
1.41	(0
.89-2.2
2)	
0.14	
1.20	(0
.71-2.0
5)	
0.50	
Ag
e	
(y
rs
)	
34
	
(2
9-
41
)	
36
	
(3
1-
42
)	
35
	
(2
8-
39
)	
1.01	(1
.00-1.0
3)	
0.14	
1.01	(0
.98-1.0
3)	
0.63	
Curren
t	smok
er	
39/343
	(11.4
)	
9/109	
(8.3)	
2/5	(
40)	
0.70	(0
.33-1.5
0)	
0.36	
-	
-	
Alcoho
l	use	
92/342
	(26.9
)	
29/109
	(26.6
)	
1/5	(
20)	
0.99	(0
.61-1.6
0)	
0.95	
-	
-	
HIV-po
sitive	
256/34
0	(75
.3)	
96/108
	(88.9
)	
3/5	(
60)	
2.63	(1
.37-5.0
2)	
0.004	
2.74	(1
.28-5.8
7)	
0.01	
Chroni
c	lung	
disease
	
11/340
	(3.2)
	
4/107	
(3.7)	
0/5	(
0)	
1.50	(0
.77-2.8
7)	
0.23	
-a 	
-	
Chroni
c	heart
	diseas
e	
0/340	
(0)	
3/107	
(2.8)	
0/5		(
0)	
-	
-	
-a 	
-	
Renal	d
isease	
0/340	
(0)	
1/107	
	(0.9)	
0/5		(
0)	
-	
-	
-a 	
-	
Sy
m
pt
om
	d
ur
at
io
n	
(d
ay
s)
	
7	
(5
-1
2)
	
7	
(6
-1
4)
	
14
	
(7
-1
4)
	
1.05	(1
.00-1.1
1)	
0.07	
-	
-	
Travel
	time	≥
1	hour
	
255/34
4	(74
.1)	
82/106
	(77.4
)	
4/5	(
80.0)	
1.19	(0
.71-2.0
0)	
0.50	
-	
-	
Previo
us	revi
ew	
220/34
5	(63
.8)	
60/108
	(55.6
)	
3/5	(
60)	
0.71	(0
.46-1.1
0)	
0.13	
-	
-	
Te
m
pe
ra
tu
re
	(°
C)
	
37
.9
	
(3
7.
1-
38
.9
)	
38
.0
	
(3
7.
1-
38
.9
)	
37
.0
	
(3
6.
7-
37
.9
)	
1.03	(0
.86-1.2
4)	
0.72	
-	
-	
Sy
st
ol
ic
	B
P	
(m
m
H
g)
	
10
8	
(9
4-
12
1)
	
10
0	
(8
8-
11
5)
	
12
3	
(1
14
-1
28
)	
0.99	(0
.98-1.0
0)	
0.05	
-	
-	
Di
as
to
lic
	B
P	
(m
m
H
g)
	
70
	
(6
0-
79
)	
62
	
(5
5-
74
)	
81
	
(7
0-
88
)	
0.98	(0
.96-0.9
9)	
0.001	
-c 	
-	
M
ea
n	
ar
te
ri
al
	B
P	
(m
m
H
g)
	
82
	
(7
2-
92
)	
75
	
(6
6-
86
)	
95
	
(8
4-
10
0)
	
0.98	(0
.97-0.9
9)	
0.004	
-c 	
-	
H
ea
rt
	ra
te
	(/
m
in
)	
11
7	
(1
01
-1
32
)	
12
2	
(1
03
-1
32
)	
11
3	
(6
8-
11
8)
	
1.01	(1
.00-1.0
2)	
0.27	
-c 	
-	
Re
sp
ir
at
or
y	
ra
te
	(/
m
in
)	
29
	
(2
6-
34
)	
30
	
(2
6-
36
)	
32
	
(2
6-
36
)	
1.01	(0
.98-1.0
4)	
0.39	
-	
-	
Ox
yg
en
	sa
tu
ra
tio
ns
	(%
)	
96
	
(9
2-
98
)	
92
	
(8
5-
96
)	
91
	
(8
6-
96
)	
0.92	(0
.88-0.9
5)	<
0.0001
	0.93
	(0.89-
0.96)	
<0.000
1	
Ri
sk
	fa
ct
or
s	f
or
	m
or
ta
lit
y	
an
d	
tr
ea
tm
en
t	f
ai
lu
re
	in
	C
AP
	in
	M
al
aw
i	
164	
Ch
ar
ac
te
ri
st
ic
	
Tr
ea
tm
en
t	r
es
po
nd
er
s	
(n
=3
45
)	
Tr
ea
tm
en
t	f
ai
lu
re
	
(n
=1
09
)	
O
ut
co
m
e	
un
kn
ow
n	
(n
=5
)	
U
ni
va
ri
ab
le
	a
na
ly
si
s	
M
ul
ti
va
ri
ab
le
	a
na
ly
si
s	
O
R	
(9
5%
	C
I)
	
P	
aO
R	
(9
5%
	C
I)
	
P	
BM
I	(
kg
/m
2 )
	
20
.2
	
(1
8.
4-
22
.0
)	
18
.9
	
(1
7.
4-
20
.7
)	
22
.0
	
(2
1.
9-
22
.6
)	
0.85	(0
.77-0.9
3)	<
0.0001
	0.86
	(0.77-
0.94)	
0.002	
M
UA
C	
(m
m
)	
25
0	
(2
20
-2
60
)	
24
0	
(2
22
-2
60
)	
27
0	
(2
50
-2
80
)	
1.00	(1
.00-1.0
1)	
0.68	
-c 	
-	
Confus
ion	
2/345	
(0.6)	
3/108	
(2.8)	
0/5	(
0)	
4.9	(0.8
1-26.7
2)	
0.08	
-a 	
-	
Inabili
ty	to	st
and	
47/345
	(13.6
)	
40/109
	(36.7
)	
0/5	(
0)	
3.68	(2
.24-6.0
4)	<
0.0001
	2.34
	(1.31-
4.21)	
0.004	
Pallor	
16/344
	(4.7)
	
11/109
	(10.1
)	
0/5	(
0)	
2.30	(1
.03-5.1
2)	
0.04	
-	
-	
Oedem
a	
10/342
	(2.9)
	
4/109	
(3.7)	
0/5	(
0)	
1.26	(0
.39-4.1
2)	
0.70	
-a 	
-	
H
ae
m
og
lo
bi
n	
(g
/d
L)
	
11
.2
	
(9
.2
-1
3)
	
10
.2
	
(8
.3
-1
1.
8)
	
12
.8
	
(1
2.
4-
13
.2
)	
0.89	(0
.82-0.9
6)	
0.003	
-	
-	
W
hi
te
	c
el
l	c
ou
nt
	(x
	1
09
/L
)	
8.
0	
(5
.0
-1
1.
9)
	
6.
5	
(4
.6
-9
.4
)	
8.
6	
(5
.3
-1
0)
	
0.97	(0
.93-1.0
1)	
0.18	
-	
-	
Pl
at
el
et
s	(
x	
10
9 /
L)
	
20
6	
(1
34
-3
03
)	
18
5	
(1
00
-3
14
)	
17
9	
(1
69
-2
85
)	
1.00	(1
.00-1.0
0)	
0.11	
-	
-	
Ur
ea
	(m
m
ol
/L
)	
4.
5	
(3
.2
-7
.1
)	
6.
5	
(3
.9
-1
0.
7)
	
3.
8	
(3
.5
-7
.5
)	
1.04	(1
.01-1.0
7)	
0.02	
-	
-	
Cr
ea
tin
in
e	
(μ
m
ol
/L
)	
74
	
(6
0-
98
)	
79
	
(5
8-
13
2)
	
78
	
(6
3-
79
)	
1.00	(1
.00-1.0
0)	
0.06	
-c 	
-	
Gl
uc
os
e	
(m
m
ol
/L
)	
5.
6	
(4
.9
-6
.3
)	
5.
7	
(4
.8
-6
.5
)	
5.
7	
(5
.0
-5
.8
)	
0.98	(0
.84-1.1
6)	
0.85	
-b 	
-	
BP	–	bl
ood	pr
essure
;	BMI	–
	body	m
ass	ind
ex;	CI-	
confide
nce	int
erval;	M
UAC	–	
mid-up
per	arm
	circum
ference
;	OR	–	o
dds	rat
io.	
a 	Exclu
ded	fro
m	mult
ivariab
le	anal
ysis	be
cause	o
f	preva
lence	≤
5%.	
b 	Exclu
ded	fro
m	mult
ivariab
le	anal
ysis	be
cause	d
ata	we
re	miss
ing	for
	>5%	o
f	patien
ts.		
c 	Exclu
ded	a	p
ri
or
i	from	
multiv
ariable
	analys
is	beca
use	of	a
ssumed
	colline
arity	w
ith	oth
er	vari
ables.	
	
Ri
sk
	fa
ct
or
s	f
or
	m
or
ta
lit
y	
an
d	
tr
ea
tm
en
t	f
ai
lu
re
	in
	C
AP
	in
	M
al
aw
i	
165	
Ta
bl
e	
5.
7	
As
so
ci
at
io
n	
of
	c
an
di
da
te
	c
lin
ic
al
	a
nd
	la
bo
ra
to
ry
	r
is
k	
fa
ct
or
s	
w
it
h	
tr
ea
tm
en
t	f
ai
lu
re
	in
	p
at
ie
nt
s	
w
it
h	
ra
di
og
ra
ph
ic
	p
ne
um
on
ia
.	
Catego
rical	va
riables
	shown
	as	num
ber	and
	propo
rtion;	d
enomin
ator	va
ries	wi
th	avai
lable	d
ata.	Co
ntinuo
us	vari
ables	(
in	italic
s)	show
n	as	m
edian	a
nd	
interqu
artile	r
ange.	U
nivaria
ble	and
	multiv
ariable
	analys
es	by	lo
gistic	r
egress
ion.	Fo
r	conti
nuous	
variabl
es,	odd
s	ratio	
indicat
es	chan
ge	in	ri
sk	with
	unit	
increas
e.	Trea
tment	
failure
	outcom
e	missi
ng	in	3
	patien
ts.	
Ch
ar
ac
te
ri
st
ic
	
Tr
ea
tm
en
t	r
es
po
ns
e	
(n
=2
42
)	
Tr
ea
tm
en
t	f
ai
lu
re
	
(n
=7
2)
	
U
ni
va
ri
ab
le
	a
na
ly
si
s	
M
ul
ti
va
ri
ab
le
	a
na
ly
si
s	
O
R	
(9
5%
	C
I)
	
P	
aO
R	
(9
5%
	C
I)
	
P	
Male	se
x	
159/24
2	(65.
7)	
49/72	
(68.1)	
1.11	(0
.63-1.9
5)	
0.71	
1.14	(0
.58-2.2
2)	
0.71	
Ag
e	
(y
rs
)	
35
	(
29
-4
2)
	
38
	(
32
-4
3)
	
1.02	(1
.00-1.0
4)	
0.09	
1.01	(0
.99-1.0
4)	
0.42	
Curren
t	smok
er	
26/240
	(10.8
)	
5/72	(
6.9)	
0.61	(0
.23-1.6
6)	
0.34	
-	
-	
HIV-po
sitive	
183/23
9	(76.
6)	
62/71	
(87.3)	
2.11	(0
.99-4.5
1)	
0.06	
2.58	(1
.05-6.3
5)	
0.04	
Sy
m
pt
om
	d
ur
at
io
n	
(d
ay
s)
	
7	
(5
-1
3)
	
7	
(6
-1
4)
	
1.03	(0
.97-1.1
0)	
0.36	
-	
-	
Te
m
pe
ra
tu
re
	(°
C)
	
37
.8
	(
37
.0
-3
8.
8)
	
38
.1
	(
37
.2
-3
9.
0)
	
1.10	(0
.88-1.3
8)	
0.40	
-	
-	
Sy
st
ol
ic
	B
P	
(m
m
H
g)
	
10
8	
(9
4-
12
2)
	
10
2	
(8
8-
12
2)
	
1.00	(0
.99-1.0
1)	
0.79	
-	
-	
H
ea
rt
	ra
te
	(/
m
in
)	
11
7	
(9
9-
13
2)
	
12
4	
(1
05
-1
34
)	
1.01	(1
.00-1.0
2)	
0.15	
-	
-	
Re
sp
ir
at
or
y	
ra
te
	(/
m
in
)	
29
	(
26
-3
4)
	
30
	(
26
-3
6)
	
1.01	(0
.98-1.0
5)	
0.39	
-	
-	
Ox
yg
en
	sa
tu
ra
tio
ns
	(%
)	
96
	(
92
-9
8)
	
92
	(
87
-9
6)
	
0.92	(0
.88-0.9
6)	<0
.0001	
0.92	(0
.88-0.9
6)	<
0.0001
	
BM
I	(
kg
/m
2 )
	
19
.9
	(
18
.4
-2
1.
5)
	
18
.9
	(
14
.7
-2
0.
8)
	
0.84	(0
.75-0.9
5)	0
.005	
0.79	(0
.69-0.9
1)	
0.001	
Inabili
ty	to	st
and	
32/242
	(13.2
)	
19/72	
(26.4)	
2.35	(1
.24-4.4
7)	0
.009	
-	
-	
H
ae
m
og
lo
bi
n	
(g
/d
L)
	
11
.1
	(
9.
3-
12
.7
)	
10
.4
	(
9.
0-
12
.5
)	
0.93	(0
.84-1.0
3)	
0.15	
-	
-	
W
hi
te
	c
el
l	c
ou
nt
	(x
	1
09
/L
)	
8.
7	
(5
.4
-1
2.
2)
	
7.
4	
(5
.7
-1
0.
4)
	
0.99	(0
.95-1.0
4)	
0.76	
-	
-	
Pl
at
el
et
s		
(x
	1
09
/L
)	
21
2	
(1
41
-3
30
)	
21
0	
(1
35
-3
40
)	
1.00	(1
.00-1.0
0)	
0.33	
-	
-	
Ur
ea
	(m
m
ol
/L
)	
4.
5	
(3
.2
-7
.4
)	
6.
0	
(3
.5
-1
1.
2)
	
1.04	(1
.00-1.0
8)	
0.04	
-	
-	
Multilo
bar	con
solidat
ion	
50/237
	(21.1
)	
22/69	
(31.9)	
1.75	(0
.97-3.1
7)	
0.07	
-	
-	
Cavitat
ion	
14/242
	(5.8)	
6/72	(
8.3)	
1.48	(0
.55-4.0
0)	
0.44	
-	
-	
Pleura
l	effusi
on	
87/240
	(36
.3)	
28/72	
(38.9)	
1.12	(0
.65-1.9
2)	
0.68	
-	
-	
Ri
sk
	fa
ct
or
s	f
or
	m
or
ta
lit
y	
an
d	
tr
ea
tm
en
t	f
ai
lu
re
	in
	C
AP
	in
	M
al
aw
i	
166	
Ta
bl
e	
5.
8	
As
so
ci
at
io
n	
of
	s
el
ec
te
d	
ca
nd
id
at
e	
cl
in
ic
al
	a
nd
	la
bo
ra
to
ry
	r
is
k	
fa
ct
or
s	
w
it
h	
tr
ea
tm
en
t	f
ai
lu
re
	in
	p
at
ie
nt
s	
w
it
h	
H
IV
.	Categ
orical	
variabl
es	show
n	as	nu
mber	a
nd	pro
portion
;	denom
inator	
varies	
with	av
ailable
	data.	C
ontinu
ous	var
iables	(
in	itali
cs
)	show
n	as	m
edian	a
nd	inte
rquart
ile	
range.	
Univar
iable	a
nd	mul
tivaria
ble	ana
lyses	b
y	logist
ic	regr
ession.
	For	co
ntinuo
us	vari
ables,	o
dds	rat
io	indic
ates	ch
ange	in
	risk	w
ith	uni
t	increa
se.	
Treatm
ent	fail
ure	ou
tcome	
missin
g	in	3.	
Ch
ar
ac
te
ri
st
ic
	
Tr
ea
tm
en
t	r
es
po
ns
e	
(n
=2
56
)	
Tr
ea
tm
en
t	f
ai
lu
re
	
(n
=9
6)
	
U
ni
va
ri
ab
le
	a
na
ly
si
s	
M
ul
ti
va
ri
ab
le
	a
na
ly
si
s	
O
R	
(9
5%
	C
I)
	
P	
aO
R	
(9
5%
	C
I)
	
P	
Male	se
x	
151/25
6	(59.
0)	
67/96	
(69.8)	
1.60	(0
.97-2.6
5)	
0.06	
1.10	(0
.59-2.0
4)	
0.77	
Ag
e	
(y
rs
)	
34
	(
29
-4
1)
	
36
	(
31
-4
1)
	
1.01	(0
.99-1.0
4)	
0.2	
1.00	(0
.97-1.0
2)	
0.74	
Curren
t	smok
er	
20/254
	(7.9)	
6/96	(
6.3)	
0.78	(0
.30-2.0
1)	
0.61	
-	
-	
Sy
m
pt
om
	d
ur
at
io
n	
(d
ay
s)
	
7	
(5
-1
1)
	
7	
(7
-1
4)
	
1.07	(1
.01-1.1
4)	
0.03	
-	
-	
Te
m
pe
ra
tu
re
	(°
C)
	
38
.0
	(
37
.2
-3
9.
0)
	
38
.1
	(
37
.2
-3
9.
0)
	
0.88	(0
.83-1.2
5)	
0.58	
-	
-	
Sy
st
ol
ic
	B
P	
(m
m
H
g)
	
10
5	
(9
2-
12
0)
	
98
	(
87
-1
15
)	
0.99	(0
.98-1.0
0)	
0.24	
-	
-	
H
ea
rt
	ra
te
	(/
m
in
)	
12
0	
(1
03
-1
34
)	
12
2	
(1
04
-1
34
)	
1.01	(0
.99-1.0
2)	
0.34	
-	
-	
Re
sp
ir
at
or
y	
ra
te
	(/
m
in
)	
29
	(
25
-3
4)
	
29
	(
26
-3
6)
	
1.02	(0
.99-1.0
5)	
0.33	
-	
-	
Ox
yg
en
	sa
tu
ra
tio
ns
	(%
)	
96
	(
92
-9
8)
	
92
	(
85
-9
6)
	
0.90	(0
.86-0.9
3)	<0
.0001	
0.91	(0
.87-0.9
5)	<0
.0001	
BM
I	(
kg
/m
2 )
	
20
.2
	(
18
.4
-2
1.
9)
	
18
.8
	(
17
.4
-2
0.
7)
	
0.86	(0
.78-0.9
4)	0
.002	
0.85	(0
.76-0.9
6)	0
.006	
Inabili
ty	to	st
and	
38/256
	(14.8
)	
35/96	
(36.5)	
3.29	(1
.92-5.6
5)	<0
.0001	
2.45	(1
.23-4.8
7)	
0.01	
H
ae
m
og
lo
bi
n	
(g
/d
L)
	
10
.8
	(
8.
7-
12
.3
)	
9.
8	
(7
.8
-1
1.
7)
	
0.91	(0
.83-0.9
9)	
0.03	
-	
-	
W
hi
te
	c
el
l	c
ou
nt
	(x
	1
09
/L
)	
7.
8	
(5
.0
-1
1.
5)
	
6.
1	
(4
.3
-8
.7
)	
0.96	(0
.91-1.0
0)	
0.06	
-	
-	
Pl
at
el
et
s		
(x
	1
09
/L
)	
20
8	
(1
35
-3
02
)	
18
6	
(1
05
-3
11
)	
1.00	(1
.00-1.0
0)	
0.22	
-	
-	
Ur
ea
	(m
m
ol
/L
)	
4.
7	
(3
.3
-7
.8
)	
6.
7	
(4
.2
-1
0.
5)
	
1.03	(1
.00-1.0
6)	
0.06	
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5.5.4 Death	within	24	hours	The	association	of	candidate	clinical	and	laboratory	risk	factors	to	death	within	24	hours	of	admission	is	shown	in	table	5.8.	In	univariable	analyses	death	within	24	hours	was	associated	with:	systolic	blood	pressure	(OR	0.95	per	mmHg	rise;	95%	CI:	0.92-0.98);	oxygen	saturations	(OR	0.90	per	%	rise;	95%	CI:	0.87-0.94);	inability	to	stand	(OR	32.32;	95%	CI:	7.14-146.25);	haemoglobin	(OR	0.78	per	g/dL	rise;	95%	CI:	0.64-0.95);	platelets	(OR	0.99	per	109/L	rise;	95%	CI:	0.98-1.00).	The	relatively	small	number	of	very	early	deaths	precluded	stable	multivariable	analysis.	The	association	of	radiographic	pneumonia	with	early	could	not	be	examined	adequately	since	only	3	of	the	15	patients	who	died	had	a	chest	radiograph	prior	to	death.	
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5.5.5 Clinical	Stability	Of	the	451	patients	in	which	data	were	available,	254	(56.3%)	attained	clinical	stability	criteria	on	at	least	one	day	during	hospital	admission.	242	(95.7%)	of	these	patients	were	subsequently	discharged	alive.	Failure	to	attain	clinical	stability	during	hospitalisation	was	associated	with	an	increased	risk	of	inpatient	mortality	(40/197	(20.3%)	vs.	11/253	(4.4%);	OR	5.61;	95%	CI:	2.71-12.44)	and,	in	those	surviving	to	discharge,	an	increased	risk	of	death	by	day	30	(11/152	(7.2%)	vs.	2/230	(0.9%);	OR	8.89;	95%	CI:	1.89-83.29).	Amongst	the	399	patients	surviving	to	hospital	discharge	with	available	data,	242	(60.7%)	had	attained	clinical	stability.	The	median	time	to	clinical	stability	in	the	cohort	overall	was	4	days.	Owing	to	an	initial	systematic	error	in	data	collection	(up	to	June	2014),	day	1	observations	were	missing	in	79	(55.6%)	of	the	142	patients	who	were	recruited	on	the	day	following	admission	who	survived	to	discharge.	An	apparent	association	of	delayed	recruitment	with	delayed	time	to	clinical	stability	was	not	evident	when	analysis	was	restricted	to	those	patients	with	day	1	data	available.	Amongst	the	319	patients	with	day	1	observations	available,	the	median	time	to	clinical	stability	was	4	days	(IQR:	2-12)		
In	univariable	analyses	using	the	Kaplan-Meier	method	(restricted	to	patients	with	day	1	observations	available),	delayed	attainment	of	clinical	stability	was	associated	with	(Table	5.8):	current	smoking	(P=0.047);	low	systolic	blood	pressure	(P	=0.01);	elevated	heart	rate	(P	=	0.0007);	elevated	respiratory	rate	(P	=	0.02);	low	oxygen	saturations	(P	=	0.0001);	low	haemoglobin	(P	=	0.02).	In	the	subgroup	of	patients	with	radiographic	pneumonia,	both	multilobar	consolidation	(P	=	0.002)	and	pleural	effusion	(P	=	0.0002)	were	associated	delayed	time	to	clinical	stability.		
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Figure	5.3	 Kaplan-Meir	failure	function	curve	of	first	attainment	of	clinical	
stability	amongst	patients	surviving	to	hospital	discharge.	Analysis	restricted	to	319	patients	with	available	data	for	day	1	observations.
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5.5.6 Relationship	of	aetiology	to	clinical	outcome	For	the	three	most	common	identified	pathogens	–S.	pneumoniae,	M.	tuberculosis	and	influenza	–	the	relationship	of	disease	aetiology	with	clinical	outcome	was	investigated	(Table	5.9).	After	adjusting	for	patient	age,	sex	and	HIV	status,	the	presence	of	M.	
tuberculosis	was	associated	with	an	increased	risk	of	30-day	mortality	(aOR	2.44;	95%	CI:	1.19-5.01)	and	treatment	failure	at	72	hours	(aOR	3.77;	95%	CI:	2.04-6.94).	Pneumococcal	aetiology	was	associated	with	a	reduced	risk	of	30-day	mortality	(aOR	0.40;	95%	CI:	0.17-0.91)	and	a	reduced	time	to	clinical	stability	(3	days	vs.	4	days;	P	=	0.04).	In	univariable	analyses	by	the	Kaplan-Meier	method,	detection	of	M.	tuberculosis	was	associated	with	delayed	clinical	stability	(P	=	0.003).		
5.5.7 Derivation	of	mortality-risk	prediction	tool	The	multivariable	analysis	of	features	associated	with	30-day	mortality	was	adapted	to	derive	a	severity	assessment	tool	that	estimated	30-day	mortality.	As	described	above,	the	intermediate	multivariable	model	of	clinical	features	associated	with	mortality	included:	male	sex,	pre-presentation	symptom	duration,	systolic	blood	pressure,	heart	rate,	oxygen	saturations	and	inability	to	stand	(see	section	5.4.2).		
Exploratory	analyses	showed	that	pre-presentation	symptom	duration	was	not	smoothly	distributed	with	reported	durations	clustering	around	3,	7	and	14	days,	suggesting	concerns	about	the	accuracy	and	consistency	of	reporting.	As	such	the	variable	was	excluded	from	the	risk-predication	tool.		
To	develop	a	tool	that	could	be	calculated	rapidly	in	a	clinical	setting,	the	continuous	variables	were	dichotomized	at	standard	thresholds	(i.e.	systolic	blood	pressure	<90mmHg;	heart	rate	≥125	beats/min;	oxygen	saturations	<90%)	before	the	multivariable	analysis	was	repeated	(Table	5.10).	As	a	categorical	variable,	systolic	blood	pressure	was	not	significantly	associated	with	30-day	mortality.	The	final	model	included	male	sex,	hypoxaemia,	inability	to	stand	and	tachycardia.	Hypoxaemia	(aOR	4.14;	95%	CI:	2.14-8.01)	and	inability	to	stand	(aOR	4.15;	95%	CI:	2.21-7.80)	were	regarded	as	major	criteria	and	assigned	2	points,	whilst	male	sex	(aOR	2.91;	95%	CI:	1.43-5.94)	and	tachycardia	(aOR	2.77;	95%	CI:	1.50-5.09)	were	minor	criteria	and	each	assigned	1	point.	The	resulting	score	was	termed	the	MOST	score	(Male	sex,	Oxygen	saturations,	inability	to	Stand,	Tachycardia).		
An	increasing	MOST	score	was	associated	with	an	increasing	rate	of	mortality	(Table	5.11).	A	score	of	≥2	identified	82.5%	of	patients	who	died.	At	this	threshold,	the	negative	predictive	value	was	95.2%	(95%	CI:	91.6-97.6)	and	negative	likelihood	ratio	
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was	0.29	(95%	CI:	0.17-0.51)	indicating	the	potential	of	the	tool	to	identify	patients	at	low	risk	of	death.	The	overall	discriminative	capability	of	the	MOST	score	for	the	prediction	of	30-day	mortality	as	assessed	by	area	under	the	receiver-operating	curve	was	0.79;	95%	CI:	0.73-0.85.		
In	HIV-positive	patients,	the	performance	of	the	MOST	score	was	similar	to	that	in	the	overall	cohort	with	an	AUROC	0.78	(95%	CI:	0.72-0.85).	Amongst	the	subgroup	of	patients	known	to	be	HIV-positive	on	admission,	AUROC	was	0.81	(95%	CI:	0.75-0.88).	At	the	threshold	value	of	>=2,	its	performance	was:	sensitivity	85.0%	(70.2-94.3);	specificity	60.9%	(53.33-68.1);	positive	predictive	value	32.7%	(23.8-42.6);	negative	predictive	value	94.8%	(89.0-98.1).	The	overall	discriminative	capability	of	the	MOST	score	did	not	vary	between	patients	recruited	directly	on	admission	and	those	recruited	on	the	following	day	(AUROC:	0.81	(95%	CI:	0.74-0.89)	vs.	0.75	(95%	CI:	0.66-0.85);	P	=	0.31).	
The	effect	of	altering	the	thresholds	values	for	dichotomizing	the	physiological	variables	included	in	the	severity	assessment	tool	was	investigated.	The	threshold	values	that	maximized	Youden’s	index	for	predicting	30-day	mortality	were:	systolic	blood	pressure	<115mmHg;	heart	rate	≥120	beats/min;	oxygen	saturations	<92%;	and	respiratory	rate	≥30	breaths/min	(Table	5.14).	At	this	threshold,	respiratory	rate	continued	to	show	no	significant	association	with	30-day	mortality.	Systolic	blood	pressure	(aOR	2.05;	95%	CI:	0.97-4.32)	was	retained	in	the	final	multivariable	model	(Table	5.15),	in	addition	to	male	sex	(aOR	2.68;	95%	CI:	1.31-5.50),	oxygen	saturations	(aOR:	3.00;	95%	CI:	1.62-5.56),	inability	to	stand	(aOR	4.45;	95%	CI:	2.36-8.39)	and	heart	rate	(aOR:	3.49;	95%	CI:	1.82-6.70).	The	discriminative	capability	of	an	alternative	severity	assessment	tool	based	on	these	five	parameters	was	not	significantly	different	to	that	of	the	MOST	score	(AUROC	0.80	(95%	CI:	0.74-0.85)	vs.	0.79	(95%	CI:	0.73-0.85);	P	=	0.60).	Using	a	threshold	value	of	≥3,	the	alternative	score	had	a	sensitivity	and	specificity	for	predicting	30-day	mortality	of	91.9%	(95%	CI:	82.2-97.3)	and	46.8%	(95%	CI:	41.6-52.1),	respectively.		
5.5.8 Accuracy	of	existing	CAP-severity	assessment	tools	The	prognostic	performance	of	MOST	was	compared	against	that	of	existing	CAP-severity	assessment	tools	(Table	5.12).	At	recommended	thresholds	for	identifying	severe	disease,	CURB65	(14.0%;	95%	CI:	6.3-25.8)	and	the	related	CRB65	tool	(27.9;	95%	CI:	17.1-40.8)	both	had	poor	sensitivity	for	identifying	individuals	at	risk	of	30-day	mortality.	The	SMRT-CO	score	-	that	was	originally	derived	to	predict	need	for	mechanical	ventilation	or	inotropic	support	-	performed	well	with	a	sensitivity	of	
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89.7%	(95%	CI:	72.6-97.8).	The	SWAT-Bp	tool	derived	in	a	previous	cohort	of	adults	with	LRTI	in	Malawi	also	included	male	sex	and	non-ambulatory	status	as	predictors	of	outcome,	but	at	the	recommended	threshold	of	3	had	poor	sensitivity	(54.1;	95%	CI:	40.8-66.9)	for	predicting	30-day	mortality.	The	overall	discriminative	capability	of	the	MOST	score	for	the	prediction	of	30-day	mortality	as	assessed	by	AUROC	compared	favourably	with	the	existing	tools.		
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Table	5.14	 Univariable	analysis	of	physiological	parameters	with	30-day	
mortality	at	varying	threshold	values.	Categorical	variables	shown	as	number	and	proportion;	denominator	varies	with	available	data.	Analysis	by	logistic	regression.	
	 No.	(%)	died	
Sensitivity	%		
(95%	CI)	
Specificity	%	
(95%	CI)	
OR	
(95%	CI)	
Respiratory	rate	(/min)	 	 	≥20	 62/417	(14.9)	 100	(94.2-100)	 2.5	(1.1-4.6)	 -	≥25	 52/334	(15.6)	 83.9	(72.3-92.0)	 22.5	(18.3-27.2)	 1.51	(0.74-3.11)	≥30	 33/205	(16.1)	 53.2	(40.1-66.0)	 52.7	(47.5-58.0)	 1.27	(0.74-2.18)	≥35	 15/95	(15.8)	 24.2	(14.2-36.7)	 78.0	(73.4-82.2)	 1.13	(0.60-2.13)	≥40	 5/40	(12.5)	 8.1	(2.7-17.8)	 90.4	(86.9-93.2)	 0.82	(0.31-2.19)	≥45	 1/20	(5.0)	 1.6	(0-8.7)	 94.8	(92.0-96.8)	 0.30	(0.04-2.26)	
Heart	rate	(/min)	 	 	≥80	 62/416	(14.9)	 96.9	(89.2-99.6)	 5.3	(3.3-8.1)	 1.75	(0.40-7.68)	≥90	 59/383	(15.4)	 92.2	(82.7-97.4)	 13.4	(10.1-17.2)	 1.82	(0.70-4.75)	≥100	 58/346	(16.8)	 90.6	(80.7-96.5)	 23.0	(18.8-27.6)	 2.38	(1.20-6.92)	≥110	 49/285	(17.2)	 76.6	(64.3-86.2)	 36.9	(32.0-42.0)	 1.91	(1.03-3.53)	≥120	 45/213	(21.1)	 70.3	(56.6-81.1)	 55.1	(49.9-60.2)	 2.90	(1.64-5.15)	≥125	 37/172	(21.5)	 57.8	(44.8-70.1)	 63.9	(58.8-68.8)	 2.43	(1.42-4.16)	≥130	 26/131	(19.9)	 40.6	(28.5-53.6)	 71.9	(67.1-76.4)	 1.75	(1.01-3.03)	≥140	 12/54	(22.2)	 18.8	(10.1-30.5)	 88.8	(85.1-91.8)	 1.82	(0.90-3.69)	
Systolic	blood	pressure	(mmHg)	 	 	<115	 51/290	(17.6)	 81.0	(69.1-89.8)	 35.6	(30.7-40.7)	 2.34	(1.21-4.56)	<110	 45/255	(17.7)	 71.4	(58.7-82.1)	 43.4	(38.3-8.1)	 1.92	(1.07-3.44)	<105	 39/211	(18.5)	 61.9	(48.8-73.9)	 53.6	(48.4-58.8)	 1.88	(1.09-3.25)	<100	 32/166	(19.3)	 50.8	(37.9-63.6)	 63.9	(58.8-68.8)	 1.83	(1.07-3.12)	<95	 23/121	(19.0)	 36.5	(24.7-49.6)	 73.6	(68.8-78.0)	 1.60	(0.91-2.81)	<90	 17/83	(20.5)	 27.0	(16.6-39.7)	 82.2	(77.9-86.0)	 1.71	(0.92-3.16)	<85	 11/54	(20.4)	 17.5	(9.1-29.1)	 88.4	(84.7-91.5)	 1.61	(0.78-3.33)	<80	 7/23	(30.4)	 11.1	(4.6-21.6)	 95.7	(93.1-97.5)	 2.77	(1.09-7.04)	
Oxygen	saturations	(%)	 	 	<98	 52/314	(16.6)	 82.5	(70.9-90.9)	 28.8	(24.2-33.7)	 1.91	(0.96-3.81)	<96	 46/227	(20.3)	 73.0	(60.3-83.4)	 50.8	(45.6-56.0)	 2.80	(1.55-5.06)	<94	 38/165	(23.0)	 60.3	(47.2-72.4)	 65.5	(60.4-70.3)	 2.88	(1.67-4.99)	<92	 33/110	(30.0)	 52.4	(39.4-65.1)	 79.1	(74.6-83.1)	 4.16	(2.39-7.24)	<90	 27/72	(37.5)	 42.9	(30.5-56.0)	 87.8	(84.0-90.9)	 5.38	(2.99-9.70)	<88	 20/59	(33.9)	 31.7	(20.6-44.7)	 89.4	(85.8-92.4)	 3.92	(2.10-7.34)	BP	–	blood	pressure;	CI	–	confidence	interval;	OR	–	adjusted	odds	ratio.			
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5.5.9 Population	attributable	fractions	for	mortality	As	a	potentially	modifiable	risk	factor,	the	population	attributable	fraction	(PAF)	of	hypoxameia	for	30-day	mortality	was	calculated.	The	estimated	proportion	of	mortality	attributable	to	hypoxaemia	(i.e.	oxygen	saturations	<90%)	was	24.5%	(95%	CI:	10.8-36.1).	PAFs	were	not	estimated	for	the	other	variables	included	in	the	final	model	since	they	are	not	directly	modifiable.		
5.6 Discussion	
5.6.1 Mortality	The	observed	overall	30-day	CAP	mortality	rate	of	14.6%	is	similar	to	that	described	in	previous	cohorts	from	Malawi	(Birkhamshaw	et	al.,	2013;	Hartung	et	al.,	2011),	Nigeria	(Mbata	et	al.,	2013),	Ethiopia	(Aderaye,	1994b),	Kenya	(Scott	et	al.,	2000)	and	South	Africa(Nyamande	et	al.,	2007a).	The	overall	mortality	rate	must	be	considered	in	the	context	of	the	age	profile	of	the	patient	population.	Whilst	comparisons	between	settings	are	often	problematic,	studies	from	well-resourced	settings	that	have	focused	on	young	CAP	patients	have	reported	much	lower	mortality	rates:	1.5%	in	patients	under	50	years	(Chalmers	et	al.,	2008;	Ewig	et	al.,	2009);	5.2%	in	those	under	65	years	(Chen	et	al.,	2010).	There	are	likely	to	be	multiple	factors	related	to	the	patient	population,	prevailing	pathogens	and	healthcare	delivery	that	contribute	to	this	elevated	mortality	rate.	Whilst	within	this	cohort,	no	independent	impact	of	HIV	infection	on	mortality	was	demonstrated,	the	high	prevalence	of	advanced	immunosuppresion	coupled	with	other	factors	such	as	under-nutrition,	are	likely	to	in	part	account	for	differences	in	outcome	between	this	and	well-resourced	setting	CAP	cohorts.	Altered	healthcare	seeking	behaviour	resulting	in	a	delayed	presentation	to	hospital	may	also	contribute.	The	association	of	increased	symptom	duration	with	increased	mortality	was	evident	in	this	cohort	despite	restricting	recruitment	to	patients	with	symptoms	of	14	days	or	less.	Delays	to	presentation	may	be	further	compounded	by	delays	to	receipt	of	appropriate	therapy	(Gattarello	et	al.,	2015).	In	keeping	with	previous	sub-Saharan	Africa	cohorts,	TB	was	very	common	and	associated	with	adverse	outcome	(Feasey	et	al.,	2013;	Jacob	et	al.,	2013b).	Data	on	the	timing	of	initiation	of	anti-TB	treatment	are	unavailable,	but	given	the	challenges	with	diagnosis,	therapy	is	commonly	delayed.	Whilst	the	data	available	on	supportive	management	(i.e.	oxygen,	intravenous	fluid	use)	in	this	study	are	limited,	they	are	sufficient	to	highlight	important	inadequacies.	Only	61%	of	patients	with	oxygen	saturations	of	less	than	90%	received	oxygen	on	admission.	Further	shortcomings	in	care	owing	to	resource	limitations	such	as	missed	medications	doses	and	limited	
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availability	of	appropriately	trained	staff	to	monitor	clinical	response	are	unaccounted	for	in	this	analysis	and	may	also	contribute	to	high	mortality	(see	section	5.6.5).	
Most	previous	studies	of	CAP	outcome	in	sub-Saharan	Africa	have	described	inpatient	mortality	only	(see	chapter	2).	With	more	detailed	and	extended	follow-up,	the	current	study	offers	additional	insights:	whilst	approximately	50%	of	deaths	occurred	within	the	first	week	following	admission,	20%	of	30-day	mortality	occurred	following	discharge	from	hospital;	amongst	patients	surviving	to	day	30,	a	further	6.5%	die	prior	to	day	90.	Early	deaths	following	a	diagnosis	of	CAP	are	typically	directly	related	to	pneumonia,	occurring	as	a	result	of	respiratory	failure	and/or	sepsis.	Studies	from	well-resourced	settings	highlight	the	importance	of	underlying	comorbid	diseases	in	contributing	to	later	deaths	following	CAP	(Mortensen	et	al.,	2002).	The	current	study	was	not	designed	to	define	causes	of	death,	but	30-day	mortality	was	related	to	treatment	failure	and	lack	of	attainment	of	clinical	stability,	perhaps	indicating	the	predominant	role	of	inadequately	treated	primary	infection	or	failure	to	recognise	or	respond	to	a	complication	as	a	contributor	to	death.	
In	Western	cohorts,	survivors	of	CAP	have	excess	mortality	compared	to	hospitalised	controls	for	at	least	one	year	(Koivula	et	al.,	1999;	Waterer	et	al.,	2004).	In	the	absence	of	a	control	group,	it	is	not	possible	to	quantify	the	numerical	significance	of	the	deaths	occurring	beyond	day	30.	Whether	these	deaths	represent	decompensation	of	underlying	comorbid	illness,	in	particular	cardiovascular	disease	(Musher	et	al.,	2007),	as	is	common	in	well-resourced	settings	or	are	due	to	other	factors	(e.g.	recurrent	infection,	tuberculosis,	related	to	antiretroviral	treatment)	warrants	further	study.	
5.6.2 Early	clinical	endpoints	Most	patients	with	CAP	do	not	die	(Welte	et	al.,	2012).	Clinical	endpoints	such	as	requirement	for	intensive	care	support,	treatment	failure	or	time	to	clinical	stability	provide	a	more	comprehensive	description	of	CAP	disease	course	and	severity	(Wiemken	et	al.,	2013).	In	low-resource	settings	where	investigations	to	define	microbiology	or	identify	complications	may	be	lacking,	clinical	response	to	treatment	is	the	major	factor	in	guiding	therapeutic	decisions	(World	Health	Organization,	2011c).	However,	the	optimal	criteria	to	define	adequate	clinical	response	are	unclear.		
Treatment	failure	as	defined	by	early	death	or	persistent	hypotension,	hypoxaemia	or	fever	at	72	hours	occurred	in	24%.	Using	a	similar	definition,	treatment	failure	has	been	reported	in	13-48%	of	hospitalised	CAP	patients	(Hoogewerf	et	al.,	2006;	Martin-Loeches	et	al.,	2014;	Menendez	et	al.,	2004b).	Treatment	failure	was	associated	with	an	increased	risk	of	30-day	mortality,	as	previously	described	(Hoogewerf	et	al.,	2006;	
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Menendez	et	al.,	2004b;	Roson	et	al.,	2004).	However,	fewer	than	half	of	patients	that	died	between	day	3	and	day	30	met	treatment	failure	criteria.	If	absence	of	treatment	failure	(i.e.	resolution	of	hypotension,	hypoxaemia	and	fever)	is	alone	used	as	the	marker	of	adequate	treatment	response,	there	is	a	danger	that	clinicians	might	be	falsely	reassured	about	the	likely	prognosis	of	patients	and	inappropriately	de-escalate	treatment.		
Attainment	of	clinical	stability	is	an	alternative	marker	of	treatment	response	and	may	be	used	to	guide	timing	of	switch	from	intravenous	to	oral	antibiotics	and	timing	of	discharge	from	hospital	(Akram	et	al.,	2013;	Mandell	et	al.,	2007;	Niederman	et	al.,	2001).	In	keeping	with	previous	studies,	failure	to	attain	clinical	stability	was	associated	with	increased	risk	of	death	in	the	current	cohort	(Aliberti	et	al.,	2011;	Halm	
et	al.,	2002).	However,	inpatient	mortality	following	attainment	of	stability	was	4.4%	compared	to	less	than	1%	in	previous	studies	(Akram	et	al.,	2013;	Halm	et	al.,	1998)	and	only	60%	of	patients	overall	actually	met	criteria	for	clinical	stability	prior	to	discharge.		
The	criteria	used	to	define	treatment	response	and	clinical	stability	criteria	need	to	be	refined	and	locally	adapted	before	they	can	be	used	as	a	reliable	basis	for	making	therapeutic	decisions	in	Malawi	or	similar	settings.	In	addition,	defining	robust	clinical	endpoints	is	an	important	prelude	to	designing	appropriate	clinical	trials	of	new	interventions.	The	use	of	additional	clinical	parameters	such	as	adequate	oral	intake	and	ambulation	might	improve	the	accuracy	of	assessment	(Aliberti	et	al.,	2013).	Whilst	there	was	substantial	missing	data	for	physiological	observations	taken	on	the	first	day	following	admission,	this	had	little	overall	impact	on	the	estimate	of	the	median	time	to	clinical	stability.	Tuberculosis	was	associated	with	both	treatment	failure	and	delayed	clinical	stability.	Further	studies	are	needed	to	better	define	the	causes	of	inadequate	treatment	response	and	to	suggest	the	appropriate	panel	of	investigations	or	broadened	empirical	treatment.		
5.6.3 Risk	factors	for	adverse	outcome	Hypoxaemia–	as	measured	by	pulse	oximetry	–	was	strongly	associated	with	both	mortality	and	treatment	failure.	This	expected	finding	is	consistent	with	previous	studies	(Charles	et	al.,	2008b;	Fine	et	al.,	1997a).	The	extent	to	which	hypoxaemia	is	a	potentially	remediable	factor,	the	correction	of	which	might	improve	outcome,	rather	than	a	marker	of	disease	severity	alone,	merits	consideration	in	this	resourced-limited	context	where	the	number	of	hypoxaemic	patients	exceeds	the	capacity	of	supplemental	oxygen	delivery	systems	several	times	over	(Evans	et	al.,	2012).	
Risk	factors	for	mortality	and	treatment	failure	in	CAP	in	Malawi	 183	
Programmes	to	improve	the	detection	and	correction	of	hypoxaemia	in	paediatric	pneumonia	in	resource-limited	settings	have	resulted	in	reductions	in	mortality	of	up	to	35%	(Duke	et	al.,	2010c;	Duke	et	al.,	2008;	La	Vincente	et	al.,	2011).	The	extent	to	which	these	achievements	can	be	replicated	in	adult	pneumonia	is	uncertain.		
Tachypnoea,	although	strongly	correlated	with	oxygen	saturations,	was	not	predictive	of	adverse	outcome,	in	contrast	to	many	previous	studies	in	diverse	populations	(Charles	et	al.,	2008b;	Fine	et	al.,	1997a;	Fine	et	al.,	1996;	Lim	et	al.,	2000;	Ortqvist,	1990;	Scott	et	al.,	2000).	A	lack	of	association	between	respiratory	rate	and	mortality	has	been	observed	in	other	cohorts	from	low-resource	settings	(Birkhamshaw	et	al.,	2013;	Hartung	et	al.,	2011;	Rylance	et	al.,	2009).	It	is	possible	that	in	these	predominantly	young	adult	populations	with	presumably	improved	physiological	reserve	increased	respiratory	rate	alone	does	not	indicate	imminent	respiratory	failure.	Although	inaccuracy	in	respiratory	rate	estimation	is	well-recognised,	the	lack	of	association	with	mortality	at	even	very	elevated	respiratory	rates	suggests	that	this	is	not	relevant	(Lovett	et	al.,	2005).	The	lack	of	association	of	elevated	respiratory	rate	with	adverse	outcome	underlines	the	importance	of	pulse	oximetry	as	a	vital	component	of	pneumonia	disease	severity	assessment.	Whilst	there	are	innovations	and	initiatives	to	make	pulse	oximeters	more	affordable,	reliable	and	robust	(Dubowitz	
et	al.,	2013),	availability	in	many	low-resourced	settings	is	still	inadequate	(World	Health	Organization,	2011a).	
Inability	to	stand	unaided	was	associated	with	both	30-day	mortality	and	treatment	failure.	This	simple	observation	is	not	commonly	reported	in	studies	of	hospitalised	patients	from	most	well-resourced	settings,	but	is	attractive	for	use	in	low-resource	settings	because	it	is	rapidly	ascertainable	with	no	equipment	and	limited	training.	In	a	cohort	of	acutely	hospitalised	adults	in	Tanzania,	the	inability	to	walk	unaided	predicted	death	with	a	sensitivity	of	86%	and	a	specificity	of	52%	(Rylance	et	al.,	2009).	Further	validation	work	is	required	to	determine	the	inter-observer	variability	in	recording	this	feature.		
Male	sex	was	independently	associated	with	increased	mortality.	Several	previous	CAP	studies	have	identified	male	sex	as	risk	factor	both	for	incident	pneumonia	and	adverse	outcome	(Ewig	et	al.,	2009;	Fine	et	al.,	1996;	Kaplan	et	al.,	2002;	Ortqvist,	1990;	Welte,	2012).	Whilst	sex-related	variations	in	the	immunological	response	to	sepsis	may	in	part	account	for	the	observed	differences	in	outcome	(Angele	et	al.,	2014),	differences	in	health-seeking	behaviour	and	clinical	management	are	also	likely	to	be	relevant	(Arnold	et	al.,	2013).	
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In	contrast	to	previous	CAP	studies,	no	association	with	age	and	mortality	was	demonstrated	(Fine	et	al.,	1997a;	Kothe	et	al.,	2008;	Lim	et	al.,	2000).	In	studies	from	developed	settings,	the	increase	in	mortality	with	advancing	age	becomes	apparent	in	patients	above	the	age	of	40	(Ewig	et	al.,	2009;	Fine	et	al.,	1997a).	The	median	age	of	the	current	cohort	is	35	with	31%	age	40	years	or	older	and	13%	aged	50	years	or	older.	This	comparatively	young	average	means	that	the	study	is	relatively	underpowered	to	detect	age-related	differences	in	mortality	that	only	become	notable	beyond	40	years.	Residual	confounding	due	to	factors	related	to	pre-morbid	condition	and	healthcare	utilisation	may	also	pertain.		
HIV	was	not	associated	with	an	increased	risk	of	mortality	at	30	days,	but	was	associated	with	an	increased	risk	of	treatment	failure.	The	explanation	for	and	relevance	of	this	discrepant	result	is	uncertain.	Controlling	for	CD4	cell	count	and	ART	use	did	not	influence	these	findings.	Most	studies	from	the	ART	era	have	shown	that	the	mortality	of	acute,	presumed	bacterial	CAP	does	not	alter	with	HIV	status	(Albrich	et	al.,	2014a;	Birkhamshaw	et	al.,	2013;	Christensen	et	al.,	2005;	Malinis	et	al.,	2010;	Mwachari	et	al.,	2006;	Nyamande	et	al.,	2007a;	Scott	et	al.,	2000).	Whilst	a	small	effect	obscured	by	residual	confounding	is	possible,	it	is	clear	that	predominant	impact	of	HIV	on	CAP	is	on	the	rate	of	acquisition	of	disease	rather	than	its	outcome.	For	individual	episodes	of	pneumonia,	the	assessment	of	disease	severity	and	estimation	of	prognosis,	should	not	be	influenced	by	HIV	status.	
Reduced	haemoglobin	concentration	was	weakly	associated	with	30-day	mortality	risk.	Although	correlated	with	haemoglobin,	clinically	assessed	pallor	did	not	predict	mortality.	Anaemia	has	previously	been	associated	with	both	early	mortality	and,	in	survivors	to	hospital	discharge,	continued	excess	mortality	risk	up	to	90	days	(Fine	et	
al.,	1997a;	Hartung	et	al.,	2011;	Reade	et	al.,	2010;	Waterer	et	al.,	2004).	Further	analysis	is	needed	to	determine	whether	the	association	is	directly	causal	(i.e.	due	to	impaired	tissue	oxygen	transport	compromised)	or	a	marker	of	underlying	disease.	The	extent	to	which	correction	of	anaemia	may	improve	outcome	is	uncertain.	In	severe	sepsis,	a	restrictive	transfusion	strategy	(i.e.	haemoglobin	transfusion	threshold	of	7g/dL)	is	non-inferior	to	more	liberal	use	(i.e.	threshold	of	9g/dL)(Holst	et	al.,	2014).	
In	keeping	with	previous	studies,	leucopenia	was	also	associated	with	increased	mortality	(Fine	et	al.,	1996;	Scott	et	al.,	2000).	The	IDSA/ATS	criteria	for	predicting	intensive	care	requirement	also	include	leucopenia	(Mandell	et	al.,	2007),	but	recent	re-analyses	indicate	its	non-contributory	to	prognostic	accuracy	(Li	et	al.,	2015;	Salih	et	
al.,	2014).	Attempts	to	manipulate	white	cell	number,	function	and	differentiation	using	
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granulocyte	colony	stimulating	factor	(G-CSF)	do	not	improve	outcome	in	pneumonia	or	sepsis	(Bo	et	al.,	2011;	Cheng	et	al.,	2007).	
5.6.4 CAP	severity	assessment	tools	The	clinical	course	of	CAP	is	variable	and	difficult	to	predict.	Severity	assessment	tools	support	early	management	by	providing	an	objective	assessment	of	prognosis.	The	MOST	score	proposed	in	the	current	study	is	a	simple	tool	based	solely	on	clinical	parameters	evident	at	presentation.	Using	a	threshold	of	2,	it	had	sensitivity	of	82.5%	and	negative	predictive	value	of	95.2%	for	30-day	mortality.	If	these	findings	are	replicated	in	validation	studies,	a	MOST	score	of	less	than	2	might	be	used	to	identify	those	patients	at	low	risk	of	mortality	potentially	suitable	for	outpatient	treatment	or	early	hospital	discharge.	In	particular,	those	lacking	any	features	of	severe	disease	(i.e.	MOST	score	0)	had	a	minimal	risk	of	mortality	(less	than	1%).	Given	the	patients	with	MOST	scores	of	0	and	1	accounted	for	17%	and	38%	of	the	cohort,	respectively,	the	potential	for	admission	avoidance	and	reducing	demand	on	already	overstretched	inpatient	services	is	considerable.		
The	mortality	rate	of	patients	with	a	MOST	score	of	3	was	25%	and	rose	rapidly	with	increasing	score.	Comparable	rates	of	predicted	mortality	would	prompt	consideration	of	high-dependency	care	in	CAP	patients	in	well-resourced	settings	(Lim	et	al.,	2003).	Whilst	high-dependency	care	provision	is	minimal	in	many	sub-Saharan	African	settings	(Adhikari	et	al.,	2010),	this	group	of	patients	could	be	targeted	for	closer	monitoring	including	simple	measures	such	as	regular	nursing	observations,	repeated	assessment	of	oxygenation	and	fluid	balance,	early	review	of	treatment	response.	Similarly,	the	MOST	score,	if	validated,	could	be	used	to	target	or	stratify	interventions	in	future	clinical	trials	of	severe	pneumonia.		
Existing	CAP-severity	assessment	tools	performed	poorly	in	the	current	cohort.	CURB65	had	an	area	under	receive-operating	curve	of	0.60	for	30-day	mortality,	indicating	poor	or	moderate	discriminatory	capability.	At	the	standard	threshold	for	defining	severe	pneumonia,	CURB65	had	sensitivity	of	only	14%.	Its	poor	performance	likely	reflects	that	two	of	its	component	parameters	–	age	greater	than	65	and	confusion	–	were	uncommon,	each	occurring	in	fewer	than	5%	of	patients.	Similarly,	SMRT-CO	and	the	IDSA/ATS	minor	criteria	were	considerably	less	accurate	than	has	been	observed	in	validation	studies	in	well-resourced	settings	(Chalmers	et	al.,	2011c).	CURB65,	SMRT-CO	and	IDSA/ATS	minor	criteria	were	all	derived	in	CAP	populations	in	well-resourced	settings	where	the	demographic	distribution	and	comorbidity	profile	is	markedly	different	to	that	seen	in	Malawi	(see	chapter	4).	The	derivation	studies	also	
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specifically	excluded	patients	with	immunocompromise,	TB	or	non-radiographic	pneumonia	(Charles	et	al.,	2008b;	Lim	et	al.,	2003;	Mandell	et	al.,	2007),	all	of	which	were	common	in	the	current	cohort.	These	findings	underline	the	necessity	of	using	locally	derived	or	recalibrated	tools	to	guide	CAP	clinical	management	(Schuetz	et	al.,	2008).	
The	SWAT-Bp	score	was	designed	to	predict	the	mortality	risk	of	in	hospitalised	adults	with	clinical	lower-respiratory	tract	infection	(Birkhamshaw	et	al.,	2013).	In	the	original	derivation	cohort	in	Malawi,	it	showed	excellent	discriminative	capability	for	the	prediction	of	inpatient	(area	under	ROC	curve	0.867).	In	this	cohort,	despite	containing	variables	shown	to	be	predictive	of	mortality	(i.e.	male	sex	and	non-ambulatory	state),	it	only	showed	moderate	prognostic	performance	(area	under	ROC	curve	0.65).	This	disparity	may	reflect	important	differences	between	the	current	cohort	and	the	SWAT-Bp	derivation	cohort:	firstly,	the	diagnosis	of	LRTI/pneumonia	was	not	prospectively	standardised	against	a	case-definition;	secondly,	patients	with	chronic	or	long-standing	symptoms	were	not	systematically	excluded.		
The	risk	of	identifying	spurious	associations	of	candidate	risk	factors	with	outcome	(type	1	error)	or	failing	to	detect	true	risk	factors	(type	2	errors)	is	inherent	in	prognostics	research.	The	inappropriate	retention	of	variables	in	a	multivariable	model	-	termed	‘over-fitting’	(i.e.	type	1	error)	–	compromises	its	prognostic	performance	in	independent	datasets.	The	risk	of	over-fitting	increases	with	the	number	of	predictor	variables	examined	and	a	minimum	events	per	variable	ratio	(EPV)	of	10	has	been	recommended	(Peduzzi	et	al.,	1996),	although	this	may	be	excessively	conservative	and	EPV	of	5	may	be	sufficient	in	many	scenarios	(Vittinghoff	et	al.,	2007).	In	the	current	analysis,	31	candidate	predictor	variables	for	mortality	were	initially	considered;	12	were	excluded	on	the	basis	of	low	prevalence,	incomplete	datasets	or	assumed	collinearity	(e.g.	systolic	blood	pressure	and	diastolic	blood	pressure).	For	the	remaining	19	variables,	two	separate	intermediate	multivariable	models	for	clinical	and	laboratory	parameters	(both	adjusted	for	age,	sex	and	HIV	status)	were	derived.	Only	those	11	variables	with	a	P	value	>0.2	(plus	age	and	HIV	status)	were	included	in	the	final	multivariable	analysis.	This	approach	was	considered	superior	to	variable	selection	on	the	basis	of	preliminary	univariable	analyses	that	is	frequently	used	but	increases	the	risk	of	over-fitting.	Whilst	the	risk	of	over-fitting	remains	given	the	relatively	low	EPV	ratio,	the	identified	risk	factors	for	mortality	are	all	plausible	and	consistent	with	previous	studies.	Regardless	of	the	apparent	robustness	of	the	multivariable	analyses,	however,	external	validation	in	an	independent	cohort	is	essential	(Altman	et	al.,	2009).		
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5.6.5 Strengths	and	limitations	The	MARISO	study	is	one	of	the	largest	prospective	observational	studies	of	acute	CAP	in	hospitalised	adults	ever	conducted	in	sub-Saharan	Africa.	Whilst	most	previous	studies	have	described	CAP	outcome	solely	in	terms	of	short-term	mortality,	this	study	gives	a	comprehensive	description	of	early	clinical	outcomes	and	treatment	response.	The	clinical	case	definition	used	is	reflective	of	that	routinely	used	in	clinical	practice	in	low	resource	settings.	Data	on	prognostic	factors	was	prospectively	collected	using	consistent	methods	and	the	completeness	of	follow-up	was	good.	
There	are	several	important	limitations.	The	study	population	is	restricted	to	hospitalised	patients,	hence	the	clinical	characteristics	and	outcome	of	those	deemed	well	enough	to	be	treated	at	home	is	unknown.	The	setting	of	the	study	in	a	referral	hospital	also	potentially	limits	the	applicability	of	the	findings	to	community	level	settings	where	patients	are	initially	assessed.	Study	recruitment	was	restricted	to	working	hours:	patients	presenting	with	severe	pneumonia	that	deteriorated	and	died	rapidly	would	not	have	been	included	in	this	cohort.	The	risk	of	type	1	errors	has	been	discussed	above.		The	impact	of	treatment	related	factors	such	as	antimicrobial	choice	and	speed	of	administration,	adequacy	of	fluid	resuscitation	and	oxygen	delivery	is	not	fully	accounted	for	in	this	study.	Whilst	similar	criticisms	could	be	made	of	analogous	studies	from	well-resourced	settings,	the	potential	for	variability	in	clinical	management	is	greater	in	Malawi	given	inconsistencies	in	drug	supply,	inadequate	oxygen	provision	and	variation	in	experience	of	medical	staff.	Inadequate	nursing	staff	levels	on	the	medical	wards	may	also	compromise	timeliness	and	completeness	of	drug	administration	and	supportive	therapy.	Patient	guardians	play	a	vital	role	in	maintaining	patient	nutrition	and	hydration	throughout	hospitalisation	and	highlighting	deteriorations	in	condition	to	medical	and	nursing	staff.	The	current	analyses	do	not	adequately	account	for	these	treatment	and	care	delivery	factors.		
5.6.6 Future	research	This	study	has	described	all-cause	mortality	up	to	90	days.	Studies	from	well-resourced	settings	have	highlighted	that	CAP	is	associated	with	continued	excess	mortality	for	many	months	after	apparent	resolution	and	that	a	many	deaths	result	from	destabilisation	of	comorbid	illness	(Koivula	et	al.,	1999;	Musher	et	al.,	2007;	Waterer	et	
al.,	2004).	Further	studies	are	needed	from	sub-Saharan	African	settings	to	broadly	define	the	causes	of	death	and	to	understand	the	long-term	impacts	on	health	outcomes.		
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The	MOST	score	is	a	simple	prognostic	tool	that	could	potentially	be	used	to	provide	a	rapid	assessment	of	disease	in	low-resource	settings	by	minimally	trained	staff.	However,	to	demonstrate	its	value,	a	prognostic	tool	must	show	that	it	performs	well	in	groups	other	than	the	population	in	which	it	was	derived	(Altman	et	al.,	2009;	Moons	et	
al.,	2015).	The	size	of	the	MARISO	study	cohort	was	insufficient	to	develop	an	adequate	prognostic	model	using	a	split	dataset	(“training”	and	“test”	set)	approach.	Whilst	commonly	used,	this	form	of	internal	validation	does	not	remove	the	requirement	for	external	validation	in	a	separately	recruited	cohort	(Steyerberg	et	al.,	2013).	The	performance	of	the	MOST	score	should	be	evaluated	in	a	CAP	cohort	from	another	sub-Saharan	African	setting.	Impact	studies	are	then	required	to	demonstrate	that	the	MOST	score	(or	an	optimised	derivative)	meaningfully	influences	clinical	management	decisions	to	improve	patient	outcomes.		
For	physiological	parameters,	the	MOST	score	used	dichotomised	variables	with	threshold	values	based	on	those	widely	used	in	the	CAP	literature.	The	relevance	of	these	thresholds	to	CAP	populations	in	Malawi	or	other	sub-Saharan	African	settings	that	are	dominated	by	young	adults	is	unclear.	The	impact	on	prognostic	accuracy	of	altered	thresholds	to	define	significant	abnormality	in	physiological	parameters	should	be	explored.		
Hypoxaemia	is	a	potentially	modifiable	risk	factor	for	mortality.	Supplemental	oxygen	provision	in	many	low-resource	settings	is	poor	and	relies	mainly	on	oxygen	concentrators	(Evans	et	al.,	2012;	World	Health	Organization,	2011a).	Whether	these	devices	generate	oxygen	at	sufficient	concentration	and	rates	of	flow	to	correct	hypoxaemia	in	adults	with	acute	pneumonia	has	not	been	established.		
5.7 Conclusions	CAP	in	adults	in	Malawi	is	associated	with	substantial	mortality,	almost	half	of	which	occurs	within	7	days	of	hospitalisation.	Of	the	identified	risk	factors	for	mortality,	hypoxaemia	is	one	of	the	strongest	and	also	most	amenable	to	correction.	The	MOST	score	is	a	simple,	4-variable	tool	based	solely	on	clinical	parameters	that	appears	to	estimate	the	risk	of	30-day	mortality	with	reasonable	precision.	If	proved	accurate	in	validation	studies,	the	ability	of	the	MOST	score	to	safely	stratify	care	in	CAP	patients	in	Malawi	and	comparable	settings	should	be	assessed	in	clinical	trials.	 
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6 Addressing	hypoxaemia	in	adult	pneumonia	in	Malawi:	A	
pilot	study	of	the	effectiveness	of	supplemental	oxygen	
delivery	by	oxygen	concentrators	
6.1 Introduction	Hypoxaemia	is	common	feature	of	critical	illness	generally	and	severe	respiratory	infection	in	particular.	Pneumonia	management	guidelines	universally	recommend	that	supplemental	oxygen	be	administered	to	correct	hypoxaemia	(Lim	et	al.,	2009;	Mandell	
et	al.,	2007).	In	adults	with	pneumonia	the	presence	of	hypoxaemia	is	an	indicator	of	severe	disease	and	is	consistently	associated	with	poor	outcome	(Bowton	et	al.,	1994;	Fine	et	al.,	1996;	Lim	et	al.,	2003).	In	the	Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	Aetiology	and	Outcome	(MARISO)	Study	described	in	the	preceding	chapters,	hypoxaemia	at	presentation	was	independently	associated	with	mortality.	
In	well-resourced	settings	the	availability	of	adequate	supplies	of	supplemental	oxygen	is	largely	taken	for	granted.	In	acute	hospital	settings,	piped	wall	oxygen	is	typically	available	at	each	bed-space	and	additional	means	of	respiratory	support	such	as	high-flow	oxygen,	continuous	positive	airways	pressure	(CPAP),	non-invasive	ventilation	(NIV)	and	invasive	ventilation	are	available	for	deteriorating	patients.	This	is	in	marked	contrast	to	low-resource	settings	where	the	availability	of	supplemental	oxygen	provision	is	woefully	inadequate	(Duke	et	al.,	2010a;	Hill	et	al.,	2009).		
In	the	absence	of	piped	oxygen	infrastructure,	the	World	Health	Organization	(WHO)	recommends	that	oxygen	in	hospitals	is	provided	using	oxygen	concentrators	(Duke	et	
al.,	2008;	La	Vincente	et	al.,	2011).	Oxygen	concentrators	are	the	main	source	of	oxygen	provision	in	Queen	Elizabeth	Central	Hospital,	Blantyre,	Malawi	(Evans	et	al.,	2012).		
Oxygen	concentrators	were	initially	developed	in	the	1970s	for	domiciliary	oxygen	provision	for	patients	with	chronic	lung	disease	rather	than	for	acutely	unwell	patients	in	a	hospitalised	setting.	They	use	an	oscillating	plate	to	force	ambient	air	across	a	filter	bed	to	extract	nitrogen	and	produce	oxygen-enriched	gas.	There	is	now	wide-range	of	oxygen	concentrators	available	that	vary	considerably	in	performance	characteristics	(e.g.	maximum	flow	rate,	maximum	oxygen	concentration),	power	requirements,	and	tolerances	(i.e.	for	temperature	and	humidity).	Most	devices	produce	up	to	5	L/min	of	approximately	95%	oxygen.	Higher	flow-rate	concentrators	that	produce	up	to	10	L/min	of	85%	oxygen	are	also	available	but	typically	cost	75%	more	and	have	higher	power	requirements.		
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There	is	no	empiric	evidence	describing	the	adequacy	of	oxygen	concentrators	in	terms	of	their	ability	to	deliver	oxygen	at	sufficient	concentrations	and/or	flow-rates	to	correct	hypoxaemia.	Amongst	adults	with	pneumonia	who	are	hypoxaemic,	the	proportion	that	attain	normoxaemia	with	oxygen	delivered	by	concentrator	at	5	L/min	(i.e.	the	maximum	flow	rate	of	standard	concentrators)	is	not	known.	The	effectiveness	of	oxygen	delivery	by	oxygen	concentrator	to	induce	normoxaemia	amongst	adults	with	pneumonia	who	are	hypoxaemic	at	presentation	is	unknown.	In	particular	to	what	extent	high	flow-rate	devices	that	produce	10	L/min	are	more	effective	than	standard	flow-rate	devices	has	not	been	described.	
6.2 Objectives	
6.2.1 Broad	The	broad	objective	of	this	study	was	to	assess	the	effectiveness	of	supplemental	oxygen	provided	by	oxygen	concentrator	to	correct	hypoxaemia	in	adults	with	suspected	pneumonia.	Hypoxaemia	is	defined	as	oxygen	saturations	(SpO2)	less	than	92%	measured	by	pulse	oximetry	and	normoxaemia	(or	corrected	hypoxaemia)	is	defined	as	SpO2	greater	than	or	equal	to	92%.		
6.2.2 Specific	i. To	determine	the	proportion	of	adults	hospitalised	with	pneumonia	that	are	hypoxaemic	at	presentation	that	attain	normoxaemia	with	supplemental	oxygen	delivered	by	concentrator	at	a	standard	flow-rate	of	5	L/min.	
ii. To	determine	what	proportion	of	those	who	fail	to	attain	normoxaemia	at	a	rate	of	5	L/min,	attain	normoxaemia	at	a	high	flow-rate	of	10	L/min.	
6.3 Contributors	to	the	AHIP	Study	I	conceived	the	study	and	devised	the	protocol,	wrote	all	study	documents,	designed	and	developed	the	CRFs	and	study	database.	In	addition	to	my	supervisors,	Dr	Jamie	Rylance	(Liverpool	School	of	Tropical	Medicine,	UK),	Dr	Mulinda	Nyirenda	(QECH)	and	Dr	Aylwin	Chick	(formerly	QECH)	provided	useful	comments	in	the	development	of	the	study	protocol.	All	study	clinical	procedures	were	performed	by	a	study	clinical	officer	and	two	research	nurses	overseen	by	the	study	coordinator,	Dr	Jacqueline	Huwa.	Dr	Huwa	also	completed	the	routine	data	management	activities	including	CRF	scanning	and	data	verification.	I	completed	the	reading	and	grading	of	the	radiographs.	Clinical	specimens	were	processed	in	the	MLW	Clinical	Diagnostic	Laboratory	under	the	
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supervisions	of	the	laboratory	managers,	Brigitte	Denis	and	George	Selemani.	I	developed	the	statistical	analysis	plan	and	undertook	all	analyses	myself.	
6.4 Methods	
6.4.1 Study	design	Prospective,	open-label,	single-arm	clinical	study		
6.4.2 Setting	The	study	was	conducted	at	Queen	Elizabeth	Central	Hospital	(QECH),	Blantyre,	Malawi	as	described	in	detail	in	section	1.11.2.	Enrolment	commenced	on	25th	November	2014	and	continued	until	17th	July	2015.	Participant	follow-up	was	completed	on	29th	August	2015.	The	study	team	were	based	in	the	Adult	Emergency	and	Trauma	Centre	(AETC)	and	study	procedures	were	conducted	in	the	Resuscitation	area.	Prior	to	the	inception	of	this	study,	the	only	available	oxygen	delivery	capacity	was	within	the	resuscitation	area	where	there	were	4	or	5	oxygen	concentrators,	each	with	a	maximum	output	capacity	of	5	L/min.	The	functionality	of	the	concentrators	was	not	specifically	tested.	Previous	operational	research	at	QECH	has	found	that	approximately	10%	of	medical	inpatients	require	oxygen	(as	defined	by	saturations	of	<90%)	but	only	one-third	of	patients	receive	it.	Poor	functionality	of	oxygen	concentrators	is	common	with	many	delivering	suboptimal	flow	rates	and	inadequate	concentrations	of	oxygen	(Evans	et	al.,	2012).		
6.4.3 Study	participants	Hypoxaemic	adults	with	suspected	pneumonia.		
6.4.3.1 Inclusion	criteria	
• Adults	(aged	18	years	or	over)	
• At	least	TWO	of	the	following:	temperature	≥38°C	or	≤35°C,	fever/rigors/sweats,	new	or	worsened	cough,	new	or	worsened	dyspnoea,	chest	pain.		
• At	least	ONE	of	the	following	on	clinical	examination:	crepitations,	bronchial	breathing	or	pleural	rub	(This	criterion	was	removed	from	1st	June	in	an	amendment	to	the	study	protocol	made	in	view	of	slow	study	recruitment).		
• Oxygen	saturations	in	room	air	of	<92%	
6.4.3.2 Exclusion	criteria	
• Illness	duration	of	greater	than	21	days.	
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• Pre-admission	diagnosis	of	terminal	illness	(e.g.	metastatic	malignancy,	terminal	AIDS).	
• Patients	at	high	risk	of	hypercapnic	respiratory	failure:	
- COPD:	known	diagnosis	or	suspected	on	basis	of	smoking	history	of	≥30	pack-years,	chronic	breathlessness	on	minor	exertion	and	no	other	known	cause,	hyper-expanded	chest,	signs	of	cor	pulmonale.	
- Bronchiectasis:	known	diagnosis	or	suspected	on	basis	of	chronic	(≥6	months)	productive	cough	with	frequent	exacerbations.	
- Morbid	obesity	(clinically	assessed)	
- Severe	chest	wall	or	spinal	deformity	(e.g.	kyphoscoliosis)	
- Suspected	chronic	neuromuscular	disorder	(e.g.	motor	neurone	disease)	
6.4.4 Intervention	Monitored	response	to	supplemental	oxygen	generated	by	an	oxygen	concentrator	administered	to	all	patients	at	an	initial	flow	rate	of	5	L/min	and	increased	to	up	to	10	L/min	to	those	in	whom	hypoxaemia	persists.		
6.4.5 Outcomes	
6.4.5.1 Primary	endpoints	i) Proportion	of	patients	that	attain	SpO2	≥92%	following	60	minutes	of	supplemental	oxygen	at	a	flow	rate	of	up	to	5	L/min.	
ii) Proportion	of	patients	who	fail	to	attain	SpO2	≥92%	on	5	L/min	that	do	so	with	supplemental	oxygen	at	a	flow	rate	of	up	to	10	L/min	for	up	to	4	hours.		
6.4.5.2 Secondary	endpoints	i) Change	in	SpO2	from	baseline	levels	with	supplemental	oxygen	at	5	L/min	and	10	L/min.	
ii) Survival	to	hospital	discharge.	
6.4.6 Ethical	approval	The	study	protocol	was	independently	reviewed	and	approved	by	the	Research	Ethics	Committee	of	both	College	of	Medicine	University	of	Malawi	(Protocol	No.	P.07/14/1599)	and	Liverpool	School	of	Tropical	Medicine	(Protocol	No.	14.032).		
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6.4.7 Study	procedures	
6.4.7.1 Recruitment	Recruitment	took	place	in	the	AETC	at	QECH	between	8am	and	5pm	daily.	Patients	identified	at	triage	with	features	of	respiratory	infection	and/or	SpO2	of	<92%	were	assessed	for	inclusion	by	the	study	clinician	(clinical	officer	or	medically-qualified	investigator)	according	to	the	eligibility	criteria	above.	The	period	of	recruitment	overlapped	with	that	of	the	Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	Aetiology	and	Outcome	(MARISO)	Study	(described	in	chapters	3,	4	and	5)	for	approximately	2	months.	During	this	period,	patients	with	features	of	respiratory	infection	were	initially	screened	for	inclusion	in	the	MARISO	study	and	then	only	if	ineligible	screened	for	this	study.	Co-recruitment	to	both	studies	was	not	permitted.			
6.4.7.2 Consent	A	two-stage	consent	process	was	used	whereby	verbal	assent	for	participation	was	sought	from	the	patient	or	their	accompanying	guardian	following	a	brief	description	of	the	proposed	study.	Emergency	management	and	monitoring	was	instituted	and	following	stabilisation,	written	informed	consent	for	continued	participation	was	sought	from	the	patient	or,	in	the	case	of	continued	incapacity	or	deterioration,	from	the	guardian	(Maitland	et	al.,	2011b).	Initially	the	ethics	committee	required	that	an	assenting	accompanying	guardian	was	present	for	all	patients	recruited.	This	condition	was	removed	on	request	following	the	observation	that	a	substantial	number	of	patients	presented	to	hospital	unaccompanied.	This	two-stage	or	deferred	consent	process	has	previously	been	used	in	studies	of	acute	interventions	in	critically	unwell	patients,	including	in	low-resource	African	settings	(Food	and	Drug	Administration,	1996;	Kortgen	et	al.,	2006;	Maitland	et	al.,	2011a;	Shapiro	et	al.,	2006).		
At	QECH	the	demand	for	supplemental	oxygen	outstrips	supply;	not	all	patients	that	require	supplemental	oxygen	actually	receive	it.	To	avoid	any	coercion	to	participate,	the	study	concentrators	were	used	to	provide	oxygen	for	hypoxaemic	patients	who	wished	to	receive	it	even	if	they	declined	to	participate	in	the	study	if	there	were	no	other	concentrators	available.	
6.4.7.3 Baseline	assessment	Recruited	participants	underwent	a	thorough,	standardised	clinical	assessment.	The	medical	history	included	details	of	the	present	illness,	past	medical	and	drug	history	and	demographic	details.	Information	was	obtained	via	direct	questioning	of	the	study	participant	(or	accompanying	guardian)	and	by	reference	to	medical	notes	and	health	
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passport.	Physical	examination	consisted	of	cardiovascular,	upper	and	lower	respiratory	tract	and	abdominal	examinations.	Level	of	consciousness	was	assessed	using	the	AVPU	scale	(Kelly	et	al.,	2004).	Using	this	simplified	tool	patients	are	assessed	as	“Alert”,	“Responsive	to	voice”,	“Responsive	to	pain”	or	“Unresponsive.”	In	lieu	of	a	validated	cognitive	assessment	tool	that	is	not	available	in	Malawi,	the	presence	of	confusion	was	determined	using	three	standardised	questions	assessing	orientation	in	time,	place	and	person.		
Physiological	observations	were	measured	immediately	prior	to	the	commencement	of	oxygen	and	repeatedly	during	the	monitoring	period	in	accordance	with	detailed	standardised	operating	procedures	and	using	study-specific	equipment	(temperature	(Welch	Allyn	SureTemp	Plus	thermometer	using	an	oral	probe;	Welch	Allyn,	Buckinghamshire,	UK);	blood	pressure	(A&D	UA767	Digital	Blood	Pressure	Monitor;	A&D	Instruments,	Abingdon,	UK);	oxygen	saturations	(Nonin	2500	PalmSAT®	Pulse	Oximeter;	Nonin	Medical,	Inc.,	Minnesota,	USA)).		
A	3ml	venous	blood	specimen	was	obtained	for	full	blood	count	and	HIV	test.	A	chest	radiograph	was	requested	for	all	patients.	
6.4.7.4 Oxygen	delivery	and	monitoring	Following	baseline	observations,	supplemental	oxygen	generated	by	an	oxygen	concentrator	(NewLife	Intensity	10	Oxygen	Concentrator;	AirSep,	New	York,	USA)	was	immediately	administered	to	all	patients	at	an	initial	flow	rate	of	5	L/min	via	a	Hudson	facemask	or,	if	not	tolerated,	nasal	cannulae.	SpO2	was	monitored	continuously	and	recorded	automatically	every	five	minutes	(see	figure	6.1).	Respiratory	rate,	heart	rate	and	blood	pressure	was	recorded	every	15	minutes.	At	60	minutes,	if	SpO2	was	≥92%,	the	patient	was	classified	as	having	responded	adequately	to	the	standard	flow-rate	and	the	study	intervention	considered	complete.	If	SpO2	at	60	minutes	was	between	90	and	94%,	an	average	of	3	readings	taken	over	the	following	3	minutes	was	used.10	If	SpO2	was	<92%,	the	response	to	standard	flow-rate	oxygen	was	classified	as	inadequate	and	the	oxygen	flow	rate	increased	to	10	L/min	and	the	mask	changed	to	a	Hudson	mask	with	reservoir	bag.	Oxygen	flow-rate	was	immediately	increased	to	10	L/min	if	at	any	point	during	the	first	60	minutes	of	monitoring	the	SpO2	fell	consistently	below	85%.	Patients	were	monitored	for	up	to	a	further	4	hours	on	the	high-flow	rate	of	oxygen.	Those	that	attained	sustained	increases	in	SpO2	to	≥92%	(i.e.	on	two	readings	separated	by	at	least	5	minutes)	were	classified	as	responding	to	high	
																																								 																					10	If	SpO2	at	60	minutes	was	between	90	and	94%,	an	average	of	3	readings	taken	over	the	following	3	minutes	was	used.	
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flow-rate	oxygen,	otherwise	patients	were	classified	as	non-responders	to	oxygen	therapy.	If	SpO2	were	consistently	>98%	during	the	monitoring	period,	the	flow-rate	of	oxygen	was	reduced	incrementally	by	1	L/min	every	5	minutes	until	the	target	range	of	92-98%	was	achieved.		
	
Figure	6.1	 Overview	of	AHIP	study	oxygen	delivery	procedures.	Light	shaded	areas	indicate	study	monitoring	period;	darker	areas	indicate	post-intervention	management.	SpO2	–	oxygen	saturation		
6.4.7.5 Ancillary	management	Study	participants	were	managed	in	accordance	with	local	guidelines	for	severe	pneumonia	as	resources	permitted.	Antibiotics	were	administered	promptly	following	recruitment:	either	once	daily	intravenous	ceftriaxone	2g	or	alternatively	penicillin	2	megaunits	intravenously	and	chloramphenicol	500mg	intravenously	four	times	daily.	If	there	was	evidence	of	shock		(systolic	blood	pressure	<90	mmHg,	heart	rate	>100	beats/minute,	capillary	refill	time	>2	seconds)	1	litre	of	intravenous	crystalloid	fluid	(Ringers	lactate	or	0.9%	saline)	was	given	over	30-60	minutes.	Additional	fluids	were	given	at	the	discretion	of	the	treating	clinician.	
6.4.7.6 Continued	inpatient	care	and	follow-up	After	the	acute	response	to	supplemental	oxygen	was	determined,	patients	were	referred	to	the	clinical	teams	for	subsequent	care.	Local	guidelines	at	QECH	use	a	SpO2	threshold	of	<90%	for	continued	oxygen	provision	on	the	medical	high-dependency	units	(HDUs).	Previous	operational	research	at	QECH	has	shown	that	the	demand	for	
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supplemental	oxygen	considerably	exceeds	supply	(Evans	et	al.,	2012).	Patients	who	had	responded	to	standard	flow-rate	oxygen	who	had	SpO2	≥92%	on	5	L/min	or	less	were	trialled	off	oxygen	for	up	to	60	minutes	(see	figure	6.1).	If	SpO2	fell	to	below	90%,	oxygen	was	re-commenced	and	the	patients	referred	to	HDU	for	continued	oxygen	therapy.	Patients	with	SpO2	≥90%	were	admitted	to	the	general	medical	wards.	To	improve	the	availability	of	supplemental	oxygen,	the	study	provided	one	high	flow	oxygen	concentrator	for	each	of	the	two	medical	HDUs.	Patients	were	followed	to	determine	hospital	discharge	date	and	outcome.	
6.4.7.7 Concentrator	assessment	and	maintenance	The	oxygen	concentrators	were	maintained	in	accordance	to	the	manufacturer’s	instructions.	External	cleaning	was	performed	and	the	gross	particulate	filter	was	cleaned	and	replaced	at	weekly	intervals.	The	flow-rate,	oxygen	concentration	and	outlet	pressure	of	the	gas	delivered	was	also	checked	using	a	flowmeter	and	oxygen	analyser	(Invacare	Check	O2	Plus	Oxygen	Analyzer;	Invacare,	Ohio,	USA).	If	any	measurements	were	outside	of	manufacturer’s	recommended	tolerances,	the	concentrators	were	withdrawn	from	service	and	sent	for	maintenance.	
6.4.7.8 Clinical	specimen	processing	All	specimen	processing	and	investigations	were	performed	at	MLW	Clinical	Diagnostic	and	Molecular	Laboratories.	Clinical	diagnostic	tests	were	performed	in	the	MLW	quality	assured	laboratories.	HIV	testing	was	performed	on	whole	blood	specimens	using	rapid	diagnostic	test	kits	in	a	serial	testing	pathway	in	accordance	with	WHO	guidelines	(World	Health	Organization,	2004).	Initial	screening	was	performed	using	the	Alere	Determine	HIV-1/2	Ag/Ab	Combo	assay	(Alere,	Massachusetts,	USA);	negative	results	were	reported	and	positive	results	prompted	confirmatory	testing	using	the	Uni-Gold	Recombinogen	HIV-1/2	test	(Trinity	Biotech,	Co	Wicklow,	Ireland).	If	results	were	discrepant	a	second	confirmatory	test	was	performed	using	a	different	assay	(Bioline	HIV-1/2	3.0;	Standard	Diagnostics,	Gyeonggi-do,	Republic	of	Korea).	
6.4.7.9 Chest	radiograph	photography	Plain	chest	radiograph	films	were	photographed	on	a	light-box	using	a	standard	light-reflex	digital	camera	mounted	on	a	tripod	in	a	darkened	room.	Several	high-resolution	photographs	at	a	range	of	exposure	settings	were	taken	of	each	radiograph	to	compensate	for	some	of	the	variability	in	penetration	of	the	original	radiograph.	All	study	radiograph	reports	were	generated	by	review	of	the	set	of	digital	images	rather	than	the	original	radiograph.	Chest	radiographs	were	reported	by	myself	to	define	the	presence	of	consolidation,	multilobar	involvement,	cavitation	and	pleural	effusion.	
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Radiographic	pneumonia	was	defined	as	the	presence	of	a	parenchymal	abnormality	(consolidation	or	other	infiltrate)	or	pleural	effusion	(Jain	et	al.,	2015).			
6.4.8 Data	management	Study	participants	were	assigned	a	unique	study	number	at	the	time	of	recruitment,	under	which	all	data	were	captured.	The	clinical	data	were	collected	in	paper-based	CRFs	and	subsequently	converted	to	electronic	form	using	Intelligent	Character	Recognition	scanning	software	(TeleForm;	Cardiff	Software	Developers,	Cardiff,	UK).	Following	verification	the	data	were	initially	exported	to	a	Microsoft	Access	database	(Microsoft	Corporation,	Redmond,	Washington,	USA)	and	subsequently	to	Stata	12	(StataCorp	LP,	College	Station,	Texas,	USA)	for	cleaning	and	analysis.		
Prior	to	scanning	the	CRFs	were	checked	by	the	clinical	team	and	again	by	Dr	Jacqueline	Huwa.	Discrepancies	were	queried	and	addressed.	The	TeleForm	software	automatically	scans	each	CRF	twice;	any	discrepant	values	or	values	outwith	a	range	pre-specified	by	the	user	are	highlighted	for	manual	review.	Further	certain	essential	fields	containing,	for	example,	identifiers	or	key	outcome	variables	were	set	for	mandatory	manual	review.		
The	study	database	was	hosted	on	the	secure	MLW	server;	access	was	restricted	to	Dr	Jacqueline	Huwa,	the	MLW	data	management	and	myself.	The	corresponding	paper	records	were	held	securely	at	MLW	in	a	locked	office.	These	records	were	pseudo-anonymised,	identifiable	by	study	number	and	initials	only.		
6.4.9 Analysis	
6.4.9.1 Sample	size	considerations	The	proportion	of	patients	that	attain	normoxaemia	with	5	L/min	of	supplemental	oxygen	is	unknown.	As	there	was	no	preliminary	or	background	data	on	which	to	base	calculations,	the	study	constituted	a	pilot.	The	initial	target	study	population	was	150	patients.	This	sample	size	was	selected	to	enable	the	true	population	proportion	of	patients	that	respond	to	standard	flow-rate	oxygen	to	be	estimated	with	a	precision	of	±8%	and	95%	confidence,	assuming	that	a	treatment	response	rate	of	approximately	50%.	An	estimated	75	patients	would	therefore	receive	high-flow	oxygen;	the	proportion	that	respond	to	treatment	would	be	estimated	with	a	precision	of	±12%	and	95%	confidence,	again	assuming	a	treatment	response	rate	of	approximately	50%.	
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6.4.9.2 Statistical	methods	The	proportion	of	patients	(with	95%	confidence	intervals)	that	attain	normoxaemia	with	standard	flow-rate	and	high	flow-rate	oxygen	was	calculated.	The	primary	analysis	included	the	entire	cohort	of	patients	with	suspected	pneumonia.	Subgroup	analyses	of	patients	with	SpO2	<90%	and	radiographically	confirmed	pneumonia	were	performed.	The	demographic,	comorbid	and	radiological	characteristics	of	patients	that	attain	and	failure	to	attain	normoxaemia	was	compared	Mann	Whitney	U	test	and	Chi-squared	test	for	continuous	and	categorical	variables,	respectively.	The	association	between	response	to	oxygen	therapy	and	hospital	outcome	was	described	by	risk	ratio	(with	95%	confidence	intervals)	and	assessed	using	the	Chi-squared	test.	P	values	less	than	0.05	were	regarded	as	significant.		
6.5 Results	
6.5.1 Recruitment	and	follow-up	Patients	were	recruited	between	25th	November	2014	and	17th	July	2015	(Figure	6.2).	142	patients	were	assessed	for	inclusion	in	the	study.	Recruitment	to	the	MARISO	study	closed	on	31st	January	2015;	during	this	period	of	overlap,	6	patients	were	screened	and	2	recruited	to	the	current	study.	The	commonest	reasons	for	non-inclusion	were	illness	duration	of	greater	than	21	days,	lack	of	focal	chest	signs	and	lack	of	accompanying	patient	guardian.	The	eligibility	criteria	for	the	study	were	re-evaluated	in	the	light	of	a	slow	recruitment	rate.	The	requirement	for	the	presence	of	focal	clinical	signs	was	removed	from	1st	June.	This	is	relevant	to	the	last	40	patients	screened	and	the	last	20	patients	recruited.	However	only	2	patients	lacking	focal	signs	were	in	fact	recruited.	Following	a	review	by	the	ethics	committee,	the	requirement	for	an	accompanying	guardian	to	be	available	to	give	proxy	consent	for	the	patient	to	be	recruited	was	removed.	60	patients	were	recruited,	but	one	was	excluded	from	analysis	because	SpO2	immediately	prior	to	starting	oxygen	was	>92%.	
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Figure	6.2	 CONSORT	diagram	of	patient	screening,	recruitment	and	follow-up	
in	AHIP	study.		
6.5.2 Baseline	characteristics	The	median	age	of	the	59	patients	recruited	was	38	(IQR:	31-59)	and	there	was	a	preponderance	of	males	(39/59;	66.1%)	(Table	6.1).	37	(64.9%)	were	HIV-infected,	of	whom	27%	were	newly	diagnosed.	There	was	a	high	rate	of	both	antiretroviral	therapy	(25/27;	92.6%)	and	co-trimoxazole	prophylactic	therapy	use	(23/27;	85.2%)	amongst	known	HIV-infected	patients.	11	patients	(18.6%)	were	active	smokers,	but	no	patients	had	a	prior	diagnosis	of	chronic	lung	or	heart	disease.	A	quarter	of	patients	(15/59;	25.4%)	reported	prior	treatment	for	tuberculosis.	
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Table	6.1	 Baseline	characteristics	of	AHIP	patient	cohort.	Data	presented	as	number	and	proportion	of	total	episodes	or	in	italics	as	median	and	interquartile	range	are	shown.	Denominator	is	59	unless	specified.	
Characteristic	 No.	(%)	of	episodes	
Demographics	 	 	Male	sex	 39	 (66.1)	Age	 38	 (31-59)	Current	smoker	 11	 (18.6)	
Comorbidities	 	 	HIV	positive	Newly	diagnoseda	 37/57	10/37	 (64.9)	(27.0)	ART	usea	 25/37	 (67.6)	CPT	usea	 23/37	 (62.2)	Chronic	lung	diseaseb	 0	 (0)	Chronic	heart	diseasec	 0	 (0)	Hypertension	 2	 (3.4)	Diabetes	 0	 (0)	Cancer	 2	 (3.4)	Chronic	kidney	disease	 0	 (0)	Liver	disease	 0	 (0)	Stroke	 1	 (1.7)	Epilepsy	 0	 (0)	Dementia	 1	 (1.7)	Previous	tuberculosisd	 15	 (25.4)	Previous	pneumonia	in	last	5	yearse	 18	 (30.5)	ART	–	antiretroviral	therapy;	CPT	–	co-trimoxazole	preventative	therapy	a	Only	applies	to	HIV-positive	patients	a	Chronic	lung	disease	includes	asthma,	COPD	and	bronchiectasis.	b	Chronic	heart	disease	includes	heart	failure,	cor	pulmonale,	dilated	cardiomyopathy	and	ischaemic	heart	disease.	c	Any	previous	episode	of	treated	tuberculosis	regardless	of	site	and	confirmation.	d	Any	prior	episode	within	the	last	5	years	of	a	syndrome	compatible	with	lower	respiratory	tract	infection	reviewed	in	a	healthcare	facility	and	treated	with	antibiotics.	 	
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Characteristic	
No.	(%)	of	episodes	
Median	(IQR)	
Pneumonia-related	characteristics	 	 	Pre-admission	symptom	duration	 14	 (7-21)	Prior	antibiotics	 40	 (67.8)	Inability	to	stand	 27	 (45.8)	Confusion	 0	 (0)	Temperature	(°C)	<35	or	≥40	 37.8	2	 (37.0-39.0)	(3.4)	Systolic	blood	pressure	(mmHg)	<90	 103	18	 (88-120)	(30.5)	Diastolic	blood	pressure	(mmHg)	≤60	 66	24	 (55-82)	(40.7)	Heart	rate	(beats/min)	≥125	 120	28	 (110-135)	(47.5)	Respiratory	rate	(breaths/min)	≥30		 40	55	 (36-47)	(93.2)	Oxygen	saturations	(%)	<90	 87	52	 (81-89)	(88.1)	Haemoglobin	(g/dL)	<8	 10.4	15/57	 (7.8-11.8)	(26.3)	WBC	count	(x	109	cells/L)	<4	or	>15	 7.1	15/56	 (5.0-9.5)	(26.8)	Platelets	(x	109	cells/L)	<100	 215	9/57	 (126-337)	(15.8)	Radiographic	pneumonia	 44/48	 (91.7)	Multilobar	consolidation	 26/48	 (54.2)	Cavitation	 5/48	 (10.4)	Effusion	 16/48	 (33.3)	MOST	≥2	 55/59	 (93.2)	CRB65	≥2	 30/58	 (53.4)	SMRT-CO	≥2	 46/58	 (96.6)	CRB65	–	tool	based	on	confusion,	urea,	blood	pressure	and	age	≥65;	MOST	–	tool	based	on	male	sex,	oxygen	saturations,	inability	to	stand	and	tachycardia;	SMRT-CO	–	tool	based	on	systolic	blood	pressure,	multilobar	consolidation,	respiratory	rate,	tachycardia,	confusion	and	oxygenation;	WBC	–	white	blood	cell;					 	
Addressing	hypoxaemia	in	adult	pneumonia	in	Malawi	 202	
The	median	duration	of	symptoms	prior	to	presentation	was	14	days	(IQR:	7-21)	and	40	patients	(67.8%)	had	received	prior	antibiotics.	Interpretable	chest	radiographs	were	available	in	48	patients	(81.4%),	of	whom	44	(91.7%)	had	radiographic	evidence	of	pneumonia,	with	multilobar	consolidation	present	in	just	over	half	(26/48;	54.2%).		
Median	oxygen	saturation	in	room	air	just	prior	to	the	commencement	of	supplemental	oxygen	was	87%	(IQR:	81-89%).	Tachypnoea	was	common	and	marked;	55	patients	(93.2%)	had	a	respiratory	rate	of	30	breaths	per	minute	or	greater.	Using	the	validated	severity	assessment	tools	SMRT-CO	and	CRB65	at	standard	thresholds,	46	(96.6%)	and	30	(53.4%)	patients,	respectively,	were	classified	as	having	severe	pneumonia.		
6.5.3 Response	to	supplemental	oxygen	51	patients	(86.4%;	95%	CI:	75.0%-94.0%)	attained	SpO2	≥92%	within	the	first	60	minutes	of	supplemental	oxygen	at	standard	flow-rate	(up	to	5	litres	per	minute)	(Table	6.2).	In	one	patient,	the	study	intervention	was	interrupted	by	an	electrical	power-cut.	The	patient	was	classified	as	responding	to	standard	flow-rate	oxygen	on	the	basis	of	rapid	and	sustained	correction	of	SpO2	from	the	point	of	oxygen	delivery	to	50	minutes.	Over	the	course	of	60	minutes	of	standard	flow-rate	supplemental	oxygen	the	average	change	in	SpO2	was	10.3%	(SD	±5.6%);	the	mean	maximal	change	was	12.1%	(SD	±5.3%).		Amongst	the	52	patients	that	had	baseline	SpO2	<90%,	44	(84.6%;	95%	CI:	71.9-93.1)	attained	normoxaemia	with	standard	flow-rate	oxygen.	48	patients	(81.4%;	95%	CI:	69.1.0%-90.3%)	attained	SpO2	≥94%	(an	alternative	more	stringent	definition	of	normoxaemia)	at	60	minutes.	
The	8	patients	failing	to	attain	SpO2	≥92%	on	standard	flow-rate	oxygen	received	high	flow-rate	oxygen	(up	to	10	L/min).	7	patients	(87.5%:	95%CI:	47.3%-99.7%)	attained	stable	normoxaemia	during	the	four-hour	observation	period,	including	4	patients	(50%;	95%CI:	15.7%-84.2%)	within	the	first	hour.		
Of	the	44	patients	with	radiographic	pneumonia,	41	(93.2%;	95%	CI:	85.4%-100%)	attained	SpO2	≥92%	within	60	minutes	of	standard	flow-rate	oxygen.	The	remaining	3	patients	all	attained	normoxaemia	with	high	flow-rate	oxygen.	
52	patients	used	oxygen	delivered	by	facemask	throughout	the	standard-flow	rate	intervention	period.	2	patients	used	nasal	cannulae	throughout	the	first	hour,	a	further	2	for	at	least	45	minutes	and	a	further	3	for	between	5	and	15	minutes.	All	of	these	patients	attained	normoxaemia	with	standard	flow-rate	oxygen.	Average	change	in	SpO2	at	60	minutes	did	not	differ	between	patients	using	facemasks	and	nasal	cannuale	
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(11.2%	vs.	9.6%;	P	=	0.96).	All	patients	who	failed	standard	flow-rate	oxygen	were	switched	to	high	flow-rate	oxygen	via	facemask.	
Inability	to	stand	(RR	8.30;	95%	CI	1.09-63.28)	and	lower	SpO2	at	presentation	(P	<0.001)	were	associated	with	lack	of	response	to	standard	flow-rate	oxygen	(Table	6.3).	The	small	size	of	the	cohort	precludes	multivariable	analysis	to	further	examine	the	correlates	of	oxygen	response.		
Table	6.2	 Response	to	supplemental	oxygen.	All	patients	received	standard	flow-rate	oxygen	(≤5	L/min);	only	patients	not	attaining	oxygen	saturations	(SpO2)	≥92%	received	high	flow-rate	oxygen	(≤10	L/min).	Patients	observed	at	standard	flow-rate	for	up	to	60	minutes	and	high	flow	rate	for	up	to	4	hours.	
Standard	flow-rate	(≤5	L/min		 (All	patients;	n=59)	Baseline	SpO2	(median(IQR))	 87	(81-89)	SpO2	≥92%	at	60	mins	(n(%))	 51	(86.4)	Average	Δ	SpO2	(mean±SD)	 10.3	±5.6	Max	Δ	SpO2	(mean±SD)	 12.1	±5.3	
High	flow-rate	(≤10	L/min)		 SpO2	≥92%	after	standard	flow-rate;	n=8)	Baseline	SpO2	(median(IQR))	 82	(80-91)	SpO2	≥92%	at	60	mins	(n(%))	 4	(50)	Final	SpO2	≥92%	(n(%))	 7	(87.5)	Average	Δ	SpO2	(mean±SD)	 5.7	±3.9	Max	Δ	SpO2	(mean±SD)	 10.8	±6.6	Δ	–	change	in;	IQR	–	interquartile	range;	SD	–	standard	deviation;	SpO2	–	oxygen	saturations		 	
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Table	6.3	 Univariable	analysis	of	features	associated	with	attainment	of	
normoxaemia	with	standard	flow-rate	supplemental	oxygen.	Categorical	variables	shown	as	number	and	proportion;	continuous	variables	(in	italics)	shown	as	median	and	interquartile	range.	Denominators	as	per	columns	heads	unless	otherwise	specified.	Univariable	analysis	by	Chi-squared	test	with	risk	ratios	and	95%	confidence	intervals	for	categorical	variables	and	Mann	Whitney	U	test	for	continuous	variables.	
Characteristic	
Attained	
normoxaemia	
(n=51)	
Normoxaemia	
not	attained	
(n=8)	
Univariable	analysis	
RR	(95%	CI)	 P	Male	sex	 33	 (64.7)	 6	 (75)	 1.54	(0.34-6.94)	 0.57	
Age	(yrs)	 38	 (30-59)	 41	 (33-66)	 -	 0.61	Current	smoker	 10	 (19.6)	 1	 (12.5)	 0.62	(0.09-4.56)	 0.63	HIV-positive	 32/49	 (65.3)	 5	 (62.5)	 0.90	(0.24-3.39)	 0.88	Inability	to	stand	 20	 (39.2)	 7	 (87.5)	 8.30	(1.09-63.28)	 0.01	
Symptom	duration	(days)	 14	 (7-21)	 11	 (3-18)	 -	 0.26	
Systolic	BP	(mmHg)	 103	 (89-120)	 93	 (78-113)	 -	 0.21	
Diastolic	BP	(mmHg)	 67	 (54-82)	 66	 (60-84)	 -	 0.74	
Heart	rate	(/min)	 119	 (109-132)	 133	 (143-141)	 -	 0.32	
Respiratory	rate	(/min)	 40	 (36-47)	 40	 (34-53)	 -	 1.00	
Oxygen	saturations	(%)	 88	 (84-89)	 78	 (76-82)	 -	 <0.001	
Haemoglobin	(g/dL)	 10.7	 (8.2-12)	 9.6	 (5.9-12.2)	 -	 0.62	Multilobar	consolidation	 24/44	 (54.6)	 2/4	 (50)	 0.85	(0.13-5.52)	 0.86	BP	–	blood	pressure		 	
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6.5.4 Mortality	All	patients	were	successfully	followed	to	determine	hospital	discharge	outcome.	The	overall	in-hospital	mortality	rate	was	17.0%	(10/59).	The	acute	response	to	supplemental	oxygen	was	associated	with	in-hospital	mortality.	Failure	to	attain	normoxaemia	with	standard	flow-rate	oxygen	therapy	was	associated	with	a	more	than	four-fold	increase	in	the	risk	of	death	(4/8	(50%)	vs.	6/51	(11.8%);	RR	4.25;	95%	CI:	1.53-11.81).		
The	simple	four-parameter	MOST	score	(based	on	male	sex	(1	point),	oxygen	saturations	<90%	(2	points),	inability	to	stand	(2	points)	and	heart	rate	≥125	/min	(1	point))	derived	in	the	MARISO	score	was	calculated	for	all	patients.	In-patient	mortality	rate	increased	with	MOST	score	(MOST	0:	0/1	(0%);	1:	0/3	(0%);	2:	0/6	(0%);	3:	1/17	(5.9%);	4:	3/10	(30%);	5:	4/13	(30.8%);	6:	2/9	(22.2%)).	The	overall	discriminative	capability	of	the	MOST	score	for	the	prediction	of	in-hospital	mortality	as	assessed	by	area	under	the	receiver-operating	curve	(AUROC)	was	0.71	(95%	CI:	0.57-0.85).	Using	a	MOST	score	of	2	or	more	(present	in	52	(93.2%)	patients)	to	predict	in-hospital	mortality	had	the	following	characteristics:	sensitivity	100%	(95%	CI:	69.2-100),	specificity	8.2%	(95%	CI:	2.3-19.6),	positive	predictive	value	18.2%	(95%	CI:	9.1-30.9),	negative	predictive	value	100%	(95%	CI:	39.8-100).	
6.5.5 Oxygen	concentrator	performance	A	single	oxygen	concentrator	was	used	for	the	study.	Oxygen	concentration	always	exceeded	manufacturer’s	minimum	specifications;	minimum	concentration	at	5	L/min	was	94.8%	(specification:	92%	+3.5%/-3%)	and	10	L/min	was	95.1%	(specification:	90%	+3.5%/-3%).	Flow-rate	was	consistently	accurate	to	within	±10%.	Outlet	pressure	was	always	within	±15%	of	20	PSI.	
6.6 Discussion	
6.6.1 Main	findings	In	this	study	of	adults	with	clinically-suspected	pneumonia	in	Malawi,	hypoxaemia	is	correctable	in	a	large	majority	of	patients	using	supplemental	oxygen	delivered	by	oxygen	concentrator	at	flow-rates	of	up	to	5	L/min.	Attainment	of	normoxaemia	is	associated	with	a	markedly	reduced	risk	of	mortality.	
Whilst	previous	research	on	supplemental	oxygen	provision	in	low-resource	settings	has	largely	focused	on	programmatic	aspects	such	as	assessing	the	capacities	and	relative	costs	of	different	oxygen	delivery	systems	(Hill	et	al.,	2009;	Howie	et	al.,	2009;	
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2011a),	this	study	provides	individual	patient-level	data	to	demonstrate	the	effectiveness	of	supplemental	oxygen	provision	at	flow-rates	and	concentrations	achievable	by	oxygen	concentrator	to	correct	hypoxaemia	in	adults	with	pneumonia.	
6.6.2 Hypoxaemic	respiratory	failure	in	pneumonia	Pneumonia	is	characterised	by	the	presence	of	intra-alveolar	consolidation	that	impairs	ventilation	to	affected	lung	areas	resulting	in	a	ventilation-perfusion	mismatch	and	reduced	gas	exchange	across	the	alveolar	surface.	In	lung	areas	with	dense	consolidation	and	focal	collapse,	there	is	no	effective	ventilation	and	the	extreme	ventilation-perfusion	mismatch	is	termed	an	intra-pulmonary	shunt.	Supplemental	oxygen	increases	intra-alveolar	oxygen	concentration	in	ventilated	areas	of	the	lung,	resulting	in	a	steeper	gradient	for	diffusion,	increased	gas	transfer	and	arterial	oxygen	content	(Gea	et	al.,	1991).	However,	since	blood	oxygen	content	is	largely	haemoglobin	bound,	increased	oxygen	transfer	in	ventilated	lung	units	cannot	fully	compensate	for	non-ventilated	areas.	In	the	presence	of	a	large	intra-pulmonary	shunt,	hypoxaemia	is	not	correctable	with	supplemental	oxygen	alone;	improved	oxygenation	requires	re-recruitment	of	non-ventilated	areas	of	lung	using,	for	example,	positive	pressure	ventilation	(Cosentini	et	al.,	2010;	Ferrer	et	al.,	2012;	Gea	et	al.,	1991;	O'Driscoll	et	al.,	2008;	Wijesinghe	et	al.,	2012).		
In	the	current	study,	86%	of	hypoxaemic	pneumonia	patients	attained	SpO2	≥92%	with	modest	rates	of	supplemental	oxygen.	Few	studies	from	sub-Saharan	Africa	have	consistently	reported	and	recorded	SpO2.	In	a	cohort	of	patients	with	suspected	pneumonia	admitted	to	a	high-dependency	unit	in	Malawi,	Hartung	described	mean	SpO2	of	76%	but	did	not	describe	the	response	to	oxygen	therapy	(Hartung	et	al.,	2011).	In	Ugandan	suspected	pneumonia	cohort,	16.4%	of	patients	had	SpO2	<90%	at	presentation	and	were	at	2-fold	increased	risk	of	death,	but	again	acute	response	to	oxygen	was	not	described	(Koss	et	al.,	2015).		
Data	from	well-resourced	settings	on	oxygen	response	are	also	sparse.	In	settings	where	piped	oxygen	infrastructure	is	standard	in	acute	hospitals	and	supplemental	oxygen	at	high	flow-rates	is	routinely	available,	there	is	no	necessity	to	describe	effectiveness	of	supplemental	oxygen	delivered	at	the	modest	flow-rates	achievable	by	oxygen	concentrator.	In	recent	cohorts	of	hospitalised	community-acquired	pneumonia	(CAP)	patients,	the	rates	of	acute	hypoxaemic	respiratory	failure	vary	with	the	definition	used,	but	typically	range	from	25-40%	(Chalmers	et	al.,	2011a;	Charles	et	al.,	2008b;	Fine	et	al.,	1997a;	Lim	et	al.,	2000).	Taking	mechanical	ventilation	as	a	conservative	indication	of	failure	of	response,	between	14	and	60%	of	CAP	patients	
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with	acute	hypoxaemic	respiratory	failure	require	an	intervention	beyond	supplemental	oxygen	alone	(Brambilla	et	al.,	2014;	Confalonieri	et	al.,	1999;	Kohno	et	
al.,	2013).	
Variations	in	the	definitions	of	respiratory	failure	and	the	endpoints	used	to	indicate	lack	of	improvement	make	direct	comparisons	across	cohorts	difficult.	Nonetheless,	the	rate	of	responsiveness	to	supplemental	oxygen	at	modest	flow	rates	observed	in	the	current	study	is	relatively	high.	The	SpO2	threshold	of	<92%	used	to	define	entry	to	the	current	study	is	a	less	stringent	definition	of	respiratory	failure	compared	to	other	studies	(Brambilla	et	al.,	2014;	Confalonieri	et	al.,	1999;	Kohno	et	al.,	2013).	However,	a	similar	rate	of	response	to	standard	flow-rate	oxygen	was	seen	in	the	subgroup	of	patients	with	SpO2	<90%	at	presentation.	Other	studies	also	have	used	a	higher	threshold	of	SpO2	≥94%	to	define	normoxaemia.	More	than	80%	of	patients	attained	this	higher	threshold	with	standard	flow-rate	oxygen.		
6.6.3 Strategies	for	oxygen	delivery	in	low-resource	settings	In	the	absence	of	onsite	oxygen	generation	and	a	piped	oxygen	infrastructure,	the	options	for	the	delivery	of	supplemental	oxygen	in	low-resource	setting	are	oxygen	cylinders	and	oxygen	concentrators	(Hill	et	al.,	2009;	Howie	et	al.,	2009;	2011a).	Whilst	oxygen	cylinders	may	be	better	suited	to	low-volume	users	(e.g.	local	health	centres),	particularly	in	settings	where	the	electrical	supply	is	inconsistent,	the	costs	and	logistical	challenges	of	continually	replenishing	a	large	stock	of	cylinders	make	them	less	suitable	for	district	and	central	hospitals	(Hill	et	al.,	2009;	Schneider,	2001).	In	hospital	settings	where	the	electrical	power	supply	is	consistent,	oxygen	concentrators	provide	the	cheapest	and	most	consistent	source	of	oxygen	(Duke	et	al.,	2010a;	Duke	et	
al.,	2010b;	Duke	et	al.,	2010c;	La	Vincente	et	al.,	2011;	Matai	et	al.,	2008).		
Oxygen	concentrators	vary	considerably	in	performance	characteristics	(e.g.	maximum	flow	rate,	maximum	oxygen	concentration)	and	tolerances	(i.e.	for	temperature	and	humidity).	The	current	study	used	AirSep	NewLife	Intensity	10	concentrators	based	on	their	ability	to	operate	adequately	at	temperatures	of	up	to	40°C	and	relative	humidity	of	up	to	95%.	In	rigorous	independent	testing,	the	predecessor	concentrator	produced	by	the	same	manufacturer	(AirSep	Elite)	was	judged	most	suitable	for	use	in	low-resource	tropical	settings	(Peel	et	al.,	2013).	Experience	with	the	AirSep	NewLife	Intensity	10	over	the	course	of	the	study	would	support	its	suitability	for	use	in	Malawi	and	comparable	settings.	The	study	concentrators	performed	consistently	within	the	manufacturers	specifications	for	oxygen	concentration	production,	gas	flow-rate	and	outlet	pressure.	Regular	maintenance,	simply	consisting	of	replacement	of	the	external	
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particulate	filter	and	external	cleaning,	was	performed	readily	by	the	study	team	after	minimal	training.		
The	AirSep	NewLife	Intensity	10	concentrator	was	also	selected	because	of	its	ability	to	produce	greater	than	90%	oxygen	at	flow-rates	of	up	to	10	L/min.	Most	other	concentrators	have	a	maximum	output	of	5	L/min.	Due	to	the	small	size	of	the	study	and	the	greater	than	anticipated	rate	of	response	to	standard	flow-rate	oxygen,	no	conclusions	can	be	made	regarding	any	additional	benefit	of	high-flow	concentrators	in	this	setting	for	adults	with	pneumonia	and	whether	their	additional	cost	over	standard	flow-rate	devices	is	justified.		
6.6.4 Will	correction	of	hypoxaemia	improve	outcome?	In	adults	with	pneumonia	the	presence	of	hypoxaemia	is	an	indicator	of	severe	disease	and	is	consistently	associated	with	poor	outcome	(Bowton	et	al.,	1994;	Fine	et	al.,	1996;	Lim	et	al.,	2003).	The	results	of	the	MARISO	cohort	that	prompted	the	instigation	of	the	current	study	clearly	identified	hypoxaemia	as	independently	predictive	of	30-day	mortality	amongst	Malawian	adults	with	pneumonia.	The	results	of	the	current	study	demonstrate	that	hypoxaemia	is	correctable	using	an	intervention	that	is	a	feasible	in	low-resource	settings.	The	extent	to	which	this	may	alter	clinical	outcome	needs	to	be	determined.		
Whilst	the	administration	of	oxygen	to	acutely	hypoxaemic	patients	is	an	established	component	of	emergency	care	(Duke	et	al.,	2010a),	there	is	little	empirical	data	available	that	directly	defines	the	indications	for	and	therapeutic	benefit	of	supplemental	oxygen	(O'Driscoll	et	al.,	2008).	For	example,	there	are	no	randomised	trials	that	define	the	risks	and	benefits	of	oxygen	therapy	in	pneumonia	(Wijesinghe	et	
al.,	2012).	The	optimal	target	range	for	normoxaemia	is	not	firmly	established.	WHO	advocates	using	SpO2	<90%	as	the	definition	of	hypoxaemia	and	the	trigger	to	prompt	use	of	oxygen	since	there	is	no	known	risk	of	hypoxic	tissue	injury	above	this	level	(Bowton	et	al.,	1994;	Fulmer	et	al.,	1984;	O'Driscoll	et	al.,	2008;	World	Health	Organization,	2011a).	British	guidelines	suggest	that	oxygen	be	administered	to	maintain	SpO2	in	a	target	range	of	94-98%	to	give	a	wide	margin	of	safety	above	the	90%	threshold.		
The	potential	adverse	effects	of	supplemental	oxygen	are	increasingly	being	appreciated.	In	vulnerable	patients	such	as	those	with	advanced	COPD	or	chest	wall	deformities	excessive	supplemental	oxygen	may	lead	to	hypercapnic	respiratory	failure.	Excessive	supplemental	oxygen	has	been	associated	with	increased	peripheral	vascular	resistance,	coronary	artery	vasoconstriction,	and	reduced	coronary	blood	flow	
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and	worsened	outcome	following	myocardial	infarction	and	stroke	(Martin	et	al.,	2013;	O'Driscoll	et	al.,	2008;	Ronning	et	al.,	1999;	Wijesinghe	et	al.,	2009).	In	mechanically	ventilated	patients,	excessive	supplemental	oxygen	may	worsen	lung	injury	and	ARDS	through	the	production	of	reactive-oxygen	species.	These	findings	underline	the	need	for	further	clinical	trials	to	define	the	optimal	target	ranges	for	oxygenation	in	acutely	unwell	patients	(O'Driscoll	et	al.,	2008).		
6.6.5 Strengths	and	limitations	This	study	is	the	first	to	provide	individual	patient-level	data	on	the	effectiveness	of	oxygen	delivery	by	concentrator	in	adults	with	pneumonia	in	a	low-resource	setting.	It	demonstrates	that	hypoxaemia	is	correctable	in	most	adults	with	pneumonia	using	the	relatively	modest	rates	of	flow	deliverable	by	an	oxygen	concentrator.	The	successful	installation,	use	and	maintenance	of	the	oxygen	concentrators	following	minimal	staff	training	supports	the	feasibility	of	programmes	to	improve	supplemental	oxygen	availability	based	on	the	use	of	oxygen	concentrators.	
The	definition	of	hypoxaemia	and	assessment	of	response	to	supplemental	oxygen	therapy	was	based	entirely	on	the	measurement	of	arterial	oxygen	saturation	by	pulse	oximetry	(i.e.	SpO2).	In	low-resource	settings,	pulse	oximetry	is	strongly	advocated	as	a	robust,	affordable	and	non-invasive	means	of	rapidly	assessing	oxygenation	(Duke	et	
al.,	2010a).	However,	the	accuracy	of	pulse	oximetry	may	be	considerably	reduced	when	peripheral	perfusion	is	poor	as	in	hypotension	or	hypovolaemia	(O'Driscoll	et	al.,	2008).		In	patients	with	marked	anaemia	–	which	was	common	in	the	study	cohort	–	SpO2	may	give	a	misleadingly	high	estimate	of	blood	arterial	content.	Whilst	arterial	blood	gas	analysis	would	have	provided	a	more	accurate	estimation	of	blood	oxygen	content,	it	is	expensive,	invasive	and	not	widely	available	in	low-resource	settings	(Duke	et	al.,	2009;	Weber	et	al.,	1998;	World	Health	Organization,	2011a).		
In	isolation,	attainment	of	SpO2	above	a	threshold	values	is	not	necessarily	an	informative	endpoint	about	the	clinical	effectiveness	of	oxygen	therapy.	Recent	studies	from	well-resourced	settings	looking	at	the	benefit	of	techniques	of	non-invasive	ventilation	in	hypoxaemic	respiratory	failure	have	used	mechanical	ventilation	or	composite	criteria	of	requirement	for	mechanical	ventilation	as	endpoints	that	are	more	readily	translatable	into	clinical	practice	(Brambilla	et	al.,	2014;	Confalonieri	et	
al.,	1999).	Although	in	resource-limited	contexts	with	minimal	intensive	care	unit	capacity,	a	mechanical	ventilation	endpoint	is	unlikely	to	be	relevant.	Ultimately,	studies	capable	of	detecting	a	survival	benefit	of	different	oxygen	use	strategies	are	needed.		
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6.6.6 Future	research	The	results	of	the	current	study	indicate	the	potential	benefit	of	improved	oxygen	delivery	infrastructure	based	on	oxygen	concentrators	in	adult	pneumonia.	Randomised	clinical	trials	powered	to	detect	a	reduction	in	mortality	are	required	to	confirm	this	finding.	Since	the	correction	of	hypoxaemia	is	generally	considered	a	fundamental	component	of	clinical	care	in	pneumonia,	a	cluster-randomised	or	step-wedge	trial	would	be	the	most	robust	and	ethically	appropriate	study	design.		
The	beneficial	effect	of	correcting	hypoxaemia	is	presumed	to	relate	to	improved	tissue	oxygen	delivery.	Since	pneumonia	is	frequently	complicated	by	systemic	sepsis	in	which	tissue	perfusion	is	impaired,	the	effect	of	improved	oxygen	provision	would	need	to	be	assessed	in	parallel	with	strategies	to	optimise	fluid	resuscitation	(Aliberti	et	al.,	2014a;	Ferrer	et	al.,	2012).		
6.7 Conclusions	Hypoxaemia	in	pneumonia	is	correctable	in	the	majority	of	patients	using	simple	oxygen	delivery	equipment	that	can	be	readily	installed	with	minimal	infrastructural	change.	Response	to	oxygen	therapy	predicts	hospital	discharge	outcome;	failure	to	attain	normoxaemia	with	an	oxygen	flow-rate	of	5	L/min	or	less	is	strongly	associated	with	mortality.	As	a	potentially	reversible	risk	factor	for	mortality,	improved	correction	of	hypoxaemia	is	an	important	potential	strategy	to	improve	outcomes	in	adults	with	pneumonia	in	Malawi	and	similar	low-resource	settings.	Large-scale	clinical	trials	are	required	to	determine	the	clinical	benefit	of	increased	oxygen	provision	and	to	inform	the	expansion	of	oxygen	delivery	systems.	
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7 Overall	discussion:	Improving	outcomes	of	community-
acquired	pneumonia	in	Malawi	
7.1 Introduction	Community-acquired	pneumonia	(CAP)	is	a	leading	cause	of	adult	hospitalisation	and	death	throughout	the	world	(Lopez	et	al.,	2006;	Lozano	et	al.,	2012).	CAP	may	be	caused	by	a	broad	range	of	pathogens	and	varies	in	severity	from	a	mild,	short-lived	illness	to	an	acute,	fulminant	disease	complicated	by	respiratory	failure	and	sepsis	(Welte	et	al.,	2012).	Effective	management	of	CAP	consists	of	an	accurate	assessment	of	disease	severity	followed	by	prompt	initiation	of	appropriate	empirical	antimicrobials	(National	Clinical	Guideline	Centre,	2014).	These	components,	in	turn,	depend	upon	an	awareness	of	the	key	prognostic	factors	that	predict	adverse	outcome	and	knowledge	of	the	prevailing	causal	pathogens	based	on	local	epidemiology.	In	sub-Saharan	Africa,	as	in	the	rest	of	the	world,	CAP	is	a	major	cause	of	morbidity	and	mortality	with	an	estimated	4	million	episodes	each	year,	resulting	in	200,000	deaths	(Scott	et	al.,	2012).	However,	the	key	determinants	of	poor	outcome	and	the	aetiology	of	disease	in	the	region	are	both	poorly	described	and	as	such	the	evidence	required	to	support	appropriate	local	management	guidelines	is	lacking	(World	Health	Organization,	2011c;	Zijlstra,	2006).		
The	focus	of	the	work	presented	in	this	thesis	concerns	the	assessment	and	management	of	CAP	in	adults	in	Malawi	where	it	is	a	leading	cause	of	hospitalisation	and	death	(SanJoaquin	et	al.,	2013).	In	this	final	chapter	I	discuss	how	the	results	of	the	studies	presented	in	this	thesis	may	be	applied	to	improve	the	outcome	of	CAP	in	Malawi	and	comparable	resource-limited,	HIV-prevalent	settings.	Firstly,	I	briefly	summarise	and	evaluate	the	results	of	the	three	component	studies:	the	systematic	review	of	CAP	aetiology	and	outcome	in	sub-Saharan	Africa;	the	Malawian	Adult	Lower	Respiratory	Tract	Infection	Severity,	Aetiology	and	Outcome	(MARISO)	study;	the	Addressing	Hypoxaemia	in	Adult	Pneumonia	in	Malawi	(AHIP)	Study.	I	then	discuss	the	relevance	of	the	results	with	respect	to	CAP	prevention,	severity	assessment,	antimicrobial	treatment	and	supportive	management	before	suggesting	key	priorities	for	future	research.		
7.2 Main	results	The	systematic	review	included	data	from	47	studies	conducted	in	15	sub-Saharan	African	countries	between	1968	and	2014.	The	major	reported	burden	of	CAP	was	in	young	(mean	age	38;	95%	CI:	36-40)	and	HIV-positive	(52%;	95%	CI:	41-63)	patients.	
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Other	comorbid	illness	was	poorly	described	but	relatively	infrequent:	chronic	lung	disease	present,	9%;	heart	disease,	3%.	The	overall	mortality	rate	for	hospitalised	patients	was	9.5%	(95%	CI:	6.3-11.6%).	Data	describing	risk	factors	for	mortality,	particularly	from	studies	with	a	low	risk	of	bias,	were	limited	and	meta-analysis	restricted	to	a	small	number	of	studies.	Hypotension	(OR	4.55;	95%	CI:	2.40-8.66)	and	multilobar	consolidation	(OR	3.54;	95%	CI:	1.61-7.41)	were	associated	with	mortality.	No	significant	association	HIV	with	mortality	was	found	(OR	1.43;	95%	CI:	0.92-2.22).	Aetiological	data	were	mainly	based	on	sputum	microscopy	and	blood	and	sputum	culture	with	limited	use	of	invasively	obtained	lower	respiratory	tract	specimens	or	modern	molecular	diagnostics.	Streptococcus	pneumoniae	(27%)	and	M.	tuberculosis	(19%)	were	the	most	commonly	identified	causes.	Pneumocystis	jirovecii	was	identified	in	2-27%	of	patients	in	studies	performing	suitable	investigations.	Data	on	viral	or	atypical	bacterial	causes	of	CAP	were	limited.		
The	systematic	review	highlighted	the	need	for	large	prospective	studies	of	CAP	in	sub-Saharan	Africa	to	better	describe	its	epidemiology	and	aetiology	and	to	define	the	risk	factors	for	adverse	outcome.	The	MARISO	study	was	a	prospective	observational	study	of	adult	hospitalised	with	clinically	diagnosed	CAP	conducted	in	Blantyre,	Malawi	and	is	amongst	the	largest	studies	of	acute	CAP	in	sub-Saharan	Africa	ever	conducted.	Of	the	459	patients	recruited,	439	(95.6%)	and	418	(91.1%)	were	successfully	followed	to	determine	outcome	at	30-days	and	90-days,	respectively.	In	keeping	with	findings	of	the	systematic	review,	the	MARISO	cohort	was	predominantly	young	(median	age	34.6;	IQR	29.6-41.9)	and	HIV	positive	(78.4%),	with	limited	chronic	cardiovascular	(0.7%)	and	pulmonary	comorbidity	(3.3%).	HIV	was	typically	advanced	(median	CD4	count	99;	IQR	44-193)	and	often	undiagnosed	(34.9%	new	diagnosis)	at	presentation.		
Using	a	combination	of	blood	culture,	pneumococcal	urinary	antigen	testing,	multiplex	PCR	on	nasopharyngeal	aspirate	and	TB	diagnostic	tests	on	sputum	and	pleural	fluid,	a	potentially	causal	organism	was	identified	in	61%	of	patients.	S.	pneumoniae	was	found	in	21%.	A	sputum	specimen	for	TB	diagnostics	was	obtained	in	71%	with	a	positive	result	in	23%.	Viral	infection	was	common,	with	influenza	(9%),	adenovirus	(8%)	and	coronavirus	(7%)	most	frequently	identified.	Mycoplasma	pneumoniae	and	
Chlamydophila	pneumoniae	together	were	found	in	fewer	than	2%.	Co-infection	with	multiple	organisms	was	identified	in	22%	with	the	combination	of	a	bacterial	viral	co-infection	most	frequently	observed	(9%).		
Radiographic	pneumonia	was	identified	in	76%	and	was	positively	associated	with	the	detection	of	S.	pneumoniae	(OR	3.93;	95%	CI:	1.86-8.29)	and	negatively	associated	with	
Salmonella	typhi	(OR	0.09;	95%	CI:	0.02-0.48)	and	nontyphoidal	Salmonella	(OR	0.06;	
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95%	CI:	0.01-0.53).	The	relative	abundance	of	all	other	aetiologies	did	not	vary	significantly	with	the	presence	of	radiological	change.	M.	tuberculosis	(19%)	and	influenza	(11%)	were	the	most	frequently	identified	pathogens	in	the	subgroup	lacking	radiographic	pneumonia.	Radiographic	characteristics	did	not	vary	significantly	with	HIV	status.	
The	30-day	mortality	rate	in	the	MARISO	cohort	was	14.6%	with	25%	of	deaths	occurring	within	the	first	three	days	following	admission	and	48.4%	within	the	first	week.	Amongst	patients	surviving	to	day	30,	a	further	6.5%	died	by	day	90.	Treatment	failure	at	three	days	defined	as	death	or	persistent	hypoxaemia,	hypotension	or	fever	occurred	in	24%.	Treatment	failure	excluding	death	(i.e.	persistent	hypotension,	hypoxia	or	fever)	was	predictive	of	subsequent	mortality	(OR	3.45;	95%	CI:	1.81-6.58).	In	multivariable	analysis,	30-day	mortality	was	associated	with:	male	sex	(aOR	2.57;	95%	CI:	1.23-5.39);	pre-presentation	symptom	duration	(aOR	1.11	per	day	increase;	95%	CI	1.02-1.20);	inability	to	stand	(aOR	4.28;	95%	CI:	2.14-8.57);	heart	rate	(aOR	1.02	per	beat/minute	rise;	95%	CI:	1.00-1.04);	oxygen	saturations	(aOR	0.95	per	%	rise;	95%	CI:	0.92-0.98);	white	cell	count	(aOR	0.91	per	109/L	rise;	95%	CI:	0.84-0.98);	haemoglobin	(aOR	0.90	per	g/dL	rise;	95%	CI:	0.80-1.01).	
A	CAP	severity	assessment	tool	based	on	clinical	indices	evident	at	presentation	was	derived.	The	simple	four	parameter	MOST	score	(based	on	male	sex	(1	point),	oxygen	saturations	<90%	(2	points),	inability	to	stand	(2	points)	and	heart	rate	≥125	/min	(1	point))	predicted	30-day	mortality	with	reasonable	discriminative	capability	(area	under	the	receiver-operating	curve	(AUROC)	0.79;	95%	CI:	0.73-0.85)	and	compared	favourably	with	existing	tools	(CURB65:	AUROC	0.60;	95%	CI:	0.52-0.67;	SMRT-CO:	AUROC	0.66;	95%	CI:	0.57-0.75).	Using	a	threshold	score	of	<2,	the	MOST	score	had	a	negative	predictive	value	of	95.2%	(91.6-97.6)	for	30-day	mortality.	A	suggested	CAP	management	algorithm	based	on	MOST	score	is	shown	in	figure	7.1.	
Having	identified	the	prognostic	importance	of	hypoxaemia	in	preliminary	analyses	of	the	MARISO	study,	the	AHIP	study	was	conducted	to	determine	if	supplemental	oxygen	delivery	by	oxygen	concentrator	was	sufficient	to	correct	hypoxaemia	in	adults	with	suspected	pneumonia.	In	this	small	pilot	study	of	59	patients,	86.4%	attained	oxygen	saturations	(SpO2)	≥92%	with	supplemental	oxygen	at	standard	flow-rate	of	5	litres/minute.	Failure	to	attain	normoxaemia	with	standard	flow-rate	oxygen	therapy	was	associated	with	a	more	than	four-fold	increase	in	the	risk	of	death	(RR	4.25;	95%	CI:	1.53-11.81).		
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Figure	7.1	 Suggested	management	algorithm	for	CAP	in	low-resource,	sub-
Saharan	African	setting.	a	Xpert	MTB/RIF	preferred	when	available.	b	All	HIV-positive	patients	should	be	started	on	co-trimoxazole	prophylactic	treatment	and	referred	to	ART	clinic	on	discharge.	c	Consider	risk	of	invasive	nontyphoidal	Salmonella	in	HIV-positive	patients.		d	Risk	of	TB	increased	with	HIV	infection,	multilobar	consolidation,	reticulonodular	appearance	and	mediastinal	lymphadenopathy	e	If	HIV-positive	f	Consider	aminoglycoside	based	on	local	prevalence	of	drug	resistant	Gram-negative	pathogens,	in	particular	Klebsiella	pneumoniae.			
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7.3 Overall	strengths	and	limitations	The	systematic	review	provides	a	detailed	and	comprehensive	overview	of	the	published	literature	describing	the	aetiology	and	outcome	of	CAP	in	sub-Saharan	Africa	and	sets	the	MARISO	and	AHIP	studies	in	a	broader	context.	In	contrast	to	many	previous	CAP	studies	from	the	region,	the	MARISO	study	is	both	large	and	prospective.	Patients	were	recruited	according	to	a	standard	clinical	case	definition	reflective	of	that	used	in	clinical	practice	in	low-resource	settings;	the	demographic	and	comorbidity	profile	of	the	study	population	was	comparable	to	that	described	in	other	sub-Saharan	African	cohorts	indicating	that	the	findings	are	likely	to	be	generalisable	across	the	region.	The	panel	of	microbiological	investigations	was	broad	and	with	the	exception	of	sputum	specimens	for	mycobacterial	investigations,	specimen	collection	was	reasonably	complete.	The	clinical	outcome	data	is	more	detailed	than	previous	studies,	describing	both	early	endpoints	(i.e.	treatment	failure,	clinical	stability)	and	mortality	up	to	90	days	with	good	follow-up	retention.	The	analysis	of	risk	factors	for	adverse	outcome	focuses	on	clinical	parameters	measurable	with	minimal	equipment	and	training	that	could	form	the	basis	of	CAP	triage	assessment	in	resource-limited	settings.	The	AHIP	study	is	the	first	to	provide	individual	patient-level	data	on	the	effectiveness	of	oxygen	delivery	by	concentrator	to	correct	hypoxaemia	in	adults	with	pneumonia.		
There	are	several	important	limitations	of	the	MARISO	study	that	are	common	both	to	other	African	CAP	cohorts	and	studies	from	well-resourced	settings.	Patients	were	recruited	from	a	single,	urban	teaching	hospital	and	as	such	may	not	be	reflective	of	the	broader	CAP	population.	Certain	groups,	for	example	older	adults,	may	be	under-represented	because	of	differences	in	health	seeking	behaviour	or	access	to	care.	Recruitment	in	a	secondary	care	setting	also	means	that	the	study	population	is	pre-selected	in	terms	of	the	expected	risk	of	adverse	outcome;	prognostic	factors	identified	in	this	setting	may	not	accurately	predict	individuals	at	risk	of	death	or	deterioration	in	an	unselected,	community	population.	The	study	does	also	not	provide	information	on	the	likely	cause	of	death,	particularly	for	those	patients	dying	after	hospital	discharge.	This	information	would	usefully	guide	future	interventions	to	target	factors	associated	with	preventable	mortality.	The	MARISO	study	relied	on	blood,	urine,	upper	respiratory	tract	and	spontaneously	expectorated	sputum	specimens	to	determine	CAP	aetiology.	As	such	the	burden	of	TB	might	be	underestimated	and	the	contribution	of	opportunistic	pathogens,	in	particular	PCP,	to	acute	CAP	has	not	been	established.		
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7.4 What	strategies	can	be	used	to	prevent	pneumonia	in	Malawi?	The	major	burden	of	CAP	in	Malawi	occurs	in	patients	with	potentially	reversible	immunocompromise	and	is	due	to	pathogens	for	which	there	are	either	effective	vaccines	or	preventative	treatments.	Preventative	strategies	to	reduce	the	impact	of	CAP	are	therefore	of	key	importance.		
Antiretroviral	therapy	(ART)	markedly	reduces	the	risk	of	pneumonia	and	early	initiation	improves	survival	(Dworkin	et	al.,	2001;	Kohli	et	al.,	2006;	Sullivan	et	al.,	2000).	The	rapid	roll-out	of	ART	in	sub-Saharan	Africa	has	been	a	huge	public	health	success	with	more	than	9.1	million	started	on	treatment	(World	Health	Organization,	2014b).	In	Malawi,	the	scale	up	of	ART	has	been	associated	with	a	marked	decline	in	both	the	incidence	of	bacteraemia	overall	and	invasive	pneumococcal	disease	(IPD)	(Everett	et	al.,	2011;	Feasey	et	al.,	2014).	However,	the	experience	of	the	MARISO	cohort	highlights	the	continued	challenges	of	timely	diagnosis	and	prompt	initiation	of	ART.	Mortality	is	particularly	high	among	adults	being	assessed	for	ART	initiation,	with	the	majority	of	deaths	occurring	in	individuals	that	do	not	actually	start	treatment	(van	Lettow	et	al.,	2012).	Across	sub-Saharan	African,	average	CD4	cell	counts	at	presentation	and	ART	initiation	remain	low	at	251	and	152	cells/mm3,	respectively	(Siedner	et	al.,	2015;	World	Health	Organization,	2015b).	The	recent	shift	of	WHO	policy	to	recommending	universal	ART	for	all	HIV-infected	patients	regardless	of	CD4	count	may	be	beneficial	(World	Health	Organization,	2015b).			
Co-trimoxazole	preventative	therapy	(CPT)	continues	to	reduce	the	risk	of	hospitalisation	and	pneumonia	after	ART	initiation	(Suthar	et	al.,	2015).	In	the	MARISO	cohort,	20%	of	known	HIV-positive	patients	did	not	use	CPT.	Isoniazid	preventative	therapy	(IPT)	also	provides	an	additive	benefit	over	ART,	reducing	incident	TB	cases	by	as	much	as	43%	in	high	burden	settings	(Danel	et	al.,	2015;	Rangaka	et	al.,	2014;	Samandari	et	al.,	2015;	Samandari	et	al.,	2011),	but	to	date	has	been	widely	underutilised	in	sub-Saharan	Africa.	A	single	fixed-dose	pill	combining	both	co-trimoxazole	and	isoniazid	is	currently	in	development	(Harries	et	al.,	2015).	
In	the	MARISO	cohort,	21%	of	CAP	was	attributable	to	S.	pneumoniae.	Other	studies	from	the	region	using	additional	pneumococcal	diagnostic	tests	(e.g.	lung	aspirate	culture	(Scott	et	al.,	2000),	quantitative	nasopharyngeal	colonisation	density	(Albrich	et	
al.,	2012))	have	identified	higher	rates.	The	13-valent	pneumococcal	conjugate	vaccine	(PCV)	has	proven	effectiveness	to	protect	against	IPD	in	HIV-infected	patients	(French	
et	al.,	2010)	and	pneumococcal	pneumonia	in	elderly	adults	(Bonten	et	al.,	2015).	However,	the	need	for	direct	vaccination	of	susceptible	adults	is	unclear.	Introduction	
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of	PCV	into	the	routine	childhood	immunisation	schedule	in	the	UK	and	US,	led	to	large	falls	in	the	rates	of	vaccine-serotype	IPD	and	pneumococcal	CAP	in	adults	as	a	result	of	indirect	protection	(i.e.	reduced	pneumococcal	carriage	in	vaccine	recipients	leads	to	reduced	pneumococcal	transmission	to	contacts)	(Griffin	et	al.,	2013;	Waight	et	al.,	2015).	Similarly	in	South	Africa,	in	the	three	years	following	the	introduction	of	PCV7	into	the	routine	infant	immunization	programme,	the	incidence	of	vaccine-serotype	IPD	fell	by	57%	(HIV-positive,	59%;	HIV-negative,	52%)	in	adults	aged	25	to	44	years.	The	reduction	in	older	adults	was	less	marked	or	non-significant	(von	Gottberg	et	al.,	2014).	Universal	infant	pneumococcal	vaccination	using	PCV13	was	introduced	in	Malawi	in	November	2011	(Bar-Zeev	et	al.,	2015).	The	extent	of	indirect	effects,	particularly	in	HIV-infected	adults,	needs	careful	study	to	determine	whether	the	burden	of	residual	disease	warrants	additional	targeted	vaccination	programmes.	Preliminary	results	indicate	that	HIV-infected	adults	remain	an	important	reservoir	for	carriage	of	both	vaccine	and	non-vaccine	serotype	pneumococci	even	amongst	those	established	on	ART	for	several	years	with	apparent	immune	reconstitution	(Heinsbroek	et	al.,	2015;	Mwalukomo	et	al.,	2016;	Swarthout	et	al.,	2016	[Abstract	ID	-	367]).	Studies	from	well-resourced	settings	using	recently	developed	serotype-specific	pneumococcal	urinary	antigen	tests	that	allow	the	serotype	of	non-bacteraemic	pneumococcal	CAP	to	be	defined	have	shown	that	the	serotype	distribution	of	non-invasive	pneumococcal	pneumonia	may	differ	from	that	of	IPD	and	that	even	several	years	after	PCV	introduction,	a	substantial	proportion	of	adult	CAP	remains	attributable	to	vaccine	serotypes	(Bewick	et	al.,	2012;	Huijts	et	al.,	2013;	Pride	et	al.,	2012;	Sheppard	et	al.,	2011;	Sherwin	et	al.,	2013).	Similar	efforts	should	be	made	to	determine	the	serotype	distribution	of	pneumococcal	CAP	in	sub-Saharan	Africa.	
7.5 Optimising	severity	assessment	to	stratify	CAP	management	In	the	MARISO	cohort,	male	sex,	hypoxaemia,	inability	to	stand	and	tachycardia	were	independently	associated	with	30-day	mortality.	These	variables	were	combined	into	a	severity	assessment	tool	called	the	MOST	score	that	predicted	30-day	mortality	with	reasonable	accuracy	as	described	above.	Assuming	adequate	performance	in	an	external	validation	pneumonia	cohort,	the	MOST	score	could	be	readily	used	at	emergency	triage	in	Malawi	to	stratify	patients	into	risk	groups	to	guide	care.		
In	well-resourced	settings,	use	of	the	pneumonia	severity	index	(PSI)	to	stratify	care	allows	the	proportion	of	patients	treated	in	the	community	to	be	safely	increased	(Aujesky	et	al.,	2008).	A	similar	application	would	be	potentially	highly	valuable	in	Malawi	both	to	the	patient	(e.g.	avoidance	of	nosocomial	infection	including	tuberculosis,	reduced	lost	income	for	patient	guardians)	and	the	healthcare	system	(e.g.	
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reduced	bed-occupancy	and	costs).	A	MOST	score	of	less	than	2	had	negative	predictive	value	of	>95%	for	30-day	mortality	indicating	its	potential	use	for	identifying	low	risk	patients.	Assuming	adequate	performance	in	external	validation,	the	clinical	impact	of	the	use	of	the	MOST	tool	to	guide	early	discharge	should	be	assessed	in	a	pragmatic	clinical	trial	in	Malawi.	A	suggested	CAP	management	algorithm	based	on	MOST	score	is	shown	in	figure	7.1.		
Severity	assessment	tools	may	alternatively	be	used	to	identify	the	sickest	patients	most	at	risk	of	death	or	early	deterioration.	In	well-resourced	settings,	these	tools	are	typically	used	to	guide	ICU	admission.	In	a	resource-limited	context	such	as	Malawi	where	ICU	resources	are	largely	unavailable,	the	practical	use	of	severity	assessment	is	to	identify	the	group	of	patients	most	likely	to	benefit	from	early	aggressive	therapy.	The	IDSA/ATS	2007	minor	criteria	have	been	successfully	used	in	this	way.	In	Singapore,	Lim	et	al	showed	both	reduced	mortality	and	ICU	admission	following	introduction	of	a	scheme	of	targeted	early	aggressive	fluid	resuscitation	based	on	IDSA/ATS	2007	minor	criteria	(Lim	et	al.,	2014).		
7.6 Optimal	antimicrobial	therapy	
7.6.1 Antibacterial	therapy	Current	antimicrobial	guidelines	for	the	treatment	of	severe	CAP	in	Malawi	recommend	an	initial	regimen	of	ceftriaxone	or	a	combination	of	penicillin	plus	chloramphenicol,	with	additional	agents	added	for	patients	failing	to	improve	at	48	hours	(Zijlstra,	2006).	The	lack	of	initial	combination	treatment	with	a	macrolide	or	fluoroquinolone	is	at	odds	with	most	other	international	CAP	treatment	guidelines	(Feldman	et	al.,	2007a;	Lim	et	al.,	2009;	Mandell	et	al.,	2007).	In	the	MARISO	cohort,	60%	received	ceftriaxone	and	40%	penicillin	plus	chloramphenicol.	No	patients	received	a	macrolide	from	the	outset	and	less	than	5%	of	patients	at	any	point	in	the	admission.		
The	requirement	for	atypical	bacterial	coverage	for	hospitalised	CAP	in	adults	in	this	setting	prior	to	this	study	was	unclear.	The	systematic	review	estimated	rates	of	
Mycoplasma	and	Chlamydophila	of	8%	and	2%,	respectively,	but	data	were	limited.	In	the	MARISO	cohort	Mycoplasma	pneumoniae	and	Chlamydophila	pneumoniae	were	each	present	in	less	than	1%	of	patients.	Based	on	studies	from	South	African	and	Kenya,	the	systematic	review	estimated	the	frequency	of	Legionella	at	2%,	which	is	comparable	to	that	described	in	Europe	and	North	America	(Maartens	et	al.,	1994;	Mpe	et	al.,	2001;	Odera	et	al.,	2009).	In	the	MARISO	cohort	however,	Legionella	spp.	were	detected	by	PCR	in	18.5%	of	nasopharyngeal	aspirates.	Whilst	some	geographical	variation	in	the	frequency	of	Legionella	is	described,	this	result	is	implausibly	high.	Environmental	
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contamination	of	laboratory	water	sources	leading	to	false	positive	Legionella	PCR	results	has	previously	been	described	and	is	a	possible	explanation	here	(Avni	et	al.,	2016;	Pancer	et	al.,	2012).	Legionella	urinary	antigen	testing	on	stored	specimens	is	planned	to	clarify	this	result	before	recommendations	on	the	requirement	for	atypical	bacterial	coverage	are	made.			
The	benefits	of	dual	antimicrobial	therapy	in	severe	CAP,	particularly	β-lactam-macrolide	combination,	are	not	limited	to	those	patients	with	atypical	bacterial	infection.	There	is	observational	data	from	well-resourced	settings	that	the	inclusion	of	macrolides	in	initial	treatment	reduces	mortality	in	severe	disease	due	to	all	aetiologies	(Gattarello	et	al.,	2015;	Martin-Loeches	et	al.,	2010;	Restrepo	et	al.,	2009;	Sligl	et	al.,	2014),	particularly	pneumococcal	pneumonia	(Baddour	et	al.,	2004;	Gattarello	et	al.,	2014;	Waterer	et	al.,	2001b).	Potential	concerns	over	the	widespread	use	of	macrolides	include	the	emergence	of	antimicrobial	resistance	(Wolter	et	al.,	2008)	and	the	risk	of	cardiac	arrhythmias	(Ray	et	al.,	2012;	Wong	et	al.,	2016).	In	the	context	of	severe	CAP	in	Malawi	with	limited	access	to	diagnostic	tests	to	define	aetiology,	there	is	equipoise	for	a	clinical	trial	to	determine	the	benefit	of	universal	or	deferred	macrolide	treatment	(Restrepo	et	al.,	2016).		
7.6.2 Tuberculosis	diagnostics	and	treatment	The	MARISO	cohort	highlights	the	huge	burden	of	tuberculosis	amongst	patients	presenting	with	acute	CAP,	particularly	amongst	HIV-infected	patients.	Tuberculosis	was	identified	in	23%	of	patients	(HIV-positive	25%;	HIV-negative	16%)	and	was	independently	associated	with	30-day	mortality	and	treatment	failure.	Recent	studies	from	South	Africa,	Zambia	and	Malawi	similarly	estimate	that	up	to	one-third	of	all	HIV-positive	acute	medical	inpatients	have	TB	(Bates	et	al.,	2012;	Gupta	et	al.,	2015;	Lawn	et	
al.,	2015).	Disseminated,	bacteraemic	disease	is	common,	occurring	in	between	6	and	23%	of	febrile	inpatients,	(Crump	et	al.,	2012;	Feasey	et	al.,	2013;	Jacob	et	al.,	2013b;	Lewis	et	al.,	2002)	and	has	a	mortality	rate	in	excess	of	50%	with	most	deaths	occurring	within	the	first	week	of	admission	(Feasey	et	al.,	2013;	Jacob	et	al.,	2013b).	Even	amongst	ambulatory	HIV-infected	patients	seen	in	outpatient	settings,	TB	remains	very	common	(up	to	25%)	and	is	associated	with	six-month	mortality	of	up	to	44%	if	treatment	is	delayed	(Bedell	et	al.,	2012;	van	Lettow	et	al.,	2012).		
The	current	approach	advocated	by	the	WHO	for	acutely	hospitalised	HIV-infected	adults	with	respiratory	infection,	negative	sputum	smears	and	danger	signs	(i.e.	high	temperature,	tachycardia,	tachypnoea,	inability	to	walk	unaided)	is	to	first	trial	broad	spectrum	antibacterials	and	if	no	improvement	after	3-5	days	start	TB	treatment	
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(World	Health	Organization,	2006).	This	approach	misses	20%	of	patients	with	culture	positive	TB	and	risks	delaying	treatment	in	a	group	of	patients	with	a	high	risk	of	early	death	(Theron	et	al.,	2014).		
Recent	advances	in	TB	diagnostics	may	help	facilitate	early,	accurate	treatment.	The	Xpert	MTB/RIF	system	offers	real-world	improved	sensitivity	compared	to	smear	microscopy,	resulting	in	more	early	treatment	initiation	and	a	higher	proportion	of	smear	positive	patients	on	treatment,	but	to	date	has	not	had	a	demonstrable	effect	on	TB-related	morbidity	(Lawn	et	al.,	2013c;	Theron	et	al.,	2014).	The	Alere	Determine	TB	LAM	Ag	is	a	point-of-care	test	assay	that	detects	the	mycobacterial	cell	wall	glycopeptide	lipoarabinomannan	(LAM)	in	urine	(Lawn,	2012;	Talbot	et	al.,	2012).	It	provides	an	incremental	increase	in	sensitivity	over	sputum	smear	microscopy	alone	of	approximately	19%	(Shah	et	al.,	2016),	particularly	in	the	most	highly	immunocompromised	patients	and	those	with	features	of	severe	disease	(e.g.	anaemia,	elevated	CRP)	at	greatest	risk	of	death	(Gupta-Wright	et	al.,	2016;	Lawn	et	al.,	2012;	Minion	et	al.,	2011).	A	recent	multicentre	clinical	trial	demonstrated	that	Determine	TB	LAM	Ag	test	guided	initiation	of	anti-tuberculous	was	associated	with	a	17%	relative	reduction	in	mortality	compared	to	standard	diagnostic	strategy	(Peter	et	al.,	2016).	The	clinical	benefit	of	different	TB	diagnostic	strategies	in	acute	CAP,	particularly	amongst	sputum-sparse	patients	requires	further	assessment	in	clinical	trials.		
Even	with	the	best	available	diagnostics,	however,	post-mortem	studies	highlight	that	TB	frequently	goes	unrecognised	particularly	in	patients	with	concurrent	pyogenic	pneumonia	(Bates	et	al.,	2015).	Empirical	TB	treatment	in	which	all	patients	within	a	groups	at	high	risk	of	TB	and	high	risk	of	early	mortality	may	be	warranted	(Munseri	et	
al.,	2011).	Whilst	two	randomised	trials	of	empirical	TB	treatment	in	community-settings	amongst	patients	initiating	ART	have	failed	to	show	benefit	(Fielding	et	al.,	2015;	Grant	et	al.,	2016;	Hosseinipour	et	al.,	2016),	it	has	not	yet	been	studied	in	hospitalised	patients	who	are	more	likely	to	have	severe	or	bacteraemic	disease	where	very	early	treatment	may	be	beneficial	(Jacob	et	al.,	2013b).	The	MARISO	data	support	a	randomised	controlled	trial	of	universal	empirical	TB	treatment	versus	current	practice	of	deferred	treatment	for	non-responders	in	HIV-infected	patients	with	pneumonia	and	risk	factors	for	early	mortality.		
7.7 Optimising	supportive	care	Severe	CAP	is	frequently	complicated	by	respiratory	failure	and	severe	sepsis	(Aliberti	
et	al.,	2014a;	Mayr	et	al.,	2014).	In	the	MARISO	cohort,	16%	of	patients	were	hypoxaemia	and	43%	had	severe	sepsis	(using	criteria	proposed	by	Andrews	et	al.	for	
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use	in	low-resource	settings)	(Andrews	et	al.,	2014;	Singer	et	al.,	2016;	Vincent	et	al.,	1996).	Effective	management	of	sepsis	requires	adequate	intravenous	fluid	resuscitation	and	supplemental	oxygen	use	to	correct	tissue	hypoperfusion	and	optimise	tissue	oxygen	delivery	(Dellinger	et	al.,	2013).	The	limited	data	available	on	sepsis	in	sub-Saharan	Africa	indicate	that	it	is	frequently	under-recognised,	fluid	resuscitation	often	inadequate	and	antimicrobial	therapy	delayed	with	an	inadequate	spectrum	(Becker	et	al.,	2009;	Jacob	et	al.,	2013a;	Jacob	et	al.,	2009).	Simplified	adaptations	of	sepsis	guidelines	for	the	use	in	low-resource	settings	have	been	developed,	but	have	largely	been	bases	on	extrapolations	of	evidence	and	experience	accumulated	in	high-resource	settings	(Becker	et	al.,	2009;	Dunser	et	al.,	2012;	Jacob	et	
al.,	2013a).	Locally	derived	and	validated	strategies	for	oxygen	delivery	and	fluid	resuscitation	are	required.	
7.7.1 Oxygen	delivery	Prior	data	on	the	burden	of	hypoxaemia	in	adults	in	sub-Saharan	African	settings	are	limited.	The	MARISO	and	AHIP	studies	demonstrate	that	hypoxaemia	in	adults	with	pneumonia	is	prevalent,	prognostically	important	and	correctable	in	the	majority	of	patients	using	standard	flow-rate	oxygen	concentrators.	Large	clinical	trials	are	required	to	determine	the	clinical	benefit	of	expanded	oxygen	provision.	Further	studies	are	also	needed	to	define	the	utility	of	additional	respiratory	support	techniques	(e.g.	non-invasive	ventilation).		
Expanding	the	availability	of	oxygen	delivery	provision	represents	a	key	opportunity	to	improving	pneumonia	outcomes	in	sub-Saharan	Africa.	At	present,	fewer	than	half	of	health	care	facilities	in	sub-Saharan	Africa	have	uninterrupted	access	to	an	oxygen	source	and	one-quarter	have	no	access	at	all	(Belle	et	al.,	2010).	A	recent	cross-sectional	study	at	Queen	Elizabeth	Central	Hospital	in	Blantyre	found	that	10%	of	adults	admitted	to	medical	wards	were	hypoxaemic,	but	fewer	than	a	third	were	receiving	supplemental	oxygen	(Evans	et	al.,	2012).	Developing	a	sustainable,	efficient	and	cost-effective	oxygen	infrastructure	within	a	low-resource	setting	is	challenging.	Over	the	last	decade	there	has	been	concerted	effort	and	considerable	progress	in	achieving	this	in	paediatric	care	settings	(Duke	et	al.,	2010a;	Duke	et	al.,	2008).	The	experience	highlights	several	key	areas	that	need	to	be	considered	to	successfully	expand	oxygen	provision.	Firstly,	expansion	of	oxygen	delivery	infrastructure	is	largely	redundant	without	improved	systems	for	the	detection	hypoxaemia.	Interventions	to	improve	the	quality	of	emergency	triage	and	to	expand	the	use	of	pulse-oximetry	are	needed	(Dubowitz	et	al.,	2013;	Duke	et	al.,	2009).	Secondly,	the	dynamics	of	oxygen	need	at	a	facility	level	must	be	understood	to	ensure	demand	is	adequately	met	without	
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excess	redundant	capacity.	Single	point	assessments	of	oxygen	demand	fail	to	capture	the	day-to-day	and	seasonal	variability	and	may	substantially	underestimate	the	required	oxygen	delivery	(Bradley	et	al.,	2014).	Thirdly,	oxygen	concentrators	must	be	carefully	selected	to	ensure	suitability	in	terms	of	performance	(e.g.	oxygen	concentration,	flow-rates),	physical	tolerances	(e.g.	temperature,	humidity,	power	fluctuations)	and	maintenance	requirements	(e.g.	cost,	required	technical	expertise)	(Duke	et	al.,	2010b).	Standardisation	of	equipment	facilitates	sustainable	systems	for	equipment	maintenance	and	procurement	of	replacement	components	(Enarson	et	al.,	2008).	Finally,	the	installation	of	new	systems	should	be	allied	to	a	programme	of	staff	training	and	public	engagement	to	avoid	inappropriate	or	underutilisation	(Enarson	et	
al.,	2008).	
7.7.2 Fluid	resuscitation	In	severe	sepsis,	fluid	resuscitation	is	required	to	correct	tissue	hypoperfusion	and	optimise	tissue	oxygen	delivery.	The	optimal	approach	to	fluid	resuscitation	has	been	extensively	studied	in	well-resourced	settings	and	international	guidelines	developed	defining	the	volume	of	fluid	administration	and	haemodynamic	targets	(Dellinger	et	al.,	2013;	Survivng	Sepsis	Campaign,	2015).	Some	authors	have	attempted	to	adapt	international	sepsis	guidelines	for	use	in	low-resource	settings	(Becker	et	al.,	2009;	Dunser	et	al.,	2012;	World	Health	Organization,	2011c),	but	recommendations	are	largely	based	on	application	of	physiological	principles,	extrapolated	from	experience	in	high-resource	settings	(Jacob	et	al.,	2013a).	The	generalisability	of	recommendations	to	sub-Saharan	Africa	where	sepsis	differs	both	in	terms	of	causal	pathogen	(e.g.	TB,	NTS,	malaria)	and	host	(e.g.	immunosuppression,	nutritional	status,	comorbidities)	is	uncertain	(Jacob	et	al.,	2013a).	A	recent	clinical	trial	of	paediatric	fluid	resuscitation	strategies	in	children	with	severe	febrile	illness	conducted	in	Uganda,	Kenya	and	Tanzania	that	unexpectedly	showed	increased	mortality	with	bolus	fluid	administration	in	children	with	impaired	perfusion	highlights	the	importance	of	generating	context-relevant	data	(Maitland	et	al.,	2011a).	
Specific	data	on	fluid	resuscitation	strategies	in	adult	sepsis	in	sub-Saharan	Africa	are	limited	to	two	recent	clinical	trials	that	yielded	conflicting	results.	A	before-after	comparison	study	in	Uganda	showed	reduced	mortality	with	increased	early	fluid	resuscitation	and	prompt	antibacterial	therapy	(Jacob	et	al.,	2012).	A	similar	study	in	Zambia	in	which	up	to	4000ml	of	intravenous	fluid	was	administered	in	the	first	6	hours	guided	by	jugular	venous	pressure	assessment	was	stopped	early	because	of	futility	and	possibly	increased	mortality	amongst	patients	with	hypoxaemic	respiratory	failure	(Andrews	et	al.,	2014).		
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The	optimal	approach	to	fluid	resuscitation	in	severe	sepsis	remains	unclear.	In	the	absence	of	invasive	monitoring,	fluid	resuscitation	is	usually	guided	by	simple	physiological	markers	that	may	lack	specificity.	Tachycardia,	for	example,	may	reflect	sepsis-related	hypoperfusion	and	an	indication	for	further	fluid	resuscitation,	but	equally	may	reflect	hypoxaemia	or	anaemia	where	further	fluid	may	be	deleterious	(Andrews	et	al.,	2014).	Alternative	robust	surrogate	markers	of	intra-vascular	filling	to	guide	fluid	resuscitation	are	needed	(Jacob	et	al.,	2013a).	The	safety	of	aggressive	fluid	resuscitation	in	the	absence	of	mechanical	ventilatory	support	needs	to	be	investigated,	particularly	for	patients	with	presumed	respiratory	infection	and	hypoxaemia.	More	fundamentally,	research	is	needed	to	define	whether	an	approach	to	management	based	on	rapid	correction	of	deranged	physiology	is	appropriate	for	all	aetiologies	of	sepsis	encountered	in	sub-Saharan	Africa	given	that	a	large	proportion	may	be	secondary	to	mycobacterial	infection	and	sub-acute	in	evolution	(Andrews	et	al.,	2014).		
7.8 Future	research	
7.8.1 Access	to	care	Male	sex	and	prolonged	pre-presentation	symptom	duration	were	independently	associated	with	mortality.	Community-based	studies	including	qualitative	work	are	needed	to	better	understand	the	care	pathway	from	the	time	of	symptom	onset	to	identify	barriers	to	accessing	appropriate	care.		
7.8.2 Aetiology	The	contribution	of	PCP	to	acute	CAP	in	this	setting	is	the	key	aetiological	question	that	has	not	been	addressed	by	the	MARISO	study.	Data	from	well-resourced	settings	and	children	in	South	Africa	support	the	use	of	quantitative	real-time	PCR	on	expectorated	sputum	or	upper	respiratory	tract	specimens	for	PCP	diagnosis	(Samuel	et	al.,	2011;	To	
et	al.,	2013).	Serum	1-3-β-D-glucan	is	also	a	promising	option	(Karageorgopoulos	et	al.,	2013).	These	diagnostics	should	be	evaluated	against	the	current	reference	standard	of	detection	of	Pneumocystis	in	BAL	in	African	centres	that	can	safely	support	bronchoscopy	in	patients	with	acute	CAP.		
The	burden	of	Legionella	is	another	issue	that	has	a	direct	bearing	on	antimicrobial	treatment.	As	mentioned	above,	there	are	plans	to	address	this	by	Legionella	urinary	antigen	testing	on	stored	specimens	from	the	MARISO	cohort.			
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7.8.3 Severity	assessment	The	MOST	score	is	a	useful	starting	point	to	develop	a	CAP	severity	assessment	tool	for	use	in	low-resource	settings	in	sub-Saharan	Africa.	External	validation	in	observational	CAP	cohorts	in	both	inpatient	and	community	settings,	preferably	in	other	sub-Saharan	African	countries,	is	necessary	to	demonstrate	its	accuracy.	In	the	current	analysis,	to	avoid	over-fitting	of	data	to	the	derivation	population,	standard	thresholds	were	used	to	define	abnormal	observations	(e.g.	respiratory	rate	≥30	/min,	systolic	blood	pressure	<90	mmHg).	Given	the	differences	in	age	and	comorbidity	profile	in	sub-Saharan	African	cohorts	compared	to	well-resourced	settings,	the	use	of	alternative	thresholds	should	be	analysed	during	validation	studies	(e.g.	age-adjusted	respiratory	rate	thresholds	(Charles	et	al.,	2008b)).		
The	value	of	a	severity	assessment	tool	is	ultimately	determined	by	incorporating	it	into	a	clinical	pathway	and	its	impact	on	clinical	decisions	and	patient	outcomes	measured	(Aujesky	et	al.,	2008).	Assuming	adequate	performance	in	validation	cohorts,	the	impact	on	patient	safety,	antimicrobial	use	and	cost-effectiveness	of	a	care	pathway	that	recommended	individuals	with	a	MOST	score	of	0	or	1	be	managed	as	outpatients	should	be	evaluated.		
7.8.4 Monitoring	treatment	response	The	MARISO	study	is	unique	amongst	sub-Saharan	African	CAP	studies	in	providing	to	data	on	early	non-mortality	clinical	endpoints.	Non-death	treatment	failure	(i.e.	persistent	hypotension,	hypoxia	or	fever	at	72	hours)	was	strongly	associated	with	30-day	mortality,	but	lacked	sensitivity.	Lack	of	attainment	of	clinical	stability	criteria	by	day	3	had	improved	sensitivity	but	was	non-specific.	Exploratory	analyses	of	the	MARISO	physiological	data	may	be	useful	to	derive	locally	adapted	endpoints	of	treatment	failure	and	response	that	could	serve	as	prompts	for	further	investigation	and	escalation	of	treatment	or	de-escalation	and	discharge,	respectively.	
Serum	specimens	were	collected	at	recruitment	and	day	3	for	procalcitonin	measurement	as	part	of	the	MARISO	study	protocol.	Planned	analyses	include	examining	the	use	of	procalcitonin	to	improve	the	accuracy	of	severity	assessment	on	admission	and	correlating	changes	in	procalcitonin	with	treatment	failure,	attainment	of	clinical	stability	and	subsequent	mortality.			
7.8.5 Antimicrobial	treatment	In	many	sub-Saharan	African	settings,	a	“step-up”	approach	to	antimicrobial	therapy	in	severe	CAP	is	taken	by	default,	whereby	clinical	non-response	on	broad-spectrum	
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antibacterials	results	in	sequential	addition	of	TB	and	PCP	treatment.	This	limits	the	use	of	expensive	and	complex	treatment,	but	may	miss	the	opportunity	for	early	gains	from	aggressive	therapy.	In	patients	with	severe	CAP	at	high	risk	of	death	(as	determined	by	a	locally	validated	clinical	assessment	tool)	a	randomised	clinical	trial	of	immediate	extended	empirical	antimicrobial	therapy	including	a	broad	spectrum	antibacterial	and	TB	treatment,	and	possibly	also	a	macrolide	and	PCP	treatment,	is	warranted.		
7.8.6 Supportive	treatment	The	results	of	the	AHIP	study	support	the	expansion	of	oxygen	delivery	infrastructure	based	on	the	use	of	oxygen	concentrators.	A	step-wedge	trial	of	provision	of	oxygen	concentrators	to	healthcare	centres	and	hospitals	that	currently	have	insufficient	oxygen	capacity	is	necessary	to	define	the	clinical	and	health-economic	impacts.		
Correction	of	hypoxaemia	in	CAP	occurs	within	the	broader	context	of	supportive	therapy.	Further	studies	examining	the	effects	of	different	fluid	resuscitations	strategies	on	detailed	measurement	of	intravascular	volume	status	are	planned	in	Malawi	to	help	define	the	clinical	correlates	of	adequate	fluid	resuscitation.		
7.8.7 Long-term	follow-up	The	numerical	significance	of	the	mortality	beyond	30-days	observed	in	the	MARISO	cohort	should	to	be	compared	against	HIV-matched	control	populations	including	adults	hospitalised	for	other	indications,	and	its	relationship	to	ART	initiation,	subsequent	TB	diagnosis	and	recurrent	episodes	of	CAP	explored.	Longer-term	follow-up	should	be	undertaken	to	determine	if	the	increased	rates	of	adverse	cardiovascular	outcomes	seen	in	Western	CAP	cohorts	are	also	applicable,	particularly	given	the	higher	rates	of	cardiovascular	disease	in	HIV	(Corrales-Medina	et	al.,	2013;	Palella	et	
al.,	2011).	
7.8.8 Research	priorities	Of	the	possible	future	areas	for	research	discussed	above,	the	following	issues	should	be	prioritised	since	they	offer	potential	immediate	patient	benefit	or	are	necessary	intermediate	steps	to	inform	larger	clinical	trials:	
a) Define	the	contribution	of	Legionella	to	CAP	in	Malawi:	Current	use	of	antibiotics	with	activity	against	Legionella	in	initial	treatment	regimens	is	negligible	even	though	appropriate	agents	are	widely	available.	If	a	substantial	burden	of	legionellosis	is	demonstrated	through	repeat	molecular	assays	of	the	
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nasopharyngeal	aspirates,	urinary	Legionella	pneumophila	antigen	testing	and/or	serological	tests,	a	change	to	the	CAP	empirical	antimicrobial	treatment	regimen	could	be	rapidly	implemented. 
b) Validation	of	a	locally	adapted	severity	assessment	tool:	In	well-resourced	settings	CAP	severity	assessment	tools	are	used	both	to	guide	key	aspects	of	clinical	management	(e.g.	site	of	care,	extent	of	microbiological	investigations,	initial	empirical	antimicrobial	selection)	and	to	inform	the	design	of	research	studies	(e.g.	define	patient	eligibility).	To	determine	whether	a	similar	severity-stratified	approach	can	be	safely	employed	in	low-resource	sub-Saharan	African	settings	a	locally	validated	severity	assessment	tool	is	needed.	 
c) Define	the	burden	of	PCP	in	CAP	in	Malawi:	This	is	the	key	aetiological	question	that	the	MARISO	study	failed	to	address.	Whilst	a	previous	study	in	HDU	patients,	indicated	a	high	burden	of	PCP	in	Malawi	(Hartung	et	al.,	2011),	the	prevalence	in	acute	CAP	patients	across	the	spectrum	of	disease	severity	is	unknown.	With	the	facilities	available	to	undertake	bronchoscopy	at	QECH,	the	diagnostic	accuracy	of	quantitative	real-time	PCR	on	non-invasively	obtained	specimens	(e.g.	expectorated	sputum,	nasopharyngeal	aspirate,	oral	wash)	could	be	evaluated	against	a	gold-standard	test	(i.e.	bronchoalveolar	lavage)	in	carefully	selected	pneumonia	patients.	 
Coupled	with	current	and	planned	work	from	other	investigators	in	Malawi	on	point	of	care	diagnostics	for	TB	and	optimal	approaches	to	fluid	resuscitation,	these	studies	would	provide	the	key	data	necessary	to	inform	the	design	of	a	trial	of	severity-stratified	expanded	empirical	antimicrobial	therapy	in	HIV-positive	adults	with	acute	CAP.		
7.9 Conclusions	The	assessment	and	management	of	CAP	needs	to	be	adapted	to	local	circumstances.	Extrapolating	CAP	assessment	and	treatment	algorithms	to	Malawi	from	settings	where	the	epidemiology	and	aetiology	of	disease	is	very	different	is	flawed.	Severity	assessment	tools	derived	in	well-resourced	settings	fail	to	accurately	identify	either	those	patients	with	mild	disease	that	might	be	safely	managed	in	the	community	or	those	with	severe	disease	that	might	benefit	from	intensive	early	treatment.	The	MOST	score	derived	in	the	MARISO	cohort	is	a	simple	clinical	assessment	tool	that	could	be	readily	applied	in	emergency	departments	in	low-resource	settings	and	form	a	rational	basis	for	stratified	management.	Antimicrobial	recommendations	also	need	to	be	adapted	to	the	local	epidemiology	of	disease.	Given	the	high	prevalence	of	tuberculosis	and	its	association	with	early	mortality	in	Malawi,	empirical	anti-tuberculous	treatment	strategies	in	patients	at	high	risk	of	early	deterioration	should	be	evaluated	
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in	clinical	trials.	Strategies	to	improve	supportive	care,	in	particular	the	correction	of	hypoxaemia,	hold	considerable	promise	for	improving	CAP	outcomes	and	should	also	be	evaluated	in	clinical	trials.	
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Appendix	A:	Supplementary	materials	for	systematic	review	of	
community-acquired	pneumonia	in	sub-Saharan	Africa		
1. Study	eligibility	assessment	form	
2. Data	extraction	form	
3. Risk	of	bias	and	quality	assessment	tool	
4. Summary	of	search	strategies		
Aetiology	and	outcome	of	pneumonia	in	sub-Saharan	Africa	systematic	review	
Study	Eligibility	Assessment	Form;	Version	2.1,	26th	January	2015	
	
Study	Eligibility	Assessment	Form		
First	author	 	 Publication	Year	 	
Article	title	 	
Journal	title	 	
Inclusion	criteria	
Study	design		
(Any	one	of	the	
following	acceptable)	
Randomised	clinical	trial	 	
Cohort	study	 	
Case-control	study	 	
Case	series	reporting	25	or	more	cases	 	
Exposure	
(Any	acceptable)	
Describes	population	with	radiographic	pneumonia		
(Defined	as:	Acute	illness	with	radiographic	evidence	of	pulmonary	
consolidation/infiltrate)	
	
Describes	population	with	clinical	pneumonia	
(Defined	as:	Symptoms	of	acute	lower	respiratory	tract	infection	(any	
one	of	cough,	shortness	of	breath,	chest	pain)	with	systemic	features	of	
infection	(any	of	fever,	shivers,	aches	and	pains,	temperature	of	38°C	or	
more)	and	new	focal	chest	signs	on	examination	
	
Author	reported	pneumonia	
(Not	otherwise	specified	or	not	meeting	above	criteria)	
	
Participants	
(Both	must	apply)	
Residents	of	any	sub-Saharan	African	country	 	
Adults	aged	15	years	or	older	 	
Additional	inclusion	criteria	for	specific	analyses	
1.	Mortality	
Either	deaths	in-hospital	or	by	day	30	following	admission/enrolment	reported	 	
2.	Risk	factors	for	mortality	
In-hospital	or	30-day	mortality	rates	reported	separately	for	patient	groups	with	and	without	putative	
risk	factor	(Indicate	below	all	risk	factor	groups	reported)	
	
	 Demographic	(age,	sex,	smoking	status)	 	
	 Comorbid	illness	(HIV,	chronic	lung,	heart,	renal	or	liver	disease,	neurological	disease)	 	
	 Clinical	features	at	presentation	(confusion,	raised	respiratory	rate,	hypoxia,	hypotension,	
hypothermia/pyrexia)	
	
	 Radiological	features	(cavitation,	multilobar	involvement)	 	
	 Laboratory	parameters	(raised	urea,	anaemia,	high	or	low	white	cell	count,	low	CD4	cell	count,	
blood	culture	positivity)	
	
	 Severity	score	indices	(CURB65,	CRB65,	Pneumonia	severity	index)	 	
	 Other	 	
3.	Aetiology			(Both	of	the	following	must	apply)	
Recruitment	not	restricted	to	specific	causative	organism	 	
Microbiological	methods	for	defining	aetiology	are	adequately	described	 	
Exclusion	criteria	
Multicentre	study	in	which	data	for	African	patients	not	presented	separately	 	
Pneumonia	data	not	presented	separately	in	pathogen-defined	cohort	 	
SARI	or	other	RTI	population	not	meeting	above	definitions	for	pneumonia		 	
Hospital-acquired/nosocomial	pneumonia	study	population	 	
Recruitment	restricted	to	confirmed/suspected	Pneumocystis	jirovecii	pneumonia	 	
Recruitment	restricted	to	confirmed/suspected	tuberculosis	 	
Non-acute	presentation	 	
Other	reason	–	Specify:	
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Data	Extraction	and	Quality	Assessment	Form;	Version	2,	24th	June	2015	
Data	Extraction	Form	
First	author	 		 Publication	Year	 	
Journal	title	 	
Study	population	and	setting	
Country	and	region	 	
Recruitment	period/study	
duration	 	
Study	design	
	
Single	centre		☐							Multicentre		☐	
Prospective		☐					Retrospective		☐	
Observational		☐					Interventional	☐	
Clinical	trial		☐					Cohort		☐					Case-control	☐				Case	series		☐	
Setting	
(i.e.	community,	hospital,	ICU)	
	
Study	population		
(Specify	any	restrictions	by	age,	
sex,	occupation,	aetiology,	
comorbidity,	occupation)	
	
Patients	screened/excluded	if	+ve	AFB	smear/culture	☐	
Other	exclusions:	
	
Pneumonia	case-definition	 	
Mortality	endpoint?	
Assessed	when?	
	
Other	comments	 	
Confirmation	of	eligibility/Included	analyses	
Criteria	 Included	analyses	
Study	design	 ☐	 Mortality	 ☐	
Pneumonia	 ☐	 Risk	factors	 ☐	
Participants	 ☐	 Aetiology	 ☐	
Other	exclusions	 ☐	 	
Results		 	 	
Total	number	of	participants	in	study	 		
Sex		 	
Age	(average,	range,	distribution	as	presented)	 		
Comorbid	illnesses	 	
	
	
	
	 	
Study	No.	 	 Reviewer	 	 Date	 	
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Data	Extraction	and	Quality	Assessment	Form;	Version	2,	24th	June	2015	
	
1. MORTALITY	
Number	(%)	for	whom	outcome	determined	and	
included	in	analysis	
	
Number	(%)	died	 	
	
2. RISK	FACTORS	FOR	MORTALITY	
For	categorical	variables,	record	number	and	proportion	of	patients	with	and	without	characteristic	by	
outcome	status.	For	continuous	variables,	record	average	(median/mean)	and	appropriate	range;	if	
presented	as	ordinal	variables,	record	cut-off(s)	and	number	and	proportion	in	each	group.	Where	necessary	
record	how	risk	factor	defined.	‘Missing’	refers	to	number	of	patients	for	whom	data	is	lacking	for	that	
specific	risk	factor.	Leave	row	blank	if	data	on	factor	not	reported.	
	 Definition	/		
Other	comments	
Deaths	with	
factor	
OR	
No.(%)	with	
factor	dying	
(delete	as	
appropriate)	
Deaths	w/o	
factor	
OR	
No.(%)	with	
factor	
surviving	
(delete	as	
appropriate)	
Missing	 Effect	size	
Sex	 	 	 	 	 		
Age		 	 	 	 	 	
Smoking	status		 	 	 	 	 	
HIV	positive	 	 	 	 	 	
Chronic	lung	disease	 	 	 	 	 	
Chronic	heart	
disease	
	 	 	 	 	
Chronic	renal	failure	 	 	 	 	 	
Neurological	disease	 	 	 	 	 	
Confusion	 	 	 	 	 	
Heart	rate	 	 	 	 	 	
Respiratory	rate	 	 	 	 	 	
Hypoxia	 	 		 	 	 	
Hypotension	 			 	 		 	 	
Pyrexia	and/or	
pyrexia	
	 	 	 	 	
Cavitation	 	 	 	 	 	
Multilobar	
involvement	
		 		 		 		 	
Urea	 		 		 		 	 	
Haemoglobin	 	 	 	 	 	
White	cell	count	 		 		 		 	 		
CD4	cell	count	 	 	 	 	 	
Blood	culture	
positivity	
	 	 	 	 	
CURB65	≥3		 	 	 	 	 	
CRB65	≥3	 	 	 	 	 	
PSI	≥4	 	 	 	 	 	
PSI	≥5	 	 	 	 	 	
Other:		 	 	 	 	 	
Comments:			
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Data	Extraction	and	Quality	Assessment	Form;	Version	2,	24th	June	2015	
3. AETIOLOGY	
Indicate	all	clinical	specimen	type	collected	for	microbiological	testing	and	list	each	microbiological	
technique	used.		
Clinical	specimen	 Test	 No.	done	
Blood	 ☐	 	 	
Spontaneous	sputum	 ☐	 	 	
Induced	sputum	 ☐	 	 	
Bronchoalveolar	lavage	 ☐	 	 	
Transbronchial	aspirate	 ☐	 	 	
Transthoracic	needle	
aspirate	
☐	 	 	
Pleural	fluid	 ☐	 	 	
Nasopharyngeal	
swab/aspirate	
☐	 	 	
Urine	 ☐	 	 	
Other,	specify:	
	
☐	 	 	
Comments:	
e.g.	adequacy	of	description	of	
techniques;	quality	control	
procedures	
	
	
For	each	organism	identified,	record	the	number	and	proportion	of	patients	affected.	If	organism	identified	by	multiple	
tests,	record	the	total	number	identified	by	all	methods	combined.		
Organism	 Number	(proportion)	patients/episodes	(delete	as	appropriate)	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
	 	
Unknown	aetiology	 	
*	Not	reported	
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Data	Extraction	and	Quality	Assessment	Form;	Version	2,	24th	June	2015	
Risk	of	Bias	and	Quality	Assessment	Tool	
Key	Quality	Indicator	Domains	
1. Pneumonia	case	definition	
Participants	prospectively	identified	and	recruited	using	a	standardised	case	definition	 	
Radiological	confirmation	of	pneumonia	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
2. Generalisability	
Recruitment	restricted	on	the	basis	of	a	specific	factor	likely	to	influence	outcome:		
(NB.	This	does	not	refer	to	clinical	setting	(e.g.	ICU	vs	ward	patients)	since	these	groups	will	be	analysed	separately:	
	 Age	 	
	 HIV	status	 	
	 Disease	aetiology	 	
	 Other,	specify:		 	
If	any	of	the	above	PRESENT,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
3. Assessment	of	outcome1	
Loss	to	follow	is	less	than	10%	of	total	cohort	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
4. Assessment	of	exposure2	
Data	on	potential	prognostic	factors	collected	prospectively	using	standardised	methods	 	
Data	on	prognostic	factors	analysed	are	available	in	greater	than	90%	patients	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
5. Completeness	of	outcome	data2		
Considering	the	reported	event	rate,	the	extent	of	missing	exposure/outcome	data	is	insufficient	to	have	
clinically	relevant	impact	on	result.	
	
Missing	outcome	data	are	balanced	between	exposure	groups	and	reasons	for	missing	are	similar	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
6. Analysis2	
Association	of	potential	prognostic	factor	with	mortality	reported	with	adjustment	for	important	confounding	
variables	
	
Analysis	completed	according	to	pre-specified	methods	and	all	outcomes	have	been	reported	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
7. Assessment	of	microbiological	work-up3	
Systematic	collection	of	clinical	specimens	with	minimal	missingness	 	
Clear	description	of	laboratory	techniques	with	appropriate	quality	control	measures	 	
If	any	of	the	above	NOT	present,	assign	high	risk	of	bias.	 Low	risk	 	 High	risk	 	
8. Other	
There	is	another	source	of	significant	bias	 	
Describe:	
	
If	PRESENT,	assign	high	risk	of	bias.	 Low-risk	 	 High	risk	 	
1Only	for	studies	included	in	mortality	analysis;	2Only	for	studies	reporting	included	in	risk	factor	for	mortality	
analysis;	3Only	for	studies	included	in	aetiology	analysis.	
Overall	Assessment	
Overall	risk	of	bias	for	each	analysis	 Low	 High	 Unclear	
Mortality	analysis	
Assign	high/unclear	risk	if	high/unclear	risk	in	one	or	more	of	domains	1-3	and	8;	
otherwise	low	risk.	
☐	 ☐	 ☐	
Risk	factors	for	mortality	analysis	
Assign	high/unclear	risk	if	high/unclear	risk	in	one	or	more	of	domains	1-6	and	8;	
otherwise	low	risk.	
☐	 ☐	 ☐	
Aetiology	analysis	
Assign	high/unclear	risk	if	high/unclear	risk	in	one	or	more	of	domains	1,	2,	7	and	
8;	otherwise	low	risk.	
☐	 ☐	 ☐	
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Databases:	Medline	(OVID;	1946	to	Present)	and	Embase	(OVID;	1947-Present)	1 Pneumonia/		2 limit	1	to	humans		3 pneumonia.ab.	or	pneumonia.ti.		4 limit	3	to	humans		5 community-acquired	pneumonia.mp.		6 limit	5	to	humans		7 Respiratory	Tract	Infections/	8 limit	7	to	humans	9 lower	respiratory	tract	infection*.mp.	10 limit	9	to	humans	11 acute	respiratory	infection*.mp.	12 limit	11	to	humans	13 SARI.ab.	or	SARI.ti.		14 limit	13	to	humans	15 Pneumonia,	Pneumococcal/	16 Streptococcus	pneumoniae/	17 Bronchopneumonia/	18 limit	17	to	humans		19 Pleuropneumonia/	20 limit	19	to	humans	21 Legionnaires'	Disease/	22 limit	21	to	humans	23 Legionella	pneumophila/	24 ((lung*	or	pulmonary	or	pleur*)	adj2	(infect*	or	inflam*)).ab.	or	((lung*	or	pulmonary	or	pleur*)	adj2	(infect*	or	inflam*)).ti.	25 limit	24	to	humans	26 2	or	4	or	6	or	8	or	10	or	12	or	14	or	15	or	16	or	18	or	20	or	22	or	23	or	25	27 sub-saharan	Africa.mp.	or	"Africa	South	of	the	Sahara"/	28 (Angola	or	Benin	or	Botswana	or	Burkina	Faso	or	Burundi	or	Cameroon	or	Cape	Verde	or	Central	African	Republic	or	Chad	or	Comoros	or	Congo	or	Democratic	Republic	of	Congo	or	DRC	or	Djibouti	or	Equatorial	Guinea	or	Eritrea	or	Ethiopia	or	Gabon	or	Gambia	or	Ghana	or	Guinea	or	Bissau	or	Ivory	Coast	or	(Cote	and	Ivoire)	or	Jamahiriya	or	Kenya	or	Lesotho	or	Liberia	or	Madagascar	or	Malawi	or	Mali	or	Mauritania	or	Mauritius	or	Mayote	or	Mozambique	or	Mocambique	or	Namibia	or	Niger	or	Nigeria	or	Principe	or	Reunion	or	Rwanda	or	Sao	Tome	or	Senegal	or	Seychelles	or	Sierra	Leone	or	Somalia	or	South	Africa	or	St	Helena	or	Sudan	or	Swaziland	or	Tanzania	or	Togo	or	Uganda	or	Zaire	or	Zambia	or	Zimbabwe	or	Central	Africa	or	Central	African	or	West	Africa	or	West	African	or	Western	Africa	or	Western	African	or	East	Africa	or	East	African	or	Eastern	Africa	or	Eastern	African	or	South	African	or	Southern	Africa	or	Southern	African	or	South	Africa).mp.	[mp=title,	abstract,	original	title,	name	of	substance	word,	subject	heading	word,	keyword	heading	word,	protocol	supplementary	concept	word,	rare	disease	supplementary	concept	word,	unique	identifier]	29 27	or	28	30 26	and	29	31 (baby	or	babies	or	infant*	or	toddler*	or	preschool*	or	pre-school*	or	neonate*	or	newborn*).mp.	[mp=title,	abstract,	original	title,	name	of	substance	word,	subject	heading	word,	keyword	heading	word,	protocol	supplementary	concept	word,	rare	disease	supplementary	concept	word,	unique	identifier]	32 30	and	31	33 30	not	32	34 Guinea	Pigs/	or	guinea	pig*.mp.	35 33	not	34	
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--------------------------------------------------------------------------------	
Databases:	Science	Citation	Index	Expanded	and	Conference	Proceedings	Citation	
Index	(Web	of	Science)		TOPIC:	(pneumonia)	OR	TOPIC:	(respiratory	infection*)	OR	TOPIC:	(pulmonary	infection*)	OR	TOPIC:	(legionnaires'	AND	disease)		Refined	by:	TOPIC:	(Angola	or	Benin	or	Botswana	or	Burkina	Faso	or	Burundi	or	Cameroon	or	Cape	Verde	or	Central	African	Republic	or	Chad	or	Comoros	or	Congo	or	Democratic	Republic	of	Congo	or	DRC	or	Djibouti	OR	Equatorial	Guinea	or	Eritrea	or	Ethiopia	or	Gabon	or	Gambia	or	Ghana	or	Guinea	or	Bissau	or	Ivory	Coast	or	(Cote	and	Ivoire)	or	Jamahiriya	or	Kenya	or	Lesotho	or	Liberia	or	Madagascar	or	Malawi	or	Mali	or	Mauritania	or	Mauritius	or	Mayote	or	Mozambique	or	Mocambique	or	Namibia	or	Niger	or	Nigeria	or	Principe	or	Reunion	or	Rwanda	or	Sao	Tome	or	Senegal	or	Seychelles	or	Sierra	Leone	or	Somalia	or	South	Africa	or	St	Helena	or	Sudan	or	Swaziland	or	Tanzania	or	Togo	or	Uganda	or	Zaire	or	Zambia	or	Zimbabwe	or	Central	Africa	or	Central	African	or	West	Africa	or	West	African	or	Western	Africa	or	Western	African	or	East	Africa	or	East	African	or	Eastern	Africa	or	Eastern	African	or	South	African	or	Southern	Africa	or	Southern	African	or	South	Africa	or	sub-saharan	Africa)	AND	TOPIC:	(adult*	OR	elderly)		Indexes=SCI-EXPANDED,	CPCI-S	Timespan=All	years	--------------------------------------------------------------------------------	
Database:	CINAHL	(EBSCOHost)	1 1	TX	pneumonia	OR	TX	pulmonary	infection*	OR	TX	respiratory	infection*	2 TX	legionell*		3 1	OR	2	4 Angola	or	Benin	or	Botswana	or	Burkina	Faso	or	Burundi	or	Cameroon	or	Cape	Verde	or	Central	African	Republic	or	Chad	or	Comoros	or	Congo	or	Democratic	Republic	of	Congo	or	DRC	or	Djibouti	OR	Equatorial	Guinea	or	Eritrea	or	Ethiopia	or	Gabon	or	Gambia	or	Ghana	or	Guinea	or	Bissau	or	Ivory	Coast	or	(Cote	and	Ivoire)	or	Jamahiriya	or	Kenya	or	Lesotho	or	Liberia	or	Madagascar	or	Malawi	or	Mali	or	Mauritania	or	Mauritius	or	Mayote	or	Mozambique	or	Mocambique	or	Namibia	or	Niger	or	Nigeria	or	Principe	or	Reunion	or	Rwanda	or	Sao	Tome	or	Senegal	or	Seychelles	or	Sierra	Leone	or	Somalia	or	South	Africa	or	St	Helena	or	Sudan	or	Swaziland	or	Tanzania	or	Togo	or	Uganda	or	Zaire	or	Zambia	or	Zimbabwe	or	Central	Africa	or	Central	African	or	West	Africa	or	West	African	or	Western	Africa	or	Western	African	or	East	Africa	or	East	African	or	Eastern	Africa	or	Eastern	African	or	South	African	or	Southern	Africa	or	Southern	African	or	South	Africa	or	sub-Saharan	Africa	5 4	AND	3	
-------------------------------------------------------------------------------- 
Database:	CAB	Abstracts®	and	Global	Health®	(CABI,	Web	of	Science)	1 TS	=	pneumonia	OR	TS	=pulmonary	infection*	OR	TS	=	respiratory	infection*	OR	TS	=	Legionnaires'	disease	2 TOPIC:	(Angola	or	Benin	or	Botswana	or	Burkina	Faso	or	Burundi	or	Cameroon	or	Cape	Verde	or	Central	African	Republic	or	Chad	or	Comoros	or	Congo	or	Democratic	Republic	of	Congo	or	DRC	or	Djibouti	OR	Equatorial	Guinea	or	Eritrea	or	Ethiopia	or	Gabon	or	Gambia	or	Ghana	or	Guinea	or	Bissau	or	Ivory	Coast	or	(Cote	and	Ivoire)	or	Jamahiriya	or	Kenya	or	Lesotho	or	Liberia	or	Madagascar	or	Malawi	or	Mali	or	Mauritania	or	Mauritius	or	Mayote	or	Mozambique	or	Mocambique	or	Namibia	or	Niger	or	Nigeria	or	Principe	or	Reunion	or	Rwanda	or	Sao	Tome	or	Senegal	or	Seychelles	or	Sierra	Leone	or	Somalia	or	South	Africa	or	St	Helena	or	Sudan	or	Swaziland	or	Tanzania	or	Togo	or	Uganda	or	Zaire	or	Zambia	or	
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Zimbabwe	or	Central	Africa	or	Central	African	or	West	Africa	or	West	African	or	Western	Africa	or	Western	African	or	East	Africa	or	East	African	or	Eastern	Africa	or	Eastern	African	or	South	African	or	Southern	Africa	or	Southern	African	or	South	Africa	or	sub-Saharan	Africa)		3 #2	AND	#1	4 TOPIC:	(adult*	OR	elderly)		5 #4	AND	#3		--------------------------------------------------------------------------------	
Database:	Scopus		(	ABS	(	africa*	)		AND		ABS	(	adult*	)		AND		SUBJAREA	(	mult		OR		agri		OR		bioc		OR		immu		OR		neur		OR		phar		OR		mult		OR		medi		OR		nurs		OR		vete		OR		dent		OR		heal	)	)		AND		(	(	TITLE-ABS-KEY	(	pneumonia	)		OR		TITLE-ABS-KEY	(	pulmonary		infection*	)		OR		TITLE-ABS-KEY	(	acute		respiratory		infection*	)	)		AND		SUBJAREA	(	mult		OR		agri		OR		bioc		OR		immu		OR		neur		OR		phar		OR		mult		OR		medi		OR		nurs		OR		vete		OR		dent		OR		heal	)	)		AND		(	LIMIT-TO	(	SUBJAREA	,		"MEDI"	)	)			--------------------------------------------------------------------------------	
Database:	African	Index	Medicus	(World	Health	Organisation)	pneumonia	[Key	Word]	or	pulmonary	infection$	[Key	Word]	or	respiratory	infection$	[Key	Word]	 --------------------------------------------------------------------------------	
Search	results	summary	
 
 
Search	No.	 Date	 Database	searched		 Total	hits		1	 31/10/2014	 Medline	 1198	2	 31/10/2014	 Embase	 2303		3	 31/10/2014	 Science	Citation	Index	Expanded	and	Conference	Proceedings	Citation	Index-	Science	 795	4	 31/10/2014	 CINAHL	 170	5	 31/10/2014	 CAB	Abstracts	and	Global	Health	 699	6	 02/11/2014	 Scopus		 401	7	 03/11/2014	 African	Index	Medicus		 32	
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Appendix	B:	Supplementary	materials	for	MARISO	study		
1. Patient	consent	forms	
2. Chest	radiograph	reporting	proforma	and	guide	
3. Other	case	report	forms	(see	attached	CD)		
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Burden and Severity of HIV-Associated Influenza Illness in Malawi (BASH-FLU) 
Malawian Adult Lower Respiratory Tract Infection Severity, Aetiology and Outcome Study (MARISO) 
H1N1 Influenza Surveillance 
Patient Consent Form, Version 5a (English); 12th March 2014 
 
THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
 
www.mlw.medcol.mw 
 
Page1 
Study Number 
 
PATIENT CONSENT FORM  
BURDEN AND SEVERITY OF HIV-ASSOCIATED INFLUENZA ILLNESS IN MALAWI  
MALAWIAN ADULT LOWER RESPIRATORY TRACT INFECTION SEVERITY, 
AETIOLOGY AND OUTCOME STUDY 
H1N1 INFLUENZA SURVEILLANCE 
Statement by patient (tick boxes as appropriate): 
 Yes No 
I have read/been read the information sheet(s) for the BASH-FLU study (Version 3; 16thJune 
2013), the MARISO study (Version 6; 12th March 2014), and the H1N1 influenza surveillance 
(version; June 2013) (delete as appropriate). I have had the opportunity to ask questions 
about this study and I am satisfied with the answers that I have been given.  
□ □ 
I understand that even after agreeing to take part now, I can withdraw at any time, without 
giving a reason and without this affecting my medical care. 
□ □ 
I agree that the information collected about me during this study may be looked at by the 
study staff and also individuals from regulatory authorities. I give permission for these 
individuals to have access to my medical records including x-rays.  
□ □ 
I agree that samples of my blood, sputum, nasal, saliva and chest fluid and urine may be 
collected for the purpose of this study. I understand that some of my samples may be stored 
for analysis later or shipped overseas for tests that cannot be done in Malawi. 
□ □ 
I voluntarily agree to take part in the BASH-FLU study.  □ □ 
I voluntarily agree also to take part in the MARISO study. □ □ 
I voluntarily agree also to take part in the H1N1 influenza surveillance. □ □ 
 
Name of participant Date Signature/Thumbprint 
   
*Name of witness Date Signature/Thumbprint 
   
*Witnessed consent will be adequate in the case of patients unable to sign their own name. Witnesses must 
be mentally competent adults over 18 years old who have no involvement with the research project. 
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Burden and Severity of HIV-Associated Influenza Illness in Malawi (BASH-FLU) 
Malawian Adult Lower Respiratory Tract Infection Severity, Aetiology and Outcome Study (MARISO) 
H1N1 Influenza Surveillance 
Patient Consent Form, Version 5a (English); 12th March 2014 
 
THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
 
www.mlw.medcol.mw 
 
Page2 
 
 
 
   □      Statement by the researcher taking consent: 
The patient information document(s) for this study has been read by/been read out to the potential study 
participant. To the best of my ability I have ensured that the participant understands 
1. The reasons for the study 
2. The sampling and follow-up arrangements for participation 
3. Plans for protection of confidential data and dissemination of results 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all questions 
have been answered correctly and to the best of my ability. I confirm that consent has been given freely and 
voluntarily. 
 
A copy of the consent form and patient information document has been given to the patient to keep. 
 
 
Name of Researcher Date Signature 
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BASH-FLU MARISO Study
Form BMBC-CXR: Chest Radiograph Review
Y0 Place BASH-FLU
MARISO ID
barcode herebmbar
Tick the box if this page
has any corrections
BASH-FLU MARISO S tudy Chest Radiograph Review, (Active) Version 1; 9-Apr-2014 Page 1 of 1
Y101 cxrqual Optimal Suboptimal Uninterpretable
parabnY201
If Y202 = Yes, indicate:
Confluent Patchy
If Uninterpretable - Skip to Form Completion
Yes NoIs there any parenchymal abnormality?
Y204 extnt Extent Segmental Lobar Multifocal
Radiograph quality
Y1
bmstid
BASH-FLU MARISO
Study Number
If No - Skip to Y301
Y202 consol Consolidation?
Y205 condis Distribution Upper zone
Lower zone
Middle zone
Diffuse
Tick all that apply
Y203 qual Quality
Yes No
Y206 cavtn Cavitation? Yes No
Y207 retic Reticular/reticulonodular/nodular pattern?
If Y207 = Yes, indicate:
Yes No
Y208 retdis Distribution
Y210 mil Miliary appearance? Yes No
Y301 plabn Is there any pleural abnormality? Yes No If No - Skip to Y401
Y302 pleff Pleural effusion?
If Y302 = Yes, indicate:
Yes No
Y303 plsde Side Unilateral Bilateral
Y304 plsze Size Small Large
Y305 ptx Pneumothorax? Yes No
Y401 mdabn Is there any mediastinal abnormality? Yes No If No - Skip to Y501
Y402 lymph Mediastinal/hilar lymphadenopathy?
If Y402 = Yes, indicate:
Yes No
Y403 lymsde Side
Y404 cardio Cardiomegaly?
Unilateral Bilateral
Yes No
Y501 othabn Is there any other abnormality? Yes No If No - Skip to Y601
Y502 othsp Other abnormalities? Volume loss/collapse
Bronchiectasis
Non-cavitating mass
Hyperinflation
Bullae
Ground glass opacification
Tick all that apply
Y601 infn Are the changes compatible with infection? Yes No
(1) (2) (9)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (0)
(1) (2)
(1) (2) (3)
(1) (2)
(3) (4)
Central Peripheral
Unilateral BilateralSideY209 retsde
(1) (2)Tick all that apply
(1) (2)
(1) (2)
(1) (2)
(1) (2)
(1) (2)
(3) (4)
(5) (6)
S taff ID Date completed
2 0 l
Y3Y2 stfid
FORM COMPLETION
date
52460
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CXR	reporting	guide	
Quality:	
Optimal	–	All	of	the	following	are	present:	
1. The	entire	thoracic	cage	is	visible	
2. Adequate	inspiration	(5th-7th	anterior	rib	intersects	the	hemidiaphragm)	
3. There	is	no/minimal	rotation	(spinous	processes	are	equidistant	from	the	medial	
ends	of	the	clavicles)	
4. Well	penetrated	(the	vertebra	are	visible	behind	the	heart)	
Sub-optimal	–	Not	all	of	the	above	are	present,	but	the	reporter	feels	the	X-ray	quality	is	
adequate.	
Uninterpretable	–	The	reporter	feels	the	X-ray	quality	is	insufficient	to	report.	
	
Consolidation	–	Homogeneous	increase	in	pulmonary	parenchymal	attenuation	that	
obscures	the	margins	of	vessels	and	airway	walls.	An	air	bronchogram	may	be	present.		
If	consolidation	is	present,	the	reporter	should	specify	the	following	characteristics.		
Consolidation	quality	–	if	there	are	areas	of	both	confluent	and	patchy	consolidation,	select	
confluent	only.	
Consolidation	size	–	tick	the	option	referring	to	the	largest	area	seen	
(segmental<lobar<multi-focal).	
Consolidation	location	–	select	all	that	apply.	
Diffuse	–	Upper,	middle	and	lower	zones	are	affected	bilaterally.	
	
Reticular/reticulonodular/nodular	pattern:		
Reticular	–	Innumerable	small	linear	opacities	that,	by	summation,	produce	an	appearance	
resembling	a	net.	
Nodular	–	Innumerable	small	rounded	opacities	that	are	discrete	and	range	in	diameter	
from	2	to	10mm.		
Reticulonodular	–	A	combined	reticular	and	nodular	pattern.	
Miliary	pattern	–	Profuse	tiny,	discrete,	rounded	pulmonary	opacities	(≤3mm	in	diameter,)	
that	are	generally	uniform	in	size	and	diffusely	distributed	throughout	the	lung.		
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If	any	of	the	above	are	present,	the	reporter	should	specify	if	the	changes	are	central	or	
peripheral,	unilateral	or	bilateral,	and	if	the	change	is	miliary.	It	is	not	necessary	to	
distinguish	between	reticular,	nodular	or	Reticulonodular	patterns.		
	
Pleural	effusion:	
Small	-	Blunting	of	the	costophrenic	angle.	
Large	-	The	hemidiaphragm	is	completely	obscured.	
	
Cardiomegaly	–	Cardiothoracic	ratio	>50%	on	PA	view.	
Hyperinflation	–	Either	the	diaphragm	is	flattened	or	>7th	anterior	rib	intersects	the	
hemidiaphragm	at	the	mid-clavicular	line.	
Bullae	–	Large	airspaces,	sharply	demarcated	by	a	thin	wall,	usually	accompanied	by	
emphysematous	changes	in	the	adjacent	lung.	
Non-cavitating	lung	mass	–	Solid	opacification	that	is	larger	than	a	nodule.	
Ground	glass	opacification	–	Hazy	opacity	within	which	margins	of	pulmonary	vessels	may	
be	indistinct.	
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Appendix	C:	Supplementary	materials	for	AHIP	study	
1. Patient	verbal	assent	form	
2. Patient	consent	form	
3. Oxygen	delivery	and	monitoring	form	
4. Other	case	report	forms	(see	attached	CD)	
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Addressing hypoxaemia in adult pneumonia in Malawi. 
Verbal Assent Form, Version 3 (English); 9th March 2015 
THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
Page1 
VERBAL ASSENT FORM  
ADDRESSING HYPOXAEMIA IN ADULT PNEUMONIA IN MALAWI 
Statement by study team member: 
 
______________________________________ (name of participant) or his/her guardian has given 
verbal indication of his/her willingness for his/her preliminary enrolment in the clinical study 
‘Addressing hypoxaemia in adult pneumonia in Malawi.’  
I have explained the purpose of the study and the main risks and benefits of taking part. I have 
specifically stated the following: 
x We would like patients to participate in this research study for us to learn the best way of 
providing oxygen for adults with pneumonia with low oxygen levels.  
x The study involves giving participants extra oxygen to breathe and carefully monitoring their 
oxygen levels. 
x We will also record some details from the medical history and take a small amount of blood 
for laboratory tests.  
x All participants will also receive the standard treatment for pneumonia provided by this 
hospital. 
x This research has been checked and approved by an independent committee to make sure 
that the potential benefits out weight the risks. 
x The risks of being in the study are expected to be low, and all participants are being 
monitored carefully for any harm. 
x All participation in research is voluntary so patients can refuse to take part and will still get 
the treatment for pneumonia recommended in this hospital. 
 
Name of participant Date Signature/Thumbprint 
   
Name of guardian Date Signature/Thumbprint 
   
*Name of witness Date Signature 
   
Name of researcher Date Signature 
   
*A witness will be used for patients/guardians unable to sign their own name. Witnesses must be mentally 
competent adults over 18 years old who have no involvement with the research project. 
Study Number: 
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Addressing hypoxaemia in adult pneumonia in Malawi. 
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THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
Page1 
PATIENT CONSENT FORM  
ADDRESSING HYPOXAEMIA IN ADULT PNEUMONIA IN MALAWI 
Statement by patient:  
 Tick boxes 
as 
appropriate    
I have read/been read and understood the information sheet for the study (Version 
4; 9th March 2015). I have had the opportunity to ask questions about this study and 
I am satisfied with the answers that I have been given.  
 
I understand that information about me is to be used for the purposes indicated in 
the information sheet and I have been informed of all types of information that will 
be collected.  
 
I have been informed of the risks and benefits of participation in this study.  
I understand that even after agreeing to take part now, I can withdraw at any time, 
without giving a reason and without this affecting my medical care.   
I agree that the information collected about me during this study may be looked at 
by the study staff, researchers at MLW, Liverpool School of Tropical Medicine and 
also individuals from regulatory authorities. 
 
I agree that samples of my blood may be taken for the purposes indicated in the 
information sheet.  
I understand that if I come to harm as a participant in this study I can claim 
appropriate compensation from the study team without this affecting my clinical 
care 
 
I voluntarily agree to take part in the study.  
I do not wish to continue to take part in this study and request that all 
information collected about me to date is destroyed.  
 
Name of participant Date Signature/Thumbprint 
   
*Name of witness Date Signature/Thumbprint 
   
*A witness will be used for patients/guardians unable to sign their own name. Witnesses must be mentally 
competent adults over 18 years old who have no involvement with the research project 
 
 
    
Study Number: 
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Addressing hypoxaemia in adult pneumonia in Malawi. 
Patient Consent Form, Version 2 (English); 9th  March 2015 
THE COLLEGE OF MEDICINE 
Malawi-Liverpool-Wellcome Trust  
Clinical Research Programme 
Page2 
Statement by the researcher taking consent: 
The patient information document(s) for this study has been read by/been read out to the potential 
study participant. To the best of my ability I have ensured that the participant understands 
1. The reasons for the study 
2. The sampling and follow-up arrangements for participation 
3. Plans for protection of confidential data and dissemination of results 
 
I confirm that the participant was given an opportunity to ask questions about the study, and all 
questions have been answered correctly and to the best of my ability. I confirm that consent has 
been given freely and voluntarily. 
 
A copy of the consent form and patient information document has been given to the patient to 
keep. 
 
 
Name of Researcher Date Signature 
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